{"2e9141540f932d9e2923c96a9dd27b74985007aa": [["IntroductionThe gastrointestinal tract is the main site of entry to the body for many pathogens.", [["gastrointestinal tract", "ANATOMY", 16, 38], ["body", "ANATOMY", 72, 76], ["gastrointestinal tract", "DISEASE", 16, 38], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 16, 38], ["body", "ORGANISM_SUBDIVISION", 72, 76], ["many pathogens", "PROBLEM", 81, 95], ["gastrointestinal tract", "ANATOMY", 16, 38], ["main", "OBSERVATION_MODIFIER", 46, 50], ["entry", "OBSERVATION", 59, 64], ["body", "ANATOMY", 72, 76], ["many", "OBSERVATION_MODIFIER", 81, 85], ["pathogens", "OBSERVATION", 86, 95]]], ["Intestinal epithelial cells interact with enteric pathogens and mediate mucosal immune responses Maynard et al. 2012; Rusu et al. 2005) .", [["Intestinal epithelial cells", "ANATOMY", 0, 27], ["mucosal", "ANATOMY", 72, 79], ["Intestinal epithelial cells", "CELL", 0, 27], ["Intestinal epithelial cells", "CELL_TYPE", 0, 27], ["Intestinal epithelial cells", "PROBLEM", 0, 27], ["enteric pathogens", "PROBLEM", 42, 59], ["epithelial cells", "OBSERVATION", 11, 27]]], ["These cells express various pattern recognition receptors (PRRs) of which Toll-like receptors (TLRs) are the most widely studied (Janeway 1989; Rakoff-Nahoum et al. 2004; Takanashi et al. 2013) .", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 28, 57], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 74, 93], ["TLRs", "GENE_OR_GENE_PRODUCT", 95, 99], ["pattern recognition receptors", "PROTEIN", 28, 57], ["PRRs", "PROTEIN", 59, 63], ["Toll-like receptors", "PROTEIN", 74, 93], ["TLRs", "PROTEIN", 95, 99]]], ["The TLRs recognize pathogenassociated molecular patterns (PAMPs) of microbes which results in subsequent cell signaling and innate immune responses (Janeway 1989; Janeway and Medzhitov 2002; Medzhitov and Janeway 1997) .IntroductionIntestinal epithelial cell surface also expresses various glycoconjugates that may serve as receptors or entry factors for many enteric pathogens (Mestecky 2005) .IntroductionIntestinal epithelial cell cultures from various animals including mouse, rabbit, and pigs have been reported (Booth et al. 1995 (Booth et al. , 1999 Kaeffer 2002; Kaeffer et al. 1993; Rusu et al. 2005; Vidrich et al. 1988 ).", [["cell", "ANATOMY", 105, 109], ["Intestinal epithelial cell surface", "ANATOMY", 232, 266], ["Intestinal epithelial cell cultures", "ANATOMY", 407, 442], ["TLRs", "GENE_OR_GENE_PRODUCT", 4, 8], ["cell", "CELL", 105, 109], ["Intestinal epithelial cell surface", "CELL", 232, 266], ["Intestinal epithelial cell cultures", "CELL", 407, 442], ["mouse", "ORGANISM", 474, 479], ["rabbit", "ORGANISM", 481, 487], ["pigs", "ORGANISM", 493, 497], ["TLRs", "PROTEIN", 4, 8], ["pathogenassociated molecular patterns", "PROTEIN", 19, 56], ["PAMPs", "PROTEIN", 58, 63], ["entry factors", "PROTEIN", 337, 350], ["Intestinal epithelial cell cultures", "CELL_LINE", 407, 442], ["mouse", "SPECIES", 474, 479], ["rabbit", "SPECIES", 481, 487], ["pigs", "SPECIES", 493, 497], ["mouse", "SPECIES", 474, 479], ["rabbit", "SPECIES", 481, 487], ["pigs", "SPECIES", 493, 497], ["subsequent cell signaling", "PROBLEM", 94, 119], ["Intestinal epithelial cell surface", "TREATMENT", 232, 266], ["various glycoconjugates", "PROBLEM", 282, 305], ["entry factors", "PROBLEM", 337, 350], ["many enteric pathogens", "PROBLEM", 355, 377], ["IntroductionIntestinal epithelial cell cultures", "TEST", 395, 442], ["cell signaling", "OBSERVATION", 105, 119], ["Intestinal", "ANATOMY", 232, 242], ["epithelial cell surface", "OBSERVATION", 243, 266], ["Intestinal", "ANATOMY", 407, 417], ["epithelial cell", "OBSERVATION", 418, 433]]], ["However, very few studies have described the establishment and characterization of primary bovine intestinal cell cultures.", [["intestinal cell cultures", "ANATOMY", 98, 122], ["bovine", "ORGANISM", 91, 97], ["intestinal cell cultures", "CELL", 98, 122], ["primary bovine intestinal cell cultures", "CELL_LINE", 83, 122], ["bovine", "SPECIES", 91, 97], ["bovine", "SPECIES", 91, 97], ["primary bovine intestinal cell cultures", "TEST", 83, 122], ["intestinal", "ANATOMY", 98, 108], ["cell cultures", "OBSERVATION", 109, 122]]], ["Bovine intestinal epithelial cell cultures have been established from the duodenum, jejunum, ileum, and colon of adult cattle and fetal calves (Birkner et al. 2004; Kaushik et al. 2008; Loret et al. 2009; Rusu et al. 2005; Yang et al. 2015; Zhan et al. 2017) .", [["intestinal epithelial cell cultures", "ANATOMY", 7, 42], ["duodenum", "ANATOMY", 74, 82], ["jejunum", "ANATOMY", 84, 91], ["ileum", "ANATOMY", 93, 98], ["colon", "ANATOMY", 104, 109], ["fetal calves", "ANATOMY", 130, 142], ["Bovine", "ORGANISM", 0, 6], ["intestinal epithelial cell cultures", "CELL", 7, 42], ["duodenum", "MULTI-TISSUE_STRUCTURE", 74, 82], ["jejunum", "MULTI-TISSUE_STRUCTURE", 84, 91], ["ileum", "MULTI-TISSUE_STRUCTURE", 93, 98], ["colon", "ORGAN", 104, 109], ["cattle", "ORGANISM", 119, 125], ["fetal calves", "MULTI-TISSUE_STRUCTURE", 130, 142], ["Bovine intestinal epithelial cell cultures", "CELL_LINE", 0, 42], ["Bovine", "SPECIES", 0, 6], ["cattle", "SPECIES", 119, 125], ["calves", "SPECIES", 136, 142], ["Bovine", "SPECIES", 0, 6], ["cattle", "SPECIES", 119, 125], ["Bovine intestinal epithelial cell cultures", "TEST", 0, 42], ["intestinal", "ANATOMY", 7, 17], ["epithelial cell", "OBSERVATION", 18, 33], ["duodenum", "ANATOMY", 74, 82], ["jejunum", "ANATOMY", 84, 91], ["ileum", "ANATOMY", 93, 98], ["colon", "ANATOMY", 104, 109], ["fetal calves", "ANATOMY", 130, 142]]], ["Recently, intestinal epithelial cell culture established from the jejunum of buffalo has been reported (Chaudhary et al. 2018) .IntroductionEstablishment of primary intestinal cell cultures is a big challenge due to the high rate of cell death that occurs during cell isolation (Kaeffer 2002; Rusu et al. 2005) .", [["intestinal epithelial cell culture", "ANATOMY", 10, 44], ["jejunum", "ANATOMY", 66, 73], ["primary intestinal cell cultures", "ANATOMY", 157, 189], ["cell", "ANATOMY", 233, 237], ["cell", "ANATOMY", 263, 267], ["death", "DISEASE", 238, 243], ["intestinal epithelial cell", "CELL", 10, 36], ["jejunum", "ORGAN", 66, 73], ["buffalo", "ORGANISM", 77, 84], ["intestinal cell cultures", "CELL", 165, 189], ["cell", "CELL", 233, 237], ["cell", "CELL", 263, 267], ["intestinal epithelial cell culture", "CELL_LINE", 10, 44], ["primary intestinal cell cultures", "CELL_LINE", 157, 189], ["buffalo", "SPECIES", 77, 84], ["intestinal epithelial cell culture", "TEST", 10, 44], ["primary intestinal cell cultures", "TEST", 157, 189], ["a big challenge", "TREATMENT", 193, 208], ["cell death", "PROBLEM", 233, 243], ["intestinal", "ANATOMY", 10, 20], ["epithelial cell", "OBSERVATION", 21, 36], ["jejunum", "ANATOMY", 66, 73], ["intestinal", "ANATOMY", 165, 175], ["cell cultures", "OBSERVATION", 176, 189], ["cell death", "OBSERVATION", 233, 243]]], ["Also, frequent contamination of epithelial cells with fibroblasts is another impediment in the generation of pure epithelial cell cultures (Freshney 1994; Rusu et al. 2005) .", [["epithelial cells", "ANATOMY", 32, 48], ["fibroblasts", "ANATOMY", 54, 65], ["epithelial cell cultures", "ANATOMY", 114, 138], ["epithelial cells", "CELL", 32, 48], ["fibroblasts", "CELL", 54, 65], ["epithelial cell cultures", "CELL", 114, 138], ["epithelial cells", "CELL_TYPE", 32, 48], ["fibroblasts", "CELL_TYPE", 54, 65], ["pure epithelial cell cultures", "CELL_LINE", 109, 138], ["epithelial cells", "PROBLEM", 32, 48], ["fibroblasts", "PROBLEM", 54, 65], ["pure epithelial cell cultures", "TEST", 109, 138], ["frequent", "OBSERVATION_MODIFIER", 6, 14], ["contamination", "OBSERVATION_MODIFIER", 15, 28], ["epithelial cells", "OBSERVATION", 32, 48], ["fibroblasts", "OBSERVATION", 54, 65], ["epithelial cell", "OBSERVATION", 114, 129]]], ["It is important to establish a stable cell culture system so that cells can proliferate for many generations without entering early replicative senescence (Freshney 1994; Rusu et al. 2005) .", [["cell", "ANATOMY", 38, 42], ["cells", "ANATOMY", 66, 71], ["cell", "CELL", 38, 42], ["cells", "CELL", 66, 71], ["a stable cell culture system", "TREATMENT", 29, 57]]], ["This facilitates consistent and long-term studies on the interaction of intestinal epithelial cells with various enteric pathogens.IntroductionInnate immune receptors play a major role in host defense mechanisms through the early recognition of pathogens before effective adaptive immune responses can be mounted.", [["intestinal epithelial cells", "ANATOMY", 72, 99], ["intestinal epithelial cells", "CELL", 72, 99], ["Innate immune receptors", "GENE_OR_GENE_PRODUCT", 143, 166], ["intestinal epithelial cells", "CELL_TYPE", 72, 99], ["Innate immune receptors", "PROTEIN", 143, 166], ["intestinal epithelial cells", "PROBLEM", 72, 99], ["various enteric pathogens", "PROBLEM", 105, 130], ["IntroductionInnate immune receptors", "TREATMENT", 131, 166], ["pathogens", "PROBLEM", 245, 254], ["effective adaptive immune responses", "TREATMENT", 262, 297], ["intestinal epithelial", "ANATOMY", 72, 93], ["cells", "OBSERVATION", 94, 99], ["enteric", "OBSERVATION_MODIFIER", 113, 120], ["pathogens", "OBSERVATION", 121, 130]]], ["PRRs can be broadly divided into two types: non-cytosolic receptors (expressed either on the cell membrane or within endosomal compartments) and cytosolic receptors.", [["cell membrane", "ANATOMY", 93, 106], ["endosomal compartments", "ANATOMY", 117, 139], ["cytosolic", "ANATOMY", 145, 154], ["PRRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["non-cytosolic receptors", "GENE_OR_GENE_PRODUCT", 44, 67], ["cell membrane", "CELLULAR_COMPONENT", 93, 106], ["endosomal compartments", "CELLULAR_COMPONENT", 117, 139], ["PRRs", "PROTEIN", 0, 4], ["non-cytosolic receptors", "PROTEIN", 44, 67], ["cytosolic receptors", "PROTEIN", 145, 164], ["non-cytosolic receptors", "PROBLEM", 44, 67]]], ["A total of ten bovine TLRs have been identified which are designated as TLRs 1-10 (Fisher et al. 2011; Menzies and Ingham 2006; Werling et al. 2006) .", [["bovine", "ORGANISM", 15, 21], ["TLRs", "GENE_OR_GENE_PRODUCT", 22, 26], ["bovine TLRs", "PROTEIN", 15, 26], ["TLRs", "PROTEIN", 72, 76], ["bovine", "SPECIES", 15, 21], ["A total of ten bovine TLRs", "TREATMENT", 0, 26], ["TLRs", "TEST", 72, 76], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["In general, TLR1, TLR2, TLR4, TLR5, and TLR6 are expressed on the cell surface, while TLRs 3, 7, 8, and 9 are expressed in the cell within endosomal compartments and are mostly involved in the recognition of nucleic acids (Akira et al. 2006; Werling and Jungi 2003; Werling et al. 2006 ).", [["cell surface", "ANATOMY", 66, 78], ["cell", "ANATOMY", 127, 131], ["endosomal compartments", "ANATOMY", 139, 161], ["nucleic acids", "CHEMICAL", 208, 221], ["TLR1", "GENE_OR_GENE_PRODUCT", 12, 16], ["TLR2", "GENE_OR_GENE_PRODUCT", 18, 22], ["TLR4", "GENE_OR_GENE_PRODUCT", 24, 28], ["TLR5", "GENE_OR_GENE_PRODUCT", 30, 34], ["TLR6", "GENE_OR_GENE_PRODUCT", 40, 44], ["cell surface", "CELLULAR_COMPONENT", 66, 78], ["TLRs 3", "GENE_OR_GENE_PRODUCT", 86, 92], ["7", "GENE_OR_GENE_PRODUCT", 94, 95], ["8", "GENE_OR_GENE_PRODUCT", 97, 98], ["9", "GENE_OR_GENE_PRODUCT", 104, 105], ["cell", "CELL", 127, 131], ["endosomal compartments", "CELLULAR_COMPONENT", 139, 161], ["nucleic acids", "SIMPLE_CHEMICAL", 208, 221], ["TLR1", "PROTEIN", 12, 16], ["TLR2", "PROTEIN", 18, 22], ["TLR4", "PROTEIN", 24, 28], ["TLR5", "PROTEIN", 30, 34], ["TLR6", "PROTEIN", 40, 44], ["TLRs 3, 7, 8, and 9", "PROTEIN", 86, 105], ["TLR1", "TEST", 12, 16], ["TLR2", "TEST", 18, 22], ["TLR4", "TEST", 24, 28], ["TLR5", "TEST", 30, 34], ["TLRs", "TEST", 86, 90], ["TLR1", "ANATOMY", 12, 16]]], ["These receptors broadly recognize different classes of pathogens and are also important in the recognition of danger signals of tissue damage (Iwasaki and Medzhitov 2010; Miyake 2007) .", [["tissue", "ANATOMY", 128, 134], ["tissue", "TISSUE", 128, 134], ["pathogens", "PROBLEM", 55, 64], ["tissue damage", "PROBLEM", 128, 141], ["pathogens", "OBSERVATION", 55, 64]]], ["This leads to the initiation of proinflammatory signaling cascade through activation of transcription factor NF-jB (Mogensen 2009 ).", [["NF-jB", "GENE_OR_GENE_PRODUCT", 109, 114], ["transcription factor NF-jB", "PROTEIN", 88, 114], ["Mogensen 2009", "PROTEIN", 116, 129], ["proinflammatory signaling cascade", "TREATMENT", 32, 65]]], ["The proinflammatory response involves the production of various cytokines, chiefly IL-1, IL-6, and IL-18 and is a major step in the clearance of pathogens (Peterson and Artis 2014) .IntroductionMany enteric pathogens infect young calves.", [["enteric pathogens", "DISEASE", 199, 216], ["IL-1", "GENE_OR_GENE_PRODUCT", 83, 87], ["IL-6", "GENE_OR_GENE_PRODUCT", 89, 93], ["IL-18", "GENE_OR_GENE_PRODUCT", 99, 104], ["calves", "ORGANISM", 230, 236], ["cytokines", "PROTEIN", 64, 73], ["IL-1, IL-6", "PROTEIN", 83, 93], ["IL-18", "PROTEIN", 99, 104], ["calves", "SPECIES", 230, 236], ["various cytokines", "TEST", 56, 73], ["chiefly IL", "TEST", 75, 85], ["IL", "TEST", 89, 91], ["IL", "TEST", 99, 101], ["proinflammatory response", "OBSERVATION", 4, 28], ["enteric", "OBSERVATION_MODIFIER", 199, 206], ["pathogens", "OBSERVATION", 207, 216]]], ["Bovine rotavirus (BRV), bovine coronavirus (BCV), and bovine viral diarrhea virus (BVDV) infect epithelial enterocytes and cause severe diarrhea in young calves (Cho and Yoon 2014) .", [["epithelial enterocytes", "ANATOMY", 96, 118], ["Bovine rotavirus (BRV), bovine coronavirus (BCV)", "DISEASE", 0, 48], ["bovine viral diarrhea virus", "DISEASE", 54, 81], ["diarrhea", "DISEASE", 136, 144], ["Bovine rotavirus", "ORGANISM", 0, 16], ["BRV", "ORGANISM", 18, 21], ["bovine coronavirus", "ORGANISM", 24, 42], ["BCV", "ORGANISM", 44, 47], ["bovine viral diarrhea virus", "ORGANISM", 54, 81], ["BVDV", "ORGANISM", 83, 87], ["epithelial enterocytes", "CELL", 96, 118], ["calves", "ORGANISM", 154, 160], ["epithelial enterocytes", "CELL_TYPE", 96, 118], ["Bovine", "SPECIES", 0, 6], ["bovine", "SPECIES", 24, 30], ["coronavirus", "SPECIES", 31, 42], ["bovine", "SPECIES", 54, 60], ["viral diarrhea virus", "SPECIES", 61, 81], ["BVDV", "SPECIES", 83, 87], ["calves", "SPECIES", 154, 160], ["Bovine rotavirus", "SPECIES", 0, 16], ["BRV", "SPECIES", 18, 21], ["bovine coronavirus", "SPECIES", 24, 42], ["BCV", "SPECIES", 44, 47], ["bovine viral diarrhea virus", "SPECIES", 54, 81], ["BVDV", "SPECIES", 83, 87], ["Bovine rotavirus (BRV", "PROBLEM", 0, 21], ["bovine coronavirus", "PROBLEM", 24, 42], ["bovine viral diarrhea virus", "PROBLEM", 54, 81], ["BVDV", "PROBLEM", 83, 87], ["epithelial enterocytes", "PROBLEM", 96, 118], ["severe diarrhea in young calves", "PROBLEM", 129, 160], ["epithelial enterocytes", "OBSERVATION", 96, 118], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["diarrhea", "OBSERVATION", 136, 144]]], ["Equally important are various bacterial pathogens, namely enterotoxigenic Escherichia coli, Clostridium perfringens, Mycobacterium avium subspecies paratuberculosis (MAP), Salmonella enterica; and the protozoan parasite Cryptosporidium parvum (C. parvum) (Cho and Yoon 2014; Foster and Smith 2009; Khare et al. 2009; Mohler et al. 2009; Rings 2004) .", [["enterotoxigenic Escherichia coli", "DISEASE", 58, 90], ["Clostridium perfringens", "DISEASE", 92, 115], ["Cryptosporidium parvum", "DISEASE", 220, 242], ["enterotoxigenic", "ORGANISM", 58, 73], ["Escherichia coli", "ORGANISM", 74, 90], ["Clostridium perfringens", "ORGANISM", 92, 115], ["Mycobacterium avium subspecies paratuberculosis", "ORGANISM", 117, 164], ["MAP", "GENE_OR_GENE_PRODUCT", 166, 169], ["Salmonella enterica", "ORGANISM", 172, 191], ["protozoan parasite", "ORGANISM", 201, 219], ["Cryptosporidium parvum", "ORGANISM", 220, 242], ["C. parvum", "ORGANISM", 244, 253], ["Escherichia coli", "SPECIES", 74, 90], ["Clostridium perfringens", "SPECIES", 92, 115], ["Mycobacterium avium", "SPECIES", 117, 136], ["subspecies paratuberculosis", "SPECIES", 137, 164], ["Salmonella enterica", "SPECIES", 172, 191], ["Cryptosporidium parvum", "SPECIES", 220, 242], ["C. parvum", "SPECIES", 244, 253], ["Escherichia coli", "SPECIES", 74, 90], ["Clostridium perfringens", "SPECIES", 92, 115], ["Mycobacterium avium subspecies paratuberculosis", "SPECIES", 117, 164], ["MAP", "SPECIES", 166, 169], ["Salmonella enterica", "SPECIES", 172, 191], ["Cryptosporidium parvum", "SPECIES", 220, 242], ["C. parvum", "SPECIES", 244, 253], ["various bacterial pathogens", "PROBLEM", 22, 49], ["namely enterotoxigenic Escherichia coli", "PROBLEM", 51, 90], ["Clostridium perfringens", "PROBLEM", 92, 115], ["Mycobacterium avium subspecies paratuberculosis", "PROBLEM", 117, 164], ["Salmonella enterica", "PROBLEM", 172, 191], ["the protozoan parasite Cryptosporidium parvum", "PROBLEM", 197, 242], ["various", "OBSERVATION_MODIFIER", 22, 29], ["bacterial pathogens", "OBSERVATION", 30, 49], ["enterotoxigenic Escherichia coli", "OBSERVATION", 58, 90], ["Clostridium perfringens", "OBSERVATION_MODIFIER", 92, 115], ["Mycobacterium", "OBSERVATION_MODIFIER", 117, 130], ["avium", "OBSERVATION_MODIFIER", 131, 136], ["subspecies paratuberculosis", "OBSERVATION", 137, 164]]], ["Bovine jejunal and ileal epithelial cell cultures derived from adult cattle and fetal calves are currently available as homologous cell lines for studying innate immune responses against these pathogens .", [["jejunal", "ANATOMY", 7, 14], ["ileal epithelial cell cultures", "ANATOMY", 19, 49], ["fetal calves", "ANATOMY", 80, 92], ["cell lines", "ANATOMY", 131, 141], ["Bovine", "ORGANISM", 0, 6], ["jejunal", "MULTI-TISSUE_STRUCTURE", 7, 14], ["ileal epithelial cell cultures", "CELL", 19, 49], ["cattle", "ORGANISM", 69, 75], ["fetal calves", "MULTI-TISSUE_STRUCTURE", 80, 92], ["cell lines", "CELL", 131, 141], ["Bovine jejunal and ileal epithelial cell cultures", "CELL_LINE", 0, 49], ["homologous cell lines", "CELL_LINE", 120, 141], ["Bovine", "SPECIES", 0, 6], ["cattle", "SPECIES", 69, 75], ["calves", "SPECIES", 86, 92], ["Bovine", "SPECIES", 0, 6], ["cattle", "SPECIES", 69, 75], ["Bovine jejunal", "TREATMENT", 0, 14], ["ileal epithelial cell cultures", "TEST", 19, 49], ["adult cattle and fetal calves", "TREATMENT", 63, 92], ["homologous cell lines", "TREATMENT", 120, 141], ["these pathogens", "PROBLEM", 187, 202], ["jejunal", "ANATOMY", 7, 14], ["ileal epithelial", "ANATOMY", 19, 35], ["cell cultures", "OBSERVATION", 36, 49], ["fetal calves", "ANATOMY", 80, 92]]], ["The fetal bovine intestinal epithelial cell line has been studied for interaction with enteric pathogens (Takanashi et al. 2013) .", [["fetal", "ANATOMY", 4, 9], ["intestinal epithelial cell line", "ANATOMY", 17, 48], ["bovine", "ORGANISM", 10, 16], ["intestinal epithelial cell line", "CELL", 17, 48], ["fetal bovine intestinal epithelial cell line", "CELL_LINE", 4, 48], ["bovine", "SPECIES", 10, 16], ["bovine", "SPECIES", 10, 16], ["The fetal bovine intestinal epithelial cell line", "TREATMENT", 0, 48], ["enteric pathogens", "PROBLEM", 87, 104], ["fetal", "ANATOMY_MODIFIER", 4, 9], ["bovine", "ANATOMY_MODIFIER", 10, 16], ["intestinal", "ANATOMY", 17, 27], ["epithelial cell line", "OBSERVATION", 28, 48]]], ["Surgically prepared jejunal loops from 1-day old calves have also been used for comparative study of the innate immune responses against BRV and BCV infection (Aich et al. 2007) .", [["jejunal loops", "ANATOMY", 20, 33], ["BCV infection", "DISEASE", 145, 158], ["jejunal loops", "MULTI-TISSUE_STRUCTURE", 20, 33], ["calves", "ORGANISM", 49, 55], ["BRV", "ORGANISM", 137, 140], ["BCV", "ORGANISM", 145, 148], ["calves", "SPECIES", 49, 55], ["BRV", "SPECIES", 137, 140], ["BCV", "SPECIES", 145, 148], ["Surgically prepared jejunal loops", "PROBLEM", 0, 33], ["comparative study", "TEST", 80, 97], ["BRV", "PROBLEM", 137, 140], ["BCV infection", "PROBLEM", 145, 158], ["jejunal loops", "ANATOMY", 20, 33], ["BCV", "ANATOMY", 145, 148], ["infection", "OBSERVATION", 149, 158]]], ["Therefore, BIEC cell lines from young calves can provide important knowledge on the innate immune responses against enteric pathogens that chiefly infect young calves.IntroductionThe established epithelial cultures from fetal calf and adult cattle may not be a suitable model to study enteric infections of young calves .", [["BIEC cell lines", "ANATOMY", 11, 26], ["epithelial cultures", "ANATOMY", 195, 214], ["fetal calf", "ANATOMY", 220, 230], ["enteric infections", "DISEASE", 285, 303], ["BIEC cell lines", "CELL", 11, 26], ["calves", "ORGANISM", 38, 44], ["calves", "ORGANISM", 160, 166], ["epithelial cultures", "CELL", 195, 214], ["fetal calf", "ORGANISM_SUBSTANCE", 220, 230], ["cattle", "ORGANISM", 241, 247], ["calves", "ORGANISM", 313, 319], ["BIEC cell lines", "CELL_LINE", 11, 26], ["established epithelial cultures", "CELL_LINE", 183, 214], ["calves", "SPECIES", 38, 44], ["calves", "SPECIES", 160, 166], ["calf", "SPECIES", 226, 230], ["cattle", "SPECIES", 241, 247], ["calves", "SPECIES", 313, 319], ["cattle", "SPECIES", 241, 247], ["BIEC cell lines", "TREATMENT", 11, 26], ["the innate immune responses", "TREATMENT", 80, 107], ["enteric pathogens", "PROBLEM", 116, 133], ["The established epithelial cultures", "TEST", 179, 214], ["enteric infections of young calves", "PROBLEM", 285, 319], ["cell lines", "OBSERVATION", 16, 26], ["epithelial cultures", "OBSERVATION", 195, 214], ["fetal calf", "ANATOMY", 220, 230], ["infections", "OBSERVATION", 293, 303]]], ["At present, only limited studies on intestinal epithelial cell cultures from young calves are available (Cenci\u010d and Langerholc 2010; Cencic et al. 2007; Steube et al. 2012) .", [["intestinal epithelial cell cultures", "ANATOMY", 36, 71], ["intestinal epithelial cell cultures", "CELL", 36, 71], ["calves", "ORGANISM", 83, 89], ["intestinal epithelial cell cultures", "CELL_LINE", 36, 71], ["calves", "SPECIES", 83, 89], ["intestinal epithelial cell cultures", "TEST", 36, 71], ["intestinal", "ANATOMY", 36, 46], ["epithelial cell", "OBSERVATION", 47, 62]]], ["In this study, the main aim was to establish primary and immortalized cultures of bovine intestinal epithelial cells (BIECs) derived from young calf and then characterize them using biochemical and immunological techniques.", [["cultures", "ANATOMY", 70, 78], ["intestinal epithelial cells", "ANATOMY", 89, 116], ["BIECs", "ANATOMY", 118, 123], ["calf", "ANATOMY", 144, 148], ["bovine", "ORGANISM", 82, 88], ["intestinal epithelial cells", "CELL", 89, 116], ["BIECs", "CELL", 118, 123], ["calf", "ORGANISM", 144, 148], ["primary and immortalized cultures", "CELL_LINE", 45, 78], ["bovine intestinal epithelial cells", "CELL_TYPE", 82, 116], ["BIECs", "CELL_TYPE", 118, 123], ["bovine", "SPECIES", 82, 88], ["calf", "SPECIES", 144, 148], ["bovine", "SPECIES", 82, 88], ["this study", "TEST", 3, 13], ["bovine intestinal epithelial cells", "PROBLEM", 82, 116], ["biochemical and immunological techniques", "TEST", 182, 222], ["intestinal epithelial cells", "OBSERVATION", 89, 116], ["calf", "ANATOMY", 144, 148]]], ["A pure BIEC clone (BIEC-c4) was established and immortalized using SV40, hTERT, and HPV E6/E7 genes for establishing continuous cell lines.", [["BIEC clone", "ANATOMY", 7, 17], ["cell lines", "ANATOMY", 128, 138], ["BIEC clone", "CELL", 7, 17], ["BIEC-c4", "CELL", 19, 26], ["SV40", "ORGANISM", 67, 71], ["hTERT", "GENE_OR_GENE_PRODUCT", 73, 78], ["HPV E6", "ORGANISM", 84, 90], ["E7", "GENE_OR_GENE_PRODUCT", 91, 93], ["cell lines", "CELL", 128, 138], ["BIEC clone", "CELL_LINE", 7, 17], ["BIEC", "CELL_LINE", 19, 23], ["c4", "CELL_LINE", 24, 26], ["SV40, hTERT, and HPV E6/E7 genes", "DNA", 67, 99], ["continuous cell lines", "CELL_LINE", 117, 138], ["HPV", "SPECIES", 84, 87], ["A pure BIEC clone (BIEC-c4)", "TREATMENT", 0, 27], ["SV40", "TREATMENT", 67, 71], ["hTERT", "TEST", 73, 78], ["HPV E6/E7 genes", "TREATMENT", 84, 99], ["continuous cell lines", "TREATMENT", 117, 138], ["cell lines", "OBSERVATION", 128, 138]]], ["Growth kinetics of BIEC-c4 was compared with the immortalized BIECs.", [["BIECs", "ANATOMY", 62, 67], ["BIEC-c4", "GENE_OR_GENE_PRODUCT", 19, 26], ["BIECs", "CELL", 62, 67], ["BIEC", "PROTEIN", 19, 23], ["c4", "PROTEIN", 24, 26], ["immortalized BIECs", "CELL_LINE", 49, 67], ["Growth kinetics", "TEST", 0, 15], ["BIEC", "TEST", 19, 23], ["kinetics", "OBSERVATION_MODIFIER", 7, 15]]], ["The expression of TLR genes was also studied in each of the four BIEC cell types.", [["BIEC cell", "ANATOMY", 65, 74], ["TLR", "GENE_OR_GENE_PRODUCT", 18, 21], ["BIEC cell", "CELL", 65, 74], ["TLR genes", "DNA", 18, 27], ["BIEC cell types", "CELL_LINE", 65, 80], ["TLR genes", "OBSERVATION", 18, 27], ["BIEC cell types", "OBSERVATION", 65, 80]]], ["The BIEC cell lines established in this study may be applicable for understanding the role of intestinal epithelial cells in innate immunity against enteric pathogens.", [["BIEC cell lines", "ANATOMY", 4, 19], ["intestinal epithelial cells", "ANATOMY", 94, 121], ["enteric pathogens", "DISEASE", 149, 166], ["BIEC cell lines", "CELL", 4, 19], ["intestinal epithelial cells", "CELL", 94, 121], ["BIEC cell lines", "CELL_LINE", 4, 19], ["intestinal epithelial cells", "CELL_TYPE", 94, 121], ["The BIEC cell lines", "TREATMENT", 0, 19], ["this study", "TEST", 35, 45], ["intestinal epithelial cells", "TREATMENT", 94, 121], ["enteric pathogens", "PROBLEM", 149, 166], ["cell lines", "OBSERVATION", 9, 19], ["intestinal epithelial", "ANATOMY", 94, 115]]], ["Therefore, these cells may be a useful model for studying epithelial cell biology, hostmicrobe interaction, immunomodulation, and pathogenesis.Establishment of primary and early passage bovine intestinal epithelial culturesA 2-day-old colostrum-deprived Holstein male calf (Bos taurus) was obtained from the South Dakota State University (SDSU) dairy farm.", [["cells", "ANATOMY", 17, 22], ["epithelial cell", "ANATOMY", 58, 73], ["hostmicrobe", "ANATOMY", 83, 94], ["intestinal epithelial", "ANATOMY", 193, 214], ["cells", "CELL", 17, 22], ["epithelial cell", "CELL", 58, 73], ["bovine", "ORGANISM", 186, 192], ["intestinal epithelial", "CELL", 193, 214], ["colostrum", "ORGANISM", 235, 244], ["calf", "ORGANISM", 268, 272], ["Bos taurus", "ORGANISM", 274, 284], ["bovine", "SPECIES", 186, 192], ["colostrum", "SPECIES", 235, 244], ["calf", "SPECIES", 268, 272], ["Bos taurus", "SPECIES", 274, 284], ["bovine", "SPECIES", 186, 192], ["Holstein male calf", "SPECIES", 254, 272], ["Bos taurus", "SPECIES", 274, 284], ["immunomodulation", "TREATMENT", 108, 124], ["pathogenesis", "PROBLEM", 130, 142], ["primary and early passage bovine intestinal epithelial culturesA", "PROBLEM", 160, 224], ["epithelial cell", "OBSERVATION", 58, 73], ["primary", "OBSERVATION_MODIFIER", 160, 167], ["early", "OBSERVATION_MODIFIER", 172, 177], ["passage", "OBSERVATION_MODIFIER", 178, 185], ["intestinal epithelial", "ANATOMY", 193, 214], ["calf", "ANATOMY", 268, 272]]], ["The animal was negative for bovine viral diarrhea, bovine leukemia virus, and Johne's disease.", [["viral diarrhea", "DISEASE", 35, 49], ["bovine leukemia virus", "DISEASE", 51, 72], ["Johne's disease", "DISEASE", 78, 93], ["animal", "ORGANISM", 4, 10], ["bovine", "ORGANISM", 28, 34], ["viral diarrhea", "ORGANISM", 35, 49], ["bovine leukemia virus", "ORGANISM", 51, 72], ["bovine", "SPECIES", 28, 34], ["bovine", "SPECIES", 51, 57], ["leukemia virus", "SPECIES", 58, 72], ["Johne", "SPECIES", 78, 83], ["bovine leukemia virus", "SPECIES", 51, 72], ["Johne", "SPECIES", 78, 83], ["bovine viral diarrhea", "PROBLEM", 28, 49], ["bovine leukemia virus", "PROBLEM", 51, 72], ["Johne's disease", "PROBLEM", 78, 93], ["negative for", "UNCERTAINTY", 15, 27], ["viral diarrhea", "OBSERVATION", 35, 49], ["bovine leukemia virus", "OBSERVATION", 51, 72]]], ["All animal protocols were approved by SDSU Institutional Animal Care and Use Committee (IACUC).", [["All animal protocols", "TREATMENT", 0, 20]]], ["The ileal intestinal cultures were established using the procedures described earlier with some modification Rusu et al. 2005) .", [["ileal intestinal cultures", "ANATOMY", 4, 29], ["ileal intestinal cultures", "CELL", 4, 29], ["ileal intestinal cultures", "CELL_LINE", 4, 29], ["The ileal intestinal cultures", "TEST", 0, 29], ["the procedures", "TREATMENT", 53, 67], ["ileal intestinal", "ANATOMY", 4, 20]]], ["Briefly, ileal tissue fragments from a 2-day old dairy calf were collected in ice-cold Hanks balanced salt solution (HBSS) supplemented with 1% strepto-penicillin-antimycotic solution, gentamycin (5 lg/ml) and L-glutamine (2 mM), referred as supplemented HBSS (HBSS-S).", [["ileal tissue fragments", "ANATOMY", 9, 31], ["strepto-", "CHEMICAL", 144, 152], ["penicillin", "CHEMICAL", 152, 162], ["gentamycin", "CHEMICAL", 185, 195], ["-glutamine", "CHEMICAL", 211, 221], ["penicillin", "CHEMICAL", 152, 162], ["gentamycin", "CHEMICAL", 185, 195], ["L-glutamine", "CHEMICAL", 210, 221], ["ileal tissue", "TISSUE", 9, 21], ["calf", "ORGANISM", 55, 59], ["strepto-penicillin-antimycotic", "SIMPLE_CHEMICAL", 144, 174], ["gentamycin", "SIMPLE_CHEMICAL", 185, 195], ["L-glutamine", "SIMPLE_CHEMICAL", 210, 221], ["calf", "SPECIES", 55, 59], ["ileal tissue fragments", "PROBLEM", 9, 31], ["a 2-day old dairy calf", "TREATMENT", 37, 59], ["ice-cold Hanks balanced salt solution (HBSS)", "TREATMENT", 78, 122], ["1% strepto", "TREATMENT", 141, 151], ["penicillin", "TREATMENT", 152, 162], ["antimycotic solution", "TREATMENT", 163, 183], ["gentamycin", "TREATMENT", 185, 195], ["L-glutamine", "TREATMENT", 210, 221], ["ileal tissue", "ANATOMY", 9, 21], ["fragments", "OBSERVATION", 22, 31], ["calf", "ANATOMY", 55, 59]]], ["Intestinal lumen was flushed with HBSS-S and then both ends of the intestinal segment were ligated with silk suture.", [["Intestinal lumen", "ANATOMY", 0, 16], ["intestinal segment", "ANATOMY", 67, 85], ["Intestinal lumen", "MULTI-TISSUE_STRUCTURE", 0, 16], ["intestinal segment", "MULTI-TISSUE_STRUCTURE", 67, 85], ["Intestinal lumen", "TREATMENT", 0, 16], ["HBSS", "TREATMENT", 34, 38], ["S", "TREATMENT", 39, 40], ["silk suture", "TREATMENT", 104, 115], ["lumen", "ANATOMY_MODIFIER", 11, 16], ["flushed", "OBSERVATION", 21, 28], ["intestinal segment", "ANATOMY", 67, 85], ["ligated", "OBSERVATION", 91, 98], ["silk suture", "OBSERVATION", 104, 115]]], ["Intestinal loops were filled with phosphate-bufferedsaline (PBS) containing 1 mM dithiothreitol and kept for 5-10 min in shaking water bath (37\u00b0C) to remove the mucus.", [["Intestinal", "ANATOMY", 0, 10], ["mucus", "ANATOMY", 161, 166], ["phosphate-bufferedsaline", "CHEMICAL", 34, 58], ["dithiothreitol", "CHEMICAL", 81, 95], ["phosphate", "CHEMICAL", 34, 43], ["bufferedsaline", "CHEMICAL", 44, 58], ["dithiothreitol", "CHEMICAL", 81, 95], ["Intestinal loops", "MULTI-TISSUE_STRUCTURE", 0, 16], ["phosphate-bufferedsaline", "SIMPLE_CHEMICAL", 34, 58], ["PBS", "SIMPLE_CHEMICAL", 60, 63], ["dithiothreitol", "SIMPLE_CHEMICAL", 81, 95], ["mucus", "ORGANISM_SUBSTANCE", 161, 166], ["phosphate-bufferedsaline (PBS)", "TREATMENT", 34, 64], ["1 mM dithiothreitol", "TREATMENT", 76, 95], ["shaking water bath", "TREATMENT", 121, 139], ["loops", "ANATOMY", 11, 16], ["mucus", "ANATOMY", 161, 166]]], ["Subsequently, intestinal loops were filled with pre-warmed (37\u00b0C) HBSS-S containing collagenase (300 units/ml) and dispase (0.24 units/ml) enzymes to digest the intestinal tissue.", [["intestinal", "ANATOMY", 14, 24], ["intestinal tissue", "ANATOMY", 161, 178], ["intestinal loops", "MULTI-TISSUE_STRUCTURE", 14, 30], ["collagenase", "GENE_OR_GENE_PRODUCT", 84, 95], ["intestinal tissue", "TISSUE", 161, 178], ["collagenase", "PROTEIN", 84, 95], ["HBSS-S containing collagenase", "TREATMENT", 66, 95], ["dispase", "TREATMENT", 115, 122], ["enzymes", "TEST", 139, 146], ["intestinal loops", "ANATOMY", 14, 30], ["intestinal tissue", "ANATOMY", 161, 178]]], ["Collagenasedispase filled intestinal loops were kept in shaking water bath (37\u00b0C) for 15 min.", [["intestinal", "ANATOMY", 26, 36], ["Collagenasedispase", "SIMPLE_CHEMICAL", 0, 18], ["intestinal loops", "MULTI-TISSUE_STRUCTURE", 26, 42], ["Collagenasedispase filled intestinal loops", "TREATMENT", 0, 42], ["intestinal loops", "ANATOMY", 26, 42]]], ["Collagenase, type 2 and dispase-II were bought from Worthington Biochemical Corporation, NJ, USA (Cat # LS004176) and Roche Diagnostics, IN, respectively.", [["Collagenase", "GENE_OR_GENE_PRODUCT", 0, 11], ["type 2", "GENE_OR_GENE_PRODUCT", 13, 19], ["dispase-II", "GENE_OR_GENE_PRODUCT", 24, 34], ["Collagenase", "PROTEIN", 0, 11], ["Collagenase", "TREATMENT", 0, 11]]], ["The contents obtained through this step were discarded.", [["contents", "OBSERVATION", 4, 12]]], ["Then using the same collagenasedispase digestion medium, the digestion step was repeated for 45 min and the contents were discarded.", [["the same collagenasedispase digestion medium", "TREATMENT", 11, 55], ["the digestion step", "TEST", 57, 75]]], ["Then ileal loops were opened longitudinally, and predigested epithelium was scraped using a sterile scalpel blade.", [["ileal", "ANATOMY", 5, 10], ["epithelium", "ANATOMY", 61, 71], ["ileal loops", "MULTI-TISSUE_STRUCTURE", 5, 16], ["epithelium", "TISSUE", 61, 71], ["ileal loops", "TREATMENT", 5, 16], ["a sterile scalpel blade", "TREATMENT", 90, 113], ["ileal loops", "ANATOMY", 5, 16]]], ["The resulting contents were incubated with HBSS containing 2.4 units/ml dispase for 10 min.", [["HBSS", "SIMPLE_CHEMICAL", 43, 47], ["HBSS", "TREATMENT", 43, 47]]], ["Cells obtained after enzymatic digestion of scraped tissue were washed and resuspended in Dulbecco's Modified Eagle's Medium (DMEM).", [["Cells", "ANATOMY", 0, 5], ["tissue", "ANATOMY", 52, 58], ["Cells", "CELL", 0, 5], ["tissue", "TISSUE", 52, 58], ["Cells", "TEST", 0, 5], ["enzymatic digestion of scraped tissue", "PROBLEM", 21, 58], ["scraped tissue", "OBSERVATION_MODIFIER", 44, 58]]], ["The cell suspension was treated with DMEM containing 2% sorbitol (Sigma) and centrifuged to remove the fibroblasts (Rusu et al. 2005) .", [["cell", "ANATOMY", 4, 8], ["fibroblasts", "ANATOMY", 103, 114], ["sorbitol", "CHEMICAL", 56, 64], ["sorbitol", "CHEMICAL", 56, 64], ["cell", "CELL", 4, 8], ["sorbitol", "SIMPLE_CHEMICAL", 56, 64], ["Sigma", "SIMPLE_CHEMICAL", 66, 71], ["fibroblasts", "CELL", 103, 114], ["fibroblasts", "CELL_TYPE", 103, 114], ["The cell suspension", "TREATMENT", 0, 19], ["DMEM", "TREATMENT", 37, 41], ["2% sorbitol (Sigma)", "TREATMENT", 53, 72], ["cell suspension", "OBSERVATION", 4, 19], ["fibroblasts", "ANATOMY", 103, 114]]], ["The pellet of cells was resuspended in DMEM medium containing 10% fetal calf serum (FCS; Atlanta Biologicals, GA, USA).", [["cells", "ANATOMY", 14, 19], ["fetal calf serum", "ANATOMY", 66, 82], ["cells", "CELL", 14, 19], ["calf", "ORGANISM", 72, 76], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["calf", "SPECIES", 72, 76], ["The pellet of cells", "TREATMENT", 0, 19], ["pellet", "OBSERVATION_MODIFIER", 4, 10], ["fetal calf", "ANATOMY", 66, 76]]], ["Cells were then incubated at 37\u00b0C for 90 min in a cell culture Primaria flask (Becton-Dickinson, Franklin Lakes, NJ) to remove adherent fibroblast-like cells.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 50, 54], ["fibroblast-like cells", "ANATOMY", 136, 157], ["Cells", "CELL", 0, 5], ["cell", "CELL", 50, 54], ["fibroblast-like cells", "CELL", 136, 157], ["adherent fibroblast-like cells", "CELL_TYPE", 127, 157], ["a cell culture", "TEST", 48, 62], ["NJ)", "TREATMENT", 113, 116], ["adherent fibroblast-like cells", "PROBLEM", 127, 157], ["adherent fibroblast", "OBSERVATION", 127, 146], ["like cells", "OBSERVATION", 147, 157]]], ["The nonadherent cells were collected, then centrifuged for 5 min at 195 g and resuspended in DMEM-2 medium.", [["cells", "ANATOMY", 16, 21], ["nonadherent cells", "CELL", 4, 21], ["nonadherent cells", "CELL_TYPE", 4, 21], ["The nonadherent cells", "TREATMENT", 0, 21], ["nonadherent cells", "OBSERVATION", 4, 21]]], ["The DMEM-2 medium was composed of DMEM high glucose medium as base, HEPES buffer (10 mM), antibiotic-antimycotic solution (1%), gentamycin (50 lg/ml), L-glutamine (2 mM), hydrocortisone (100 mM), apo-transferrin (5 lg/ml), epidermal growth factor (25 ng/ml), bovine insulin (10 lg/ml), Triiodothyronine (20 ng/ml), acid linoleic/albumin (10 lg/ml), 1% non-essential amino acids and 2% FCS.", [["glucose", "CHEMICAL", 44, 51], ["gentamycin", "CHEMICAL", 128, 138], ["L-glutamine", "CHEMICAL", 151, 162], ["hydrocortisone", "CHEMICAL", 171, 185], ["apo-transferrin", "CHEMICAL", 196, 211], ["Triiodothyronine", "CHEMICAL", 286, 302], ["amino acids", "CHEMICAL", 366, 377], ["glucose", "CHEMICAL", 44, 51], ["HEPES", "CHEMICAL", 68, 73], ["gentamycin", "CHEMICAL", 128, 138], ["L-glutamine", "CHEMICAL", 151, 162], ["hydrocortisone", "CHEMICAL", 171, 185], ["apo-transferrin", "CHEMICAL", 196, 211], ["Triiodothyronine", "CHEMICAL", 286, 302], ["linoleic", "CHEMICAL", 320, 328], ["amino acids", "CHEMICAL", 366, 377], ["DMEM-2", "CELL", 4, 10], ["glucose", "SIMPLE_CHEMICAL", 44, 51], ["gentamycin", "SIMPLE_CHEMICAL", 128, 138], ["L-glutamine", "SIMPLE_CHEMICAL", 151, 162], ["hydrocortisone", "SIMPLE_CHEMICAL", 171, 185], ["apo-transferrin", "SIMPLE_CHEMICAL", 196, 211], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 223, 246], ["bovine", "ORGANISM", 259, 265], ["insulin", "GENE_OR_GENE_PRODUCT", 266, 273], ["Triiodothyronine", "SIMPLE_CHEMICAL", 286, 302], ["linoleic", "SIMPLE_CHEMICAL", 320, 328], ["albumin", "SIMPLE_CHEMICAL", 329, 336], ["amino acids", "AMINO_ACID", 366, 377], ["epidermal growth factor", "PROTEIN", 223, 246], ["bovine", "SPECIES", 259, 265], ["The DMEM", "TEST", 0, 8], ["HEPES buffer", "TREATMENT", 68, 80], ["antibiotic-antimycotic solution", "TREATMENT", 90, 121], ["gentamycin", "TREATMENT", 128, 138], ["L-glutamine", "TREATMENT", 151, 162], ["hydrocortisone", "TREATMENT", 171, 185], ["apo-transferrin", "TREATMENT", 196, 211], ["epidermal growth factor", "TREATMENT", 223, 246], ["bovine insulin", "TREATMENT", 259, 273], ["Triiodothyronine", "TREATMENT", 286, 302], ["acid linoleic/albumin", "TREATMENT", 315, 336], ["1% non-essential amino acids", "TREATMENT", 349, 377], ["2% FCS", "TREATMENT", 382, 388]]], ["The cell suspension was transferred to Primaria flasks and incubated at 37\u00b0C for the growth of ileal cells in primary cultures.", [["cell", "ANATOMY", 4, 8], ["ileal cells", "ANATOMY", 95, 106], ["primary cultures", "ANATOMY", 110, 126], ["cell", "CELL", 4, 8], ["C", "GENE_OR_GENE_PRODUCT", 75, 76], ["ileal cells", "CELL", 95, 106], ["ileal cells", "CELL_TYPE", 95, 106], ["primary cultures", "CELL_LINE", 110, 126], ["The cell suspension", "TREATMENT", 0, 19], ["ileal cells", "PROBLEM", 95, 106], ["primary cultures", "TEST", 110, 126], ["cell suspension", "OBSERVATION", 4, 19], ["ileal cells", "OBSERVATION", 95, 106]]], ["Sub-cultivation of a primary culture begins, by convention, a cell line (Schaeffer 1990 ).", [["cell line", "ANATOMY", 62, 71], ["cell line", "CELL", 62, 71], ["cell line", "CELL_LINE", 62, 71], ["a primary culture", "TEST", 19, 36], ["a cell line", "TREATMENT", 60, 71], ["cell line", "OBSERVATION", 62, 71]]], ["For a cell line, the first dozen or so subcultivations results in cultures that can be referred to as an early passage cell line.", [["cell line", "ANATOMY", 6, 15], ["cell line", "ANATOMY", 119, 128], ["cell line", "CELL", 6, 15], ["cell line", "CELL", 119, 128], ["cell line", "CELL_LINE", 6, 15], ["early passage cell line", "CELL_LINE", 105, 128], ["a cell line", "TREATMENT", 4, 15], ["cultures", "TEST", 66, 74], ["cell line", "OBSERVATION", 6, 15], ["passage cell line", "OBSERVATION", 111, 128]]], ["An early passage cell line can be subjected to immortalization treatments to lead to an immortal cell line.Establishment of primary and early passage bovine intestinal epithelial culturesInstead of using DMEM-2 medium, a mixed culture of bovine ileal epithelial and fibroblast-like cells at passage 4 was cultured at 37\u00b0C and 5% CO 2 in DMEM/F12 medium which is supplemented with 5% fetal bovine serum (FBS), 1% streptomycin-penicillin, 1% L-glutamine, 0.1% mouse epidermal growth factor (EGF) (Corning \u00d2 , Cat.", [["cell line", "ANATOMY", 17, 26], ["cell line", "ANATOMY", 97, 106], ["primary", "ANATOMY", 124, 131], ["intestinal epithelial cultures", "ANATOMY", 157, 187], ["ileal epithelial", "ANATOMY", 245, 261], ["fibroblast-like cells", "ANATOMY", 266, 287], ["fetal bovine serum", "ANATOMY", 383, 401], ["FBS", "ANATOMY", 403, 406], ["streptomycin", "CHEMICAL", 412, 424], ["penicillin", "CHEMICAL", 425, 435], ["L-glutamine", "CHEMICAL", 440, 451], ["CO 2", "CHEMICAL", 329, 333], ["streptomycin", "CHEMICAL", 412, 424], ["penicillin", "CHEMICAL", 425, 435], ["L-glutamine", "CHEMICAL", 440, 451], ["cell line", "CELL", 17, 26], ["cell line", "CELL", 97, 106], ["bovine", "ORGANISM", 150, 156], ["intestinal epithelial cultures", "CELL", 157, 187], ["DMEM-2", "CELL", 204, 210], ["bovine", "ORGANISM", 238, 244], ["ileal epithelial", "CELL", 245, 261], ["fibroblast-like cells", "CELL", 266, 287], ["passage 4", "CELL", 291, 300], ["bovine", "ORGANISM", 389, 395], ["serum", "ORGANISM_SUBSTANCE", 396, 401], ["FBS", "ORGANISM_SUBSTANCE", 403, 406], ["streptomycin-penicillin", "SIMPLE_CHEMICAL", 412, 435], ["L-glutamine", "SIMPLE_CHEMICAL", 440, 451], ["mouse", "ORGANISM", 458, 463], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 464, 487], ["EGF", "GENE_OR_GENE_PRODUCT", 489, 492], ["early passage cell line", "CELL_LINE", 3, 26], ["immortal cell line", "CELL_LINE", 88, 106], ["primary and early passage bovine intestinal epithelial cultures", "CELL_LINE", 124, 187], ["bovine ileal epithelial and fibroblast-like cells", "CELL_TYPE", 238, 287], ["EGF", "PROTEIN", 489, 492], ["bovine", "SPECIES", 150, 156], ["bovine", "SPECIES", 238, 244], ["bovine", "SPECIES", 389, 395], ["mouse", "SPECIES", 458, 463], ["bovine", "SPECIES", 150, 156], ["bovine", "SPECIES", 238, 244], ["bovine", "SPECIES", 389, 395], ["mouse", "SPECIES", 458, 463], ["An early passage cell line", "TREATMENT", 0, 26], ["immortalization treatments", "TREATMENT", 47, 73], ["an immortal cell line", "TREATMENT", 85, 106], ["early passage bovine intestinal epithelial cultures", "PROBLEM", 136, 187], ["DMEM", "TREATMENT", 204, 208], ["a mixed culture", "TEST", 219, 234], ["bovine ileal epithelial and fibroblast-like cells", "PROBLEM", 238, 287], ["DMEM/F12 medium", "TEST", 337, 352], ["5% fetal bovine serum (FBS", "TREATMENT", 380, 406], ["streptomycin", "TREATMENT", 412, 424], ["penicillin", "TREATMENT", 425, 435], ["1% L-glutamine", "TREATMENT", 437, 451], ["early", "OBSERVATION_MODIFIER", 3, 8], ["passage cell line", "OBSERVATION", 9, 26], ["immortal cell line", "OBSERVATION", 88, 106], ["intestinal epithelial", "ANATOMY", 157, 178], ["ileal epithelial", "ANATOMY", 245, 261]]], ["No. 4069007), and 0.1% each of insulin, human transferrin and selenous acid (ITS) (Corning \u00d2 , Cat.", [["selenous acid", "CHEMICAL", 62, 75], ["selenous acid", "CHEMICAL", 62, 75], ["insulin", "GENE_OR_GENE_PRODUCT", 31, 38], ["human", "ORGANISM", 40, 45], ["transferrin", "GENE_OR_GENE_PRODUCT", 46, 57], ["selenous acid", "SIMPLE_CHEMICAL", 62, 75], ["insulin", "PROTEIN", 31, 38], ["human transferrin", "PROTEIN", 40, 57], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["insulin", "TREATMENT", 31, 38], ["human transferrin", "TEST", 40, 57]]], ["This medium was designated as supplemented DMEM/F12 medium and had been previously used in our lab for the growth of porcine intestinal epithelial cells (Johnson et al. 2010; Koh et al. 2008) .", [["intestinal epithelial cells", "ANATOMY", 125, 152], ["porcine", "ORGANISM", 117, 124], ["intestinal epithelial cells", "CELL", 125, 152], ["porcine intestinal epithelial cells", "CELL_TYPE", 117, 152], ["porcine", "SPECIES", 117, 124], ["porcine", "SPECIES", 117, 124], ["supplemented DMEM/F12 medium", "TREATMENT", 30, 58], ["porcine intestinal epithelial cells", "PROBLEM", 117, 152], ["intestinal", "ANATOMY", 125, 135], ["epithelial cells", "OBSERVATION", 136, 152]]], ["Cells were cultured in supplemented DMEM/F12 medium for the next 4 passages (up to 8 passages) where they showed a larger percentage of epithelial-like cells.Establishment of primary and early passage bovine intestinal epithelial culturesFurther, a limiting dilution method was used to obtain pure bovine intestinal epithelial cell (BIEC) cultures from a mixed fibroblast and epithelial cell culture (Miyazawa et al. 2010) .", [["Cells", "ANATOMY", 0, 5], ["epithelial-like cells", "ANATOMY", 136, 157], ["primary", "ANATOMY", 175, 182], ["intestinal epithelial", "ANATOMY", 208, 229], ["intestinal epithelial cell", "ANATOMY", 305, 331], ["BIEC", "ANATOMY", 333, 337], ["cultures", "ANATOMY", 339, 347], ["fibroblast", "ANATOMY", 361, 371], ["epithelial cell culture", "ANATOMY", 376, 399], ["Cells", "CELL", 0, 5], ["epithelial-like cells", "CELL", 136, 157], ["bovine", "ORGANISM", 201, 207], ["intestinal epithelial", "TISSUE", 208, 229], ["bovine", "ORGANISM", 298, 304], ["intestinal epithelial cell", "CELL", 305, 331], ["BIEC", "CELL", 333, 337], ["fibroblast", "CELL", 361, 371], ["epithelial cell culture", "CELL", 376, 399], ["epithelial-like cells", "CELL_TYPE", 136, 157], ["pure bovine intestinal epithelial cell (BIEC) cultures", "CELL_LINE", 293, 347], ["mixed fibroblast and epithelial cell culture", "CELL_LINE", 355, 399], ["bovine", "SPECIES", 201, 207], ["bovine", "SPECIES", 298, 304], ["bovine", "SPECIES", 201, 207], ["bovine", "SPECIES", 298, 304], ["Cells", "TEST", 0, 5], ["epithelial-like cells", "PROBLEM", 136, 157], ["early passage bovine intestinal epithelial culturesFurther", "PROBLEM", 187, 245], ["a limiting dilution method", "TREATMENT", 247, 273], ["pure bovine intestinal epithelial cell", "PROBLEM", 293, 331], ["cultures", "TEST", 339, 347], ["a mixed fibroblast", "PROBLEM", 353, 371], ["epithelial cell culture", "TEST", 376, 399], ["larger", "OBSERVATION_MODIFIER", 115, 121], ["percentage", "OBSERVATION_MODIFIER", 122, 132], ["epithelial", "ANATOMY_MODIFIER", 136, 146], ["like cells", "OBSERVATION", 147, 157], ["primary", "OBSERVATION_MODIFIER", 175, 182], ["early", "OBSERVATION_MODIFIER", 187, 192], ["passage bovine intestinal epithelial culturesFurther", "OBSERVATION", 193, 245], ["intestinal", "ANATOMY", 305, 315], ["epithelial cell", "OBSERVATION", 316, 331], ["epithelial cell", "OBSERVATION", 376, 391]]], ["Briefly, the cells from passage 8 epithelial cell-enriched cultures were treated with 0.05% trypsin-EDTA for 5 min at 37\u00b0C to detach fibroblasts.", [["cells", "ANATOMY", 13, 18], ["epithelial cell", "ANATOMY", 34, 49], ["cultures", "ANATOMY", 59, 67], ["fibroblasts", "ANATOMY", 133, 144], ["trypsin-EDTA", "CHEMICAL", 92, 104], ["EDTA", "CHEMICAL", 100, 104], ["cells", "CELL", 13, 18], ["passage 8 epithelial cell", "CELL", 24, 49], ["cultures", "CELL", 59, 67], ["trypsin-EDTA", "SIMPLE_CHEMICAL", 92, 104], ["fibroblasts", "CELL", 133, 144], ["passage 8 epithelial cell-enriched cultures", "CELL_LINE", 24, 67], ["fibroblasts", "CELL_TYPE", 133, 144], ["the cells", "PROBLEM", 9, 18], ["enriched cultures", "TEST", 50, 67], ["0.05% trypsin-EDTA", "TREATMENT", 86, 104], ["epithelial cell", "OBSERVATION", 34, 49], ["fibroblasts", "OBSERVATION", 133, 144]]], ["These cells were discarded and remaining cells were again trypsinized to obtain epithelial-like cells.", [["cells", "ANATOMY", 6, 11], ["cells", "ANATOMY", 41, 46], ["epithelial-like cells", "ANATOMY", 80, 101], ["cells", "CELL", 6, 11], ["cells", "CELL", 41, 46], ["epithelial-like cells", "CELL", 80, 101], ["epithelial-like cells", "CELL_TYPE", 80, 101], ["These cells", "PROBLEM", 0, 11], ["remaining cells", "PROBLEM", 31, 46], ["epithelial-like cells", "PROBLEM", 80, 101], ["like cells", "OBSERVATION", 91, 101]]], ["The epithelial-like cells were transferred to a petri dish (100 mm 9 15 mm) at a low density of 1000 cells (passage 9) in supplemented DMEM/F12 medium.", [["epithelial-like cells", "ANATOMY", 4, 25], ["cells", "ANATOMY", 101, 106], ["epithelial-like cells", "CELL", 4, 25], ["cells", "CELL", 101, 106], ["epithelial-like cells", "CELL_TYPE", 4, 25], ["epithelial", "ANATOMY_MODIFIER", 4, 14], ["like cells", "OBSERVATION", 15, 25], ["low density", "OBSERVATION_MODIFIER", 81, 92]]], ["After 48 h, the selected clones were identified based on epithelial morphology and marked on the petri dish with a black marker.", [["clones", "ANATOMY", 25, 31], ["epithelial", "ANATOMY", 57, 67], ["clones", "CELL", 25, 31], ["epithelial", "TISSUE", 57, 67], ["the selected clones", "PROBLEM", 12, 31], ["a black marker", "TREATMENT", 113, 127], ["epithelial morphology", "OBSERVATION_MODIFIER", 57, 78], ["marked", "OBSERVATION_MODIFIER", 83, 89], ["petri dish", "OBSERVATION", 97, 107]]], ["The growth of these clones was followed.", [["clones", "CELL", 20, 26], ["these clones", "TEST", 14, 26], ["growth", "OBSERVATION_MODIFIER", 4, 10]]], ["After 4 days of incubation on the petri dish, cells were obtained from five selected clones.", [["cells", "ANATOMY", 46, 51], ["clones", "ANATOMY", 85, 91], ["cells", "CELL", 46, 51], ["clones", "CELL", 85, 91], ["incubation", "TREATMENT", 16, 26], ["the petri dish, cells", "TREATMENT", 30, 51]]], ["Sterilized small hollow plastic wells coated with vaseline at the bottom were used for separating the clones on the petri dish.", [["vaseline", "CHEMICAL", 50, 58], ["Sterilized small hollow plastic wells coated", "TREATMENT", 0, 44], ["vaseline at the bottom", "TREATMENT", 50, 72], ["small", "OBSERVATION_MODIFIER", 11, 16], ["hollow", "OBSERVATION_MODIFIER", 17, 23], ["plastic", "OBSERVATION_MODIFIER", 24, 31], ["wells coated", "OBSERVATION", 32, 44], ["petri dish", "OBSERVATION", 116, 126]]], ["Selected five clones were obtained by trypsinization and transferred to individual wells on a 24-well plate (passage 10) and further propagated.", [["clones", "ANATOMY", 14, 20], ["clones", "CELL", 14, 20], ["a 24-well plate (passage", "TREATMENT", 92, 116]]], ["After 96 h, cells from well number 4 were trypsinized and further propagated in 6-well plate (passage 11).", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17]]], ["These cells were further subcloned in a 96-well plate by serial dilution method (Miyazawa et al. 2010) .", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["serial dilution method", "TREATMENT", 57, 79]]], ["A clone growing very well in the 96-well plate was further amplified in a 24-well plate, then 6-well plate, and finally in a T-25 flask.", [["clone", "ANATOMY", 2, 7], ["clone", "CELL", 2, 7], ["A clone", "TEST", 0, 7], ["clone", "OBSERVATION_MODIFIER", 2, 7], ["growing", "OBSERVATION_MODIFIER", 8, 15], ["very", "OBSERVATION_MODIFIER", 16, 20]]], ["These cells were kept for further studies and named as bovine intestinal epithelial cells obtained from colony 4 (BIEC-c4).", [["cells", "ANATOMY", 6, 11], ["intestinal epithelial cells", "ANATOMY", 62, 89], ["colony 4", "ANATOMY", 104, 112], ["cells", "CELL", 6, 11], ["bovine", "ORGANISM", 55, 61], ["intestinal epithelial cells", "CELL", 62, 89], ["colony 4", "CELL", 104, 112], ["BIEC-c4", "CELL", 114, 121], ["bovine intestinal epithelial cells", "CELL_TYPE", 55, 89], ["bovine", "SPECIES", 55, 61], ["bovine", "SPECIES", 55, 61], ["further studies", "TEST", 26, 41], ["bovine intestinal epithelial cells", "TEST", 55, 89], ["colony", "TEST", 104, 110], ["BIEC", "TEST", 114, 118], ["intestinal", "ANATOMY", 62, 72], ["epithelial cells", "OBSERVATION", 73, 89]]], ["The BIEC-c4 cells were then transferred and maintained in the T-75 flask by passaging using the same culture conditions and supplemented DMEM/F12 medium.", [["BIEC-c4 cells", "ANATOMY", 4, 17], ["BIEC-c4 cells", "CELL", 4, 17], ["T-75 flask", "CELL", 62, 72], ["BIEC-c4 cells", "CELL_LINE", 4, 17], ["the same culture conditions", "TEST", 92, 119], ["c4 cells", "OBSERVATION", 9, 17]]], ["Phase contrast photographs of cells at various stages of the establishment of epithelial cultures were taken at 10 9 or 20 9 magnification using an Olympus IX70 inverted microscope.Establishment of primary and early passage bovine intestinal epithelial culturesImmunocytochemical staining of early passage and immortalized BIEC-c4 cells for cell markers Immunocytochemical (ICC) staining of primary and immortalized BIEC cells was performed using earlier described protocols Thomas et al. 2018) .", [["cells", "ANATOMY", 30, 35], ["epithelial cultures", "ANATOMY", 78, 97], ["primary", "ANATOMY", 198, 205], ["intestinal epithelial cultures", "ANATOMY", 231, 261], ["BIEC-c4 cells", "ANATOMY", 323, 336], ["cell", "ANATOMY", 341, 345], ["primary", "ANATOMY", 391, 398], ["BIEC cells", "ANATOMY", 416, 426], ["cells", "CELL", 30, 35], ["epithelial cultures", "CELL", 78, 97], ["bovine", "ORGANISM", 224, 230], ["intestinal epithelial cultures", "CELL", 231, 261], ["BIEC-c4 cells", "CELL", 323, 336], ["cell", "CELL", 341, 345], ["BIEC cells", "CELL", 416, 426], ["epithelial cultures", "CELL_LINE", 78, 97], ["primary and early passage bovine intestinal epithelial cultures", "CELL_LINE", 198, 261], ["immortalized BIEC", "CELL_LINE", 310, 327], ["c4 cells", "CELL_LINE", 328, 336], ["BIEC cells", "CELL_LINE", 416, 426], ["bovine", "SPECIES", 224, 230], ["bovine", "SPECIES", 224, 230], ["Phase contrast photographs", "TEST", 0, 26], ["epithelial cultures", "TEST", 78, 97], ["an Olympus IX70 inverted microscope", "TREATMENT", 145, 180], ["early passage bovine intestinal epithelial cultures", "PROBLEM", 210, 261], ["Immunocytochemical staining", "TEST", 261, 288], ["early passage", "PROBLEM", 292, 305], ["immortalized BIEC-c4 cells", "PROBLEM", 310, 336], ["cell markers", "TEST", 341, 353], ["primary and immortalized BIEC cells", "PROBLEM", 391, 426], ["epithelial", "ANATOMY", 78, 88], ["intestinal epithelial", "ANATOMY", 231, 252], ["early passage", "OBSERVATION_MODIFIER", 292, 305], ["c4 cells", "OBSERVATION", 328, 336]]], ["Briefly, primary and immortalized BIEC-c4 cells were cultured in a T-75 flask in the supplemented DMEM/F12 medium.", [["primary", "ANATOMY", 9, 16], ["BIEC-c4 cells", "ANATOMY", 34, 47], ["BIEC-c4 cells", "CELL", 34, 47], ["primary and immortalized BIEC-c4 cells", "CELL_LINE", 9, 47], ["c4 cells", "PROBLEM", 39, 47], ["c4 cells", "OBSERVATION", 39, 47]]], ["After 48 h, cells were trypsinized and a cell suspension at a concentration of 1 9 10 6 cells/ml was prepared in DMEM/F12 medium.", [["cells", "ANATOMY", 12, 17], ["cell", "ANATOMY", 41, 45], ["cells", "ANATOMY", 88, 93], ["cells", "CELL", 12, 17], ["cell", "CELL", 41, 45], ["cells", "CELL", 88, 93], ["a cell suspension", "TREATMENT", 39, 56]]], ["Then, 100 ll of the suspension was used to prepare each cytospin using a cytofuge (Cytospin 3; Thermo Shandon Inc., Cheshire, UK) at 800 rpm for 5 min.", [["the suspension", "TREATMENT", 16, 30], ["a cytofuge (Cytospin", "TREATMENT", 71, 91]]], ["The cytospins were air dried for 1 h and fixed with absolute acetone for 7 min.", [["acetone", "CHEMICAL", 61, 68], ["acetone", "CHEMICAL", 61, 68], ["cytospins", "SIMPLE_CHEMICAL", 4, 13], ["acetone", "SIMPLE_CHEMICAL", 61, 68], ["absolute acetone", "TREATMENT", 52, 68], ["air dried", "OBSERVATION", 19, 28]]], ["The slides were washed three times with 1 9 phosphate-buffered saline (PBS) for 5 min and incubated at room temperature with 1 9 PBS containing 0.1% sodium azide and 0.3% hydrogen peroxide (H 2 O 2 ) to block endogenous peroxidase activity.", [["9 phosphate", "CHEMICAL", 42, 53], ["sodium azide", "CHEMICAL", 149, 161], ["hydrogen peroxide", "CHEMICAL", 171, 188], ["H 2 O 2", "CHEMICAL", 190, 197], ["phosphate", "CHEMICAL", 44, 53], ["sodium azide", "CHEMICAL", 149, 161], ["hydrogen peroxide", "CHEMICAL", 171, 188], ["H 2 O 2", "CHEMICAL", 190, 197], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 44, 69], ["sodium azide", "SIMPLE_CHEMICAL", 149, 161], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 171, 188], ["H 2 O 2", "SIMPLE_CHEMICAL", 190, 197], ["peroxidase", "GENE_OR_GENE_PRODUCT", 220, 230], ["endogenous peroxidase", "PROTEIN", 209, 230], ["1 9 phosphate-buffered saline (PBS", "TREATMENT", 40, 74], ["0.1% sodium azide", "TREATMENT", 144, 161], ["0.3% hydrogen peroxide", "TREATMENT", 166, 188], ["block endogenous peroxidase activity", "PROBLEM", 203, 239], ["peroxidase activity", "OBSERVATION", 220, 239]]], ["The cells were blocked for non-specific protein binding using 1% goat serum in PBS.", [["cells", "ANATOMY", 4, 9], ["serum", "ANATOMY", 70, 75], ["cells", "CELL", 4, 9], ["goat", "ORGANISM", 65, 69], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["goat", "SPECIES", 65, 69], ["goat", "SPECIES", 65, 69], ["non-specific protein binding", "PROBLEM", 27, 55], ["1% goat serum in PBS", "TREATMENT", 62, 82]]], ["Each slide was washed once with 1 9 PBS and then incubated in a humid chamber for 1 h with 100 ll of primary antibodies diluted at a final concentration of 1 lg/ml.", [["primary antibodies", "PROTEIN", 101, 119], ["1 9 PBS", "TREATMENT", 32, 39], ["a humid chamber", "TREATMENT", 62, 77], ["primary antibodies", "TREATMENT", 101, 119]]], ["The presence of cytokeratin, vimentin, alpha-smooth muscle actin, and desmin proteins was detected by ICC staining using anticytokeratin monoclonal antibody (mAb) C6909 (clone K8.13, IgG2a isotype), anti-vimentin mAb V5255 (IgM isotype), anti-alpha smooth muscle actin mAb A2547 (IgG2a) and anti-desmin mAb D1033 (IgG1) respectively Sun et al. 2012; Thomas et al. 2018) .", [["cytokeratin", "GENE_OR_GENE_PRODUCT", 16, 27], ["vimentin", "GENE_OR_GENE_PRODUCT", 29, 37], ["alpha-smooth muscle actin", "GENE_OR_GENE_PRODUCT", 39, 64], ["desmin", "GENE_OR_GENE_PRODUCT", 70, 76], ["anticytokeratin", "GENE_OR_GENE_PRODUCT", 121, 136], ["IgG2a", "GENE_OR_GENE_PRODUCT", 183, 188], ["anti-vimentin mAb V5255", "GENE_OR_GENE_PRODUCT", 199, 222], ["IgM isotype", "GENE_OR_GENE_PRODUCT", 224, 235], ["anti-alpha smooth muscle actin mAb A2547", "GENE_OR_GENE_PRODUCT", 238, 278], ["IgG2a", "GENE_OR_GENE_PRODUCT", 280, 285], ["anti-desmin mAb D1033", "GENE_OR_GENE_PRODUCT", 291, 312], ["IgG1", "GENE_OR_GENE_PRODUCT", 314, 318], ["cytokeratin", "PROTEIN", 16, 27], ["vimentin", "PROTEIN", 29, 37], ["alpha-smooth muscle actin", "PROTEIN", 39, 64], ["desmin proteins", "PROTEIN", 70, 85], ["anticytokeratin monoclonal antibody (mAb) C6909", "PROTEIN", 121, 168], ["clone K8.13", "PROTEIN", 170, 181], ["IgG2a isotype", "PROTEIN", 183, 196], ["anti-vimentin mAb V5255", "PROTEIN", 199, 222], ["IgM isotype", "PROTEIN", 224, 235], ["anti-alpha smooth muscle actin mAb A2547", "PROTEIN", 238, 278], ["IgG2a", "PROTEIN", 280, 285], ["anti-desmin mAb D1033", "PROTEIN", 291, 312], ["IgG1", "PROTEIN", 314, 318], ["cytokeratin", "TEST", 16, 27], ["vimentin", "TEST", 29, 37], ["smooth muscle actin", "PROBLEM", 45, 64], ["desmin proteins", "TEST", 70, 85], ["ICC staining", "TEST", 102, 114], ["anticytokeratin monoclonal antibody", "TEST", 121, 156], ["mAb", "TEST", 158, 161], ["clone K8.13", "TEST", 170, 181], ["IgG2a isotype", "TEST", 183, 196], ["anti-vimentin mAb", "TEST", 199, 216], ["IgM isotype", "TEST", 224, 235], ["anti-alpha smooth muscle actin mAb", "TEST", 238, 272], ["IgG2a", "TEST", 280, 285], ["anti-desmin mAb", "TEST", 291, 306], ["cytokeratin", "OBSERVATION", 16, 27], ["smooth muscle", "ANATOMY", 45, 58]]], ["As isotype-matched controls, mAbs M9269 (IgG1 isotype), M9144 (IgG2a isotype) and M5170 (IgM isotype) were used.", [["mAbs M9269", "GENE_OR_GENE_PRODUCT", 29, 39], ["IgG1", "GENE_OR_GENE_PRODUCT", 41, 45], ["M9144", "GENE_OR_GENE_PRODUCT", 56, 61], ["isotype-matched controls", "PROTEIN", 3, 27], ["mAbs M9269", "PROTEIN", 29, 39], ["IgG1 isotype", "PROTEIN", 41, 53], ["M9144", "PROTEIN", 56, 61], ["IgG2a isotype", "PROTEIN", 63, 76], ["M5170", "PROTEIN", 82, 87], ["IgM isotype", "PROTEIN", 89, 100], ["mAbs", "TEST", 29, 33], ["IgG1 isotype", "TEST", 41, 53], ["IgG2a isotype", "TEST", 63, 76], ["IgM isotype", "TEST", 89, 100]]], ["All of these primary antibodies were purchased from Sigma-Aldrich, St. Louis, MO, USA.", [["Sigma-Aldrich", "ORGANISM", 52, 65], ["St. Louis", "ORGANISM", 67, 76], ["MO", "ORGANISM", 78, 80], ["primary antibodies", "PROTEIN", 13, 31]]], ["The mAb C6909 was specific for polypeptides of cytokeratins 1, 5, 6, 7, 8, 10, 11, and 18.", [["cytokeratins 1", "GENE_OR_GENE_PRODUCT", 47, 61], ["5", "GENE_OR_GENE_PRODUCT", 63, 64], ["6", "GENE_OR_GENE_PRODUCT", 66, 67], ["7", "GENE_OR_GENE_PRODUCT", 69, 70], ["8", "GENE_OR_GENE_PRODUCT", 72, 73], ["10", "GENE_OR_GENE_PRODUCT", 75, 77], ["mAb C6909", "PROTEIN", 4, 13], ["cytokeratins 1, 5, 6, 7, 8, 10, 11, and 18", "PROTEIN", 47, 89], ["The mAb", "TEST", 0, 7], ["cytokeratins", "TEST", 47, 59]]], ["As a negative control, cells were incubated with PBS containing 1% goat serum.", [["cells", "ANATOMY", 23, 28], ["serum", "ANATOMY", 72, 77], ["cells", "CELL", 23, 28], ["goat", "ORGANISM", 67, 71], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["goat", "SPECIES", 67, 71], ["goat", "SPECIES", 67, 71], ["PBS", "TEST", 49, 52]]], ["Further, all slides were washed three times with 1 9 PBS, followed by incubation for 30 min with 100 ll of isotype-specific, biotinylated goat anti-mouse IgG1 (Caltag Laboratories, M32115), IgG2a (Caltag Laboratories, M32215) or IgM (Caltag Laboratories, M31515) secondary antibody at 1:2000 dilution.", [["goat", "ORGANISM", 138, 142], ["IgG1", "GENE_OR_GENE_PRODUCT", 154, 158], ["biotinylated goat anti-mouse IgG1", "PROTEIN", 125, 158], ["Caltag Laboratories", "PROTEIN", 160, 179], ["M32115", "PROTEIN", 181, 187], ["IgG2a", "PROTEIN", 190, 195], ["Caltag Laboratories", "PROTEIN", 197, 216], ["M32215", "PROTEIN", 218, 224], ["IgM", "PROTEIN", 229, 232], ["Caltag Laboratories, M31515) secondary antibody", "PROTEIN", 234, 281], ["goat", "SPECIES", 138, 142], ["anti-mouse", "SPECIES", 143, 153], ["goat", "SPECIES", 138, 142], ["1 9 PBS", "TREATMENT", 49, 56], ["biotinylated goat anti-mouse IgG1", "TEST", 125, 158], ["Caltag Laboratories", "TEST", 160, 179], ["IgG2a", "TEST", 190, 195], ["Caltag Laboratories", "TEST", 197, 216], ["IgM", "TEST", 229, 232], ["Caltag Laboratories", "TEST", 234, 253], ["secondary antibody", "TEST", 263, 281]]], ["The cytospins were washed three times with 1 9 PBS and treated with ready-to-use (RTU) HRP-streptavidin solution from Vector Elite vectastain kit (Vector Laboratories, Burlingame, CA, USA) for 30 min.", [["cytospins", "ANATOMY", 4, 13], ["HRP-streptavidin", "SIMPLE_CHEMICAL", 87, 103], ["The cytospins", "TREATMENT", 0, 13], ["1 9 PBS", "TREATMENT", 43, 50], ["HRP-streptavidin solution", "TREATMENT", 87, 112]]], ["After three washes with 1 9 PBS, each slide was incubated for 10 min with 100 ll of RTU diaminobenzene (DAB) substrate (Vector Laboratories, Burlingame, CA, USA) and counterstained for 2 min with hematoxylin (Vector Laboratories, Burlingame, CA, USA).", [["RTU diaminobenzene", "CHEMICAL", 84, 102], ["DAB", "CHEMICAL", 104, 107], ["diaminobenzene", "CHEMICAL", 88, 102], ["DAB", "CHEMICAL", 104, 107], ["hematoxylin", "CHEMICAL", 196, 207], ["RTU", "SIMPLE_CHEMICAL", 84, 87], ["diaminobenzene", "SIMPLE_CHEMICAL", 88, 102], ["DAB", "SIMPLE_CHEMICAL", 104, 107], ["hematoxylin", "SIMPLE_CHEMICAL", 196, 207], ["1 9 PBS", "TREATMENT", 24, 31], ["hematoxylin (Vector Laboratories", "TEST", 196, 228]]], ["Slides were then washed in running tap water, air dried overnight, and mounted with a coverslip and cytoseal 60 mounting medium (Thermo Scientific, Waltham, MA, USA).", [["running tap water", "TREATMENT", 27, 44], ["a coverslip and cytoseal", "TREATMENT", 84, 108]]], ["Images were taken at 20 9 magnification using an Olympus AX70 microscope.Polarization of BIEC-c4 cellsThe polarization of primary BIEC-c4 cells was performed using the methods described earlier (Johnson et al. 2010) .", [["BIEC-c4 cells", "ANATOMY", 89, 102], ["primary BIEC-c4 cells", "ANATOMY", 122, 143], ["BIEC-c4 cells", "CELL", 89, 102], ["BIEC-c4 cells", "CELL", 130, 143], ["Olympus AX70 microscope", "DNA", 49, 72], ["BIEC-c4 cells", "CELL_LINE", 89, 102], ["primary BIEC-c4 cells", "CELL_LINE", 122, 143], ["Images", "TEST", 0, 6], ["an Olympus AX70 microscope", "TEST", 46, 72], ["Polarization of BIEC-c4 cells", "TREATMENT", 73, 102], ["primary BIEC-c4 cells", "PROBLEM", 122, 143], ["c4 cells", "OBSERVATION", 94, 102], ["polarization", "OBSERVATION_MODIFIER", 106, 118]]], ["To each of the three wells in a 6-well plate, 2 ml of DMEM/F12 media was added.", [["a 6-well plate", "TREATMENT", 30, 44], ["DMEM/F12 media", "TREATMENT", 54, 68]]], ["Then transwell-inserts (0.4 lm pore size, 4 9 10 6 pores/ cm 2 , polyester membrane) (Costar \u00d2 Transwell \u00d2 ) were placed over each of the three wells.", [["pore", "ANATOMY", 31, 35], ["membrane", "ANATOMY", 75, 83], ["transwell-inserts (0.4 lm pore size", "TREATMENT", 5, 40], ["pores/ cm 2 , polyester membrane", "TREATMENT", 51, 83], ["Costar \u00d2 Transwell \u00d2 )", "TREATMENT", 86, 108]]], ["Briefly, 5 9 10 5 cells of BIEC-c4 (passage # 24) in 2 ml DMEM/F12 medium were transferred to a transwell insert in the first well.", [["cells", "ANATOMY", 18, 23], ["BIEC-c4", "ANATOMY", 27, 34], ["cells", "CELL", 18, 23], ["BIEC-c4", "CELL", 27, 34], ["BIEC", "TEST", 27, 31], ["a transwell insert", "TREATMENT", 94, 112], ["c4", "ANATOMY", 32, 34]]], ["The insert in the second well contained media alone without cells (negative control) while the positive control in third well had insert seeded with the porcine jejunal epithelial cell (IPEC-J2, passage # 57) (Geens and Niewold 2011; Johnson et al. 2010 ).", [["cells", "ANATOMY", 60, 65], ["jejunal epithelial cell", "ANATOMY", 161, 184], ["cells", "CELL", 60, 65], ["porcine", "ORGANISM", 153, 160], ["jejunal epithelial cell", "CELL", 161, 184], ["IPEC-J2", "CELL", 186, 193], ["porcine jejunal epithelial cell", "CELL_TYPE", 153, 184], ["porcine", "SPECIES", 153, 160], ["The insert", "TREATMENT", 0, 10], ["the porcine jejunal epithelial cell", "TREATMENT", 149, 184], ["insert", "OBSERVATION_MODIFIER", 4, 10], ["jejunal", "ANATOMY", 161, 168], ["epithelial cell", "OBSERVATION", 169, 184]]], ["The 6-well plate was incubated at 37\u00b0C and 5% CO 2 .", [["CO 2", "CHEMICAL", 46, 50]]], ["Every 24 h, transepithelial electrical resistance (TEER) was measured using a standard procedure (Miyazawa et al. 2010) .", [["transepithelial", "ANATOMY", 12, 27], ["transepithelial electrical resistance", "TEST", 12, 49], ["a standard procedure", "TREATMENT", 76, 96], ["electrical resistance", "OBSERVATION", 28, 49]]], ["The electrode was connected to EVOM voltmeter (World Precision Instruments) and then set to measure resistance in ohm (X).", [["The electrode", "TREATMENT", 0, 13], ["electrode", "OBSERVATION_MODIFIER", 4, 13]]], ["Every 48 h, media in both the wells containing cells was replaced without disturbing the cells.", [["cells", "ANATOMY", 47, 52], ["cells", "ANATOMY", 89, 94], ["cells", "CELL", 47, 52], ["cells", "CELL", 89, 94], ["media in both the wells containing cells", "TREATMENT", 12, 52], ["disturbing the cells", "PROBLEM", 74, 94]]], ["TEER measurements were taken for all three wells for a period of 7 days.Polarization of BIEC-c4 cellsGeneration of SV40, hTERT and HPV E6/E7 immortalized BIECs Approximately 5 9 10 5 cells of the BIEC-c4 clone were seeded into a 6-well tissue culture plate.", [["BIEC-c4 cells", "ANATOMY", 88, 101], ["BIECs", "ANATOMY", 154, 159], ["cells", "ANATOMY", 183, 188], ["BIEC-c4 clone", "ANATOMY", 196, 209], ["tissue", "ANATOMY", 236, 242], ["BIEC-c4 cells", "CELL", 88, 101], ["SV40", "ORGANISM", 115, 119], ["hTERT", "GENE_OR_GENE_PRODUCT", 121, 126], ["HPV E6", "ORGANISM", 131, 137], ["E7", "ORGANISM", 138, 140], ["cells", "CELL", 183, 188], ["BIEC-c4 clone", "CELL", 196, 209], ["tissue", "TISSUE", 236, 242], ["BIEC-c4 cells", "CELL_LINE", 88, 101], ["hTERT", "PROTEIN", 121, 126], ["HPV E6/E7 immortalized BIECs", "CELL_LINE", 131, 159], ["BIEC-c4 clone", "CELL_LINE", 196, 209], ["TEER measurements", "TEST", 0, 17], ["BIEC", "TEST", 88, 92], ["SV40", "TEST", 115, 119], ["hTERT", "TEST", 121, 126], ["HPV E6/E7 immortalized BIECs", "TREATMENT", 131, 159], ["the BIEC-c4 clone", "TREATMENT", 192, 209], ["c4 cells", "OBSERVATION", 93, 101], ["c4 clone", "OBSERVATION", 201, 209]]], ["After 18 h incubation at 37\u00b0C, cells in two wells were washed with sterile 1 9 PBS and transfected with either the pSV3-neo (ATCC \u00d2 37150) plasmid vector with SV40 gene or the pGRN145 plasmid vector with hTERT gene (ATCC \u00d2 MBA-141) using Lipofectamine \u00d2 2000 reagent according to the manufacturer's protocol.", [["cells", "ANATOMY", 31, 36], ["MBA-141", "CHEMICAL", 223, 230], ["cells", "CELL", 31, 36], ["SV40", "ORGANISM", 159, 163], ["hTERT", "GENE_OR_GENE_PRODUCT", 204, 209], ["pSV3-neo (ATCC \u00d2 37150) plasmid vector", "DNA", 115, 153], ["SV40 gene", "DNA", 159, 168], ["pGRN145 plasmid vector", "DNA", 176, 198], ["hTERT gene", "DNA", 204, 214], ["ATCC \u00d2 37150", "SPECIES", 125, 137], ["ATCC \u00d2 MBA-141", "SPECIES", 216, 230], ["cells in two wells", "TREATMENT", 31, 49], ["sterile 1 9 PBS", "TREATMENT", 67, 82], ["the pSV3", "TREATMENT", 111, 119], ["neo", "TREATMENT", 120, 123], ["plasmid vector", "TREATMENT", 139, 153], ["SV40 gene", "TREATMENT", 159, 168], ["the pGRN145 plasmid vector", "TREATMENT", 172, 198], ["MBA", "TEST", 223, 226], ["Lipofectamine", "TREATMENT", 238, 251], ["the manufacturer's protocol", "TREATMENT", 280, 307]]], ["Cells were then incubated with serum-free OPTI-MEM \u00d2 media for 6 h at 37\u00b0C after which selection antibiotics were added to assess successful transfection and immortalization of cells.", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 31, 36], ["cells", "ANATOMY", 177, 182], ["OPTI", "CHEMICAL", 42, 46], ["Cells", "CELL", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["OPTI", "SIMPLE_CHEMICAL", 42, 46], ["C", "GENE_OR_GENE_PRODUCT", 73, 74], ["cells", "CELL", 177, 182], ["Cells", "TEST", 0, 5], ["serum", "TEST", 31, 36], ["selection antibiotics", "TREATMENT", 87, 108], ["successful transfection", "TREATMENT", 130, 153], ["immortalization of cells", "PROBLEM", 158, 182]]], ["Transfected cells were selected using either G418 antibiotic (Thermo Fisher, Waltham, MA, USA, Cat.", [["cells", "ANATOMY", 12, 17], ["G418", "CHEMICAL", 45, 49], ["G418", "CHEMICAL", 45, 49], ["cells", "CELL", 12, 17], ["Transfected cells", "TREATMENT", 0, 17]]], ["No. 10131-035; 1000 lg/ml concentration) for 7 days (SV40 immortalization, plate 1) or Hygromycin B (EMD Millipore, Burlington, MA, USA, Cat.", [["10131-035", "CHEMICAL", 4, 13], ["Hygromycin B", "CHEMICAL", 87, 99], ["Hygromycin B", "CHEMICAL", 87, 99], ["SV40", "ORGANISM", 53, 57], ["Hygromycin B", "GENE_OR_GENE_PRODUCT", 87, 99], ["SV40 immortalization, plate", "TREATMENT", 53, 80], ["Hygromycin B (EMD Millipore", "TREATMENT", 87, 114]]], ["No. 400052; 100 lg/ml concentration) for 14 days (hTERT immortalization, plate 2).", [["hTERT", "GENE_OR_GENE_PRODUCT", 50, 55], ["hTERT", "PROTEIN", 50, 55]]], ["The BIEC-c4 cells in one well were grown in the absence of selection antibiotics (positive control for cell growth).", [["BIEC-c4 cells", "ANATOMY", 4, 17], ["cell", "ANATOMY", 103, 107], ["BIEC-c4 cells", "CELL", 4, 17], ["cell", "CELL", 103, 107], ["BIEC-c4 cells", "CELL_LINE", 4, 17], ["The BIEC-c4 cells", "TREATMENT", 0, 17], ["selection antibiotics", "TREATMENT", 59, 80], ["cell growth", "PROBLEM", 103, 114], ["c4 cells", "OBSERVATION", 9, 17]]], ["The untransfected BIEC-c4 cells in remaining well were treated with selection antibiotics to observe cell death.", [["BIEC-c4 cells", "ANATOMY", 18, 31], ["cell", "ANATOMY", 101, 105], ["death", "DISEASE", 106, 111], ["BIEC-c4 cells", "CELL", 18, 31], ["cell", "CELL", 101, 105], ["untransfected BIEC-c4 cells", "CELL_LINE", 4, 31], ["The untransfected BIEC-c4 cells", "TREATMENT", 0, 31], ["selection antibiotics", "TREATMENT", 68, 89], ["cell death", "PROBLEM", 101, 111], ["c4 cells", "OBSERVATION", 23, 31]]], ["Selected colonies generated from transfected cells were propagated separately and culture stocks for each of SV40-BIEC and hTERT-BIEC were prepared.", [["colonies", "ANATOMY", 9, 17], ["cells", "ANATOMY", 45, 50], ["cells", "CELL", 45, 50], ["SV40", "ORGANISM", 109, 113], ["BIEC", "CELL", 114, 118], ["hTERT", "GENE_OR_GENE_PRODUCT", 123, 128], ["transfected cells", "CELL_LINE", 33, 50], ["SV40", "DNA", 109, 113], ["BIEC", "DNA", 114, 118], ["hTERT", "DNA", 123, 128], ["BIEC", "DNA", 129, 133], ["Selected colonies", "PROBLEM", 0, 17], ["transfected cells", "PROBLEM", 33, 50], ["culture stocks", "TEST", 82, 96], ["SV40", "TEST", 109, 113], ["transfected cells", "OBSERVATION", 33, 50]]], ["The BIEC-c4 cells at passages 33 and 27 were used for transfection with SV40 and hTERT genes respectively.", [["BIEC-c4 cells", "ANATOMY", 4, 17], ["BIEC-c4 cells", "CELL", 4, 17], ["SV40", "ORGANISM", 72, 76], ["hTERT", "GENE_OR_GENE_PRODUCT", 81, 86], ["BIEC-c4 cells", "CELL_LINE", 4, 17], ["SV40 and hTERT genes", "DNA", 72, 92], ["The BIEC-c4 cells", "TEST", 0, 17], ["passages", "TEST", 21, 29], ["transfection with SV40 and hTERT genes", "TREATMENT", 54, 92], ["c4 cells", "OBSERVATION", 9, 17]]], ["PA317 LXSN 16E6E7 cells (ATCC \u00d2 CRL-2203) were cultured in DMEM-10 medium and the supernatant was collected after 5-7 days growth of these cells.", [["PA317 LXSN 16E6E7 cells", "ANATOMY", 0, 23], ["ATCC \u00d2 CRL-2203", "ANATOMY", 25, 40], ["supernatant", "ANATOMY", 82, 93], ["cells", "ANATOMY", 139, 144], ["PA317 LXSN 16E6E7 cells", "CELL", 0, 23], ["ATCC \u00d2 CRL-2203", "CELL", 25, 40], ["DMEM-10", "CELL", 59, 66], ["cells", "CELL", 139, 144], ["PA317 LXSN 16E6E7 cells", "CELL_LINE", 0, 23], ["ATCC \u00d2 CRL-2203", "CELL_LINE", 25, 40], ["ATCC \u00d2 CRL-2203", "SPECIES", 25, 40], ["cells", "TEST", 18, 23], ["ATCC", "TEST", 25, 29], ["CRL", "TEST", 32, 35], ["DMEM", "TEST", 59, 63], ["these cells", "PROBLEM", 133, 144]]], ["Pooled supernatant derived from culturing PA317 LXSN 16E6E7 cells was used for inducing HPV E6/E7 immortalization of BIEC-c4 cells.", [["supernatant", "ANATOMY", 7, 18], ["PA317 LXSN 16E6E7 cells", "ANATOMY", 42, 65], ["BIEC-c4 cells", "ANATOMY", 117, 130], ["PA317 LXSN 16E6E7 cells", "CELL", 42, 65], ["HPV", "ORGANISM", 88, 91], ["E6", "ORGANISM", 92, 94], ["E7", "ORGANISM", 95, 97], ["BIEC-c4 cells", "CELL", 117, 130], ["PA317 LXSN 16E6E7 cells", "CELL_LINE", 42, 65], ["E7", "PROTEIN", 95, 97], ["BIEC-c4 cells", "CELL_LINE", 117, 130], ["PA317 LXSN 16E6E7", "SPECIES", 42, 59], ["HPV", "SPECIES", 88, 91], ["culturing", "TEST", 32, 41], ["cells", "TEST", 60, 65], ["HPV E6/E7 immortalization", "TREATMENT", 88, 113], ["c4 cells", "PROBLEM", 122, 130], ["c4 cells", "ANATOMY", 122, 130]]], ["Approximately, 0.3 9 10 6 cells of BIEC-c4 at passage 37 were seeded on a 6-well plate.", [["cells", "ANATOMY", 26, 31], ["BIEC-c4", "ANATOMY", 35, 42], ["cells", "CELL", 26, 31], ["BIEC-c4", "CELL", 35, 42], ["BIEC", "PROTEIN", 35, 39], ["BIEC-c4 at passage", "TREATMENT", 35, 53], ["a 6-well plate", "TREATMENT", 72, 86], ["c4", "ANATOMY_MODIFIER", 40, 42]]], ["After 48 h, BIEC-c4 cells maintained in OPTI-MEM \u00d2 serum-free media were transfected with the supernatant obtained from PA317 LXSN 16E6E7 using Lipofectamine \u00d2 2000 reagent.", [["BIEC-c4 cells", "ANATOMY", 12, 25], ["serum", "ANATOMY", 51, 56], ["supernatant", "ANATOMY", 94, 105], ["BIEC-c4 cells", "CELL", 12, 25], ["OPTI", "SIMPLE_CHEMICAL", 40, 44], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["PA317 LXSN 16E6E7", "CELL", 120, 137], ["BIEC-c4 cells", "CELL_LINE", 12, 25], ["PA317 LXSN 16E6E7", "CELL_LINE", 120, 137], ["PA317 LXSN 16E6E7", "SPECIES", 120, 137], ["BIEC-c4 cells", "TEST", 12, 25], ["OPTI", "TEST", 40, 44], ["serum", "TEST", 51, 56], ["Lipofectamine", "TREATMENT", 144, 157], ["c4 cells", "ANATOMY", 17, 25]]], ["Similar to the above-described protocol, transfected cells were selected by treating with G418 antibiotic at 1000 lg/ml for 15 days.", [["cells", "ANATOMY", 53, 58], ["G418", "CHEMICAL", 90, 94], ["G418", "CHEMICAL", 90, 94], ["cells", "CELL", 53, 58], ["transfected cells", "CELL_LINE", 41, 58], ["the above-described protocol", "TREATMENT", 11, 39], ["transfected cells", "PROBLEM", 41, 58], ["G418 antibiotic", "TREATMENT", 90, 105]]], ["The cells were further propagated in a T-75 flask and stocks were prepared.Polarization of BIEC-c4 cellsPolymerase chain reaction (PCR) for detection of genes used to immortalize BIEC-c4 cells DNA was isolated from each of the three immortalized BIECs: SV40-BIEC, hTERT-BIEC and HPV-BIEC cells using a DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA), and the concentration of DNA obtained from each BIEC type was measured using a Nanodrop ND-1000 Spectrophotometer.", [["cells", "ANATOMY", 4, 9], ["BIEC-c4 cells", "ANATOMY", 91, 104], ["BIEC-c4 cells", "ANATOMY", 179, 192], ["BIECs", "ANATOMY", 246, 251], ["BIEC", "ANATOMY", 258, 262], ["hTERT-BIEC", "ANATOMY", 264, 274], ["HPV-BIEC cells", "ANATOMY", 279, 293], ["cells", "CELL", 4, 9], ["BIEC-c4 cells", "CELL", 91, 104], ["BIEC-c4 cells", "CELL", 179, 192], ["DNA", "CELLULAR_COMPONENT", 193, 196], ["BIECs", "CELL", 246, 251], ["SV40", "ORGANISM", 253, 257], ["BIEC", "CELL", 258, 262], ["hTERT", "GENE_OR_GENE_PRODUCT", 264, 269], ["BIEC", "CELL", 270, 274], ["HPV-BIEC cells", "CELL", 279, 293], ["DNA", "CELLULAR_COMPONENT", 382, 385], ["BIEC-c4 cells", "CELL_LINE", 91, 104], ["BIEC-c4 cells", "CELL_LINE", 179, 192], ["immortalized BIECs", "CELL_LINE", 233, 251], ["SV40-BIEC, hTERT-BIEC and HPV-BIEC cells", "CELL_LINE", 253, 293], ["BIEC", "TEST", 91, 95], ["c4 cellsPolymerase chain reaction", "PROBLEM", 96, 129], ["PCR", "TEST", 131, 134], ["genes", "PROBLEM", 153, 158], ["BIEC", "TEST", 179, 183], ["c4 cells DNA", "PROBLEM", 184, 196], ["SV40", "TEST", 253, 257], ["BIEC", "TEST", 258, 262], ["hTERT", "TEST", 264, 269], ["BIEC", "TEST", 270, 274], ["HPV", "TEST", 279, 282], ["BIEC cells", "PROBLEM", 283, 293], ["Tissue Kit", "TEST", 317, 327], ["the concentration of DNA", "TEST", 361, 385], ["a Nanodrop ND", "TREATMENT", 434, 447], ["c4 cells", "ANATOMY", 96, 104]]], ["To confirm the presence of SV40, hTERT, and HPV E6/E7 genes in the immortalized BIECs, PCR was conducted using primers specific to these genes (Table 1 ).", [["BIECs", "ANATOMY", 80, 85], ["SV40", "ORGANISM", 27, 31], ["hTERT", "GENE_OR_GENE_PRODUCT", 33, 38], ["HPV E6", "ORGANISM", 44, 50], ["E7", "GENE_OR_GENE_PRODUCT", 51, 53], ["BIECs", "CELL", 80, 85], ["SV40, hTERT, and HPV E6/E7 genes", "DNA", 27, 59], ["immortalized BIECs", "CELL_LINE", 67, 85], ["HPV", "SPECIES", 44, 47], ["SV40", "PROBLEM", 27, 31], ["hTERT", "TEST", 33, 38], ["PCR", "TEST", 87, 90], ["primers", "TREATMENT", 111, 118]]], ["All the PCR reactions were performed using Taq PCR Kit (New England Biolabs, Ipswich, MA, USA) and the following amplification conditions were used: initial denaturation at 95\u00b0C for 10 min, followed by 50 cycles of:Polarization of BIEC-c4 cells(1) denaturation at 94\u00b0C for 30 s, (2) annealing at 60\u00b0C (SV40 and hTERT genes) or 55\u00b0C (HPV E6/E7 gene) for 30 s, (3) extension at 72\u00b0C for 1 min; and final extension at 72\u00b0C for 7 min.", [["BIEC-c4 cells", "ANATOMY", 231, 244], ["BIEC-c4 cells", "CELL", 231, 244], ["SV40", "ORGANISM", 302, 306], ["hTERT", "GENE_OR_GENE_PRODUCT", 311, 316], ["E7", "GENE_OR_GENE_PRODUCT", 340, 342], ["BIEC-c4 cells", "CELL_LINE", 231, 244], ["hTERT genes", "DNA", 311, 322], ["55\u00b0C", "DNA", 327, 331], ["HPV E6/E7 gene", "DNA", 333, 347], ["All the PCR reactions", "TEST", 0, 21], ["Taq PCR", "TEST", 43, 50], ["initial denaturation", "PROBLEM", 149, 169], ["Polarization of BIEC-c4 cells", "TREATMENT", 215, 244], ["denaturation", "TEST", 248, 260], ["hTERT genes", "TEST", 311, 322], ["HPV E6/E7 gene", "TREATMENT", 333, 347], ["c4 cells", "ANATOMY", 236, 244]]], ["The PCR products were resolved on a 1.5% agarose gel at 80 V for 25 min.", [["agarose", "SIMPLE_CHEMICAL", 41, 48], ["The PCR products", "TREATMENT", 0, 16], ["a 1.5% agarose gel", "TREATMENT", 34, 52], ["resolved", "OBSERVATION_MODIFIER", 22, 30]]], ["The pLXSN-16E6E7 plasmid was kindly provided by Dr. Xiuqing Wang (Wang and Moutsoglou 2009 ).Immunocytochemical staining of immortalized BIECs for the expression of specific proteinsThe SV40-BIEC and hTERT-BIEC cells were cultured in two separate T-75 flasks in DMEM/F12 medium supplemented with 5% FBS.", [["BIECs", "ANATOMY", 137, 142], ["hTERT-BIEC cells", "ANATOMY", 200, 216], ["FBS", "ANATOMY", 299, 302], ["pLXSN-16E6E7", "GENE_OR_GENE_PRODUCT", 4, 16], ["BIECs", "CELL", 137, 142], ["SV40", "ORGANISM", 186, 190], ["BIEC", "GENE_OR_GENE_PRODUCT", 191, 195], ["hTERT", "GENE_OR_GENE_PRODUCT", 200, 205], ["BIEC cells", "CELL", 206, 216], ["FBS", "ORGANISM_SUBSTANCE", 299, 302], ["pLXSN-16E6E7 plasmid", "DNA", 4, 24], ["immortalized BIECs", "CELL_LINE", 124, 142], ["specific proteins", "PROTEIN", 165, 182], ["SV40-BIEC and hTERT-BIEC cells", "CELL_LINE", 186, 216], ["Immunocytochemical staining", "TEST", 93, 120], ["specific proteins", "TEST", 165, 182], ["The SV40", "TEST", 182, 190], ["BIEC", "TEST", 191, 195], ["hTERT", "TEST", 200, 205], ["BIEC cells", "PROBLEM", 206, 216], ["5% FBS", "TREATMENT", 296, 302]]], ["After 48 h of incubation at 37\u00b0C, when cells were 80% confluent, they were trypsinized with 0.05% trypsin-EDTA.", [["cells", "ANATOMY", 39, 44], ["trypsin-EDTA", "CHEMICAL", 98, 110], ["cells", "CELL", 39, 44], ["trypsin-EDTA", "SIMPLE_CHEMICAL", 98, 110], ["incubation", "TREATMENT", 14, 24], ["0.05% trypsin-EDTA", "TREATMENT", 92, 110]]], ["Then cytospins with 1 9 10 5 cells were prepared using a cytofuge (Cytospin 3; Thermo Shandon Inc., Cheshire, UK).", [["cells", "ANATOMY", 29, 34], ["cells", "CELL", 29, 34], ["cytospins", "TEST", 5, 14], ["a cytofuge (Cytospin", "TREATMENT", 55, 75]]], ["Immunocytochemical (ICC) staining was performed for the confirmation of SV40 large T antigen (LT Ag) and hTERT proteins in SV40 and hTERT-BIEC cells respectively.", [["SV40", "ANATOMY", 123, 127], ["hTERT-BIEC cells", "ANATOMY", 132, 148], ["SV40", "ORGANISM", 72, 76], ["large T antigen", "GENE_OR_GENE_PRODUCT", 77, 92], ["LT Ag", "GENE_OR_GENE_PRODUCT", 94, 99], ["hTERT", "GENE_OR_GENE_PRODUCT", 105, 110], ["SV40", "ORGANISM", 123, 127], ["hTERT-BIEC cells", "CELL", 132, 148], ["SV40 large T antigen", "PROTEIN", 72, 92], ["LT Ag", "PROTEIN", 94, 99], ["hTERT proteins", "PROTEIN", 105, 119], ["SV40 and hTERT-BIEC cells", "CELL_LINE", 123, 148], ["Immunocytochemical (ICC) staining", "TEST", 0, 33], ["the confirmation", "TEST", 52, 68], ["SV40 large T antigen", "TEST", 72, 92], ["LT Ag", "TEST", 94, 99], ["hTERT proteins", "TEST", 105, 119], ["SV40", "TEST", 123, 127], ["hTERT", "TEST", 132, 137]]], ["For the detection of SV40 protein, ICC staining was performed using 100 ll of mouse anti-SV40 specific monoclonal IgG2a antibody (Santa Cruz Biotechnology, Dallas, TX, USA; sc-53488) at 1:50 dilution.", [["sc-53488", "CHEMICAL", 173, 181], ["SV40", "ORGANISM", 21, 25], ["ICC", "GENE_OR_GENE_PRODUCT", 35, 38], ["mouse", "ORGANISM", 78, 83], ["anti-SV40", "GENE_OR_GENE_PRODUCT", 84, 93], ["SV40 protein", "PROTEIN", 21, 33], ["mouse anti-SV40 specific monoclonal IgG2a antibody", "PROTEIN", 78, 128], ["Santa Cruz Biotechnology", "PROTEIN", 130, 154], ["mouse", "SPECIES", 78, 83], ["mouse", "SPECIES", 78, 83], ["SV40 protein", "PROBLEM", 21, 33], ["ICC staining", "TEST", 35, 47]]], ["For the detection of TERT protein in hTERT immortalized BIECs, ICC staining was performed using 100 ll of rabbit anti-hTERT (H-231) specific polyclonal IgG antibody (Santa Cruz Biotechnology, Dallas, TX, USA; sc-7212) at 1:50 dilution.", [["BIECs", "ANATOMY", 56, 61], ["H-231", "CHEMICAL", 125, 130], ["sc-7212", "CHEMICAL", 209, 216], ["TERT", "GENE_OR_GENE_PRODUCT", 21, 25], ["hTERT", "GENE_OR_GENE_PRODUCT", 37, 42], ["BIECs", "CELL", 56, 61], ["rabbit", "ORGANISM", 106, 112], ["anti-hTERT", "GENE_OR_GENE_PRODUCT", 113, 123], ["H-231", "CELL", 125, 130], ["sc-7212", "SIMPLE_CHEMICAL", 209, 216], ["TERT protein", "PROTEIN", 21, 33], ["hTERT immortalized BIECs", "CELL_LINE", 37, 61], ["rabbit anti-hTERT (H-231) specific polyclonal IgG antibody", "PROTEIN", 106, 164], ["Santa Cruz Biotechnology", "PROTEIN", 166, 190], ["rabbit", "SPECIES", 106, 112], ["rabbit", "SPECIES", 106, 112], ["TERT protein", "PROBLEM", 21, 33], ["ICC staining", "TEST", 63, 75], ["specific polyclonal IgG antibody", "TEST", 132, 164]]], ["As isotype-matched controls, mAbs M9144 (mouse IgG2a isotype) and sc-3888 (rabbit IgG isotype) were used.", [["sc-3888", "CHEMICAL", 66, 73], ["mouse", "ORGANISM", 41, 46], ["IgG2a", "GENE_OR_GENE_PRODUCT", 47, 52], ["sc-3888", "GENE_OR_GENE_PRODUCT", 66, 73], ["rabbit", "ORGANISM", 75, 81], ["IgG", "GENE_OR_GENE_PRODUCT", 82, 85], ["mAbs M9144", "PROTEIN", 29, 39], ["mouse IgG2a isotype", "PROTEIN", 41, 60], ["sc-3888", "PROTEIN", 66, 73], ["rabbit IgG isotype", "PROTEIN", 75, 93], ["mouse", "SPECIES", 41, 46], ["rabbit", "SPECIES", 75, 81], ["mouse", "SPECIES", 41, 46], ["rabbit", "SPECIES", 75, 81], ["mAbs", "TEST", 29, 33], ["mouse IgG2a isotype", "TEST", 41, 60], ["sc", "TEST", 66, 68], ["rabbit IgG isotype", "TREATMENT", 75, 93]]], ["The mouse IgG2a isotype was purchased from Sigma (St. Louis, MO, USA), and the rabbit IgG isotype was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).", [["mouse", "ORGANISM", 4, 9], ["IgG2a", "GENE_OR_GENE_PRODUCT", 10, 15], ["St. Louis", "ORGANISM", 50, 59], ["rabbit", "ORGANISM", 79, 85], ["IgG", "GENE_OR_GENE_PRODUCT", 86, 89], ["mouse IgG2a isotype", "PROTEIN", 4, 23], ["rabbit IgG isotype", "PROTEIN", 79, 97], ["mouse", "SPECIES", 4, 9], ["rabbit", "SPECIES", 79, 85], ["mouse", "SPECIES", 4, 9], ["rabbit", "SPECIES", 79, 85], ["the rabbit IgG isotype", "TREATMENT", 75, 97], ["IgG2a isotype", "OBSERVATION", 10, 23]]], ["Cells without primary antibody staining were used as negative control.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["primary antibody staining", "TEST", 14, 39], ["antibody staining", "OBSERVATION", 22, 39]]], ["After incubation in a humid chamber for 1 h, cytospins were washed three times with 1 9 PBS and then incubated with 100 ll of isotypespecific, biotinylated goat anti-mouse IgG2a (Caltag Laboratories, M32215) or Goat anti-rabbit IgG secondary antibody (Southern Biotech, Birmingham, AL, USA; 4050-08).", [["goat", "ORGANISM", 156, 160], ["biotinylated goat anti-mouse IgG2a", "PROTEIN", 143, 177], ["Caltag Laboratories", "PROTEIN", 179, 198], ["M32215", "PROTEIN", 200, 206], ["Goat anti-rabbit IgG secondary antibody", "PROTEIN", 211, 250], ["goat", "SPECIES", 156, 160], ["anti-mouse", "SPECIES", 161, 171], ["Goat", "SPECIES", 211, 215], ["anti-rabbit", "SPECIES", 216, 227], ["goat", "SPECIES", 156, 160], ["Goat", "SPECIES", 211, 215], ["anti-rabbit", "SPECIES", 216, 227], ["a humid chamber", "TREATMENT", 20, 35], ["cytospins", "TREATMENT", 45, 54], ["1 9 PBS", "TREATMENT", 84, 91], ["isotypespecific", "TREATMENT", 126, 141], ["biotinylated goat anti-mouse IgG2a", "TEST", 143, 177], ["Caltag Laboratories", "TEST", 179, 198], ["Goat anti-rabbit IgG", "TEST", 211, 231]]], ["After incubation at 37\u00b0C for 30 min, cells were washed in 1 9 PBS and stained with HRPstreptavidin for 30 min followed by DAB substrate (Vector Laboratories, Burlingame, CA, USA).", [["cells", "ANATOMY", 37, 42], ["HRPstreptavidin", "CHEMICAL", 83, 98], ["HRPstreptavidin", "CHEMICAL", 83, 98], ["DAB", "CHEMICAL", 122, 125], ["cells", "CELL", 37, 42], ["HRPstreptavidin", "SIMPLE_CHEMICAL", 83, 98], ["DAB", "SIMPLE_CHEMICAL", 122, 125], ["HRPstreptavidin", "TREATMENT", 83, 98]]], ["Slides were then washed two times with 1 9 PBS and counterstained for 2 min with hematoxylin.", [["hematoxylin", "CHEMICAL", 81, 92], ["hematoxylin", "SIMPLE_CHEMICAL", 81, 92], ["1 9 PBS", "TREATMENT", 39, 46], ["hematoxylin", "TREATMENT", 81, 92]]], ["After washing in running tap water, slides were air dried overnight, then mounted with a coverslip and cytoseal 60 mounting medium (Thermo Scientific, Waltham, MA, USA; 8310-4) and viewed under a 20 9 magnification using an Olympus AX70 microscope.Immunocytochemical staining of immortalized BIECs for the expression of specific proteinsIndirect immunofluorescence assay for the detection of HPVE6 proteinImmunocytochemical staining of immortalized BIECs for the expression of specific proteinsThe BIEC-c4 and HPV-BIEC cells were cultured in two separate T-75 flasks in DMEM/F12 medium supplemented with 5% FBS.", [["BIECs", "ANATOMY", 292, 297], ["BIECs", "ANATOMY", 449, 454], ["BIEC-c4", "ANATOMY", 498, 505], ["HPV-BIEC cells", "ANATOMY", 510, 524], ["FBS", "ANATOMY", 607, 610], ["BIECs", "CELL", 292, 297], ["HPVE6", "GENE_OR_GENE_PRODUCT", 392, 397], ["BIECs", "CELL", 449, 454], ["BIEC-c4", "CELL", 498, 505], ["HPV-BIEC cells", "CELL", 510, 524], ["FBS", "ORGANISM_SUBSTANCE", 607, 610], ["immortalized BIECs", "CELL_LINE", 279, 297], ["immortalized BIECs", "CELL_LINE", 436, 454], ["BIEC-c4 and HPV-BIEC cells", "CELL_LINE", 498, 524], ["running tap water", "TREATMENT", 17, 34], ["a coverslip and cytoseal", "TREATMENT", 87, 111], ["an Olympus AX70 microscope", "TREATMENT", 221, 247], ["Immunocytochemical staining", "TEST", 248, 275], ["the detection", "TEST", 375, 388], ["HPVE6 proteinImmunocytochemical staining", "PROBLEM", 392, 432], ["immortalized BIECs", "PROBLEM", 436, 454], ["specific proteins", "TEST", 477, 494], ["The BIEC", "TEST", 494, 502], ["HPV", "TEST", 510, 513], ["BIEC cells", "PROBLEM", 514, 524], ["5% FBS", "TREATMENT", 604, 610]]], ["After 48 h of incubation at 37\u00b0C, cells were trypsinized with 0.05% trypsin-EDTA and cytospins with 1 9 10 5 cells were prepared using a cytofuge (Cytospin 3; Thermo Shandon Inc.).", [["cells", "ANATOMY", 34, 39], ["cells", "ANATOMY", 109, 114], ["trypsin-EDTA", "CHEMICAL", 68, 80], ["EDTA", "CHEMICAL", 76, 80], ["cells", "CELL", 34, 39], ["trypsin-EDTA", "SIMPLE_CHEMICAL", 68, 80], ["cells", "CELL", 109, 114], ["incubation", "TREATMENT", 14, 24], ["0.05% trypsin-EDTA", "TREATMENT", 62, 80], ["cytospins", "TEST", 85, 94], ["a cytofuge (Cytospin", "TREATMENT", 135, 155]]], ["The cytospins were air dried at room temperature for 90 min, fixed in absolute acetone for 7 min, dried, stored at 4\u00b0C overnight, and blocked with 1% chicken serum for 15 min.", [["serum", "ANATOMY", 158, 163], ["acetone", "CHEMICAL", 79, 86], ["acetone", "CHEMICAL", 79, 86], ["acetone", "SIMPLE_CHEMICAL", 79, 86], ["chicken", "ORGANISM", 150, 157], ["serum", "ORGANISM_SUBSTANCE", 158, 163], ["chicken", "SPECIES", 150, 157], ["chicken", "SPECIES", 150, 157], ["1% chicken serum", "TREATMENT", 147, 163], ["air dried", "OBSERVATION", 19, 28]]], ["Immunofluorescence staining for HPV E6 protein was performed by incubating the HPV-BIECs cytospin for 90 min at room temperature with 150 ll of goat anti-HPV16E6 specific polyclonal IgG antibody (Santa Cruz Biotechnology, Dallas, TX, USA; sc-1584) at 1:50 dil.", [["sc-1584", "CHEMICAL", 239, 246], ["HPV", "ORGANISM", 32, 35], ["E6", "GENE_OR_GENE_PRODUCT", 36, 38], ["HPV", "ORGANISM", 79, 82], ["goat", "ORGANISM", 144, 148], ["anti-HPV16E6", "SIMPLE_CHEMICAL", 149, 161], ["HPV E6 protein", "PROTEIN", 32, 46], ["goat anti-HPV16E6 specific polyclonal IgG antibody", "PROTEIN", 144, 194], ["Santa Cruz Biotechnology", "PROTEIN", 196, 220], ["goat", "SPECIES", 144, 148], ["HPV", "SPECIES", 32, 35], ["goat", "SPECIES", 144, 148], ["Immunofluorescence staining", "TEST", 0, 27], ["HPV E6 protein", "TEST", 32, 46], ["the HPV", "TEST", 75, 82], ["cytospin", "TEST", 89, 97]]], ["The slide was then washed 3 9 with 1 9 PBS and incubated at room temperature for 1 h with 200 ll of Alexa Fluor 488 conjugated chicken anti-goat IgG secondary antibody (Invitrogen, Grand Island, NY, USA; Cat.", [["Alexa Fluor 488", "CHEMICAL", 100, 115], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 100, 115], ["chicken", "ORGANISM", 127, 134], ["Alexa Fluor 488 conjugated chicken anti-goat IgG secondary antibody", "PROTEIN", 100, 167], ["chicken", "SPECIES", 127, 134], ["Alexa Fluor 488", "SPECIES", 100, 115], ["chicken", "SPECIES", 127, 134], ["1 9 PBS", "TREATMENT", 35, 42], ["Alexa Fluor", "TEST", 100, 111], ["conjugated chicken anti-goat IgG", "TEST", 116, 148]]], ["A-21467) at 1:200 dilution.", [["A-21467", "CHEMICAL", 0, 7], ["A-21467", "CHEMICAL", 0, 7]]], ["Following incubation, the cytospin was washed with 1 9 PBS three times and then counterstained with 150 ll of 1.5 mM propidium iodide for 5 min.", [["cytospin", "ANATOMY", 26, 34], ["propidium iodide", "CHEMICAL", 117, 133], ["propidium iodide", "CHEMICAL", 117, 133], ["propidium iodide", "SIMPLE_CHEMICAL", 117, 133], ["the cytospin", "TEST", 22, 34], ["1.5 mM propidium iodide", "TREATMENT", 110, 133]]], ["Then it was washed once, air dried, and mounted with permafluor mounting reagent.", [["permafluor", "CHEMICAL", 53, 63], ["permafluor mounting reagent", "TREATMENT", 53, 80]]], ["Photographs were taken at a 20 9 magnification using an Olympus AX70 epifluorescence microscope (Olympus Corp., Tokyo, Japan).Cell growth kinetics studyApproximately, 20,000 cells of BIEC-c4, SV40-BIEC, hTERT-BIEC, and HPV-BIEC were seeded in 6-well plates.", [["Cell", "ANATOMY", 126, 130], ["cells", "ANATOMY", 174, 179], ["BIEC-c4", "ANATOMY", 183, 190], ["BIEC", "ANATOMY", 197, 201], ["hTERT-BIEC", "ANATOMY", 203, 213], ["HPV-BIEC", "ANATOMY", 219, 227], ["Cell", "CELL", 126, 130], ["cells", "CELL", 174, 179], ["BIEC-c4", "CELL", 183, 190], ["SV40", "ORGANISM", 192, 196], ["BIEC", "CELL", 197, 201], ["hTERT", "GENE_OR_GENE_PRODUCT", 203, 208], ["HPV-BIEC", "ORGANISM", 219, 227], ["20,000 cells", "CELL_LINE", 167, 179], ["BIEC-c4, SV40-BIEC, hTERT-BIEC, and HPV-BIEC", "DNA", 183, 227], ["Photographs", "TEST", 0, 11], ["Cell growth kinetics studyApproximately", "TEST", 126, 165], ["BIEC", "TEST", 183, 187], ["SV40", "TEST", 192, 196], ["BIEC", "TEST", 197, 201], ["hTERT", "TEST", 203, 208], ["BIEC", "TEST", 209, 213], ["HPV", "TEST", 219, 222], ["BIEC", "TREATMENT", 223, 227]]], ["Five 6-well plates were cultured with all four BIEC cell types and incubated at 37\u00b0C. After 48 h, the first plate was taken out; each well was trypsinized and counted using hemocytometer.", [["cell", "ANATOMY", 52, 56], ["BIEC cell", "CELL", 47, 56], ["BIEC cell types", "CELL_LINE", 47, 62], ["the first plate", "TREATMENT", 98, 113], ["hemocytometer", "TEST", 173, 186]]], ["The number of cells for each cell type was counted every 24 h, beginning on day 2 and counted until day 6.", [["cells", "ANATOMY", 14, 19], ["cell", "ANATOMY", 29, 33], ["cells", "CELL", 14, 19], ["cell type", "CELL", 29, 38]]], ["The same procedure was repeated two more times with all cell types.", [["cell", "ANATOMY", 56, 60], ["cell", "CELL", 56, 60], ["The same procedure", "TREATMENT", 0, 18], ["cell types", "OBSERVATION", 56, 66]]], ["The time required by the culture to double in population, also called the doubling time (DT), was calculated by using the formula: DT = T ln2/ln(X2/ X1), where T is the incubation time in hours, X1 is the cell number at the beginning of the incubation time and X2 is the cell number at the end of the incubation time (Miyazawa et al. 2010) .RNA extraction and cDNA preparationEarly passage BIEC-c4 cells and the three immortalized BIECs (hTERT, SV40, and HPV E6/E7) were used for RNA isolation.", [["cell", "ANATOMY", 205, 209], ["cell", "ANATOMY", 271, 275], ["BIEC-c4 cells", "ANATOMY", 390, 403], ["BIECs", "ANATOMY", 431, 436], ["cell", "CELL", 205, 209], ["cell", "CELL", 271, 275], ["BIEC-c4 cells", "CELL", 390, 403], ["BIECs", "CANCER", 431, 436], ["hTERT", "GENE_OR_GENE_PRODUCT", 438, 443], ["SV40", "ORGANISM", 445, 449], ["HPV E6", "ORGANISM", 455, 461], ["E7", "ORGANISM", 462, 464], ["BIEC", "CELL_LINE", 390, 394], ["c4 cells", "CELL_LINE", 395, 403], ["immortalized BIECs", "CELL_LINE", 418, 436], ["hTERT", "PROTEIN", 438, 443], ["E7", "PROTEIN", 462, 464], ["the culture", "TEST", 21, 32], ["RNA extraction", "TREATMENT", 341, 355], ["cDNA preparationEarly passage", "TEST", 360, 389], ["c4 cells", "PROBLEM", 395, 403], ["hTERT", "TEST", 438, 443], ["SV40", "TEST", 445, 449], ["HPV E6/E7)", "TREATMENT", 455, 465], ["RNA isolation", "TREATMENT", 480, 493], ["ln", "ANATOMY", 142, 144], ["c4 cells", "OBSERVATION", 395, 403]]], ["Approximately 5 9 10 5 cells per well were cultured in two wells of a 6-well plate.", [["cells", "ANATOMY", 23, 28], ["cells", "CELL", 23, 28], ["a 6-well plate", "TREATMENT", 68, 82]]], ["For each cell type, cells were cultured in a separate 6-well plate.", [["cell", "ANATOMY", 9, 13], ["cells", "ANATOMY", 20, 25], ["cell type", "CELL", 9, 18], ["cells", "CELL", 20, 25], ["cell type", "OBSERVATION", 9, 18]]], ["After 18 h, 1 9 10 6 cells of each cell type were used for RNA extraction.", [["cells", "ANATOMY", 21, 26], ["cell", "ANATOMY", 35, 39], ["cells", "CELL", 21, 26], ["cell type", "CELL", 35, 44], ["each cell type", "TREATMENT", 30, 44], ["RNA extraction", "TREATMENT", 59, 73]]], ["Total RNA from bovine intestinal epithelial cells was extracted using a RNeasy Mini Kit (Qiagen, Valencia, CA, USA).", [["intestinal epithelial cells", "ANATOMY", 22, 49], ["bovine", "ORGANISM", 15, 21], ["intestinal epithelial cells", "CELL", 22, 49], ["bovine intestinal epithelial cells", "CELL_TYPE", 15, 49], ["bovine", "SPECIES", 15, 21], ["bovine", "SPECIES", 15, 21], ["Total RNA from bovine intestinal epithelial cells", "PROBLEM", 0, 49], ["bovine", "ANATOMY_MODIFIER", 15, 21], ["intestinal", "ANATOMY", 22, 32], ["epithelial cells", "OBSERVATION", 33, 49]]], ["RNA concentration in the four samples was determined using a Nanodrop ND-2000 Spectrophotometer.", [["samples", "ANATOMY", 30, 37], ["RNA concentration", "TEST", 0, 17], ["a Nanodrop ND", "TREATMENT", 59, 72], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["One lg of RNA was reverse transcribed using a TaqMan \u00d2 Reverse Transcription Reagents Kit (Applied Biosystems, NJ, USA), following the manufacturer's protocol, to obtain 20 ll of cDNA.", [["cDNA", "DNA", 179, 183], ["a TaqMan", "TREATMENT", 44, 52], ["the manufacturer's protocol", "TREATMENT", 131, 158], ["lg", "OBSERVATION_MODIFIER", 4, 6], ["RNA", "OBSERVATION", 10, 13]]], ["Briefly, the protocol of cDNA synthesis involved preparing two mixtures: mixture I and mixture II.", [["cDNA", "DNA", 25, 29], ["cDNA synthesis", "TREATMENT", 25, 39]]], ["Mixture I contained 1ug of RNA and 1ul of oligo dT 16, and mixture II contained 10 9 RT buffer, 25 mM MgCl 2 , 10 mM dNTP mix, 0.1 mM dTT, 1ul of RNase inhibitor, and 1ul of Multiscribe RT (50 U/ll).", [["oligo dT", "CHEMICAL", 42, 50], ["MgCl", "CHEMICAL", 102, 106], ["NTP", "CHEMICAL", 118, 121], ["MgCl 2", "CHEMICAL", 102, 108], ["NTP", "CHEMICAL", 118, 121], ["dTT", "CHEMICAL", 134, 137], ["MgCl 2", "SIMPLE_CHEMICAL", 102, 108], ["RNase", "GENE_OR_GENE_PRODUCT", 146, 151], ["RNA", "TREATMENT", 27, 30], ["oligo dT", "TREATMENT", 42, 50], ["mixture II", "TREATMENT", 59, 69], ["10 mM dNTP mix", "TREATMENT", 111, 125], ["RNase inhibitor", "TREATMENT", 146, 161], ["Multiscribe RT", "TREATMENT", 174, 188]]], ["It was then mixed with mixture II and final volume was made to 20 ll by adding nuclease-free water.", [["nuclease", "PROTEIN", 79, 87], ["mixture II", "TREATMENT", 23, 33], ["nuclease-free water", "TREATMENT", 79, 98]]], ["This new mixture was incubated at 37\u00b0C for 30 min, then at 95\u00b0C for 5 min and 4\u00b0C until final storage at -20\u00b0C. The cDNA was diluted fivefold in nuclease-free water to make working stock.Quantitative analysis of TLR expression by realtime reverse transcription PCRThe quantification of TLR mRNA in bovine intestinal epithelial cell lines was accomplished using two-step real-time RT-PCR (QuantStudio TM 6 Flex Real-Time PCR System; Applied Biosystems, NJ, USA) using RT 2 SYBR \u00d2 Green/ROX qPCR Mastermix (Qiagen, Valencia, CA, USA).", [["intestinal epithelial cell lines", "ANATOMY", 305, 337], ["TLR", "GENE_OR_GENE_PRODUCT", 212, 215], ["TLR", "GENE_OR_GENE_PRODUCT", 286, 289], ["bovine", "ORGANISM", 298, 304], ["intestinal epithelial cell lines", "CELL", 305, 337], ["cDNA", "DNA", 116, 120], ["nuclease", "PROTEIN", 145, 153], ["TLR", "PROTEIN", 212, 215], ["TLR mRNA", "RNA", 286, 294], ["bovine intestinal epithelial cell lines", "CELL_LINE", 298, 337], ["bovine", "SPECIES", 298, 304], ["bovine", "SPECIES", 298, 304], ["The cDNA", "TREATMENT", 112, 120], ["TLR expression", "TREATMENT", 212, 226], ["TLR mRNA in bovine intestinal epithelial cell lines", "TREATMENT", 286, 337], ["QuantStudio TM", "TREATMENT", 388, 402], ["RT 2 SYBR", "TREATMENT", 467, 476], ["Green/ROX qPCR Mastermix", "TREATMENT", 479, 503], ["intestinal", "ANATOMY", 305, 315], ["epithelial cell lines", "OBSERVATION", 316, 337]]], ["TLR mRNA gene amplification was done using following PCR cycling conditions: 2 min at 50\u00b0C; 10 min at 95\u00b0C; followed by 40 cycles of 45 s at 95\u00b0C, 30 s at 60\u00b0C and 30 s at 72\u00b0C. The reaction mixture for each TLR contained 2 ll of cDNA and 10 ll of 2 9 mastermix with 1 ll each of forward and reverse primer.", [["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["TLR mRNA", "RNA", 0, 8], ["TLR", "PROTEIN", 208, 211], ["cDNA", "DNA", 230, 234], ["1 ll each of forward and reverse primer", "DNA", 267, 306], ["TLR mRNA gene amplification", "TREATMENT", 0, 27], ["The reaction mixture", "TREATMENT", 178, 198], ["cDNA", "TEST", 230, 234], ["10 ll", "OBSERVATION_MODIFIER", 239, 244], ["reverse primer", "OBSERVATION", 292, 306]]], ["A total reaction volume of 20 ll was prepared by adding nuclease-free water.", [["nuclease", "PROTEIN", 56, 64], ["A total reaction volume", "TEST", 0, 23], ["nuclease-free water", "TREATMENT", 56, 75], ["total", "OBSERVATION_MODIFIER", 2, 7], ["20 ll", "OBSERVATION_MODIFIER", 27, 32]]], ["Altogether, ten sets of primers (Table 2) were used for amplification of bovine TLR 1-10 genes (Takanashi et al. 2013 ).", [["bovine", "ORGANISM", 73, 79], ["TLR 1-10", "GENE_OR_GENE_PRODUCT", 80, 88], ["bovine TLR 1-10 genes", "DNA", 73, 94], ["bovine", "SPECIES", 73, 79], ["amplification of bovine TLR", "TREATMENT", 56, 83]]], ["The housekeeping gene hypoxanthine phosphoribosyltransferase-1 (HPRT-1) was used for normalization and comparing the expression levels of TLR genes.", [["hypoxanthine", "CHEMICAL", 22, 34], ["hypoxanthine", "CHEMICAL", 22, 34], ["hypoxanthine phosphoribosyltransferase-1", "GENE_OR_GENE_PRODUCT", 22, 62], ["HPRT-1", "GENE_OR_GENE_PRODUCT", 64, 70], ["TLR", "GENE_OR_GENE_PRODUCT", 138, 141], ["housekeeping gene hypoxanthine phosphoribosyltransferase-1", "DNA", 4, 62], ["HPRT-1", "DNA", 64, 70], ["TLR genes", "DNA", 138, 147], ["The housekeeping gene hypoxanthine phosphoribosyltransferase-1", "TREATMENT", 0, 62], ["HPRT", "TEST", 64, 68]]], ["Gene amplification was calculated with the following formula: change in cycle threshold (DCt) = Ct of the gene of interest-Ct of HPRT-1.", [["HPRT-1", "GENE_OR_GENE_PRODUCT", 129, 135], ["HPRT-1", "DNA", 129, 135], ["Gene amplification", "TREATMENT", 0, 18], ["change in cycle threshold", "TREATMENT", 62, 87], ["Ct of HPRT", "TEST", 123, 133]]], ["A lower DCt value represented a higher concentration of the gene of interest.Statistical analysisThe comparison of mean doubling time was performed using the two-tailed Student's t test and the TLR expression was analyzed using the Wilcoxonsigned-rank test in GraphPad Prism 7.0.", [["TLR", "GENE_OR_GENE_PRODUCT", 194, 197], ["DCt", "PROTEIN", 8, 11], ["TLR", "PROTEIN", 194, 197], ["A lower DCt value", "TEST", 0, 17], ["Statistical analysis", "TEST", 77, 97], ["Student's t test", "TEST", 169, 185], ["Prism", "TEST", 269, 274], ["higher concentration", "OBSERVATION_MODIFIER", 32, 52]]], ["A P value of \u00a00.05 was considered as statistically significant.Establishment and biochemical characterization of BIEC-c4 and immortalized BIECsCells obtained from ileal tissue of two-day-old calf after cell scrapping were cultured in DMEM-2 medium in order to obtain epithelial cell cultures.", [["BIEC-c4", "ANATOMY", 113, 120], ["BIECsCells", "ANATOMY", 138, 148], ["ileal tissue", "ANATOMY", 163, 175], ["cell", "ANATOMY", 202, 206], ["epithelial cell cultures", "ANATOMY", 267, 291], ["BIEC-c4", "CELL", 113, 120], ["BIECsCells", "CELL", 138, 148], ["ileal tissue", "TISSUE", 163, 175], ["calf", "ORGANISM", 191, 195], ["cell", "CELL", 202, 206], ["DMEM-2", "CELL", 234, 240], ["epithelial cell cultures", "CELL", 267, 291], ["BIEC-c4 and immortalized BIECsCells", "CELL_LINE", 113, 148], ["epithelial cell cultures", "CELL_LINE", 267, 291], ["calf", "SPECIES", 191, 195], ["A P value", "TEST", 0, 9], ["biochemical characterization", "TEST", 81, 109], ["BIEC", "TEST", 113, 117], ["immortalized BIECsCells", "PROBLEM", 125, 148], ["cell scrapping", "TREATMENT", 202, 216], ["epithelial cell cultures", "TEST", 267, 291], ["c4", "ANATOMY", 118, 120], ["ileal tissue", "ANATOMY", 163, 175], ["calf", "ANATOMY", 191, 195], ["cell scrapping", "OBSERVATION", 202, 216], ["epithelial cell", "OBSERVATION", 267, 282]]], ["First, scrapped cell suspension was incubated in a T25 primaria flask for 90 min for the removal of fibroblastlike cells and then non-adherent cells were transferred to a new flask for further cell growth.", [["cell", "ANATOMY", 16, 20], ["fibroblastlike cells", "ANATOMY", 100, 120], ["cells", "ANATOMY", 143, 148], ["cell", "ANATOMY", 193, 197], ["cell", "CELL", 16, 20], ["fibroblastlike cells", "CELL", 100, 120], ["cells", "CELL", 143, 148], ["cell", "CELL", 193, 197], ["scrapped cell suspension", "CELL_LINE", 7, 31], ["fibroblastlike cells", "CELL_TYPE", 100, 120], ["non-adherent cells", "CELL_TYPE", 130, 148], ["scrapped cell suspension", "TREATMENT", 7, 31], ["a T25 primaria flask", "TREATMENT", 49, 69], ["the removal of fibroblastlike cells", "TREATMENT", 85, 120], ["non-adherent cells", "TREATMENT", 130, 148], ["a new flask", "TREATMENT", 169, 180], ["further cell growth", "PROBLEM", 185, 204], ["cell suspension", "OBSERVATION", 16, 31], ["fibroblastlike cells", "OBSERVATION", 100, 120], ["non-adherent cells", "OBSERVATION", 130, 148]]], ["Epithelial cells in culture show cobblestone morphology whereas mesenchyme-derived fibroblast cells show spindle-shaped morphology Zhan et al. 2017) .Establishment and biochemical characterization of BIEC-c4 and immortalized BIECsThe cells in the first passage adhered to the flask, grew well in isolated clusters, and showed a mixed fibroblast and epithelial-like phenotype (Fig. 1a, b) .", [["Epithelial cells", "ANATOMY", 0, 16], ["mesenchyme", "ANATOMY", 64, 74], ["fibroblast cells", "ANATOMY", 83, 99], ["spindle", "ANATOMY", 105, 112], ["BIEC-c4", "ANATOMY", 200, 207], ["BIECs", "ANATOMY", 225, 230], ["cells", "ANATOMY", 234, 239], ["fibroblast", "ANATOMY", 334, 344], ["epithelial", "ANATOMY", 349, 359], ["Epithelial cells", "CELL", 0, 16], ["mesenchyme-derived fibroblast cells", "CELL", 64, 99], ["BIEC-c4", "CELL", 200, 207], ["BIECs", "CELL", 225, 230], ["cells", "CELL", 234, 239], ["fibroblast", "CELL", 334, 344], ["epithelial", "TISSUE", 349, 359], ["Epithelial cells", "CELL_TYPE", 0, 16], ["mesenchyme-derived fibroblast cells", "CELL_TYPE", 64, 99], ["BIEC-c4 and immortalized BIECs", "CELL_LINE", 200, 230], ["Epithelial cells in culture", "TEST", 0, 27], ["cobblestone morphology", "TEST", 33, 55], ["mesenchyme", "TEST", 64, 74], ["fibroblast cells", "TEST", 83, 99], ["biochemical characterization", "TEST", 168, 196], ["BIEC", "TEST", 200, 204], ["The cells", "PROBLEM", 230, 239], ["the flask", "TEST", 272, 281], ["a mixed fibroblast", "PROBLEM", 326, 344], ["epithelial-like phenotype", "PROBLEM", 349, 374], ["cobblestone morphology", "OBSERVATION", 33, 55], ["fibroblast cells", "OBSERVATION", 83, 99], ["shaped", "OBSERVATION_MODIFIER", 113, 119], ["cells", "OBSERVATION", 234, 239], ["first", "OBSERVATION_MODIFIER", 247, 252], ["passage", "OBSERVATION_MODIFIER", 253, 260], ["mixed fibroblast", "OBSERVATION", 328, 344], ["epithelial", "ANATOMY_MODIFIER", 349, 359]]], ["Upon further passage to new flasks, cells continued to grow in clusters with an enriched epithelial-like phenotype, but fibroblast-like cells were still present in these cultures (Fig. 1c, d) .", [["cells", "ANATOMY", 36, 41], ["epithelial", "ANATOMY", 89, 99], ["fibroblast-like cells", "ANATOMY", 120, 141], ["cultures", "ANATOMY", 170, 178], ["cells", "CELL", 36, 41], ["epithelial", "TISSUE", 89, 99], ["fibroblast-like cells", "CELL", 120, 141], ["fibroblast-like cells", "CELL_TYPE", 120, 141], ["new flasks", "PROBLEM", 24, 34], ["cells", "PROBLEM", 36, 41], ["an enriched epithelial-like phenotype", "PROBLEM", 77, 114], ["fibroblast-like cells", "PROBLEM", 120, 141], ["these cultures", "TEST", 164, 178], ["new", "OBSERVATION_MODIFIER", 24, 27], ["flasks", "OBSERVATION", 28, 34], ["enriched", "OBSERVATION_MODIFIER", 80, 88], ["epithelial", "ANATOMY_MODIFIER", 89, 99], ["like phenotype", "OBSERVATION", 100, 114]]], ["As supplemented DMEM/F12 medium has been successfully used to culture porcine intestinal epithelial cells, we cultured the fibroblast and epithelial-like cultures from passage 4 onwards in supplemented DMEM/F12 medium instead of DMEM-2 medium.", [["intestinal epithelial cells", "ANATOMY", 78, 105], ["fibroblast", "ANATOMY", 123, 133], ["epithelial-like cultures", "ANATOMY", 138, 162], ["porcine", "ORGANISM", 70, 77], ["intestinal epithelial cells", "CELL", 78, 105], ["fibroblast", "CELL", 123, 133], ["epithelial-like cultures", "CELL", 138, 162], ["DMEM-2", "CELL", 229, 235], ["porcine intestinal epithelial cells", "CELL_TYPE", 70, 105], ["fibroblast and epithelial-like cultures", "CELL_LINE", 123, 162], ["porcine", "SPECIES", 70, 77], ["porcine", "SPECIES", 70, 77], ["supplemented DMEM/F12 medium", "TREATMENT", 3, 31], ["culture porcine intestinal epithelial cells", "PROBLEM", 62, 105], ["the fibroblast and epithelial-like cultures", "PROBLEM", 119, 162], ["intestinal epithelial cells", "OBSERVATION", 78, 105], ["epithelial", "ANATOMY", 138, 148]]], ["In passage 8 cultures, mixed fibroblast and epithelial-like cells were present in some locations (Fig. 2a) while at other places, distinct epithelial-like clusters were present (Fig. 2b) .", [["fibroblast", "ANATOMY", 29, 39], ["epithelial-like cells", "ANATOMY", 44, 65], ["epithelial", "ANATOMY", 139, 149], ["fibroblast", "CELL", 29, 39], ["epithelial-like cells", "CELL", 44, 65], ["epithelial-like clusters", "CANCER", 139, 163], ["passage 8 cultures", "CELL_LINE", 3, 21], ["mixed fibroblast and epithelial-like cells", "CELL_TYPE", 23, 65], ["passage 8 cultures", "TEST", 3, 21], ["mixed fibroblast and epithelial-like cells", "PROBLEM", 23, 65], ["mixed fibroblast", "OBSERVATION", 23, 39], ["epithelial", "ANATOMY", 44, 54], ["like cells", "OBSERVATION", 55, 65], ["distinct", "OBSERVATION_MODIFIER", 130, 138], ["epithelial", "ANATOMY", 139, 149]]], ["Thus, at passage 8, we decided to culture these cells in a petri dish in low numbers (1000 cells per petri dish) in order to get individualized epithelial-like cell clusters (Fig. 2c, d) .", [["cells", "ANATOMY", 48, 53], ["cells", "ANATOMY", 91, 96], ["epithelial", "ANATOMY", 144, 154], ["cell", "ANATOMY", 160, 164], ["cells", "CELL", 48, 53], ["cells", "CELL", 91, 96], ["epithelial-like cell", "CELL", 144, 164], ["these cells", "PROBLEM", 42, 53], ["a petri dish in low numbers", "PROBLEM", 57, 84], ["petri dish", "OBSERVATION", 59, 69], ["low numbers", "OBSERVATION_MODIFIER", 73, 84], ["epithelial", "ANATOMY", 144, 154], ["like cell clusters", "OBSERVATION", 155, 173]]], ["The individual epithelial like clusters were collected and amplified in 24 and 6-well plates.", [["epithelial", "ANATOMY", 15, 25], ["epithelial like clusters", "CANCER", 15, 39], ["The individual epithelial like clusters", "PROBLEM", 0, 39], ["epithelial", "ANATOMY_MODIFIER", 15, 25], ["clusters", "OBSERVATION_MODIFIER", 31, 39]]], ["Then the cells from colony 4 from the petri dish were further subcloned in a 96-well plate and amplified further.", [["cells", "ANATOMY", 9, 14], ["colony 4", "ANATOMY", 20, 28], ["cells", "CELL", 9, 14], ["colony 4", "CELL", 20, 28], ["colony", "OBSERVATION_MODIFIER", 20, 26]]], ["These cells were designated as BIEC-c4 cells.", [["cells", "ANATOMY", 6, 11], ["BIEC-c4 cells", "ANATOMY", 31, 44], ["cells", "CELL", 6, 11], ["BIEC-c4 cells", "CELL", 31, 44], ["BIEC-c4 cells", "CELL_LINE", 31, 44], ["These cells", "TEST", 0, 11], ["c4 cells", "OBSERVATION", 36, 44]]], ["Upon confluency, BIEC-c4 cells had a cobble-stone TLR1 F: CAT TCC TAG CAG CTA CCA CAA GCT R: TGG GCC ATT CCA AAT AAG TTC T NM_001046504 TLR2 F: GGG TGC TGT GTC ACC GTT TC R: GCC ACG CCC ACA TCA TCT NM_174197 TLR3 morphology, indicative of epithelial phenotype (Fig. 3a) .", [["BIEC-c4 cells", "ANATOMY", 17, 30], ["epithelial", "ANATOMY", 239, 249], ["BIEC-c4 cells", "CELL", 17, 30], ["TLR1", "GENE_OR_GENE_PRODUCT", 50, 54], ["TLR3", "GENE_OR_GENE_PRODUCT", 208, 212], ["epithelial", "TISSUE", 239, 249], ["BIEC-c4 cells", "CELL_LINE", 17, 30], ["cobble-stone TLR1 F", "DNA", 37, 56], ["CAT", "PROTEIN", 58, 61], ["confluency", "TEST", 5, 15], ["BIEC", "TEST", 17, 21], ["c4 cells", "PROBLEM", 22, 30], ["CAT TCC TAG", "TEST", 58, 69], ["CAG", "TEST", 70, 73], ["CTA", "TEST", 74, 77], ["CCA", "TEST", 78, 81], ["CAA", "TEST", 82, 85], ["GCT", "TEST", 86, 89], ["TGG", "TEST", 93, 96], ["GCC", "TEST", 97, 100], ["CCA", "TEST", 105, 108], ["AAG", "TEST", 113, 116], ["TTC", "TEST", 117, 120], ["NM", "TEST", 123, 125], ["GGG", "TEST", 144, 147], ["TGC", "TEST", 148, 151], ["TGT", "TEST", 152, 155], ["GTC", "TEST", 156, 159], ["ACC", "TEST", 160, 163], ["TC", "TEST", 168, 170], ["GCC", "TEST", 174, 177], ["ACG", "TEST", 178, 181], ["ACA TCA TCT NM_", "TEST", 186, 201], ["TLR3 morphology", "TEST", 208, 223], ["epithelial phenotype", "PROBLEM", 239, 259], ["confluency", "OBSERVATION_MODIFIER", 5, 15], ["c4 cells", "OBSERVATION", 22, 30], ["stone", "OBSERVATION", 44, 49], ["indicative of", "UNCERTAINTY", 225, 238], ["epithelial phenotype", "OBSERVATION", 239, 259]]], ["We expected that primary BIEC cells would have limited growth potential in subsequent passages so primary BIEC-c4 cells were further immortalized using SV40 gene (Fig. 3b) , hTERT gene (Fig. 3c) , and human papilloma virus HPV E6/E7 genes (Fig. 3d ).", [["primary BIEC cells", "ANATOMY", 17, 35], ["primary BIEC-c4 cells", "ANATOMY", 98, 119], ["BIEC cells", "CELL", 25, 35], ["BIEC-c4 cells", "CELL", 106, 119], ["SV40", "ORGANISM", 152, 156], ["Fig. 3b", "GENE_OR_GENE_PRODUCT", 163, 170], ["hTERT", "GENE_OR_GENE_PRODUCT", 174, 179], ["human papilloma virus HPV E6", "ORGANISM", 201, 229], ["E7", "ORGANISM", 230, 232], ["primary BIEC cells", "CELL_LINE", 17, 35], ["primary BIEC-c4 cells", "CELL_LINE", 98, 119], ["SV40 gene", "DNA", 152, 161], ["hTERT gene", "DNA", 174, 184], ["human papilloma virus HPV E6/E7 genes", "DNA", 201, 238], ["human", "SPECIES", 201, 206], ["papilloma virus HPV", "SPECIES", 207, 226], ["human papilloma virus HPV E6/E7", "SPECIES", 201, 232], ["primary BIEC cells", "PROBLEM", 17, 35], ["primary BIEC-c4 cells", "TREATMENT", 98, 119], ["SV40 gene (Fig. 3b)", "TREATMENT", 152, 171], ["hTERT gene (Fig. 3c", "TREATMENT", 174, 193], ["human papilloma virus", "TREATMENT", 201, 222]]], ["All the three immortalized BIEC cell types also showed a cobble-stone morphology upon confluency (Fig. 3b, d) .Establishment and biochemical characterization of BIEC-c4 and immortalized BIECsThe BIEC-c4 cells and three immortalized BIEC cell types were further characterized by immunocytochemistry using cell marker-specific antibodies.", [["BIEC cell", "ANATOMY", 27, 36], ["cobble-stone", "ANATOMY", 57, 69], ["BIEC-c4", "ANATOMY", 161, 168], ["BIECs", "ANATOMY", 186, 191], ["BIEC-c4 cells", "ANATOMY", 195, 208], ["BIEC cell", "ANATOMY", 232, 241], ["cell", "ANATOMY", 304, 308], ["BIEC cell", "CELL", 27, 36], ["BIEC-c4", "CELL", 161, 168], ["BIECs", "CELL", 186, 191], ["BIEC-c4 cells", "CELL", 195, 208], ["BIEC cell", "CELL", 232, 241], ["cell", "CELL", 304, 308], ["immortalized BIEC cell types", "CELL_LINE", 14, 42], ["BIEC-c4 and immortalized BIECs", "CELL_LINE", 161, 191], ["BIEC-c4 cells", "CELL_LINE", 195, 208], ["immortalized BIEC cell types", "CELL_LINE", 219, 247], ["cell marker-specific antibodies", "PROTEIN", 304, 335], ["a cobble-stone morphology", "PROBLEM", 55, 80], ["biochemical characterization", "TEST", 129, 157], ["BIEC", "TEST", 161, 165], ["immunocytochemistry", "TEST", 278, 297], ["cell marker", "TEST", 304, 315], ["BIEC cell types", "OBSERVATION", 27, 42], ["stone", "OBSERVATION", 64, 69], ["confluency", "OBSERVATION_MODIFIER", 86, 96], ["c4", "ANATOMY", 166, 168], ["c4 cells", "ANATOMY", 200, 208], ["BIEC cell types", "OBSERVATION", 232, 247]]], ["Mouse IgG, IgG2a and IgM antibodies were used as isotype controls for cytokeratin, vimentin, alpha smooth muscle actin, and desmin staining respectively.", [["Mouse", "ORGANISM", 0, 5], ["IgG", "GENE_OR_GENE_PRODUCT", 6, 9], ["IgG2a", "GENE_OR_GENE_PRODUCT", 11, 16], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 21, 35], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 70, 81], ["vimentin", "GENE_OR_GENE_PRODUCT", 83, 91], ["alpha smooth muscle actin", "GENE_OR_GENE_PRODUCT", 93, 118], ["desmin", "GENE_OR_GENE_PRODUCT", 124, 130], ["Mouse IgG", "PROTEIN", 0, 9], ["IgG2a", "PROTEIN", 11, 16], ["IgM antibodies", "PROTEIN", 21, 35], ["cytokeratin", "PROTEIN", 70, 81], ["vimentin", "PROTEIN", 83, 91], ["alpha smooth muscle actin", "PROTEIN", 93, 118], ["desmin", "PROTEIN", 124, 130], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse IgG", "TEST", 0, 9], ["IgG2a", "TEST", 11, 16], ["IgM antibodies", "TEST", 21, 35], ["cytokeratin", "TEST", 70, 81], ["vimentin", "TEST", 83, 91], ["smooth muscle", "ANATOMY", 99, 112]]], ["The anti-cytokeratin IgG2a antibody used for ICC was specific for cytokeratins 1, 5, 6, 7, 8, 10, 11, and 18 .", [["IgG2a", "GENE_OR_GENE_PRODUCT", 21, 26], ["cytokeratins 1", "GENE_OR_GENE_PRODUCT", 66, 80], ["5", "GENE_OR_GENE_PRODUCT", 82, 83], ["6", "GENE_OR_GENE_PRODUCT", 85, 86], ["7", "GENE_OR_GENE_PRODUCT", 88, 89], ["8", "GENE_OR_GENE_PRODUCT", 91, 92], ["10", "GENE_OR_GENE_PRODUCT", 94, 96], ["anti-cytokeratin IgG2a antibody", "PROTEIN", 4, 35], ["cytokeratins 1, 5, 6, 7, 8, 10, 11, and 18", "PROTEIN", 66, 108], ["The anti-cytokeratin IgG2a antibody", "TEST", 0, 35], ["ICC", "TEST", 45, 48], ["cytokeratins", "TEST", 66, 78]]], ["Isotype control antibodies did not stain any of the cells (Fig. 4a, b) .", [["cells", "ANATOMY", 52, 57], ["cells", "CELL", 52, 57], ["Isotype control antibodies", "PROTEIN", 0, 26], ["Isotype control antibodies", "TEST", 0, 26]]], ["Primary BIEC-c4 cells and the BIECs immortalized with SV40, hTERT, and HPV E6/E7 genes expressed cytokeratin (Fig. 4c, e, g, i) .", [["Primary BIEC-c4 cells", "ANATOMY", 0, 21], ["BIECs", "ANATOMY", 30, 35], ["BIEC-c4 cells", "CELL", 8, 21], ["BIECs", "CELL", 30, 35], ["SV40", "ORGANISM", 54, 58], ["hTERT", "GENE_OR_GENE_PRODUCT", 60, 65], ["HPV E6", "ORGANISM", 71, 77], ["E7", "GENE_OR_GENE_PRODUCT", 78, 80], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 97, 108], ["BIEC-c4 cells", "CELL_LINE", 8, 21], ["BIECs", "CELL_LINE", 30, 35], ["SV40, hTERT, and HPV E6/E7 genes", "DNA", 54, 86], ["cytokeratin", "PROTEIN", 97, 108], ["SV40", "TEST", 54, 58], ["hTERT", "TEST", 60, 65], ["HPV", "TEST", 71, 74], ["cytokeratin", "TEST", 97, 108], ["c4 cells", "OBSERVATION", 13, 21]]], ["Low levels of vimentin expression were detected in primary BIEC-c4 cells, SV40-BIECs, and hTERT-BIECs (Fig. 4d, f, h) .", [["primary BIEC-c4 cells", "ANATOMY", 51, 72], ["SV40-BIECs", "ANATOMY", 74, 84], ["hTERT-BIECs", "ANATOMY", 90, 101], ["vimentin", "GENE_OR_GENE_PRODUCT", 14, 22], ["BIEC-c4 cells", "CELL", 59, 72], ["SV40", "ORGANISM", 74, 78], ["-BIECs", "CELL", 78, 84], ["hTERT", "GENE_OR_GENE_PRODUCT", 90, 95], ["vimentin", "PROTEIN", 14, 22], ["primary BIEC-c4 cells", "CELL_LINE", 51, 72], ["BIECs", "CELL_LINE", 79, 84], ["hTERT", "PROTEIN", 90, 95], ["Low levels of vimentin expression", "PROBLEM", 0, 33], ["SV40", "TEST", 74, 78], ["BIECs", "TEST", 79, 84], ["hTERT", "TEST", 90, 95], ["vimentin expression", "OBSERVATION", 14, 33], ["c4 cells", "ANATOMY", 64, 72]]], ["Vimentin expression was not detected in HPV-BIECs (Fig. 4j) .", [["BIECs", "ANATOMY", 44, 49], ["Vimentin", "GENE_OR_GENE_PRODUCT", 0, 8], ["HPV-BIECs", "ORGANISM", 40, 49], ["Vimentin", "PROTEIN", 0, 8], ["Vimentin expression", "PROBLEM", 0, 19]]], ["Alpha-smooth muscle actin and desmin proteins were not expressed in both primary BIEC-c4 and immortalized SV40 and hTERT BIECs (data not shown).Confirmation of immortalization of BIEC-c4 cells by PCR and protein expressionThe expression of hTERT, SV40, and HPV E6/E7 genes in the immortalized BIECs (Fig. 5a-c) were confirmed using the oligonucleotide primers specific to each gene using PCR (Table 1 ).", [["muscle", "ANATOMY", 13, 19], ["primary BIEC-c4", "ANATOMY", 73, 88], ["SV40", "ANATOMY", 106, 110], ["hTERT BIECs", "ANATOMY", 115, 126], ["BIEC-c4 cells", "ANATOMY", 179, 192], ["BIECs", "ANATOMY", 293, 298], ["Alpha-smooth muscle actin", "GENE_OR_GENE_PRODUCT", 0, 25], ["desmin", "GENE_OR_GENE_PRODUCT", 30, 36], ["BIEC-c4", "CELL", 81, 88], ["SV40", "ORGANISM", 106, 110], ["hTERT", "GENE_OR_GENE_PRODUCT", 115, 120], ["BIEC-c4 cells", "CELL", 179, 192], ["hTERT", "GENE_OR_GENE_PRODUCT", 240, 245], ["SV40", "GENE_OR_GENE_PRODUCT", 247, 251], ["HPV E6", "ORGANISM", 257, 263], ["E7", "GENE_OR_GENE_PRODUCT", 264, 266], ["BIECs", "CELL", 293, 298], ["Fig. 5a-c", "CELL", 300, 309], ["Alpha-smooth muscle actin", "PROTEIN", 0, 25], ["desmin proteins", "PROTEIN", 30, 45], ["BIEC", "CELL_LINE", 81, 85], ["c4", "CELL_LINE", 86, 88], ["immortalized SV40 and hTERT BIECs", "CELL_LINE", 93, 126], ["BIEC-c4 cells", "CELL_LINE", 179, 192], ["hTERT, SV40, and HPV E6/E7 genes", "DNA", 240, 272], ["immortalized BIECs", "CELL_LINE", 280, 298], ["Alpha-smooth muscle actin", "PROBLEM", 0, 25], ["desmin proteins", "TEST", 30, 45], ["hTERT BIECs", "TEST", 115, 126], ["immortalization of BIEC-c4 cells", "TREATMENT", 160, 192], ["PCR", "TEST", 196, 199], ["protein expression", "TEST", 204, 222], ["hTERT", "TEST", 240, 245], ["SV40", "TEST", 247, 251], ["HPV E6", "TEST", 257, 263], ["the oligonucleotide primers", "TREATMENT", 332, 359], ["PCR", "TEST", 388, 391], ["muscle", "ANATOMY", 13, 19], ["c4 cells", "ANATOMY", 184, 192]]], ["The genomic DNA extracted from SV40-BIEC was used as a template to amplify SV40 gene which yielded a product of 105 base pairs when resolved on 1.5% agarose gel (Fig. 5b) .", [["DNA", "CELLULAR_COMPONENT", 12, 15], ["SV40", "ORGANISM", 31, 35], ["BIEC", "GENE_OR_GENE_PRODUCT", 36, 40], ["SV40", "ORGANISM", 75, 79], ["agarose", "SIMPLE_CHEMICAL", 149, 156], ["genomic DNA", "DNA", 4, 15], ["SV40", "DNA", 31, 35], ["BIEC", "DNA", 36, 40], ["SV40 gene", "DNA", 75, 84], ["The genomic DNA", "PROBLEM", 0, 15], ["SV40-BIEC", "TREATMENT", 31, 40], ["a template to amplify SV40 gene", "TREATMENT", 53, 84], ["1.5% agarose gel", "TREATMENT", 144, 160], ["genomic DNA", "OBSERVATION", 4, 15]]], ["Similarly, genomic DNA isolated from hTERT and HPV immortalized BIECs yielded amplified PCR products of 525 bp (Fig. 5a ) and 628 bp (Fig. 5c ) length respectively.", [["BIECs", "ANATOMY", 64, 69], ["DNA", "CELLULAR_COMPONENT", 19, 22], ["hTERT", "GENE_OR_GENE_PRODUCT", 37, 42], ["HPV", "ORGANISM", 47, 50], ["BIECs", "CELL", 64, 69], ["genomic DNA", "DNA", 11, 22], ["hTERT and HPV immortalized BIECs", "CELL_LINE", 37, 69], ["PCR products", "DNA", 88, 100], ["HPV", "SPECIES", 47, 50], ["genomic DNA", "PROBLEM", 11, 22], ["hTERT", "PROBLEM", 37, 42], ["amplified PCR products", "TREATMENT", 78, 100], ["bp", "TEST", 108, 110], ["bp", "TEST", 130, 132]]], ["A DNA ladder of 100 base pairs was run to confirm the size of PCR products 1 (a, b) and passage 3 (c, d).", [["DNA", "CELLULAR_COMPONENT", 2, 5], ["A DNA ladder", "TEST", 0, 12], ["PCR products", "TEST", 62, 74], ["size", "OBSERVATION_MODIFIER", 54, 58]]], ["Additionally, pGRN145, pSV3-neo plasmid, and pLXSN-16E6E7 plasmids containing hTERT, SV40, and HPV 16E6/E7 genes respectively, were used as a template for positive controls.", [["pGRN145", "GENE_OR_GENE_PRODUCT", 14, 21], ["pSV3", "GENE_OR_GENE_PRODUCT", 23, 27], ["neo", "GENE_OR_GENE_PRODUCT", 28, 31], ["pLXSN-16E6E7", "GENE_OR_GENE_PRODUCT", 45, 57], ["hTERT", "GENE_OR_GENE_PRODUCT", 78, 83], ["SV40", "GENE_OR_GENE_PRODUCT", 85, 89], ["HPV 16E6", "ORGANISM", 95, 103], ["E7", "GENE_OR_GENE_PRODUCT", 104, 106], ["pGRN145, pSV3-neo plasmid", "DNA", 14, 39], ["pLXSN", "DNA", 45, 50], ["16E6E7 plasmids", "DNA", 51, 66], ["hTERT, SV40, and HPV 16E6/E7 genes", "DNA", 78, 112], ["pGRN145", "TEST", 14, 21], ["pSV3", "TEST", 23, 27], ["neo plasmid", "TREATMENT", 28, 39], ["pLXSN", "TEST", 45, 50], ["hTERT", "TEST", 78, 83], ["SV40", "TEST", 85, 89], ["HPV", "TEST", 95, 98]]], ["The genes were amplified using gene-specific primers as described above and the PCR products were resolved on a 1.5% agarose gel (Fig. 5) .Confirmation of immortalization of BIEC-c4 cells by PCR and protein expressionImmunocytochemistry confirmed the expression of large T antigen (LT Ag) in SV40 immortalized BIECs (Fig. 6b) , and hTERT protein in hTERT immortalized BIECs (Fig. 6d) .", [["BIEC-c4 cells", "ANATOMY", 174, 187], ["BIECs", "ANATOMY", 310, 315], ["BIECs", "ANATOMY", 368, 373], ["agarose", "SIMPLE_CHEMICAL", 117, 124], ["BIEC-c4 cells", "CELL", 174, 187], ["large T antigen", "GENE_OR_GENE_PRODUCT", 265, 280], ["LT Ag", "GENE_OR_GENE_PRODUCT", 282, 287], ["SV40", "ORGANISM", 292, 296], ["BIECs", "CELL", 310, 315], ["Fig. 6b", "GENE_OR_GENE_PRODUCT", 317, 324], ["hTERT", "GENE_OR_GENE_PRODUCT", 332, 337], ["hTERT", "GENE_OR_GENE_PRODUCT", 349, 354], ["PCR products", "DNA", 80, 92], ["BIEC-c4 cells", "CELL_LINE", 174, 187], ["T antigen", "PROTEIN", 271, 280], ["LT Ag", "PROTEIN", 282, 287], ["SV40 immortalized BIECs", "CELL_LINE", 292, 315], ["hTERT protein", "PROTEIN", 332, 345], ["hTERT immortalized BIECs", "CELL_LINE", 349, 373], ["gene-specific primers", "TREATMENT", 31, 52], ["the PCR products", "TREATMENT", 76, 92], ["a 1.5% agarose gel", "TREATMENT", 110, 128], ["immortalization of BIEC-c4 cells", "TEST", 155, 187], ["PCR", "TEST", 191, 194], ["protein expression", "TEST", 199, 217], ["Immunocytochemistry", "TEST", 217, 236], ["large T antigen", "PROBLEM", 265, 280], ["hTERT protein", "TEST", 332, 345], ["c4 cells", "ANATOMY", 179, 187], ["large", "OBSERVATION_MODIFIER", 265, 270]]], ["In the negative control BIEC-c4 cells, some immunoreactivity for the SV40 LT Ag (Fig. 6a) and hTERT (Fig. 6c) proteins was observed, possibly due to incomplete blocking.", [["BIEC-c4 cells", "ANATOMY", 24, 37], ["Ag", "CHEMICAL", 77, 79], ["BIEC-c4 cells", "CELL", 24, 37], ["SV40", "ORGANISM", 69, 73], ["LT Ag (Fig. 6a", "GENE_OR_GENE_PRODUCT", 74, 88], ["hTERT (Fig. 6c", "GENE_OR_GENE_PRODUCT", 94, 108], ["BIEC-c4 cells", "CELL_LINE", 24, 37], ["SV40 LT Ag", "PROTEIN", 69, 79], ["Fig. 6a", "PROTEIN", 81, 88], ["hTERT (Fig. 6c) proteins", "PROTEIN", 94, 118], ["some immunoreactivity", "PROBLEM", 39, 60], ["the SV40 LT Ag", "TEST", 65, 79], ["hTERT (Fig. 6c) proteins", "TREATMENT", 94, 118], ["incomplete blocking", "PROBLEM", 149, 168], ["negative", "OBSERVATION", 7, 15], ["c4 cells", "ANATOMY", 29, 37], ["possibly due to", "UNCERTAINTY", 133, 148]]], ["This background staining was restricted to the cytoplasm or the cell membrane.", [["cytoplasm", "ANATOMY", 47, 56], ["cell membrane", "ANATOMY", 64, 77], ["cytoplasm", "ORGANISM_SUBSTANCE", 47, 56], ["cell membrane", "CELLULAR_COMPONENT", 64, 77], ["cell membrane", "OBSERVATION", 64, 77]]], ["However, the desired proteins were expressed mostly in the nucleus as observed in SV40-BIEC (Fig. 6b ) and hTERT-BIEC (Fig. 6d) .", [["nucleus", "ANATOMY", 59, 66], ["nucleus", "CELLULAR_COMPONENT", 59, 66], ["SV40", "ORGANISM", 82, 86], ["hTERT", "GENE_OR_GENE_PRODUCT", 107, 112], ["hTERT", "PROTEIN", 107, 112], ["BIEC", "CELL_LINE", 113, 117], ["SV40", "TEST", 82, 86], ["hTERT", "TEST", 107, 112], ["nucleus", "ANATOMY", 59, 66]]], ["The immunofluorescence assay was used to confirm the expression of HPV E6 protein (Fig. 7g , i) using the HPV E6 specific primary antibody and the Alexa Fluor 488 conjugated secondary antibody (Fig. 7g) , and propidium iodide staining for the nucleus (Fig. 7h) .", [["nucleus", "ANATOMY", 243, 250], ["propidium iodide", "CHEMICAL", 209, 225], ["Alexa Fluor 488", "CHEMICAL", 147, 162], ["propidium iodide", "CHEMICAL", 209, 225], ["HPV", "ORGANISM", 67, 70], ["E6", "GENE_OR_GENE_PRODUCT", 71, 73], ["HPV E6", "ORGANISM", 106, 112], ["propidium iodide", "SIMPLE_CHEMICAL", 209, 225], ["nucleus", "CELLULAR_COMPONENT", 243, 250], ["HPV E6 protein", "PROTEIN", 67, 81], ["Fig. 7g , i", "PROTEIN", 83, 94], ["HPV E6 specific primary antibody", "PROTEIN", 106, 138], ["Alexa Fluor 488 conjugated secondary antibody", "PROTEIN", 147, 192], ["Fig. 7g", "PROTEIN", 194, 201], ["HPV", "SPECIES", 67, 70], ["HPV", "SPECIES", 106, 109], ["Alexa Fluor 488", "SPECIES", 147, 162], ["The immunofluorescence assay", "TEST", 0, 28], ["HPV E6 protein", "TEST", 67, 81], ["the HPV", "TEST", 102, 109], ["the Alexa Fluor", "TEST", 143, 158], ["propidium iodide staining", "TREATMENT", 209, 234], ["nucleus", "ANATOMY", 243, 250]]], ["As a negative control, BIEC-c4 cells were also stained using a similar set of primary and secondary antibodies (Fig. 7d) .", [["BIEC-c4 cells", "ANATOMY", 23, 36], ["BIEC-c4 cells", "CELL", 23, 36], ["BIEC-c4 cells", "CELL_LINE", 23, 36], ["primary and secondary antibodies", "PROTEIN", 78, 110], ["BIEC-c4 cells", "PROBLEM", 23, 36], ["c4 cells", "ANATOMY", 28, 36], ["secondary antibodies", "OBSERVATION", 90, 110]]], ["However, primary BIEC-c4 cells did not express HPV E6 protein, as evident from the lack of immunofluorescence staining in the nucleus of BIEC-c4 cells (Fig. 7d, f) .", [["primary BIEC-c4 cells", "ANATOMY", 9, 30], ["nucleus", "ANATOMY", 126, 133], ["BIEC-c4 cells", "ANATOMY", 137, 150], ["BIEC-c4 cells", "CELL", 17, 30], ["HPV", "ORGANISM", 47, 50], ["E6", "GENE_OR_GENE_PRODUCT", 51, 53], ["nucleus", "CELLULAR_COMPONENT", 126, 133], ["BIEC-c4 cells", "CELL", 137, 150], ["primary BIEC-c4 cells", "CELL_LINE", 9, 30], ["HPV E6 protein", "PROTEIN", 47, 61], ["BIEC-c4 cells", "CELL_LINE", 137, 150], ["HPV", "SPECIES", 47, 50], ["primary BIEC-c4 cells", "TEST", 9, 30], ["HPV E6 protein", "PROBLEM", 47, 61], ["immunofluorescence staining", "PROBLEM", 91, 118], ["nucleus", "ANATOMY_MODIFIER", 126, 133], ["c4 cells", "ANATOMY", 142, 150]]], ["Some immunoreactivity was observed in the negative control BIEC-c4 cells (Fig. 7d) .", [["BIEC-c4 cells", "ANATOMY", 59, 72], ["BIEC-c4 cells", "CELL", 59, 72], ["BIEC-c4 cells", "CELL_LINE", 59, 72], ["Some immunoreactivity", "PROBLEM", 0, 21], ["immunoreactivity", "OBSERVATION", 5, 21], ["c4 cells", "ANATOMY", 64, 72]]], ["However, it was also non-specific cytoplasmic staining since the HPV protein in HPV-BIEC was specifically expressed in the nucleus (Fig. 7g, i) .", [["cytoplasmic", "ANATOMY", 34, 45], ["nucleus", "ANATOMY", 123, 130], ["cytoplasmic", "ORGANISM_SUBSTANCE", 34, 45], ["HPV", "ORGANISM", 65, 68], ["HPV-BIEC", "ORGANISM", 80, 88], ["nucleus", "CELLULAR_COMPONENT", 123, 130], ["HPV protein", "PROTEIN", 65, 76], ["BIEC", "PROTEIN", 84, 88], ["HPV-BIEC", "SPECIES", 80, 88], ["non-specific cytoplasmic staining", "PROBLEM", 21, 54], ["the HPV protein", "TEST", 61, 76], ["HPV", "TEST", 80, 83], ["non-specific", "OBSERVATION_MODIFIER", 21, 33], ["cytoplasmic staining", "OBSERVATION", 34, 54], ["nucleus", "ANATOMY", 123, 130]]], ["Also, BIEC-c4 cells with no primary antibody (treated with 1% chicken serum) did not show any staining for the HPV E6 protein, confirming the specificity of secondary antibody binding (Fig. 7a, c) .", [["BIEC-c4 cells", "ANATOMY", 6, 19], ["serum", "ANATOMY", 70, 75], ["BIEC-c4 cells", "CELL", 6, 19], ["chicken", "ORGANISM", 62, 69], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["HPV", "ORGANISM", 111, 114], ["E6", "GENE_OR_GENE_PRODUCT", 115, 117], ["BIEC-c4 cells", "CELL_LINE", 6, 19], ["primary antibody", "PROTEIN", 28, 44], ["HPV E6 protein", "PROTEIN", 111, 125], ["secondary antibody", "PROTEIN", 157, 175], ["chicken", "SPECIES", 62, 69], ["chicken", "SPECIES", 62, 69], ["HPV", "SPECIES", 111, 114], ["BIEC-c4 cells", "PROBLEM", 6, 19], ["primary antibody", "PROBLEM", 28, 44], ["1% chicken serum", "TEST", 59, 75], ["any staining", "PROBLEM", 90, 102], ["the HPV E6 protein", "TEST", 107, 125], ["secondary antibody binding", "PROBLEM", 157, 183], ["c4 cells", "OBSERVATION", 11, 19], ["no", "UNCERTAINTY", 25, 27], ["primary", "OBSERVATION_MODIFIER", 28, 35], ["antibody", "OBSERVATION", 36, 44]]], ["Analysis of the tight junction formation and polarization of BIEC-c4 cells was performed by measuring the transepithelial electrical resistance (TEER) for both BIEC-c4 cells and IPEC-J2 as positive control cells every 24 h, over a period of 7 days.", [["tight junction", "ANATOMY", 16, 30], ["BIEC-c4 cells", "ANATOMY", 61, 74], ["transepithelial", "ANATOMY", 106, 121], ["BIEC-c4 cells", "ANATOMY", 160, 173], ["IPEC-J2", "ANATOMY", 178, 185], ["cells", "ANATOMY", 206, 211], ["tight junction", "CELLULAR_COMPONENT", 16, 30], ["BIEC-c4 cells", "CELL", 61, 74], ["BIEC-c4 cells", "CELL", 160, 173], ["IPEC-J2", "CELL", 178, 185], ["cells", "CELL", 206, 211], ["BIEC-c4 cells", "CELL_LINE", 61, 74], ["BIEC", "CELL_LINE", 160, 164], ["c4 cells", "CELL_LINE", 165, 173], ["IPEC-J2", "CELL_LINE", 178, 185], ["positive control cells", "CELL_LINE", 189, 211], ["Analysis", "TEST", 0, 8], ["the tight junction formation", "PROBLEM", 12, 40], ["polarization of BIEC-c4 cells", "PROBLEM", 45, 74], ["the transepithelial electrical resistance", "TEST", 102, 143], ["both BIEC-c4 cells", "TREATMENT", 155, 173], ["IPEC", "TEST", 178, 182], ["tight junction", "OBSERVATION", 16, 30], ["polarization", "OBSERVATION_MODIFIER", 45, 57], ["c4 cells", "OBSERVATION", 66, 74], ["transepithelial electrical resistance", "OBSERVATION", 106, 143], ["c4 cells", "OBSERVATION", 165, 173], ["J2", "ANATOMY", 183, 185]]], ["The resistance of BIEC-c4 cells did not increase with time and remained the same as the negative control well (filter without cells), varying between 101 and 124 X. In contrast, the measurement of resistance in IPEC-J2 cells increased every 24 h until day 5, beginning at 154 X, and then reaching a maximum of 2830 X on day 5 (data not shown).Growth kinetics analysis of early passage and immortalized BIECsGrowth kinetics was studied for all four types of BIECs.", [["BIEC-c4 cells", "ANATOMY", 18, 31], ["cells", "ANATOMY", 126, 131], ["IPEC-J2 cells", "ANATOMY", 211, 224], ["BIECs", "ANATOMY", 457, 462], ["BIEC-c4 cells", "CELL", 18, 31], ["cells", "CELL", 126, 131], ["IPEC-J2 cells", "CELL", 211, 224], ["BIECs", "CELL", 457, 462], ["BIEC-c4 cells", "CELL_LINE", 18, 31], ["IPEC-J2 cells", "CELL_LINE", 211, 224], ["BIECs", "CELL_TYPE", 457, 462], ["BIEC-c4 cells", "TREATMENT", 18, 31], ["resistance in IPEC-J2 cells", "TREATMENT", 197, 224], ["Growth kinetics analysis", "TEST", 343, 367], ["early passage", "PROBLEM", 371, 384], ["resistance", "OBSERVATION_MODIFIER", 4, 14], ["c4 cells", "OBSERVATION", 23, 31], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["early", "OBSERVATION_MODIFIER", 371, 376], ["passage", "OBSERVATION_MODIFIER", 377, 384]]], ["Cells were counted every 24 h, beginning on day 2, until day 6.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5]]], ["Growth curves were plotted and mean doubling time was calculated for all four BIEC cell types (Fig. 8a) .", [["BIEC cell", "ANATOMY", 78, 87], ["BIEC cell", "CELL", 78, 87], ["BIEC cell types", "CELL_LINE", 78, 93], ["Growth curves", "TEST", 0, 13]]], ["BIEC-c4, SV40-BIEC, hTERT-BIEC, and HPV-BIEC cell lines had a mean doubling time of 14.16 h, 14.26 h, 13.33 h, and 13.26 h respectively (Fig. 8b) .", [["BIEC-c4", "ANATOMY", 0, 7], ["HPV-BIEC cell lines", "ANATOMY", 36, 55], ["BIEC-c4", "CELL", 0, 7], ["SV40", "ORGANISM", 9, 13], ["BIEC", "CELL", 14, 18], ["hTERT", "GENE_OR_GENE_PRODUCT", 20, 25], ["HPV-BIEC cell lines", "CELL", 36, 55], ["BIEC-c4, SV40-BIEC, hTERT-BIEC, and HPV-BIEC cell lines", "CELL_LINE", 0, 55], ["BIEC", "TEST", 0, 4], ["SV40", "TEST", 9, 13], ["BIEC", "TEST", 14, 18], ["hTERT", "TEST", 20, 25], ["BIEC", "TEST", 26, 30], ["HPV", "TEST", 36, 39], ["c4", "ANATOMY", 5, 7], ["cell lines", "OBSERVATION", 45, 55]]], ["There was no significant difference in the mean doubling time between BIEC-c4 cells and immortalized BIECs.Analysis of TLR expression in early passage and immortalized BIECsTwo-step real-time RT-PCR was performed on the early passage BIEC-c4 cells and all three immortalized BIECs.", [["BIEC-c4 cells", "ANATOMY", 70, 83], ["BIECs", "ANATOMY", 101, 106], ["BIECs", "ANATOMY", 168, 173], ["BIEC-c4 cells", "ANATOMY", 234, 247], ["BIECs", "ANATOMY", 275, 280], ["BIEC-c4 cells", "CELL", 70, 83], ["BIECs", "CELL", 101, 106], ["TLR", "GENE_OR_GENE_PRODUCT", 119, 122], ["BIECs", "CELL", 168, 173], ["BIEC-c4 cells", "CELL", 234, 247], ["BIECs", "CELL", 275, 280], ["BIEC-c4 cells", "CELL_LINE", 70, 83], ["immortalized BIECs", "CELL_LINE", 88, 106], ["TLR", "PROTEIN", 119, 122], ["immortalized BIECs", "CELL_LINE", 155, 173], ["BIEC", "CELL_LINE", 234, 238], ["c4 cells", "CELL_LINE", 239, 247], ["immortalized BIECs", "CELL_LINE", 262, 280], ["significant difference", "PROBLEM", 13, 35], ["BIEC-c4 cells", "TREATMENT", 70, 83], ["TLR expression", "PROBLEM", 119, 133], ["RT-PCR", "TEST", 192, 198], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["c4 cells", "OBSERVATION", 75, 83], ["TLR expression", "OBSERVATION", 119, 133], ["c4 cells", "OBSERVATION", 239, 247]]], ["Altogether, ten TLRs were tested for mRNA gene expression using specific primers, and Ct values were normalized using the housekeeping gene, HPRT-1 ( Table 2 ).", [["TLRs", "GENE_OR_GENE_PRODUCT", 16, 20], ["HPRT-1", "GENE_OR_GENE_PRODUCT", 141, 147], ["TLRs", "PROTEIN", 16, 20], ["housekeeping gene", "DNA", 122, 139], ["HPRT-1", "DNA", 141, 147], ["mRNA gene expression", "PROBLEM", 37, 57], ["specific primers", "TEST", 64, 80], ["Ct values", "TEST", 86, 95], ["HPRT", "TEST", 141, 145]]], ["The mean Ct value and standard deviation for the housekeeping HPRT-1 gene in early passage BIEC-c4 cells was 23.53 \u00b1 0.45.", [["BIEC-c4 cells", "ANATOMY", 91, 104], ["HPRT-1", "GENE_OR_GENE_PRODUCT", 62, 68], ["early passage BIEC-c4 cells", "CELL", 77, 104], ["housekeeping HPRT-1 gene", "DNA", 49, 73], ["BIEC", "CELL_LINE", 91, 95], ["c4 cells", "CELL_LINE", 96, 104], ["The mean Ct value", "TEST", 0, 17], ["standard deviation", "TEST", 22, 40], ["the housekeeping HPRT", "TEST", 45, 66], ["early passage BIEC-c4 cells", "TEST", 77, 104]]], ["The mean Ct values for other three immortalized cell lines also did not vary significantly from BIEC-c4 cells.", [["cell lines", "ANATOMY", 48, 58], ["BIEC-c4 cells", "ANATOMY", 96, 109], ["cell lines", "CELL", 48, 58], ["BIEC-c4 cells", "CELL", 96, 109], ["immortalized cell lines", "CELL_LINE", 35, 58], ["BIEC-c4 cells", "CELL_LINE", 96, 109], ["The mean Ct values", "TEST", 0, 18], ["other three immortalized cell lines", "PROBLEM", 23, 58], ["immortalized cell lines", "OBSERVATION", 35, 58], ["c4 cells", "OBSERVATION", 101, 109]]], ["Primary and immortalized BIEC-c4 cells expressed all ten (Fig. 9 ).", [["Primary", "ANATOMY", 0, 7], ["BIEC-c4 cells", "ANATOMY", 25, 38], ["BIEC-c4 cells", "CELL", 25, 38], ["Primary and immortalized BIEC", "CELL_LINE", 0, 29], ["c4 cells", "CELL_LINE", 30, 38], ["c4 cells", "OBSERVATION", 30, 38]]], ["Gene expression for each TLR was compared between early passage and immortalized cell types.", [["cell", "ANATOMY", 81, 85], ["TLR", "GENE_OR_GENE_PRODUCT", 25, 28], ["cell", "CELL", 81, 85], ["TLR", "PROTEIN", 25, 28], ["immortalized cell types", "CELL_LINE", 68, 91], ["immortalized cell types", "OBSERVATION", 68, 91]]], ["There were no significant differences in gene expression among the early passage and (Table 1 ) and products were resolved on 1.5% agarose gel for the confirmation of hTERT gene in hTERT-BIEC DNA (a); SV40 gene in SV40-BIEC DNA (b); and E6/E7 gene in HPV-BIEC DNA (c) Fig. 6 Immunocytochemical staining for SV40 and hTERT proteins.", [["agarose", "SIMPLE_CHEMICAL", 131, 138], ["hTERT", "GENE_OR_GENE_PRODUCT", 167, 172], ["hTERT", "GENE_OR_GENE_PRODUCT", 181, 186], ["DNA", "CELLULAR_COMPONENT", 192, 195], ["SV40", "ORGANISM", 201, 205], ["SV40", "ORGANISM", 214, 218], ["-BIEC DNA", "GENE_OR_GENE_PRODUCT", 218, 227], ["E6", "GENE_OR_GENE_PRODUCT", 237, 239], ["E7", "GENE_OR_GENE_PRODUCT", 240, 242], ["SV40", "ORGANISM", 307, 311], ["hTERT", "GENE_OR_GENE_PRODUCT", 316, 321], ["hTERT gene", "DNA", 167, 177], ["hTERT", "DNA", 181, 186], ["BIEC DNA", "DNA", 187, 195], ["SV40 gene", "DNA", 201, 210], ["SV40", "DNA", 214, 218], ["BIEC DNA", "DNA", 219, 227], ["E6/E7 gene", "DNA", 237, 247], ["HPV-BIEC DNA", "DNA", 251, 263], ["SV40 and hTERT proteins", "PROTEIN", 307, 330], ["significant differences in gene expression", "PROBLEM", 14, 56], ["1.5% agarose gel", "TREATMENT", 126, 142], ["the confirmation", "TEST", 147, 163], ["hTERT gene in hTERT", "PROBLEM", 167, 186], ["SV40 gene in SV40", "TEST", 201, 218], ["E6/E7 gene", "TEST", 237, 247], ["HPV", "TEST", 251, 254], ["Immunocytochemical staining", "TEST", 275, 302], ["SV40", "PROBLEM", 307, 311], ["hTERT proteins", "PROBLEM", 316, 330], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["BIEC-c4 cells at passage 61 (a) and SV40-BIECs at passage 58 (b) were stained for SV40 protein with mouse SV40specific monoclonal IgG2a Ab.", [["BIEC-c4 cells", "ANATOMY", 0, 13], ["BIECs", "ANATOMY", 41, 46], ["BIEC-c4 cells", "CELL", 0, 13], ["SV40", "ORGANISM", 36, 40], ["BIECs", "CELL", 41, 46], ["SV40", "ORGANISM", 82, 86], ["mouse", "ORGANISM", 100, 105], ["BIEC-c4 cells", "CELL_LINE", 0, 13], ["SV40 protein", "PROTEIN", 82, 94], ["mouse SV40specific monoclonal IgG2a", "PROTEIN", 100, 135], ["mouse", "SPECIES", 100, 105], ["mouse", "SPECIES", 100, 105], ["BIEC", "TEST", 0, 4], ["c4 cells", "PROBLEM", 5, 13], ["SV40", "TEST", 36, 40], ["BIECs", "TEST", 41, 46], ["SV40 protein", "TEST", 82, 94], ["c4 cells", "OBSERVATION", 5, 13], ["monoclonal IgG2a", "OBSERVATION", 119, 135]]], ["BIEC-c4 cells at passage 34 (c) and hTERT-BIECs at passage 32 (d) were stained for hTERT protein with rabbit hTERT-specific polyclonal IgG Ab.", [["BIEC-c4 cells", "ANATOMY", 0, 13], ["hTERT-BIECs", "ANATOMY", 36, 47], ["BIEC-c4 cells", "CELL", 0, 13], ["c", "CELL", 29, 30], ["hTERT", "GENE_OR_GENE_PRODUCT", 36, 41], ["hTERT", "GENE_OR_GENE_PRODUCT", 83, 88], ["rabbit", "ORGANISM", 102, 108], ["hTERT", "GENE_OR_GENE_PRODUCT", 109, 114], ["BIEC-c4 cells", "CELL_LINE", 0, 13], ["hTERT", "PROTEIN", 36, 41], ["hTERT protein", "PROTEIN", 83, 96], ["hTERT", "PROTEIN", 109, 114], ["rabbit", "SPECIES", 102, 108], ["rabbit", "SPECIES", 102, 108], ["BIEC", "TEST", 0, 4], ["c4 cells", "PROBLEM", 5, 13], ["passage", "TEST", 17, 24], ["hTERT", "TEST", 36, 41], ["BIECs", "TEST", 42, 47], ["hTERT protein", "TEST", 83, 96], ["rabbit hTERT", "TEST", 102, 114], ["c4 cells", "OBSERVATION", 5, 13]]], ["Pictures were taken at 20 9 magnification and scale bar indicates 50 lm length immortalized BIEC-c4 for any of the TLRs tested.", [["BIEC-c4", "ANATOMY", 92, 99], ["BIEC-c4", "CELL", 92, 99], ["BIEC", "PROTEIN", 92, 96], ["c4", "CELL_LINE", 97, 99], ["TLRs", "PROTEIN", 115, 119], ["Pictures", "TEST", 0, 8]]], ["In general, TLRs 3 and 4 showed relatively strong expression, while TLRs 1, 6, and 10 showed relatively low expression for all four cell types (Fig. 9) .Maintenance of bovine intestinal epithelial cells by continuous cultureEarly passage BIEC-c4 cells, SV40-BIECs, hTERT-BIECs, and HPV-BIECs were each cultured in T25 flasks and were maintained by passaging them every 96 h.", [["cell", "ANATOMY", 132, 136], ["intestinal epithelial cells", "ANATOMY", 175, 202], ["BIEC-c4 cells", "ANATOMY", 238, 251], ["SV40-BIECs", "ANATOMY", 253, 263], ["hTERT-BIECs", "ANATOMY", 265, 276], ["HPV-BIECs", "ANATOMY", 282, 291], ["TLRs 3", "GENE_OR_GENE_PRODUCT", 12, 18], ["4", "GENE_OR_GENE_PRODUCT", 23, 24], ["TLRs 1", "GENE_OR_GENE_PRODUCT", 68, 74], ["6", "GENE_OR_GENE_PRODUCT", 76, 77], ["10", "GENE_OR_GENE_PRODUCT", 83, 85], ["cell", "CELL", 132, 136], ["bovine", "ORGANISM", 168, 174], ["intestinal epithelial cells", "CELL", 175, 202], ["BIEC-c4 cells", "CELL", 238, 251], ["SV40", "ORGANISM", 253, 257], ["BIECs", "CELL", 258, 263], ["hTERT", "GENE_OR_GENE_PRODUCT", 265, 270], ["HPV-BIECs", "ORGANISM", 282, 291], ["TLRs 3 and 4", "PROTEIN", 12, 24], ["TLRs 1, 6, and 10", "PROTEIN", 68, 85], ["bovine intestinal epithelial cells", "CELL_TYPE", 168, 202], ["continuous cultureEarly passage BIEC", "CELL_LINE", 206, 242], ["c4 cells", "CELL_LINE", 243, 251], ["BIECs", "CELL_LINE", 258, 263], ["hTERT", "PROTEIN", 265, 270], ["BIECs", "CELL_LINE", 271, 276], ["bovine", "SPECIES", 168, 174], ["bovine", "SPECIES", 168, 174], ["TLRs", "TEST", 12, 16], ["TLRs", "TEST", 68, 72], ["relatively low expression", "PROBLEM", 93, 118], ["bovine intestinal epithelial cells", "TREATMENT", 168, 202], ["continuous cultureEarly passage", "TEST", 206, 237], ["BIEC", "TEST", 238, 242], ["c4 cells", "TEST", 243, 251], ["SV40", "TEST", 253, 257], ["BIECs", "TEST", 258, 263], ["hTERT", "TEST", 265, 270], ["BIECs", "TEST", 271, 276], ["HPV", "TEST", 282, 285], ["BIECs", "TEST", 286, 291], ["bovine intestinal epithelial cells", "OBSERVATION", 168, 202]]], ["Supplemented DMEM/F12 media was replaced with fresh media every 48 h to maintain the normal cellular physiological conditions.", [["cellular", "ANATOMY", 92, 100], ["cellular", "CELL", 92, 100], ["Supplemented DMEM/F12 media", "TREATMENT", 0, 27], ["fresh media", "TREATMENT", 46, 57], ["normal cellular physiological conditions", "OBSERVATION", 85, 125]]], ["All the four BIEC types were free of microbial contamination and retained their viability throughout the culture period.Maintenance of bovine intestinal epithelial cells by continuous cultureBIEC-c4, SV40-BIEC, hTERT-BIEC, and HPV-BIEC cells were maintained in continuous cultures for 109, 148, 103, and 106 passages respectively.DiscussionMixed bovine ileal epithelial and fibroblast-like cells established from a 2-day old calf in DMEM-2 up to passage 4 were cultured in supplemented DMEM/F12 medium for the enrichment of epithelial cells up to 8 passages.", [["intestinal epithelial cells", "ANATOMY", 142, 169], ["cultureBIEC-c4", "ANATOMY", 184, 198], ["HPV-BIEC cells", "ANATOMY", 227, 241], ["ileal epithelial", "ANATOMY", 353, 369], ["fibroblast-like cells", "ANATOMY", 374, 395], ["epithelial cells", "ANATOMY", 524, 540], ["bovine", "ORGANISM", 135, 141], ["intestinal epithelial cells", "CELL", 142, 169], ["cultureBIEC-c4", "CELL", 184, 198], ["SV40", "ORGANISM", 200, 204], ["BIEC", "CELL", 205, 209], ["hTERT", "GENE_OR_GENE_PRODUCT", 211, 216], ["HPV-BIEC cells", "CELL", 227, 241], ["bovine", "ORGANISM", 346, 352], ["ileal epithelial", "CELL", 353, 369], ["fibroblast-like cells", "CELL", 374, 395], ["calf", "ORGANISM", 425, 429], ["DMEM-2", "CELL", 433, 439], ["epithelial cells", "CELL", 524, 540], ["bovine intestinal epithelial cells", "CELL_TYPE", 135, 169], ["continuous cultureBIEC-c4, SV40-BIEC, hTERT-BIEC, and HPV-BIEC cells", "CELL_LINE", 173, 241], ["Mixed bovine ileal epithelial and fibroblast-like cells", "CELL_LINE", 340, 395], ["epithelial cells", "CELL_TYPE", 524, 540], ["bovine", "SPECIES", 135, 141], ["bovine", "SPECIES", 346, 352], ["calf", "SPECIES", 425, 429], ["bovine", "SPECIES", 135, 141], ["microbial contamination", "PROBLEM", 37, 60], ["bovine intestinal epithelial cells", "TREATMENT", 135, 169], ["continuous cultureBIEC", "TEST", 173, 195], ["SV40", "TEST", 200, 204], ["BIEC", "TEST", 205, 209], ["hTERT", "TEST", 211, 216], ["BIEC", "TEST", 217, 221], ["HPV", "TEST", 227, 230], ["BIEC cells", "PROBLEM", 231, 241], ["continuous cultures", "TEST", 261, 280], ["Mixed bovine ileal epithelial and fibroblast-like cells", "PROBLEM", 340, 395], ["a 2-day old calf in DMEM", "TREATMENT", 413, 437], ["epithelial cells", "PROBLEM", 524, 540], ["microbial contamination", "OBSERVATION", 37, 60], ["viability", "OBSERVATION_MODIFIER", 80, 89], ["bovine intestinal epithelial cells", "OBSERVATION", 135, 169], ["ileal epithelial", "ANATOMY", 353, 369], ["fibroblast", "ANATOMY", 374, 384], ["calf", "ANATOMY", 425, 429], ["epithelial cells", "OBSERVATION", 524, 540]]], ["Pure epithelial cell clone designated as BIEC-c4 was established from passage 8 and characterized for the epithelial phenotype.", [["epithelial cell clone", "ANATOMY", 5, 26], ["BIEC-c4", "ANATOMY", 41, 48], ["epithelial", "ANATOMY", 106, 116], ["epithelial cell clone", "CELL", 5, 26], ["BIEC-c4", "CELL", 41, 48], ["epithelial", "TISSUE", 106, 116], ["Pure epithelial cell clone", "CELL_LINE", 0, 26], ["BIEC-c4", "CELL_LINE", 41, 48], ["Pure epithelial cell clone", "PROBLEM", 0, 26], ["the epithelial phenotype", "PROBLEM", 102, 126], ["epithelial cell clone", "OBSERVATION", 5, 26], ["epithelial phenotype", "OBSERVATION", 106, 126]]], ["Further, BIEC-c4 early passage cells were immortalized using SV40, hTERT, and HPV E6/E7 genes and were designated as Ultrastructure of intestinal epithelial cells show microvilli and tight junctions (Chopra et al. 2010; Miyazawa et al. 2010) .", [["BIEC-c4 early passage cells", "ANATOMY", 9, 36], ["intestinal epithelial cells", "ANATOMY", 135, 162], ["microvilli", "ANATOMY", 168, 178], ["tight junctions", "ANATOMY", 183, 198], ["BIEC-c4", "CELL", 9, 16], ["cells", "CELL", 31, 36], ["SV40", "ORGANISM", 61, 65], ["hTERT", "GENE_OR_GENE_PRODUCT", 67, 72], ["HPV E6", "ORGANISM", 78, 84], ["E7", "GENE_OR_GENE_PRODUCT", 85, 87], ["intestinal epithelial cells", "CELL", 135, 162], ["microvilli", "CELL", 168, 178], ["tight junctions", "CELLULAR_COMPONENT", 183, 198], ["BIEC-c4 early passage cells", "CELL_LINE", 9, 36], ["SV40, hTERT, and HPV E6/E7 genes", "DNA", 61, 93], ["intestinal epithelial cells", "CELL_TYPE", 135, 162], ["BIEC", "TEST", 9, 13], ["c4 early passage cells", "PROBLEM", 14, 36], ["SV40", "TEST", 61, 65], ["hTERT", "TEST", 67, 72], ["HPV E6/E7 genes", "TEST", 78, 93], ["passage cells", "OBSERVATION", 23, 36], ["intestinal", "ANATOMY", 135, 145], ["epithelial cells", "OBSERVATION", 146, 162], ["tight junctions", "OBSERVATION", 183, 198]]], ["When cultured on filter inserts, intestinal epithelial cells have been reported to form tight junctions, as evident from the measurement of high TEER values (Johnson et al. 2010; Miyazawa et al. 2010) .", [["intestinal epithelial cells", "ANATOMY", 33, 60], ["tight junctions", "ANATOMY", 88, 103], ["intestinal epithelial cells", "CELL", 33, 60], ["tight junctions", "CELLULAR_COMPONENT", 88, 103], ["intestinal epithelial cells", "CELL_TYPE", 33, 60], ["filter inserts", "TREATMENT", 17, 31], ["intestinal epithelial cells", "PROBLEM", 33, 60], ["intestinal", "ANATOMY", 33, 43], ["epithelial cells", "OBSERVATION", 44, 60], ["tight junctions", "OBSERVATION", 88, 103]]], ["In this study, primary BIECs along with porcine intestinal epithelial cells (IPEC-J2) as a positive control were cultured on transwell-inserts for cell polarization and TEER readings were taken over a period of 7 days (Johnson et al. 2010 ).", [["BIECs", "ANATOMY", 23, 28], ["intestinal epithelial cells", "ANATOMY", 48, 75], ["IPEC-J2", "ANATOMY", 77, 84], ["cell", "ANATOMY", 147, 151], ["BIECs", "CELL", 23, 28], ["porcine", "ORGANISM", 40, 47], ["intestinal epithelial cells", "CELL", 48, 75], ["IPEC-J2", "CELL", 77, 84], ["cell", "CELL", 147, 151], ["primary BIECs", "CELL_TYPE", 15, 28], ["porcine intestinal epithelial cells", "CELL_TYPE", 40, 75], ["IPEC", "CELL_LINE", 77, 81], ["J2", "CELL_LINE", 82, 84], ["porcine", "SPECIES", 40, 47], ["porcine", "SPECIES", 40, 47], ["this study", "TEST", 3, 13], ["primary BIECs", "PROBLEM", 15, 28], ["porcine intestinal epithelial cells", "TREATMENT", 40, 75], ["transwell", "TEST", 125, 134], ["cell polarization", "TREATMENT", 147, 164], ["TEER readings", "TEST", 169, 182], ["porcine", "ANATOMY_MODIFIER", 40, 47], ["intestinal", "ANATOMY", 48, 58], ["epithelial cells", "OBSERVATION", 59, 75], ["cell polarization", "OBSERVATION", 147, 164]]], ["The BIEC-c4 cells did not show an increase in TEER values, confirming that polarization of cells did not occur.", [["BIEC-c4 cells", "ANATOMY", 4, 17], ["cells", "ANATOMY", 91, 96], ["BIEC-c4 cells", "CELL", 4, 17], ["cells", "CELL", 91, 96], ["BIEC-c4 cells", "CELL_LINE", 4, 17], ["The BIEC-c4 cells", "TEST", 0, 17], ["an increase in TEER values", "PROBLEM", 31, 57], ["polarization of cells", "PROBLEM", 75, 96], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["TEER values", "OBSERVATION", 46, 57]]], ["This may be attributed to the inability of BIEC-c4 cells to form tight junctions.", [["BIEC-c4 cells", "ANATOMY", 43, 56], ["tight junctions", "ANATOMY", 65, 80], ["BIEC-c4 cells", "CELL", 43, 56], ["tight junctions", "CELLULAR_COMPONENT", 65, 80], ["BIEC-c4 cells", "CELL_LINE", 43, 56], ["BIEC-c4 cells", "TREATMENT", 43, 56], ["may be attributed to", "UNCERTAINTY", 5, 25], ["c4 cells", "OBSERVATION", 48, 56], ["tight junctions", "OBSERVATION", 65, 80]]], ["The BIEC-c4 cells could be tested in further studies for the expression level of tight junction proteins (Anderson and Van Itallie 1995; Chaudhary et al. 2018; McNeil et al. 2006; Miyazawa et al. 2010) .", [["BIEC-c4 cells", "ANATOMY", 4, 17], ["tight junction", "ANATOMY", 81, 95], ["BIEC-c4 cells", "CELL", 4, 17], ["BIEC-c4 cells", "CELL_LINE", 4, 17], ["tight junction proteins", "PROTEIN", 81, 104], ["The BIEC-c4 cells", "TEST", 0, 17], ["further studies", "TEST", 37, 52], ["c4 cells", "OBSERVATION", 9, 17]]], ["In an earlier study, fetalderived bovine duodenal epithelial cells not only showed high TEER values but also strongly expressed both zonula occludens-1 (ZO-1) and beta-catenin (Miyazawa et al. 2010) .", [["duodenal epithelial cells", "ANATOMY", 41, 66], ["bovine", "ORGANISM", 34, 40], ["duodenal epithelial cells", "CELL", 41, 66], ["zonula occludens-1", "GENE_OR_GENE_PRODUCT", 133, 151], ["ZO-1", "GENE_OR_GENE_PRODUCT", 153, 157], ["beta-catenin", "GENE_OR_GENE_PRODUCT", 163, 175], ["fetalderived bovine duodenal epithelial cells", "CELL_LINE", 21, 66], ["zonula occludens-1", "PROTEIN", 133, 151], ["beta-catenin", "PROTEIN", 163, 175], ["bovine", "SPECIES", 34, 40], ["bovine", "SPECIES", 34, 40], ["an earlier study", "TEST", 3, 19], ["fetalderived bovine duodenal epithelial cells", "PROBLEM", 21, 66], ["high TEER values", "PROBLEM", 83, 99], ["zonula occludens", "TEST", 133, 149], ["duodenal", "ANATOMY", 41, 49], ["epithelial cells", "OBSERVATION", 50, 66], ["zonula occludens", "OBSERVATION", 133, 149]]], ["In corneal epithelial cells, ZO-1 protein had been shown to regulate epithelial phenotype and cell differentiation (Ryeom et al. 2000) .", [["corneal epithelial cells", "ANATOMY", 3, 27], ["epithelial", "ANATOMY", 69, 79], ["cell", "ANATOMY", 94, 98], ["corneal epithelial cells", "CELL", 3, 27], ["ZO-1", "GENE_OR_GENE_PRODUCT", 29, 33], ["epithelial", "CELL", 69, 79], ["cell", "CELL", 94, 98], ["corneal epithelial cells", "CELL_TYPE", 3, 27], ["ZO-1 protein", "PROTEIN", 29, 41], ["corneal epithelial cells", "TEST", 3, 27], ["ZO-1 protein", "TEST", 29, 41], ["epithelial phenotype", "PROBLEM", 69, 89], ["corneal", "ANATOMY", 3, 10], ["epithelial cells", "OBSERVATION", 11, 27], ["epithelial phenotype", "OBSERVATION", 69, 89], ["cell differentiation", "OBSERVATION", 94, 114]]], ["It will be useful to evaluate the expression of tight junction proteins in response to specific soluble factors like cytokines or culture conditions which may enable the BIEC-c4 cells to get polarized.DiscussionBased on growth kinetics analysis, the three immortalized BIEC cell types established in this study did not show any significant differences in mean doubling time as compared to BIEC-c4 cells.", [["tight junction", "ANATOMY", 48, 62], ["BIEC-c4 cells", "ANATOMY", 170, 183], ["BIEC cell", "ANATOMY", 269, 278], ["BIEC-c4 cells", "ANATOMY", 389, 402], ["tight junction proteins", "GENE_OR_GENE_PRODUCT", 48, 71], ["BIEC-c4 cells", "CELL", 170, 183], ["BIEC cell", "CELL", 269, 278], ["BIEC-c4 cells", "CELL", 389, 402], ["tight junction proteins", "PROTEIN", 48, 71], ["soluble factors", "PROTEIN", 96, 111], ["cytokines", "PROTEIN", 117, 126], ["BIEC-c4 cells", "CELL_LINE", 170, 183], ["immortalized BIEC cell types", "CELL_LINE", 256, 284], ["BIEC-c4 cells", "CELL_LINE", 389, 402], ["tight junction proteins", "PROBLEM", 48, 71], ["specific soluble factors", "TREATMENT", 87, 111], ["cytokines", "PROBLEM", 117, 126], ["culture conditions", "PROBLEM", 130, 148], ["the BIEC-c4 cells", "TREATMENT", 166, 183], ["growth kinetics analysis", "TEST", 220, 244], ["this study", "TEST", 300, 310], ["BIEC cell", "OBSERVATION", 269, 278], ["c4 cells", "OBSERVATION", 394, 402]]], ["All four Fig. 8 Growth kinetics analysis of BIEC-c4 cells and immortalized BIECs. a Growth curve for BIEC-c4 (passage # 51), SV40-BIEC (passage # 90), hTERT-BIEC (passage # 48), and HPV-BIEC (passage # 48).", [["BIEC-c4 cells", "ANATOMY", 44, 57], ["BIECs", "ANATOMY", 75, 80], ["BIEC-c4 cells", "CELL", 44, 57], ["BIECs", "CELL", 75, 80], ["BIEC-c4", "CELL", 101, 108], ["SV40", "ORGANISM", 125, 129], ["hTERT", "GENE_OR_GENE_PRODUCT", 151, 156], ["HPV", "ORGANISM", 182, 185], ["BIEC-c4 cells", "CELL_LINE", 44, 57], ["immortalized BIECs", "CELL_LINE", 62, 80], ["hTERT", "PROTEIN", 151, 156], ["Growth kinetics analysis", "TEST", 16, 40], ["BIEC-c4 cells", "TREATMENT", 44, 57], ["a Growth curve", "TEST", 82, 96], ["BIEC", "TEST", 101, 105], ["SV40", "TEST", 125, 129], ["hTERT", "TEST", 151, 156], ["HPV", "TEST", 182, 185], ["four Fig", "OBSERVATION_MODIFIER", 4, 12], ["c4 cells", "OBSERVATION", 49, 57]]], ["On day 0, 20,000 cells were plated on five 6-well plates for each cell type.", [["cells", "ANATOMY", 17, 22], ["cell", "ANATOMY", 66, 70], ["cells", "CELL", 17, 22], ["cell type", "CELL", 66, 75], ["cell type", "OBSERVATION", 66, 75]]], ["Beginning on day 2, until day 6, cells were trypsinized every 24 h and counted using hemocytometer. b Analysis of doubling time for BIEC-c4 and immortalized BIECs.", [["cells", "ANATOMY", 33, 38], ["BIEC-c4", "ANATOMY", 132, 139], ["BIECs", "ANATOMY", 157, 162], ["cells", "CELL", 33, 38], ["BIEC-c4", "CELL", 132, 139], ["BIECs", "CELL", 157, 162], ["BIEC-c4 and immortalized BIECs", "CELL_LINE", 132, 162], ["BIEC-c4", "TREATMENT", 132, 139]]], ["Mean doubling time was calculated from three independent experiments (n = 3) for each cell type.", [["cell", "ANATOMY", 86, 90], ["cell type", "CELL", 86, 95], ["Mean doubling time", "TEST", 0, 18]]], ["Twotailed t test was performed to compare mean doubling time between BIEC-c4 and each of the three immortalized BIECs.", [["BIECs", "ANATOMY", 112, 117], ["BIEC-c4", "CELL", 69, 76], ["BIECs", "CELL", 112, 117], ["BIEC", "PROTEIN", 69, 73], ["c4", "CELL_LINE", 74, 76], ["immortalized BIECs", "CELL_LINE", 99, 117], ["Twotailed t test", "TEST", 0, 16], ["BIEC-c4", "TREATMENT", 69, 76]]], ["P value \u00a00.05 was considered as statistically significant.", [["P value", "TEST", 0, 7]]], ["Bars represent standard error of the mean Fig. 9 TLRs 1-10 expression in BIEC-c4 cells (passages 55-58) and immortalized BIECs.", [["BIEC-c4 cells", "ANATOMY", 73, 86], ["BIECs", "ANATOMY", 121, 126], ["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["1-10", "GENE_OR_GENE_PRODUCT", 54, 58], ["BIEC-c4 cells", "CELL", 73, 86], ["BIECs", "CELL", 121, 126], ["TLRs", "PROTEIN", 49, 53], ["BIEC-c4 cells", "CELL_LINE", 73, 86], ["immortalized BIECs", "CELL_LINE", 108, 126], ["BIEC-c4 cells", "TEST", 73, 86], ["passages", "TEST", 88, 96], ["standard error", "OBSERVATION", 15, 29], ["mean Fig", "OBSERVATION", 37, 45], ["c4 cells", "ANATOMY", 78, 86]]], ["In this study, SV40-BIEC at passages 38-41, hTERT-BIEC at passages 32-36, and HPV-BIEC at passages 44-47 were used.", [["SV40", "ORGANISM", 15, 19], ["BIEC", "CELL", 20, 24], ["hTERT", "GENE_OR_GENE_PRODUCT", 44, 49], ["HPV-BIEC", "ORGANISM", 78, 86], ["BIEC", "DNA", 20, 24], ["hTERT", "PROTEIN", 44, 49], ["BIEC", "DNA", 50, 54], ["this study", "TEST", 3, 13], ["SV40", "TEST", 15, 19], ["passages", "TEST", 28, 36], ["hTERT", "TEST", 44, 49], ["BIEC", "TEST", 50, 54], ["passages", "TEST", 58, 66], ["HPV", "TEST", 78, 81], ["passages", "TEST", 90, 98]]], ["Expression levels of each TLR was compared among the four BIEC cell types.", [["BIEC cell", "ANATOMY", 58, 67], ["TLR", "GENE_OR_GENE_PRODUCT", 26, 29], ["BIEC cell", "CELL", 58, 67], ["TLR", "PROTEIN", 26, 29], ["BIEC cell types", "CELL_LINE", 58, 73], ["Expression levels of each TLR", "PROBLEM", 0, 29]]], ["Change in cycle threshold, DCt was used to calculate gene expression for each TLR.", [["TLR", "GENE_OR_GENE_PRODUCT", 78, 81], ["DCt", "PROTEIN", 27, 30], ["TLR", "PROTEIN", 78, 81], ["Change in cycle threshold", "PROBLEM", 0, 25], ["DCt", "TEST", 27, 30]]], ["DCt is calculated relative to HPRT-1 gene.", [["HPRT-1", "GENE_OR_GENE_PRODUCT", 30, 36], ["DCt", "DNA", 0, 3], ["HPRT-1 gene", "DNA", 30, 41], ["DCt", "TEST", 0, 3], ["HPRT", "TEST", 30, 34]]], ["P value \u00a00.05 was considered as statistically significant.", [["P value", "TEST", 0, 7]]], ["Data presented as mean DCt from three independent experiments (n = 3) for each TLR.", [["TLR", "PROTEIN", 79, 82], ["mean DCt", "TEST", 18, 26]]], ["Bars represent standard error of the mean BIEC cell lines were maintained continuously for more than 100 passages and at present, no other study has shown the ability of any primary BIECs to grow continuously for more than 100 passages (Loret et al. 2009 ).", [["BIEC cell lines", "ANATOMY", 42, 57], ["BIECs", "ANATOMY", 182, 187], ["Bars", "GENE_OR_GENE_PRODUCT", 0, 4], ["BIEC cell lines", "CELL", 42, 57], ["BIECs", "CANCER", 182, 187], ["BIEC cell lines", "CELL_LINE", 42, 57], ["primary BIECs", "CELL_TYPE", 174, 187], ["the mean BIEC cell lines", "TREATMENT", 33, 57], ["other study", "TEST", 133, 144], ["standard error", "OBSERVATION", 15, 29], ["cell lines", "OBSERVATION", 47, 57]]], ["It is speculated that primary BIEC-c4 cells may have some stem cell-like characteristics, are less differentiated, and keep growing upon further passaging (Chopra et al. 2010) .", [["BIEC-c4 cells", "ANATOMY", 30, 43], ["stem cell", "ANATOMY", 58, 67], ["BIEC-c4 cells", "CELL", 30, 43], ["stem cell", "CELL", 58, 67], ["primary BIEC-c4 cells", "CELL_LINE", 22, 43], ["primary BIEC-c4 cells", "PROBLEM", 22, 43], ["c4 cells", "OBSERVATION", 35, 43], ["stem cell", "OBSERVATION", 58, 67], ["less differentiated", "OBSERVATION_MODIFIER", 94, 113]]], ["In future studies, the present BIEC cells may be cultured under different culture conditions in an attempt to differentiate them into a mature phenotype (Sanderson et al. 1996) .", [["BIEC cells", "ANATOMY", 31, 41], ["BIEC cells", "CELL", 31, 41], ["BIEC cells", "CELL_LINE", 31, 41], ["future studies", "TEST", 3, 17], ["the present BIEC cells", "TREATMENT", 19, 41], ["different culture conditions", "TEST", 64, 92]]], ["These studies will provide the opportunity to investigate various factors or biological agents involved in intestinal cell differentiation and maturation.", [["intestinal cell", "ANATOMY", 107, 122], ["intestinal cell", "CELL", 107, 122], ["These studies", "TEST", 0, 13], ["various factors", "PROBLEM", 58, 73], ["biological agents", "TREATMENT", 77, 94], ["intestinal cell differentiation", "TREATMENT", 107, 138], ["intestinal cell differentiation", "OBSERVATION", 107, 138]]], ["Thus, the primary BIECs cells established in this study would be of special interest and use in cell biology studies.DiscussionDue to the lack of species-specific homologous cell lines, various heterologous cell lines have been used for studying bovine enteric disease, innate immune response and pathogenesis (Bass et al. 1990; Kaushik et al. 2008; Lee et al. 1998 ).", [["primary BIECs cells", "ANATOMY", 10, 29], ["cell", "ANATOMY", 96, 100], ["cell lines", "ANATOMY", 174, 184], ["cell lines", "ANATOMY", 207, 217], ["enteric disease", "DISEASE", 253, 268], ["BIECs cells", "CELL", 18, 29], ["cell", "CELL", 96, 100], ["cell lines", "CELL", 174, 184], ["cell lines", "CELL", 207, 217], ["bovine", "ORGANISM", 246, 252], ["enteric", "ORGANISM_SUBDIVISION", 253, 260], ["primary BIECs cells", "CELL_LINE", 10, 29], ["homologous cell lines", "CELL_LINE", 163, 184], ["heterologous cell lines", "CELL_LINE", 194, 217], ["bovine", "SPECIES", 246, 252], ["bovine", "SPECIES", 246, 252], ["the primary BIECs cells", "TEST", 6, 29], ["this study", "TEST", 45, 55], ["specific homologous cell lines", "TREATMENT", 154, 184], ["various heterologous cell lines", "TREATMENT", 186, 217], ["bovine enteric disease", "PROBLEM", 246, 268], ["homologous cell lines", "OBSERVATION", 163, 184], ["heterologous cell lines", "OBSERVATION", 194, 217]]], ["In vitro cell culture models derived from bovine intestinal epithelial cells have potential application in the evaluation of drug toxicity, immune regulation, and interaction with different enteric pathogens (Buckner et al. 2006; Chiba et al. 2012; Rusu et al. 2005; Takanashi et al. 2013; Villena et al. 2018) .", [["cell", "ANATOMY", 9, 13], ["intestinal epithelial cells", "ANATOMY", 49, 76], ["toxicity", "DISEASE", 130, 138], ["cell", "CELL", 9, 13], ["bovine", "ORGANISM", 42, 48], ["intestinal epithelial cells", "CELL", 49, 76], ["bovine intestinal epithelial cells", "CELL_TYPE", 42, 76], ["bovine", "SPECIES", 42, 48], ["bovine", "SPECIES", 42, 48], ["vitro cell culture models", "TEST", 3, 28], ["bovine intestinal epithelial cells", "PROBLEM", 42, 76], ["the evaluation", "TEST", 107, 121], ["drug toxicity", "PROBLEM", 125, 138], ["immune regulation", "PROBLEM", 140, 157], ["different enteric pathogens", "PROBLEM", 180, 207], ["vitro cell", "OBSERVATION", 3, 13], ["intestinal", "ANATOMY", 49, 59], ["epithelial cells", "OBSERVATION", 60, 76], ["drug toxicity", "OBSERVATION", 125, 138]]], ["Jejunum and ileal cultures from bovine fetal tissues have been established and characterized for susceptibility to bovine rotavirus infection .", [["Jejunum", "ANATOMY", 0, 7], ["ileal cultures", "ANATOMY", 12, 26], ["fetal tissues", "ANATOMY", 39, 52], ["rotavirus infection", "DISEASE", 122, 141], ["Jejunum", "CELL", 0, 7], ["ileal cultures", "CELL", 12, 26], ["bovine", "ORGANISM", 32, 38], ["fetal tissues", "TISSUE", 39, 52], ["bovine", "ORGANISM", 115, 121], ["rotavirus", "ORGANISM", 122, 131], ["Jejunum and ileal cultures", "CELL_LINE", 0, 26], ["bovine", "SPECIES", 32, 38], ["bovine", "SPECIES", 115, 121], ["bovine", "SPECIES", 32, 38], ["bovine", "SPECIES", 115, 121], ["ileal cultures from bovine fetal tissues", "TEST", 12, 52], ["susceptibility to bovine rotavirus infection", "PROBLEM", 97, 141], ["ileal", "ANATOMY", 12, 17], ["cultures", "OBSERVATION", 18, 26], ["bovine rotavirus infection", "OBSERVATION", 115, 141]]], ["However, this is the first study reporting the development of bovine intestinal epithelial cell lines from a 2-day old calf.DiscussionSeveral challenges are encountered in the isolation and generation of intestinal epithelial cell culture.", [["intestinal epithelial cell lines", "ANATOMY", 69, 101], ["intestinal epithelial cell culture", "ANATOMY", 204, 238], ["bovine", "ORGANISM", 62, 68], ["intestinal epithelial cell lines", "CELL", 69, 101], ["calf", "ORGANISM", 119, 123], ["intestinal epithelial cell culture", "CELL", 204, 238], ["bovine intestinal epithelial cell lines", "CELL_LINE", 62, 101], ["intestinal epithelial cell culture", "CELL_LINE", 204, 238], ["bovine", "SPECIES", 62, 68], ["calf", "SPECIES", 119, 123], ["bovine", "SPECIES", 62, 68], ["the first study", "TEST", 17, 32], ["bovine intestinal epithelial cell lines", "PROBLEM", 62, 101], ["DiscussionSeveral challenges", "TREATMENT", 124, 152], ["the isolation", "TREATMENT", 172, 185], ["intestinal epithelial cell culture", "TEST", 204, 238], ["bovine", "ANATOMY_MODIFIER", 62, 68], ["intestinal", "ANATOMY", 69, 79], ["epithelial cell lines", "OBSERVATION", 80, 101], ["calf", "ANATOMY", 119, 123], ["intestinal", "ANATOMY", 204, 214], ["epithelial cell", "OBSERVATION", 215, 230]]], ["The process is hindered greatly by the high rate of cell death occurring during isolation of the primary cells (Evans et al. 1994; Rusu et al. 2005) .", [["cell", "ANATOMY", 52, 56], ["primary cells", "ANATOMY", 97, 110], ["death", "DISEASE", 57, 62], ["cell", "CELL", 52, 56], ["cells", "CELL", 105, 110], ["primary cells", "CELL_TYPE", 97, 110], ["cell death", "PROBLEM", 52, 62], ["hindered", "OBSERVATION_MODIFIER", 15, 23], ["greatly", "OBSERVATION_MODIFIER", 24, 31], ["high", "OBSERVATION_MODIFIER", 39, 43], ["cell death", "OBSERVATION", 52, 62]]], ["The disruption of extracellular matrix proteins (ECM) necessary for the cell to cell interaction leads to programmed cell death, a phenomenon called anoikis (Kaeffer 2002; Kaushik et al. 2008) .", [["extracellular matrix", "ANATOMY", 18, 38], ["ECM", "ANATOMY", 49, 52], ["cell", "ANATOMY", 72, 76], ["cell", "ANATOMY", 80, 84], ["cell", "ANATOMY", 117, 121], ["death", "DISEASE", 122, 127], ["extracellular matrix", "CELLULAR_COMPONENT", 18, 38], ["ECM", "CELLULAR_COMPONENT", 49, 52], ["cell", "CELL", 72, 76], ["cell", "CELL", 80, 84], ["cell", "CELL", 117, 121], ["extracellular matrix proteins", "PROTEIN", 18, 47], ["ECM", "PROTEIN", 49, 52], ["extracellular matrix proteins", "TREATMENT", 18, 47], ["programmed cell death", "PROBLEM", 106, 127], ["extracellular", "ANATOMY_MODIFIER", 18, 31], ["matrix", "OBSERVATION_MODIFIER", 32, 38], ["cell death", "OBSERVATION", 117, 127]]], ["Both enzymatic and non-enzymatic methods for isolation of epithelial cells have been used.", [["epithelial cells", "ANATOMY", 58, 74], ["epithelial cells", "CELL", 58, 74], ["epithelial cells", "CELL_TYPE", 58, 74], ["non-enzymatic methods", "TEST", 19, 40], ["epithelial cells", "PROBLEM", 58, 74], ["non-enzymatic", "OBSERVATION_MODIFIER", 19, 32], ["epithelial cells", "OBSERVATION", 58, 74]]], ["A combination of mechanical and enzymatic methods using collagenase has been used by others to establish bovine cultures from jejunocytes and colonocytes derived from organoid preparations (Rusu et al. 2005 ).", [["cultures", "ANATOMY", 112, 120], ["jejunocytes", "ANATOMY", 126, 137], ["colonocytes", "ANATOMY", 142, 153], ["organoid", "ANATOMY", 167, 175], ["collagenase", "GENE_OR_GENE_PRODUCT", 56, 67], ["bovine", "ORGANISM", 105, 111], ["jejunocytes", "CELL", 126, 137], ["colonocytes", "CELL", 142, 153], ["collagenase", "PROTEIN", 56, 67], ["bovine cultures", "CELL_LINE", 105, 120], ["jejunocytes", "CELL_TYPE", 126, 137], ["colonocytes", "CELL_TYPE", 142, 153], ["bovine", "SPECIES", 105, 111], ["bovine", "SPECIES", 105, 111], ["mechanical and enzymatic methods", "TREATMENT", 17, 49], ["collagenase", "TREATMENT", 56, 67], ["bovine cultures", "TEST", 105, 120], ["jejunocytes", "PROBLEM", 126, 137], ["colonocytes", "PROBLEM", 142, 153], ["organoid preparations", "TREATMENT", 167, 188]]], ["On the other hand, non-enzymatic, chelating methods using EDTA have also been used for epithelial cell isolation (Kaeffer 2002) .", [["epithelial cell", "ANATOMY", 87, 102], ["EDTA", "CHEMICAL", 58, 62], ["EDTA", "CHEMICAL", 58, 62], ["EDTA", "SIMPLE_CHEMICAL", 58, 62], ["epithelial cell", "CELL", 87, 102], ["non-enzymatic, chelating methods", "TREATMENT", 19, 51], ["EDTA", "TREATMENT", 58, 62], ["epithelial cell isolation", "TREATMENT", 87, 112], ["hand", "ANATOMY", 13, 17], ["epithelial cell", "OBSERVATION", 87, 102]]], ["While chelating methods are useful in the isolation of epithelial cells that retain their phenotypes, it has been found to affect cell surface receptors (Kaeffer 2002) .", [["epithelial cells", "ANATOMY", 55, 71], ["cell surface", "ANATOMY", 130, 142], ["epithelial cells", "CELL", 55, 71], ["cell", "CELL", 130, 134], ["epithelial cells", "CELL_TYPE", 55, 71], ["cell surface receptors", "PROTEIN", 130, 152], ["chelating methods", "TREATMENT", 6, 23], ["epithelial cells", "PROBLEM", 55, 71], ["epithelial cells", "OBSERVATION", 55, 71]]], ["Also, it is unable to maintain the cell to cell interactions (Kaeffer 2002; Kaushik et al. 2008) .", [["cell", "ANATOMY", 35, 39], ["cell", "ANATOMY", 43, 47], ["cell", "CELL", 35, 39], ["cell", "CELL", 43, 47]]], ["To overcome these difficulties, enzymatic methods are widely used today, as it is able to support the growth of crypt-like cells in organoids that can maintain epithelial phenotype Rusu et al. 2005) .", [["crypt-like cells", "ANATOMY", 112, 128], ["organoids", "ANATOMY", 132, 141], ["epithelial", "ANATOMY", 160, 170], ["crypt-like cells", "CELL", 112, 128], ["organoids", "CELL", 132, 141], ["epithelial", "CELL", 160, 170], ["crypt-like cells", "CELL_TYPE", 112, 128], ["these difficulties", "PROBLEM", 12, 30], ["enzymatic methods", "TREATMENT", 32, 49], ["crypt-like cells in organoids", "PROBLEM", 112, 141]]], ["In this study, collagenase and dispase enzymes were used for the digestion of epithelial cells from ileal tissues of the calf.", [["epithelial cells", "ANATOMY", 78, 94], ["ileal tissues", "ANATOMY", 100, 113], ["calf", "ANATOMY", 121, 125], ["collagenase", "GENE_OR_GENE_PRODUCT", 15, 26], ["dispase enzymes", "GENE_OR_GENE_PRODUCT", 31, 46], ["epithelial cells", "CELL", 78, 94], ["ileal tissues", "TISSUE", 100, 113], ["calf", "ORGANISM_SUBDIVISION", 121, 125], ["collagenase", "PROTEIN", 15, 26], ["dispase enzymes", "PROTEIN", 31, 46], ["epithelial cells", "CELL_TYPE", 78, 94], ["calf", "SPECIES", 121, 125], ["this study", "TEST", 3, 13], ["collagenase and dispase enzymes", "TEST", 15, 46], ["epithelial cells", "PROBLEM", 78, 94], ["epithelial cells", "OBSERVATION", 78, 94], ["ileal tissues", "ANATOMY", 100, 113], ["calf", "ANATOMY", 121, 125]]], ["Then for the maintenance of pure bovine intestinal epithelial cells in culture, trypsin-EDTA was used for passaging the cells upon confluency.", [["intestinal epithelial cells", "ANATOMY", 40, 67], ["cells", "ANATOMY", 120, 125], ["trypsin-EDTA", "CHEMICAL", 80, 92], ["EDTA", "CHEMICAL", 88, 92], ["bovine", "ORGANISM", 33, 39], ["intestinal epithelial cells", "CELL", 40, 67], ["trypsin-EDTA", "SIMPLE_CHEMICAL", 80, 92], ["cells", "CELL", 120, 125], ["pure bovine intestinal epithelial cells", "CELL_TYPE", 28, 67], ["trypsin", "PROTEIN", 80, 87], ["bovine", "SPECIES", 33, 39], ["bovine", "SPECIES", 33, 39], ["pure bovine intestinal epithelial cells", "TREATMENT", 28, 67], ["culture", "TEST", 71, 78], ["trypsin-EDTA", "TREATMENT", 80, 92], ["intestinal", "ANATOMY", 40, 50], ["epithelial cells", "OBSERVATION", 51, 67]]], ["Isolation processes, chiefly utilizing mechanical dissociation, lead to frequent contamination with fibroblasts (Rusu et al. 2005) .", [["fibroblasts", "ANATOMY", 100, 111], ["fibroblasts", "CELL", 100, 111], ["fibroblasts", "CELL_TYPE", 100, 111], ["Isolation processes", "TREATMENT", 0, 19], ["mechanical dissociation", "PROBLEM", 39, 62], ["frequent contamination with fibroblasts", "PROBLEM", 72, 111]]], ["A recent study demonstrating an improvement over the limiting dilution method for obtaining pure BIEC clones has also highlighted the problem of fibroblast contamination (Zhan et al. 2017) .", [["fibroblast", "ANATOMY", 145, 155], ["BIEC clones", "CELL", 97, 108], ["fibroblast", "CELL", 145, 155], ["BIEC clones", "CELL_LINE", 97, 108], ["A recent study", "TEST", 0, 14], ["the limiting dilution method", "TREATMENT", 49, 77], ["pure BIEC clones", "PROBLEM", 92, 108], ["fibroblast contamination", "PROBLEM", 145, 169], ["improvement", "OBSERVATION_MODIFIER", 32, 43], ["fibroblast contamination", "OBSERVATION", 145, 169]]], ["The growth of fibroblasts in cultures depends on the type of culture medium used, including supplementation with fetal bovine serum and trypsin-EDTA treatment .", [["fibroblasts", "ANATOMY", 14, 25], ["cultures", "ANATOMY", 29, 37], ["fetal bovine serum", "ANATOMY", 113, 131], ["trypsin-EDTA", "CHEMICAL", 136, 148], ["trypsin-EDTA", "CHEMICAL", 136, 148], ["fibroblasts", "CELL", 14, 25], ["bovine", "ORGANISM", 119, 125], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["trypsin-", "SIMPLE_CHEMICAL", 136, 144], ["EDTA", "SIMPLE_CHEMICAL", 144, 148], ["fibroblasts", "CELL_TYPE", 14, 25], ["bovine", "SPECIES", 119, 125], ["bovine", "SPECIES", 119, 125], ["fibroblasts in cultures", "PROBLEM", 14, 37], ["culture medium", "TREATMENT", 61, 75], ["supplementation", "TREATMENT", 92, 107], ["fetal bovine serum", "TREATMENT", 113, 131], ["trypsin-EDTA treatment", "TREATMENT", 136, 158], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["fibroblasts", "OBSERVATION", 14, 25]]], ["Studies seeking to elucidate the infectivity of intestinal epithelial cells with enteric pathogens can be affected by fibroblast growth in various ways.", [["intestinal epithelial cells", "ANATOMY", 48, 75], ["fibroblast", "ANATOMY", 118, 128], ["intestinal epithelial cells", "CELL", 48, 75], ["fibroblast", "CELL", 118, 128], ["intestinal epithelial cells", "CELL_TYPE", 48, 75], ["intestinal epithelial cells", "PROBLEM", 48, 75], ["enteric pathogens", "PROBLEM", 81, 98], ["fibroblast growth in various ways", "PROBLEM", 118, 151], ["intestinal epithelial cells", "OBSERVATION", 48, 75], ["enteric", "OBSERVATION_MODIFIER", 81, 88], ["pathogens", "OBSERVATION", 89, 98], ["fibroblast growth", "OBSERVATION", 118, 135]]], ["The study on bovine rotavirus infectivity showed that rotaviruses can infect fibroblasts, affecting the interpretation of results .", [["fibroblasts", "ANATOMY", 77, 88], ["bovine", "ORGANISM", 13, 19], ["rotavirus", "ORGANISM", 20, 29], ["rotaviruses", "ORGANISM", 54, 65], ["fibroblasts", "CELL", 77, 88], ["fibroblasts", "CELL_TYPE", 77, 88], ["bovine", "SPECIES", 13, 19], ["bovine", "SPECIES", 13, 19], ["rotavirus", "SPECIES", 20, 29], ["The study", "TEST", 0, 9], ["bovine rotavirus infectivity", "PROBLEM", 13, 41], ["rotaviruses", "PROBLEM", 54, 65]]], ["The phenomenon of epithelial to mesenchymal phenotype transition has been observed in immortalized rat liver cell lines, simply by changing the culture medium from DMEM/ F12 to DMEM (Takenouchi et al. 2010) .DiscussionAnother impediment to the generation of a stable cell culture system is the limited proliferative capacity of primary cells in culture due to replicative senescence (Campisi 1996; Hayflick 1979) .", [["epithelial", "ANATOMY", 18, 28], ["mesenchymal", "ANATOMY", 32, 43], ["liver cell lines", "ANATOMY", 103, 119], ["cell culture system", "ANATOMY", 267, 286], ["primary cells", "ANATOMY", 328, 341], ["epithelial", "CELL", 18, 28], ["mesenchymal", "CELL", 32, 43], ["rat", "ORGANISM", 99, 102], ["liver cell lines", "CELL", 103, 119], ["cell", "CELL", 267, 271], ["cells", "CELL", 336, 341], ["immortalized rat liver cell lines", "CELL_LINE", 86, 119], ["primary cells", "CELL_TYPE", 328, 341], ["rat", "SPECIES", 99, 102], ["rat", "SPECIES", 99, 102], ["epithelial to mesenchymal phenotype transition", "PROBLEM", 18, 64], ["immortalized rat liver cell lines", "TREATMENT", 86, 119], ["a stable cell culture system", "TEST", 258, 286], ["primary cells", "PROBLEM", 328, 341], ["culture", "TEST", 345, 352], ["replicative senescence", "PROBLEM", 360, 382], ["epithelial", "ANATOMY_MODIFIER", 18, 28], ["mesenchymal phenotype", "OBSERVATION", 32, 53], ["liver", "ANATOMY", 103, 108], ["cell lines", "OBSERVATION", 109, 119], ["primary cells", "OBSERVATION", 328, 341]]], ["Very few studies have reported on the maintenance of primary culture for more than 10 generations (Kaeffer 2002; Loret et al. 2009 ).", [["primary culture", "TEST", 53, 68]]], ["One of the major challenges is the difficulty in the isolation of intestinal epithelial crypts which affects the population of proliferating cells.", [["intestinal epithelial crypts", "ANATOMY", 66, 94], ["cells", "ANATOMY", 141, 146], ["intestinal epithelial crypts", "TISSUE", 66, 94], ["cells", "CELL", 141, 146], ["intestinal epithelial crypts", "CELL_TYPE", 66, 94], ["proliferating cells", "CELL_TYPE", 127, 146], ["intestinal epithelial crypts", "PROBLEM", 66, 94], ["proliferating cells", "PROBLEM", 127, 146], ["major", "OBSERVATION_MODIFIER", 11, 16], ["challenges", "OBSERVATION", 17, 27], ["intestinal", "ANATOMY", 66, 76], ["epithelial crypts", "OBSERVATION", 77, 94], ["population", "OBSERVATION_MODIFIER", 113, 123], ["proliferating cells", "OBSERVATION", 127, 146]]], ["Primary colonocytes and jejunocytes from both adult and fetal calves have been isolated and immortalized using SV40 large T antigen (Loret et al. 2009 ).", [["Primary colonocytes", "ANATOMY", 0, 19], ["jejunocytes", "ANATOMY", 24, 35], ["fetal calves", "ANATOMY", 56, 68], ["colonocytes", "CELL", 8, 19], ["jejunocytes", "CELL", 24, 35], ["fetal", "ORGAN", 56, 61], ["calves", "ORGANISM", 62, 68], ["SV40", "ORGANISM", 111, 115], ["large T antigen", "GENE_OR_GENE_PRODUCT", 116, 131], ["Primary colonocytes", "CELL_TYPE", 0, 19], ["jejunocytes", "CELL_TYPE", 24, 35], ["SV40 large T antigen", "PROTEIN", 111, 131], ["calves", "SPECIES", 62, 68], ["calves", "SPECIES", 62, 68], ["Primary colonocytes and jejunocytes from both adult and fetal calves", "PROBLEM", 0, 68], ["SV40 large T antigen", "TREATMENT", 111, 131], ["colonocytes", "OBSERVATION", 8, 19], ["jejunocytes", "OBSERVATION", 24, 35], ["both", "ANATOMY_MODIFIER", 41, 45], ["adult", "ANATOMY_MODIFIER", 46, 51], ["fetal calves", "ANATOMY", 56, 68]]], ["These immortalized epithelial cells were cultured for 50 passages and were able to retain the epithelial phenotype, while the untreated primocultures were only maintained for 7 passages (Loret et al. 2009 ).", [["epithelial cells", "ANATOMY", 19, 35], ["epithelial", "ANATOMY", 94, 104], ["primocultures", "ANATOMY", 136, 149], ["epithelial cells", "CELL", 19, 35], ["epithelial", "TISSUE", 94, 104], ["immortalized epithelial cells", "CELL_LINE", 6, 35], ["the epithelial phenotype", "PROBLEM", 90, 114], ["the untreated primocultures", "PROBLEM", 122, 149], ["epithelial cells", "OBSERVATION", 19, 35], ["epithelial phenotype", "OBSERVATION", 94, 114]]], ["Ovine endometrial cell lines immortalized with HPV E6/E7 genes were also shown to retain original cell phenotype (Johnson et al. 1999) .", [["endometrial cell lines", "ANATOMY", 6, 28], ["cell", "ANATOMY", 98, 102], ["Ovine", "ORGANISM", 0, 5], ["endometrial cell lines", "CELL", 6, 28], ["HPV E6", "ORGANISM", 47, 53], ["E7", "GENE_OR_GENE_PRODUCT", 54, 56], ["cell", "CELL", 98, 102], ["Ovine endometrial cell lines", "CELL_LINE", 0, 28], ["HPV E6/E7 genes", "DNA", 47, 62], ["HPV", "SPECIES", 47, 50], ["Ovine endometrial cell lines", "TREATMENT", 0, 28], ["HPV E6/E7 genes", "TEST", 47, 62], ["endometrial", "ANATOMY", 6, 17], ["cell lines", "OBSERVATION", 18, 28], ["cell phenotype", "OBSERVATION", 98, 112]]], ["Human cytotrophoblast cells and bovine mammary gland epithelial cells (bMGEs) immortalized with hTERT gene not only showed enhanced lifespan but also retained original parental phenotype (He et al. 2011; Wang et al. 2006) .DiscussionTransfection reagents used to transfect plasmid DNA containing immortalization genes could influence the transfection efficiency.", [["cytotrophoblast cells", "ANATOMY", 6, 27], ["mammary gland epithelial cells", "ANATOMY", 39, 69], ["bMGEs", "ANATOMY", 71, 76], ["plasmid", "ANATOMY", 273, 280], ["Human", "ORGANISM", 0, 5], ["cytotrophoblast cells", "CELL", 6, 27], ["bovine", "ORGANISM", 32, 38], ["mammary gland epithelial cells", "CELL", 39, 69], ["bMGEs", "CELL", 71, 76], ["hTERT", "GENE_OR_GENE_PRODUCT", 96, 101], ["DNA", "CELLULAR_COMPONENT", 281, 284], ["Human cytotrophoblast cells", "CELL_TYPE", 0, 27], ["bovine mammary gland epithelial cells", "CELL_TYPE", 32, 69], ["bMGEs", "CELL_TYPE", 71, 76], ["hTERT gene", "DNA", 96, 106], ["plasmid DNA", "DNA", 273, 284], ["immortalization genes", "DNA", 296, 317], ["Human", "SPECIES", 0, 5], ["bovine", "SPECIES", 32, 38], ["Human", "SPECIES", 0, 5], ["Human cytotrophoblast cells", "TEST", 0, 27], ["bovine mammary gland epithelial cells", "TEST", 32, 69], ["hTERT gene", "TEST", 96, 106], ["enhanced lifespan", "PROBLEM", 123, 140], ["DiscussionTransfection reagents", "TREATMENT", 223, 254], ["transfect plasmid DNA", "TREATMENT", 263, 284], ["immortalization genes", "PROBLEM", 296, 317], ["the transfection efficiency", "PROBLEM", 334, 361], ["cytotrophoblast cells", "OBSERVATION", 6, 27], ["mammary gland", "ANATOMY", 39, 52], ["epithelial cells", "OBSERVATION", 53, 69], ["transfection efficiency", "OBSERVATION", 338, 361]]], ["Lipid-based Lipofectamine reagent used in this study was shown to have a transfection efficiency of 12-22% in mouse embryonic fibroblast (MEF) cells .", [["embryonic fibroblast (MEF) cells", "ANATOMY", 116, 148], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["mouse", "ORGANISM", 110, 115], ["embryonic fibroblast (MEF) cells", "CELL", 116, 148], ["mouse embryonic fibroblast (MEF) cells", "CELL_LINE", 110, 148], ["mouse", "SPECIES", 110, 115], ["mouse", "SPECIES", 110, 115], ["Lipid-based Lipofectamine reagent", "TREATMENT", 0, 33], ["this study", "TEST", 42, 52], ["a transfection efficiency", "PROBLEM", 71, 96], ["mouse embryonic fibroblast (MEF) cells", "PROBLEM", 110, 148], ["transfection efficiency", "OBSERVATION", 73, 96], ["embryonic fibroblast", "OBSERVATION", 116, 136]]], ["In another study, bovine mammary epithelial alveolar (MACT) cells showed transfection efficiency of 16.3%, while Madin Darby Bovine Kidney (MDBK) cells showed an efficiency of 2.2% (Osorio and Bionaz 2017) .", [["mammary epithelial alveolar (MACT) cells", "ANATOMY", 25, 65], ["Kidney (MDBK) cells", "ANATOMY", 132, 151], ["bovine", "ORGANISM", 18, 24], ["mammary epithelial alveolar (MACT) cells", "CELL", 25, 65], ["MDBK) cells", "CELL", 140, 151], ["bovine mammary epithelial alveolar (MACT) cells", "CELL_LINE", 18, 65], ["Madin Darby Bovine Kidney (MDBK) cells", "CELL_LINE", 113, 151], ["bovine", "SPECIES", 18, 24], ["Bovine", "SPECIES", 125, 131], ["bovine", "SPECIES", 18, 24], ["MDBK", "SPECIES", 140, 144], ["another study", "TEST", 3, 16], ["bovine mammary epithelial alveolar (MACT) cells", "TEST", 18, 65], ["transfection efficiency", "TEST", 73, 96], ["Madin Darby Bovine Kidney (MDBK) cells", "TEST", 113, 151], ["an efficiency", "TEST", 159, 172], ["mammary", "ANATOMY", 25, 32], ["epithelial", "ANATOMY_MODIFIER", 33, 43], ["alveolar", "ANATOMY", 44, 52], ["transfection efficiency", "OBSERVATION", 73, 96], ["Kidney", "ANATOMY", 132, 138], ["efficiency", "OBSERVATION_MODIFIER", 162, 172]]], ["It is critical that the selected transfection method does not affect normal cellular characteristics.", [["cellular", "ANATOMY", 76, 84], ["cellular", "CELL", 76, 84], ["cellular characteristics", "OBSERVATION", 76, 100]]], ["Transfection reagents have been evaluated for toxicity and activation of cellular stress responses (Fiszer-Kierzkowska et al. 2011; Masotti et al. 2009 ).", [["cellular", "ANATOMY", 73, 81], ["toxicity", "DISEASE", 46, 54], ["cellular", "CELL", 73, 81], ["Transfection reagents", "TREATMENT", 0, 21], ["toxicity", "PROBLEM", 46, 54], ["cellular stress responses", "PROBLEM", 73, 98]]], ["More importantly, the transfection efficiency can be affected by cell type, passage number, cell density, and the amount of plasmid DNA transfected (Dalby et al. 2004; Lee et al. 2017) .", [["cell", "ANATOMY", 65, 69], ["cell", "ANATOMY", 92, 96], ["plasmid", "ANATOMY", 124, 131], ["cell", "CELL", 65, 69], ["cell", "CELL", 92, 96], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["plasmid DNA", "DNA", 124, 135], ["the transfection efficiency", "PROBLEM", 18, 45], ["plasmid DNA transfected", "TREATMENT", 124, 147], ["transfection efficiency", "OBSERVATION", 22, 45], ["cell type", "OBSERVATION", 65, 74], ["cell density", "OBSERVATION", 92, 104], ["amount", "OBSERVATION_MODIFIER", 114, 120], ["plasmid DNA transfected", "OBSERVATION", 124, 147]]], ["In this study, we transfected BIEC-c4 cells with Lipofectamine 2000 reagent.", [["BIEC-c4 cells", "ANATOMY", 30, 43], ["BIEC-c4 cells", "CELL", 30, 43], ["BIEC-c4 cells", "CELL_LINE", 30, 43], ["this study", "TEST", 3, 13], ["Lipofectamine 2000 reagent", "TREATMENT", 49, 75], ["c4 cells", "ANATOMY", 35, 43]]], ["The BIEC-c4 cells at different passages were transfected with SV40, hTERT, and HPV E6/E7 genes respectively to establish three immortalized BIEC cell lines.", [["BIEC-c4 cells", "ANATOMY", 4, 17], ["BIEC cell lines", "ANATOMY", 140, 155], ["BIEC-c4 cells", "CELL", 4, 17], ["SV40", "ORGANISM", 62, 66], ["hTERT", "GENE_OR_GENE_PRODUCT", 68, 73], ["HPV E6", "ORGANISM", 79, 85], ["E7", "GENE_OR_GENE_PRODUCT", 86, 88], ["BIEC cell lines", "CELL", 140, 155], ["BIEC-c4 cells", "CELL_LINE", 4, 17], ["SV40, hTERT, and HPV E6/E7 genes", "DNA", 62, 94], ["immortalized BIEC cell lines", "CELL_LINE", 127, 155], ["The BIEC-c4 cells", "TREATMENT", 0, 17], ["SV40", "TEST", 62, 66], ["hTERT", "TEST", 68, 73], ["HPV E6/E7 genes", "TREATMENT", 79, 94], ["three immortalized BIEC cell lines", "TREATMENT", 121, 155], ["c4 cells", "OBSERVATION", 9, 17], ["BIEC cell lines", "OBSERVATION", 140, 155]]], ["We confirmed by PCR the expression of desired plasmids in the three immortalized BIECs.", [["plasmids", "ANATOMY", 46, 54], ["BIECs", "ANATOMY", 81, 86], ["BIECs", "CELL", 81, 86], ["plasmids", "DNA", 46, 54], ["immortalized BIECs", "CELL_LINE", 68, 86], ["desired plasmids", "TREATMENT", 38, 54]]], ["These cells also expressed the SV40, hTERT, and HPV E6 gene products.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["SV40", "GENE_OR_GENE_PRODUCT", 31, 35], ["hTERT", "GENE_OR_GENE_PRODUCT", 37, 42], ["E6", "GENE_OR_GENE_PRODUCT", 52, 54], ["SV40, hTERT, and HPV E6 gene products", "DNA", 31, 68], ["HPV", "SPECIES", 48, 51], ["the SV40", "TEST", 27, 35], ["hTERT", "TEST", 37, 42], ["HPV E6 gene products", "TREATMENT", 48, 68], ["HPV E6", "OBSERVATION", 48, 54]]], ["The detection of SV40 LT Ag, hTERT and HPV E6 proteins in the immortalized BIECs was done at late passages 58, 32, and 48 respectively.DiscussionVarious studies have shown alterations in glycosylation pattern in immortalized cell lines as compared to normal cells.", [["BIECs", "ANATOMY", 75, 80], ["cell lines", "ANATOMY", 225, 235], ["cells", "ANATOMY", 258, 263], ["SV40", "ORGANISM", 17, 21], ["LT Ag", "GENE_OR_GENE_PRODUCT", 22, 27], ["hTERT", "GENE_OR_GENE_PRODUCT", 29, 34], ["HPV E6", "GENE_OR_GENE_PRODUCT", 39, 45], ["BIECs", "CANCER", 75, 80], ["cell lines", "CELL", 225, 235], ["cells", "CELL", 258, 263], ["SV40 LT Ag", "PROTEIN", 17, 27], ["hTERT", "PROTEIN", 29, 34], ["HPV E6 proteins", "PROTEIN", 39, 54], ["immortalized BIECs", "CELL_LINE", 62, 80], ["immortalized cell lines", "CELL_LINE", 212, 235], ["normal cells", "CELL_TYPE", 251, 263], ["HPV", "SPECIES", 39, 42], ["The detection", "TEST", 0, 13], ["SV40 LT Ag", "TEST", 17, 27], ["hTERT", "TEST", 29, 34], ["HPV E6 proteins", "TEST", 39, 54], ["the immortalized BIECs", "TEST", 58, 80], ["DiscussionVarious studies", "TEST", 135, 160], ["alterations in glycosylation pattern", "PROBLEM", 172, 208], ["immortalized cell lines", "TREATMENT", 212, 235], ["glycosylation pattern", "OBSERVATION", 187, 208], ["immortalized cell lines", "OBSERVATION", 212, 235], ["normal cells", "OBSERVATION", 251, 263]]], ["Intestinal epithelial cells express various sugar residues, chiefly N-acetylglucosamine (GlcNAc), galactose (Gal), N-acetylgalactosamine (GalNAc), fucose, N-acetylneuraminic acid and sialic acid (Freitas et al. 2005) .", [["Intestinal epithelial cells", "ANATOMY", 0, 27], ["N-acetylglucosamine", "CHEMICAL", 68, 87], ["galactose", "CHEMICAL", 98, 107], ["Gal), N-acetylgalactosamine (GalNAc), fucose, N-acetylneuraminic acid", "CHEMICAL", 109, 178], ["sialic acid", "CHEMICAL", 183, 194], ["sugar", "CHEMICAL", 44, 49], ["N-acetylglucosamine", "CHEMICAL", 68, 87], ["GlcNAc", "CHEMICAL", 89, 95], ["galactose", "CHEMICAL", 98, 107], ["Gal", "CHEMICAL", 109, 112], ["N-acetylgalactosamine", "CHEMICAL", 115, 136], ["GalNAc", "CHEMICAL", 138, 144], ["fucose", "CHEMICAL", 147, 153], ["N-acetylneuraminic acid", "CHEMICAL", 155, 178], ["sialic acid", "CHEMICAL", 183, 194], ["Intestinal epithelial cells", "CELL", 0, 27], ["N-acetylglucosamine", "SIMPLE_CHEMICAL", 68, 87], ["GlcNAc", "SIMPLE_CHEMICAL", 89, 95], ["galactose", "SIMPLE_CHEMICAL", 98, 107], ["Gal)", "SIMPLE_CHEMICAL", 109, 113], ["N-acetylgalactosamine", "SIMPLE_CHEMICAL", 115, 136], ["GalNAc", "SIMPLE_CHEMICAL", 138, 144], ["fucose", "SIMPLE_CHEMICAL", 147, 153], ["N-acetylneuraminic acid", "SIMPLE_CHEMICAL", 155, 178], ["sialic acid", "SIMPLE_CHEMICAL", 183, 194], ["Intestinal epithelial cells", "CELL_TYPE", 0, 27], ["Intestinal epithelial cells", "PROBLEM", 0, 27], ["various sugar residues", "PROBLEM", 36, 58], ["acetylglucosamine (GlcNAc)", "TREATMENT", 70, 96], ["galactose (Gal)", "TREATMENT", 98, 113], ["N-acetylgalactosamine (GalNAc)", "TREATMENT", 115, 145], ["fucose, N-acetylneuraminic acid", "TREATMENT", 147, 178], ["sialic acid", "TREATMENT", 183, 194], ["epithelial cells", "OBSERVATION", 11, 27], ["sugar residues", "OBSERVATION", 44, 58]]], ["Lectin binding profile of porcine intestinal tissue for the expression of carbohydrate moieties has been reported (George et al. 2007) .", [["intestinal tissue", "ANATOMY", 34, 51], ["carbohydrate", "CHEMICAL", 74, 86], ["Lectin", "GENE_OR_GENE_PRODUCT", 0, 6], ["porcine", "ORGANISM", 26, 33], ["intestinal tissue", "TISSUE", 34, 51], ["carbohydrate moieties", "PROTEIN", 74, 95], ["porcine", "SPECIES", 26, 33], ["porcine", "SPECIES", 26, 33], ["Lectin binding profile of porcine intestinal tissue", "PROBLEM", 0, 51], ["carbohydrate moieties", "TREATMENT", 74, 95], ["porcine intestinal tissue", "OBSERVATION", 26, 51]]], ["Many carbohydrate moieties serve as a receptor for binding and subsequent entry of pathogens to initiate infection (Kato and Ishiwa 2015) .", [["infection", "DISEASE", 105, 114], ["carbohydrate", "CHEMICAL", 5, 17], ["Many carbohydrate moieties", "TREATMENT", 0, 26], ["a receptor", "TREATMENT", 36, 46], ["pathogens", "PROBLEM", 83, 92], ["infection", "PROBLEM", 105, 114]]], ["Sialic acid and heparan sulfate are used as receptors by many viruses (Kato and Ishiwa 2015; Mestecky 2005) .", [["Sialic acid", "CHEMICAL", 0, 11], ["heparan sulfate", "CHEMICAL", 16, 31], ["Sialic acid", "CHEMICAL", 0, 11], ["heparan sulfate", "CHEMICAL", 16, 31], ["Sialic acid", "SIMPLE_CHEMICAL", 0, 11], ["heparan sulfate", "SIMPLE_CHEMICAL", 16, 31], ["Sialic acid", "TREATMENT", 0, 11], ["heparan sulfate", "TREATMENT", 16, 31]]], ["Members of the Paramyxovirus family, Rotaviruses, Coronaviruses and Influenza viruses (A, B and C), bind to sialoglycoconjugate receptors on host cell surface (Mestecky 2005) .", [["cell surface", "ANATOMY", 146, 158], ["Influenza viruses", "DISEASE", 68, 85], ["Paramyxovirus", "GENE_OR_GENE_PRODUCT", 15, 28], ["Rotaviruses", "GENE_OR_GENE_PRODUCT", 37, 48], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 50, 63], ["Influenza viruses", "ORGANISM", 68, 85], ["A, B and C", "ORGANISM", 87, 97], ["sialoglycoconjugate receptors", "GENE_OR_GENE_PRODUCT", 108, 137], ["host cell", "CELL", 141, 150], ["surface", "CELLULAR_COMPONENT", 151, 158], ["Paramyxovirus family", "PROTEIN", 15, 35], ["Coronaviruses", "PROTEIN", 50, 63], ["sialoglycoconjugate receptors", "PROTEIN", 108, 137], ["Influenza", "SPECIES", 68, 77], ["Influenza viruses", "SPECIES", 68, 85], ["Rotaviruses", "PROBLEM", 37, 48], ["Coronaviruses", "PROBLEM", 50, 63], ["Influenza viruses", "PROBLEM", 68, 85], ["host cell", "OBSERVATION_MODIFIER", 141, 150]]], ["Immortalized ras-MDCK cells showed increased cell surface fucosylation while showing a decrease in O-linked glycans and sialylation (Bruyneel et al. 1990 ).", [["ras-MDCK cells", "ANATOMY", 13, 27], ["cell surface", "ANATOMY", 45, 57], ["O", "CHEMICAL", 99, 100], ["Immortalized ras-MDCK cells", "CELL", 0, 27], ["cell", "CELL", 45, 49], ["ras-MDCK cells", "CELL_LINE", 13, 27], ["Immortalized ras-MDCK cells", "TEST", 0, 27], ["increased cell surface fucosylation", "PROBLEM", 35, 70], ["a decrease in O-linked glycans", "PROBLEM", 85, 115], ["increased cell", "OBSERVATION", 35, 49], ["surface fucosylation", "OBSERVATION", 50, 70], ["decrease", "OBSERVATION_MODIFIER", 87, 95]]], ["In another study, human stromal cells immortalized with hTERT gene showed increased galactosylation (Kuwahara et al. 2003) .", [["stromal cells", "ANATOMY", 24, 37], ["human", "ORGANISM", 18, 23], ["stromal cells", "CELL", 24, 37], ["hTERT", "GENE_OR_GENE_PRODUCT", 56, 61], ["human stromal cells", "CELL_TYPE", 18, 37], ["hTERT gene", "DNA", 56, 66], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["another study", "TEST", 3, 16], ["human stromal cells", "TREATMENT", 18, 37], ["hTERT gene", "TEST", 56, 66], ["increased galactosylation", "PROBLEM", 74, 99]]], ["Therefore, in future studies, it will be useful to study if immortalization process changes the expression of carbohydrates on BIEC cell surface.", [["BIEC cell surface", "ANATOMY", 127, 144], ["carbohydrates", "CHEMICAL", 110, 123], ["carbohydrates", "SIMPLE_CHEMICAL", 110, 123], ["BIEC cell surface", "CELLULAR_COMPONENT", 127, 144], ["future studies", "TEST", 14, 28], ["immortalization process", "PROBLEM", 60, 83], ["BIEC cell surface", "TREATMENT", 127, 144]]], ["Furthermore, as all the three immortalized cells lines in this study were derived from the primary BIEC-c4 cells, these cells can be effectively used to study the physiological, biochemical and immunological changes various immortalization methods may induce in these cells.DiscussionStudies on the characterization of bovine intestinal epithelial cells have revealed important morphological and biochemical characteristics of cultured intestinal epithelial cells.", [["cells lines", "ANATOMY", 43, 54], ["primary BIEC-c4 cells", "ANATOMY", 91, 112], ["cells", "ANATOMY", 120, 125], ["cells", "ANATOMY", 268, 273], ["intestinal epithelial cells", "ANATOMY", 326, 353], ["intestinal epithelial cells", "ANATOMY", 436, 463], ["cells lines", "CELL", 43, 54], ["BIEC-c4 cells", "CELL", 99, 112], ["cells", "CELL", 120, 125], ["cells", "CELL", 268, 273], ["bovine", "ORGANISM", 319, 325], ["intestinal epithelial cells", "CELL", 326, 353], ["intestinal epithelial cells", "CELL", 436, 463], ["immortalized cells lines", "CELL_LINE", 30, 54], ["primary BIEC-c4 cells", "CELL_LINE", 91, 112], ["bovine intestinal epithelial cells", "CELL_TYPE", 319, 353], ["cultured intestinal epithelial cells", "CELL_LINE", 427, 463], ["bovine", "SPECIES", 319, 325], ["bovine", "SPECIES", 319, 325], ["this study", "TEST", 58, 68], ["immunological changes various immortalization methods", "TREATMENT", 194, 247], ["bovine intestinal epithelial cells", "PROBLEM", 319, 353], ["cultured intestinal epithelial cells", "PROBLEM", 427, 463], ["cells lines", "OBSERVATION", 43, 54], ["c4 cells", "OBSERVATION", 104, 112], ["intestinal epithelial", "ANATOMY", 326, 347], ["intestinal epithelial cells", "OBSERVATION", 436, 463]]], ["The epithelial tissue is in close association with fibroblasts, also called endodermal structural proliferative units (Kaeffer 2002) .", [["epithelial tissue", "ANATOMY", 4, 21], ["fibroblasts", "ANATOMY", 51, 62], ["endodermal", "ANATOMY", 76, 86], ["epithelial tissue", "TISSUE", 4, 21], ["fibroblasts", "CELL", 51, 62], ["endodermal", "CELL", 76, 86], ["fibroblasts", "CELL_TYPE", 51, 62], ["epithelial tissue", "OBSERVATION", 4, 21], ["fibroblasts", "OBSERVATION", 51, 62], ["proliferative", "OBSERVATION_MODIFIER", 98, 111]]], ["Epithelial cells are characterized by the expression of the protein cytokeratin, while cells of mesenchymal origins, chiefly fibroblasts, express vimentin (Kaeffer 2002; Rusu et al. 2005) .", [["Epithelial cells", "ANATOMY", 0, 16], ["cells", "ANATOMY", 87, 92], ["mesenchymal", "ANATOMY", 96, 107], ["fibroblasts", "ANATOMY", 125, 136], ["Epithelial cells", "CELL", 0, 16], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 68, 79], ["cells", "CELL", 87, 92], ["mesenchymal", "CELL", 96, 107], ["fibroblasts", "CELL", 125, 136], ["vimentin", "GENE_OR_GENE_PRODUCT", 146, 154], ["Epithelial cells", "CELL_TYPE", 0, 16], ["protein cytokeratin", "PROTEIN", 60, 79], ["fibroblasts", "CELL_TYPE", 125, 136], ["vimentin", "PROTEIN", 146, 154], ["Epithelial cells", "PROBLEM", 0, 16], ["the protein cytokeratin", "PROBLEM", 56, 79], ["cells", "OBSERVATION", 11, 16], ["protein cytokeratin", "OBSERVATION", 60, 79], ["mesenchymal origins", "OBSERVATION", 96, 115]]], ["Cytokeratin is a protein of intermediate filaments found within the cytoskeletal regions of epithelial cells (Kaeffer 2002) .", [["filaments", "ANATOMY", 41, 50], ["cytoskeletal regions", "ANATOMY", 68, 88], ["epithelial cells", "ANATOMY", 92, 108], ["Cytokeratin", "GENE_OR_GENE_PRODUCT", 0, 11], ["cytoskeletal regions", "CELLULAR_COMPONENT", 68, 88], ["epithelial cells", "CELL", 92, 108], ["Cytokeratin", "PROTEIN", 0, 11], ["epithelial cells", "CELL_TYPE", 92, 108], ["a protein of intermediate filaments", "PROBLEM", 15, 50], ["intermediate filaments", "OBSERVATION", 28, 50], ["cytoskeletal", "ANATOMY_MODIFIER", 68, 80], ["regions", "ANATOMY_MODIFIER", 81, 88], ["epithelial cells", "OBSERVATION", 92, 108]]], ["Cytokeratins (CK) can be grouped into two types: type I (acidic) which includes cytokeratins CK9-CK20 and type II (neutralbasic) which includes CK1-CK8 (Weng et al. 2012) .", [["Cytokeratins", "GENE_OR_GENE_PRODUCT", 0, 12], ["CK", "GENE_OR_GENE_PRODUCT", 14, 16], ["type I (acidic", "GENE_OR_GENE_PRODUCT", 49, 63], ["cytokeratins CK9-CK20", "GENE_OR_GENE_PRODUCT", 80, 101], ["type II", "GENE_OR_GENE_PRODUCT", 106, 113], ["CK1-CK8", "GENE_OR_GENE_PRODUCT", 144, 151], ["Cytokeratins", "PROTEIN", 0, 12], ["CK", "PROTEIN", 14, 16], ["cytokeratins", "PROTEIN", 80, 92], ["CK9", "PROTEIN", 93, 96], ["CK20", "PROTEIN", 97, 101], ["type II", "PROTEIN", 106, 113], ["CK1", "PROTEIN", 144, 147], ["CK8", "PROTEIN", 148, 151], ["Cytokeratins (CK)", "TEST", 0, 17], ["type I (acidic)", "PROBLEM", 49, 64], ["cytokeratins CK9", "TEST", 80, 96], ["CK20", "TEST", 97, 101], ["type II (neutralbasic)", "PROBLEM", 106, 128], ["CK1", "TEST", 144, 147], ["CK8", "TEST", 148, 151]]], ["Cytokeratin expression has been found to be tissuespecific (Chu and Weiss 2002) .", [["Cytokeratin", "GENE_OR_GENE_PRODUCT", 0, 11], ["Cytokeratin", "PROTEIN", 0, 11], ["Cytokeratin expression", "PROBLEM", 0, 22]]], ["Epithelial cells express cytokeratins in different combinations which may be dependent on cellular differentiation level or certain cellular characteristics (Moll 1991) .", [["Epithelial cells", "ANATOMY", 0, 16], ["cellular", "ANATOMY", 90, 98], ["cellular", "ANATOMY", 132, 140], ["Epithelial cells", "CELL", 0, 16], ["cytokeratins", "GENE_OR_GENE_PRODUCT", 25, 37], ["cellular", "CELL", 90, 98], ["cellular", "CELL", 132, 140], ["Epithelial cells", "CELL_TYPE", 0, 16], ["cytokeratins", "PROTEIN", 25, 37], ["Epithelial cells", "PROBLEM", 0, 16], ["cytokeratins in different combinations", "PROBLEM", 25, 63], ["dependent on cellular differentiation level", "PROBLEM", 77, 120], ["cytokeratins", "OBSERVATION", 25, 37], ["different combinations", "OBSERVATION_MODIFIER", 41, 63], ["may be", "UNCERTAINTY", 70, 76], ["dependent", "OBSERVATION_MODIFIER", 77, 86], ["cellular differentiation", "OBSERVATION", 90, 114]]], ["Detailed cellular and molecular characterization of cytokeratins in bovine tissues have been reported by others (Blessing et al. 1987; Hu et al. 2009; Paladino et al. 2004 ).", [["cellular", "ANATOMY", 9, 17], ["tissues", "ANATOMY", 75, 82], ["cellular", "CELL", 9, 17], ["cytokeratins", "GENE_OR_GENE_PRODUCT", 52, 64], ["bovine", "ORGANISM", 68, 74], ["tissues", "TISSUE", 75, 82], ["cytokeratins", "PROTEIN", 52, 64], ["bovine", "SPECIES", 68, 74], ["bovine", "SPECIES", 68, 74], ["cytokeratins in bovine tissues", "PROBLEM", 52, 82], ["bovine tissues", "OBSERVATION", 68, 82]]], ["The established BIEC-c4 clone and the three immortalized BIEC cell lines all expressed cytokeratin, with low levels of vimentin expression.", [["BIEC-c4 clone", "ANATOMY", 16, 29], ["BIEC cell lines", "ANATOMY", 57, 72], ["BIEC-c4 clone", "CELL", 16, 29], ["BIEC cell lines", "CELL", 57, 72], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 87, 98], ["vimentin", "GENE_OR_GENE_PRODUCT", 119, 127], ["BIEC-c4 clone", "CELL_LINE", 16, 29], ["immortalized BIEC cell lines", "CELL_LINE", 44, 72], ["cytokeratin", "PROTEIN", 87, 98], ["vimentin", "PROTEIN", 119, 127], ["The established BIEC-c4 clone", "TREATMENT", 0, 29], ["the three immortalized BIEC cell lines", "TREATMENT", 34, 72], ["vimentin expression", "TREATMENT", 119, 138], ["c4 clone", "OBSERVATION", 21, 29], ["BIEC cell lines", "OBSERVATION", 57, 72], ["cytokeratin", "OBSERVATION_MODIFIER", 87, 98], ["low levels", "OBSERVATION_MODIFIER", 105, 115], ["vimentin expression", "OBSERVATION", 119, 138]]], ["Analysis of gene transcripts and western blot have demonstrated that bovine and porcine epithelial cells in culture can co-express cytokeratin and vimentin Rusu et al. 2005; Sun et al. 2012) .", [["epithelial cells", "ANATOMY", 88, 104], ["bovine", "ORGANISM", 69, 75], ["porcine", "ORGANISM", 80, 87], ["epithelial cells", "CELL", 88, 104], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 131, 142], ["vimentin", "GENE_OR_GENE_PRODUCT", 147, 155], ["bovine and porcine epithelial cells", "CELL_TYPE", 69, 104], ["cytokeratin", "PROTEIN", 131, 142], ["vimentin", "PROTEIN", 147, 155], ["bovine", "SPECIES", 69, 75], ["porcine", "SPECIES", 80, 87], ["bovine", "SPECIES", 69, 75], ["gene transcripts", "PROBLEM", 12, 28], ["western blot", "TEST", 33, 45], ["bovine and porcine epithelial cells", "PROBLEM", 69, 104], ["culture", "TEST", 108, 115], ["cytokeratin", "TEST", 131, 142], ["epithelial cells", "OBSERVATION", 88, 104]]], ["Fetal-derived bovine intestinal epithelial cells in culture were found to express both cytokeratin and vimentin, and the percentage of cells expressing vimentin increased with further passaging .", [["Fetal", "ANATOMY", 0, 5], ["intestinal epithelial cells", "ANATOMY", 21, 48], ["cells", "ANATOMY", 135, 140], ["Fetal", "ORGANISM", 0, 5], ["bovine", "ORGANISM", 14, 20], ["intestinal epithelial cells", "CELL", 21, 48], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 87, 98], ["vimentin", "GENE_OR_GENE_PRODUCT", 103, 111], ["cells", "CELL", 135, 140], ["vimentin", "GENE_OR_GENE_PRODUCT", 152, 160], ["Fetal-derived bovine intestinal epithelial cells", "CELL_TYPE", 0, 48], ["cytokeratin", "PROTEIN", 87, 98], ["vimentin", "PROTEIN", 103, 111], ["vimentin", "PROTEIN", 152, 160], ["bovine", "SPECIES", 14, 20], ["bovine", "SPECIES", 14, 20], ["Fetal-derived bovine intestinal epithelial cells", "PROBLEM", 0, 48], ["culture", "TEST", 52, 59], ["vimentin", "TREATMENT", 103, 111], ["further passaging", "TREATMENT", 176, 193], ["intestinal", "ANATOMY", 21, 31], ["epithelial cells", "OBSERVATION", 32, 48]]], ["However, only epithelial cells express cytokeratin protein which is absent in fibroblasts.", [["epithelial cells", "ANATOMY", 14, 30], ["fibroblasts", "ANATOMY", 78, 89], ["epithelial cells", "CELL", 14, 30], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 39, 50], ["fibroblasts", "CELL", 78, 89], ["epithelial cells", "CELL_TYPE", 14, 30], ["cytokeratin protein", "PROTEIN", 39, 58], ["fibroblasts", "CELL_TYPE", 78, 89], ["epithelial cells", "PROBLEM", 14, 30], ["cytokeratin protein", "PROBLEM", 39, 58], ["fibroblasts", "PROBLEM", 78, 89], ["epithelial cells", "OBSERVATION", 14, 30], ["cytokeratin protein", "OBSERVATION", 39, 58], ["absent", "OBSERVATION_MODIFIER", 68, 74], ["fibroblasts", "OBSERVATION", 78, 89]]], ["One possibility for the expression of mesenchymal phenotype is contamination with mesenchymal cells Rusu et al. 2005) .", [["mesenchymal", "ANATOMY", 38, 49], ["mesenchymal cells", "ANATOMY", 82, 99], ["mesenchymal", "CELL", 38, 49], ["mesenchymal cells", "CELL", 82, 99], ["mesenchymal cells", "CELL_TYPE", 82, 99], ["mesenchymal phenotype", "PROBLEM", 38, 59], ["mesenchymal cells", "PROBLEM", 82, 99], ["mesenchymal phenotype", "OBSERVATION", 38, 59]]], ["More importantly, primary enterocytes in culture can undergo a process of de-differentiation, whereby they lose certain epithelial phenotype (Rusu et al. 2005) .", [["primary enterocytes", "ANATOMY", 18, 37], ["epithelial", "ANATOMY", 120, 130], ["enterocytes", "CELL", 26, 37], ["epithelial", "TISSUE", 120, 130], ["primary enterocytes", "CELL_TYPE", 18, 37], ["primary enterocytes in culture", "PROBLEM", 18, 48], ["epithelial phenotype", "PROBLEM", 120, 140], ["enterocytes", "ANATOMY", 26, 37]]], ["Also, the inability to select epithelial crypts could favor the proliferation of mesenchymal cells as compared to epithelial cells (Rusu et al. 2005) .", [["epithelial crypts", "ANATOMY", 30, 47], ["mesenchymal cells", "ANATOMY", 81, 98], ["epithelial cells", "ANATOMY", 114, 130], ["epithelial crypts", "TISSUE", 30, 47], ["mesenchymal cells", "CELL", 81, 98], ["epithelial cells", "CELL", 114, 130], ["mesenchymal cells", "CELL_TYPE", 81, 98], ["epithelial cells", "CELL_TYPE", 114, 130], ["epithelial crypts", "PROBLEM", 30, 47], ["the proliferation of mesenchymal cells", "PROBLEM", 60, 98], ["epithelial crypts", "OBSERVATION", 30, 47], ["proliferation", "OBSERVATION_MODIFIER", 64, 77], ["mesenchymal cells", "OBSERVATION", 81, 98], ["epithelial cells", "OBSERVATION", 114, 130]]], ["Usually, mesenchymal cells express both vimentin and a-smooth muscle actin (a-SMA).", [["mesenchymal cells", "ANATOMY", 9, 26], ["a-smooth muscle", "ANATOMY", 53, 68], ["mesenchymal cells", "CELL", 9, 26], ["vimentin", "GENE_OR_GENE_PRODUCT", 40, 48], ["a-smooth muscle actin", "GENE_OR_GENE_PRODUCT", 53, 74], ["a-SMA", "GENE_OR_GENE_PRODUCT", 76, 81], ["mesenchymal cells", "CELL_TYPE", 9, 26], ["vimentin", "PROTEIN", 40, 48], ["a-smooth muscle actin", "PROTEIN", 53, 74], ["a-SMA", "PROTEIN", 76, 81], ["mesenchymal cells", "OBSERVATION", 9, 26], ["vimentin", "OBSERVATION_MODIFIER", 40, 48], ["a-smooth muscle", "ANATOMY", 53, 68]]], ["However, the BIEC-c4 and the immortalized cells were negative for a-SMA, which is a marker of smooth muscle cells.", [["BIEC-c4", "ANATOMY", 13, 20], ["cells", "ANATOMY", 42, 47], ["smooth muscle cells", "ANATOMY", 94, 113], ["BIEC-c4", "GENE_OR_GENE_PRODUCT", 13, 20], ["cells", "CELL", 42, 47], ["a-SMA", "GENE_OR_GENE_PRODUCT", 66, 71], ["smooth muscle cells", "CELL", 94, 113], ["BIEC", "DNA", 13, 17], ["c4", "DNA", 18, 20], ["immortalized cells", "CELL_LINE", 29, 47], ["a-SMA", "PROTEIN", 66, 71], ["smooth muscle cells", "CELL_TYPE", 94, 113], ["the BIEC-c4", "TEST", 9, 20], ["the immortalized cells", "TEST", 25, 47], ["a-SMA", "PROBLEM", 66, 71], ["immortalized cells", "OBSERVATION", 29, 47], ["SMA", "ANATOMY", 68, 71], ["smooth muscle cells", "OBSERVATION", 94, 113]]], ["Therefore, the BIECs established in this study were pure epithelial cells, devoid of mesenchymal contamination.", [["BIECs", "ANATOMY", 15, 20], ["epithelial cells", "ANATOMY", 57, 73], ["mesenchymal", "ANATOMY", 85, 96], ["BIECs", "CANCER", 15, 20], ["epithelial cells", "CELL", 57, 73], ["mesenchymal", "CELL", 85, 96], ["BIECs", "CELL_TYPE", 15, 20], ["pure epithelial cells", "CELL_TYPE", 52, 73], ["the BIECs", "TEST", 11, 20], ["this study", "TEST", 36, 46], ["pure epithelial cells", "PROBLEM", 52, 73], ["mesenchymal contamination", "PROBLEM", 85, 110], ["epithelial cells", "OBSERVATION", 57, 73], ["mesenchymal contamination", "OBSERVATION", 85, 110]]], ["We performed morphological and phenotypic characterization of BIECs at passages varying from 19 to 58.", [["BIECs", "ANATOMY", 62, 67], ["BIECs", "PATHOLOGICAL_FORMATION", 62, 67], ["BIECs", "CELL_TYPE", 62, 67], ["phenotypic characterization", "TEST", 31, 58], ["BIECs", "TEST", 62, 67]]], ["The BIEC-c4 cells at passage 51 showed strong cytokeratin expression, as evident from ICC staining.", [["BIEC-c4 cells", "ANATOMY", 4, 17], ["BIEC-c4 cells", "CELL", 4, 17], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 46, 57], ["ICC", "GENE_OR_GENE_PRODUCT", 86, 89], ["BIEC-c4 cells", "CELL_LINE", 4, 17], ["cytokeratin", "PROTEIN", 46, 57], ["The BIEC-c4 cells at passage", "TEST", 0, 28], ["strong cytokeratin expression", "PROBLEM", 39, 68], ["ICC staining", "PROBLEM", 86, 98], ["c4 cells", "OBSERVATION", 9, 17], ["strong", "OBSERVATION_MODIFIER", 39, 45], ["cytokeratin expression", "OBSERVATION", 46, 68], ["ICC staining", "OBSERVATION", 86, 98]]], ["We also confirmed the expression of epithelial phenotype in the three immortalized BIECs at different passages.", [["epithelial", "ANATOMY", 36, 46], ["BIECs", "ANATOMY", 83, 88], ["epithelial", "CELL", 36, 46], ["BIECs", "CELL", 83, 88], ["immortalized BIECs", "CELL_LINE", 70, 88], ["epithelial phenotype", "PROBLEM", 36, 56], ["epithelial phenotype", "OBSERVATION", 36, 56]]], ["Cytokeratin protein was expressed in SV40, hTERT, and HPV immortalized BIECs at passages 53, 32, and 48 respectively.", [["BIECs", "ANATOMY", 71, 76], ["Cytokeratin", "GENE_OR_GENE_PRODUCT", 0, 11], ["SV40", "ORGANISM", 37, 41], ["hTERT", "GENE_OR_GENE_PRODUCT", 43, 48], ["BIECs", "CELL", 71, 76], ["Cytokeratin protein", "PROTEIN", 0, 19], ["hTERT", "PROTEIN", 43, 48], ["HPV immortalized BIECs", "CELL_LINE", 54, 76], ["Cytokeratin protein", "TEST", 0, 19], ["hTERT", "TEST", 43, 48]]], ["Therefore, immortalization did not affect the epithelial phenotype for the cell passages studied.", [["epithelial", "ANATOMY", 46, 56], ["cell", "ANATOMY", 75, 79], ["epithelial", "TISSUE", 46, 56], ["cell", "CELL", 75, 79], ["the cell passages", "TEST", 71, 88], ["cell passages", "OBSERVATION", 75, 88]]], ["Study of both epithelial phenotype in BIEC-c4 and the expression of SV40, hTERT, and HPV proteins in the immortalized BIECs at late passages is important to demonstrate stable expression of the desired phenotypes.DiscussionCharacterization of PRRs on bovine tissues has provided important knowledge on innate immune responses.", [["epithelial", "ANATOMY", 14, 24], ["BIEC-c4", "ANATOMY", 38, 45], ["BIECs", "ANATOMY", 118, 123], ["tissues", "ANATOMY", 258, 265], ["epithelial", "TISSUE", 14, 24], ["BIEC-c4", "CELL", 38, 45], ["SV40", "GENE_OR_GENE_PRODUCT", 68, 72], ["hTERT", "GENE_OR_GENE_PRODUCT", 74, 79], ["HPV", "GENE_OR_GENE_PRODUCT", 85, 88], ["BIECs", "CELL", 118, 123], ["PRRs", "GENE_OR_GENE_PRODUCT", 243, 247], ["bovine", "ORGANISM", 251, 257], ["tissues", "TISSUE", 258, 265], ["BIEC", "PROTEIN", 38, 42], ["c4", "CELL_LINE", 43, 45], ["SV40, hTERT, and HPV proteins", "PROTEIN", 68, 97], ["immortalized BIECs", "CELL_LINE", 105, 123], ["PRRs", "PROTEIN", 243, 247], ["bovine", "SPECIES", 251, 257], ["bovine", "SPECIES", 251, 257], ["BIEC", "TEST", 38, 42], ["hTERT, and HPV proteins", "PROBLEM", 74, 97], ["both", "ANATOMY_MODIFIER", 9, 13], ["epithelial", "ANATOMY_MODIFIER", 14, 24], ["stable", "OBSERVATION_MODIFIER", 169, 175]]], ["A variety of cells including macrophages, dendritic cells, and intestinal epithelial cells have been shown to express TLRs (Charavaryamath et al. 2011; Turin and Riva 2008; Werling et al. 2006 ).", [["cells", "ANATOMY", 13, 18], ["macrophages", "ANATOMY", 29, 40], ["dendritic cells", "ANATOMY", 42, 57], ["intestinal epithelial cells", "ANATOMY", 63, 90], ["cells", "CELL", 13, 18], ["macrophages", "CELL", 29, 40], ["dendritic cells", "CELL", 42, 57], ["intestinal epithelial cells", "CELL", 63, 90], ["TLRs", "GENE_OR_GENE_PRODUCT", 118, 122], ["macrophages", "CELL_TYPE", 29, 40], ["dendritic cells", "CELL_TYPE", 42, 57], ["intestinal epithelial cells", "CELL_TYPE", 63, 90], ["TLRs", "PROTEIN", 118, 122], ["A variety of cells", "PROBLEM", 0, 18], ["macrophages", "PROBLEM", 29, 40], ["dendritic cells", "PROBLEM", 42, 57], ["intestinal epithelial cells", "PROBLEM", 63, 90], ["macrophages", "OBSERVATION", 29, 40], ["dendritic cells", "OBSERVATION", 42, 57], ["intestinal", "ANATOMY", 63, 73], ["epithelial cells", "OBSERVATION", 74, 90]]], ["The published partial sequences of bovine TLRs 1-10 have been found to share homology with ovine TLRs (Werling et al. 2006) .", [["bovine", "ORGANISM", 35, 41], ["TLRs 1-10", "GENE_OR_GENE_PRODUCT", 42, 51], ["ovine", "ORGANISM", 91, 96], ["TLRs", "GENE_OR_GENE_PRODUCT", 97, 101], ["bovine TLRs 1-10", "DNA", 35, 51], ["ovine TLRs", "PROTEIN", 91, 101], ["bovine", "SPECIES", 35, 41], ["bovine TLRs", "TEST", 35, 46]]], ["Recently, much of the work on bovine TLRs has focused on elucidating its role in mediating innate immune responses.", [["bovine", "ORGANISM", 30, 36], ["TLRs", "GENE_OR_GENE_PRODUCT", 37, 41], ["bovine TLRs", "PROTEIN", 30, 41], ["bovine", "SPECIES", 30, 36], ["bovine TLRs", "TREATMENT", 30, 41]]], ["Mutations and polymorphism studies have revealed a difference in bovine TLRs which could have implications in the selection of cattle breeds resistant to diseases (Fisher et al. 2011; Werling et al. 2006) .", [["bovine", "ORGANISM", 65, 71], ["TLRs", "GENE_OR_GENE_PRODUCT", 72, 76], ["cattle", "ORGANISM", 127, 133], ["bovine TLRs", "PROTEIN", 65, 76], ["bovine", "SPECIES", 65, 71], ["cattle", "SPECIES", 127, 133], ["polymorphism studies", "TEST", 14, 34], ["a difference in bovine TLRs", "PROBLEM", 49, 76], ["cattle breeds", "PROBLEM", 127, 140], ["diseases", "PROBLEM", 154, 162]]], ["Analyses of TLR mRNA transcripts in eight different bovine antigenpresenting cell subsets have revealed differences in TLR mRNA expression level among the different subsets (Werling et al. 2006) .", [["antigenpresenting cell", "ANATOMY", 59, 81], ["TLR", "GENE_OR_GENE_PRODUCT", 12, 15], ["bovine", "ORGANISM", 52, 58], ["antigenpresenting cell subsets", "CELL", 59, 89], ["TLR", "GENE_OR_GENE_PRODUCT", 119, 122], ["TLR mRNA transcripts", "RNA", 12, 32], ["bovine antigenpresenting cell subsets", "CELL_TYPE", 52, 89], ["TLR mRNA", "RNA", 119, 127], ["bovine", "SPECIES", 52, 58], ["TLR mRNA transcripts", "TREATMENT", 12, 32], ["different bovine antigenpresenting cell subsets", "TEST", 42, 89], ["differences in TLR mRNA expression level", "PROBLEM", 104, 144], ["TLR mRNA", "OBSERVATION", 119, 127]]], ["Bovine macrophage subsets differ in innate immune response against various mycobacterium species (Werling et al. 2006) .", [["macrophage", "ANATOMY", 7, 17], ["Bovine", "ORGANISM", 0, 6], ["macrophage subsets", "CELL", 7, 25], ["Bovine macrophage subsets", "CELL_TYPE", 0, 25], ["Bovine", "SPECIES", 0, 6], ["Bovine", "SPECIES", 0, 6], ["Bovine macrophage subsets", "TREATMENT", 0, 25], ["various mycobacterium species", "PROBLEM", 67, 96], ["macrophage subsets", "OBSERVATION", 7, 25], ["mycobacterium species", "OBSERVATION", 75, 96]]], ["In this present study, primary cultures of BIECs were characterized for the expression of TLR mRNA transcripts (TLRs 1-10) using two-step real-time RT-PCR.", [["primary cultures", "ANATOMY", 23, 39], ["BIECs", "ANATOMY", 43, 48], ["BIECs", "CELL", 43, 48], ["TLR", "GENE_OR_GENE_PRODUCT", 90, 93], ["TLRs 1-10", "GENE_OR_GENE_PRODUCT", 112, 121], ["primary cultures", "CELL_LINE", 23, 39], ["BIECs", "CELL_TYPE", 43, 48], ["TLR mRNA transcripts", "RNA", 90, 110], ["TLRs 1-10", "PROTEIN", 112, 121], ["this present study", "TEST", 3, 21], ["primary cultures", "TEST", 23, 39], ["BIECs", "TEST", 43, 48], ["TLR mRNA transcripts", "TREATMENT", 90, 110], ["TLRs", "TEST", 112, 116]]], ["The expression level of each TLR mRNA was compared among the four BIEC cell types.", [["BIEC cell", "ANATOMY", 66, 75], ["TLR", "GENE_OR_GENE_PRODUCT", 29, 32], ["BIEC cell", "CELL", 66, 75], ["TLR mRNA", "RNA", 29, 37], ["BIEC cell types", "CELL_LINE", 66, 81], ["BIEC cell types", "OBSERVATION", 66, 81]]], ["BIEC-c4 and immortalized BIEC-c4 cells expressed all ten TLRs and showed no significant differences in TLR expression as assessed by Wilcoxon-signed-rank test.", [["BIEC-c4", "ANATOMY", 0, 7], ["BIEC-c4 cells", "ANATOMY", 25, 38], ["BIEC-c4", "CELL", 0, 7], ["BIEC-c4 cells", "CELL", 25, 38], ["TLRs", "GENE_OR_GENE_PRODUCT", 57, 61], ["TLR", "GENE_OR_GENE_PRODUCT", 103, 106], ["BIEC-c4 and immortalized BIEC-c4 cells", "CELL_LINE", 0, 38], ["TLRs", "PROTEIN", 57, 61], ["TLR", "PROTEIN", 103, 106], ["BIEC", "TEST", 0, 4], ["c4 cells", "PROBLEM", 30, 38], ["significant differences in TLR expression", "PROBLEM", 76, 117], ["Wilcoxon", "TEST", 133, 141], ["c4", "ANATOMY", 5, 7], ["c4 cells", "OBSERVATION", 30, 38], ["no", "UNCERTAINTY", 73, 75], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["TLR expression", "OBSERVATION", 103, 117]]], ["This indicates that immortalization did not change the TLR expression of normal BIEC-c4 cells.", [["BIEC-c4 cells", "ANATOMY", 80, 93], ["TLR", "GENE_OR_GENE_PRODUCT", 55, 58], ["BIEC-c4 cells", "CELL", 80, 93], ["TLR", "PROTEIN", 55, 58], ["BIEC", "CELL_TYPE", 80, 84], ["c4 cells", "CELL_LINE", 85, 93], ["normal", "OBSERVATION", 73, 79], ["c4 cells", "OBSERVATION", 85, 93]]], ["Therefore, expression of TLR genes suggests that BIEC-c4 cells may be a good model to study innate immune response against various enteric pathogens.DiscussionStudies on TLR mediated immune responses have revealed important applications of bovine intestinal epithelial cells.", [["BIEC-c4 cells", "ANATOMY", 49, 62], ["intestinal epithelial cells", "ANATOMY", 247, 274], ["TLR", "GENE_OR_GENE_PRODUCT", 25, 28], ["BIEC-c4 cells", "CELL", 49, 62], ["TLR", "GENE_OR_GENE_PRODUCT", 170, 173], ["bovine", "ORGANISM", 240, 246], ["intestinal epithelial cells", "CELL", 247, 274], ["TLR genes", "DNA", 25, 34], ["BIEC-c4 cells", "CELL_LINE", 49, 62], ["TLR", "PROTEIN", 170, 173], ["bovine intestinal epithelial cells", "CELL_TYPE", 240, 274], ["bovine", "SPECIES", 240, 246], ["bovine", "SPECIES", 240, 246], ["BIEC-c4 cells", "PROBLEM", 49, 62], ["various enteric pathogens", "PROBLEM", 123, 148], ["bovine intestinal epithelial cells", "TREATMENT", 240, 274], ["enteric", "ANATOMY", 131, 138], ["pathogens", "OBSERVATION", 139, 148], ["bovine intestinal epithelial cells", "OBSERVATION", 240, 274]]], ["Study of innate immune responses can provide important knowledge for the development of adjuvants and immunobiotics (Buckner et al. 2006; Villena et al. 2018; Werling et al. 2006) .", [["adjuvants", "TREATMENT", 88, 97]]], ["Fetal-derived, early passage BIECs have been used in screening assays for the identification of new adjuvants, based on the stimulation of IL-8 cytokine, and also supported rotavirus infection (Buckner et al. 2006) .", [["Fetal", "ANATOMY", 0, 5], ["BIECs", "ANATOMY", 29, 34], ["rotavirus infection", "DISEASE", 173, 192], ["Fetal", "ANATOMICAL_SYSTEM", 0, 5], ["BIECs", "CELL", 29, 34], ["IL-8", "GENE_OR_GENE_PRODUCT", 139, 143], ["rotavirus", "ORGANISM", 173, 182], ["IL-8 cytokine", "PROTEIN", 139, 152], ["rotavirus", "SPECIES", 173, 182], ["screening assays", "TEST", 53, 69], ["new adjuvants", "TREATMENT", 96, 109], ["the stimulation of IL", "TREATMENT", 120, 141], ["rotavirus infection", "PROBLEM", 173, 192], ["rotavirus", "OBSERVATION_MODIFIER", 173, 182], ["infection", "OBSERVATION", 183, 192]]], ["Fetalderived bovine intestinal epithelial cells (BIECs) immortalized with SV40 LT Ag were used to study the immunomodulatory effects of lactic acid bacteria (LAB) upon challenge with enterotoxigenic E. coli (ETEC) (Takanashi et al. 2013 ).", [["intestinal epithelial cells", "ANATOMY", 20, 47], ["BIECs", "ANATOMY", 49, 54], ["lactic acid bacteria", "CHEMICAL", 136, 156], ["LAB", "CHEMICAL", 158, 161], ["enterotoxigenic E. coli", "DISEASE", 183, 206], ["Ag", "CHEMICAL", 82, 84], ["lactic acid", "CHEMICAL", 136, 147], ["bovine", "ORGANISM", 13, 19], ["intestinal epithelial cells", "CELL", 20, 47], ["BIECs", "CELL", 49, 54], ["SV40", "ORGANISM", 74, 78], ["LT Ag", "GENE_OR_GENE_PRODUCT", 79, 84], ["lactic acid bacteria", "SIMPLE_CHEMICAL", 136, 156], ["LAB", "SIMPLE_CHEMICAL", 158, 161], ["enterotoxigenic E. coli", "ORGANISM", 183, 206], ["ETEC", "ORGANISM", 208, 212], ["Fetalderived bovine intestinal epithelial cells", "CELL_LINE", 0, 47], ["BIECs", "CELL_TYPE", 49, 54], ["SV40 LT Ag", "PROTEIN", 74, 84], ["bovine", "SPECIES", 13, 19], ["E. coli", "SPECIES", 199, 206], ["bovine", "SPECIES", 13, 19], ["E. coli", "SPECIES", 199, 206], ["ETEC", "SPECIES", 208, 212], ["Fetalderived bovine intestinal epithelial cells", "TREATMENT", 0, 47], ["SV40 LT Ag", "TREATMENT", 74, 84], ["lactic acid bacteria", "PROBLEM", 136, 156], ["enterotoxigenic E. coli", "PROBLEM", 183, 206], ["intestinal epithelial cells", "OBSERVATION", 20, 47]]], ["These BIECs were characterized for the expression of all ten TLRs and were found to strongly express TLRs 1, 3, 4 and 6 (Takanashi et al. 2013) .", [["BIECs", "ANATOMY", 6, 11], ["BIECs", "CANCER", 6, 11], ["TLRs", "GENE_OR_GENE_PRODUCT", 61, 65], ["TLRs 1", "GENE_OR_GENE_PRODUCT", 101, 107], ["3", "GENE_OR_GENE_PRODUCT", 109, 110], ["4", "GENE_OR_GENE_PRODUCT", 112, 113], ["BIECs", "CELL_TYPE", 6, 11], ["TLRs", "PROTEIN", 61, 65], ["TLRs 1, 3, 4 and 6", "PROTEIN", 101, 119]]], ["Also, increased expression levels of proinflammatory cytokines IL-1, IL-6 and IL-8 were observed (Takanashi et al. 2013) .", [["IL-1", "GENE_OR_GENE_PRODUCT", 63, 67], ["IL-6", "GENE_OR_GENE_PRODUCT", 69, 73], ["IL-8", "GENE_OR_GENE_PRODUCT", 78, 82], ["proinflammatory cytokines", "PROTEIN", 37, 62], ["IL", "PROTEIN", 63, 65], ["IL-6", "PROTEIN", 69, 73], ["IL", "PROTEIN", 78, 80], ["increased expression levels", "PROBLEM", 6, 33], ["proinflammatory cytokines IL", "TEST", 37, 65], ["IL", "TEST", 69, 71], ["IL", "TEST", 78, 80], ["increased", "OBSERVATION_MODIFIER", 6, 15], ["expression", "OBSERVATION_MODIFIER", 16, 26], ["levels", "OBSERVATION_MODIFIER", 27, 33], ["proinflammatory", "OBSERVATION_MODIFIER", 37, 52]]], ["In another study, bovine intestinal epithelial cells were investigated for TLR mediated immune response against C. parvum infection (Yang et al. 2015) .", [["intestinal epithelial cells", "ANATOMY", 25, 52], ["C. parvum infection", "DISEASE", 112, 131], ["bovine", "ORGANISM", 18, 24], ["intestinal epithelial cells", "CELL", 25, 52], ["TLR", "GENE_OR_GENE_PRODUCT", 75, 78], ["C. parvum", "ORGANISM", 112, 121], ["bovine intestinal epithelial cells", "CELL_TYPE", 18, 52], ["TLR", "PROTEIN", 75, 78], ["bovine", "SPECIES", 18, 24], ["C. parvum", "SPECIES", 112, 121], ["bovine", "SPECIES", 18, 24], ["C. parvum", "SPECIES", 112, 121], ["another study", "TEST", 3, 16], ["bovine intestinal epithelial cells", "PROBLEM", 18, 52], ["TLR mediated immune response", "PROBLEM", 75, 103], ["C. parvum infection", "PROBLEM", 112, 131], ["intestinal", "ANATOMY", 25, 35], ["epithelial cells", "OBSERVATION", 36, 52], ["parvum", "OBSERVATION_MODIFIER", 115, 121], ["infection", "OBSERVATION", 122, 131]]], ["However, in this study, we not only generated BIEC clones but also studied if immortalization changed TLR expression in BIECs.", [["BIEC clones", "ANATOMY", 46, 57], ["BIECs", "ANATOMY", 120, 125], ["BIEC clones", "CELL", 46, 57], ["TLR", "GENE_OR_GENE_PRODUCT", 102, 105], ["BIECs", "PATHOLOGICAL_FORMATION", 120, 125], ["BIEC clones", "CELL_LINE", 46, 57], ["TLR", "PROTEIN", 102, 105], ["BIECs", "CELL_TYPE", 120, 125], ["this study", "TEST", 12, 22]]], ["We found a higher expression of TLRs 3 and 4 across all four BIEC cell types as compared to other TLRs.", [["BIEC cell", "ANATOMY", 61, 70], ["TLRs 3", "GENE_OR_GENE_PRODUCT", 32, 38], ["4", "GENE_OR_GENE_PRODUCT", 43, 44], ["BIEC cell", "CELL", 61, 70], ["TLRs", "GENE_OR_GENE_PRODUCT", 98, 102], ["TLRs 3 and 4", "PROTEIN", 32, 44], ["TLRs", "PROTEIN", 98, 102], ["higher", "OBSERVATION_MODIFIER", 11, 17], ["BIEC cell types", "OBSERVATION", 61, 76]]], ["TLR3 may play an important role during bovine enteric viral infections, chiefly BRV (Aich et al. 2007 ).", [["enteric viral infections", "DISEASE", 46, 70], ["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["bovine", "ORGANISM", 39, 45], ["enteric viral", "ORGANISM", 46, 59], ["TLR3", "PROTEIN", 0, 4], ["bovine", "SPECIES", 39, 45], ["TLR3", "TREATMENT", 0, 4], ["bovine enteric viral infections", "PROBLEM", 39, 70]]], ["Likewise, TLR4 may be important for both pathogen recognition as well as maintenance of immune homeostasis in the intestinal epithelium (Villena et al. 2014 ).", [["intestinal epithelium", "ANATOMY", 114, 135], ["TLR4", "GENE_OR_GENE_PRODUCT", 10, 14], ["intestinal epithelium", "TISSUE", 114, 135], ["TLR4", "PROTEIN", 10, 14], ["TLR4", "TREATMENT", 10, 14], ["both pathogen recognition", "TEST", 36, 61], ["immune homeostasis", "TREATMENT", 88, 106], ["intestinal epithelium", "ANATOMY", 114, 135]]], ["In the future, the TLRs expressed by BIEC cells may be stimulated with TLR specific ligands or challenged with different enteric pathogens to study innate immune responses.", [["BIEC cells", "ANATOMY", 37, 47], ["TLRs", "GENE_OR_GENE_PRODUCT", 19, 23], ["BIEC cells", "CELL", 37, 47], ["TLR", "GENE_OR_GENE_PRODUCT", 71, 74], ["TLRs", "PROTEIN", 19, 23], ["BIEC cells", "CELL_LINE", 37, 47], ["TLR", "PROTEIN", 71, 74], ["TLR specific ligands", "TREATMENT", 71, 91]]], ["Further investigation on this may reveal more information about the role of TLRs in BIECs.", [["BIECs", "ANATOMY", 84, 89], ["TLRs", "GENE_OR_GENE_PRODUCT", 76, 80], ["BIECs", "CELL", 84, 89], ["TLRs", "PROTEIN", 76, 80], ["BIECs", "CELL_TYPE", 84, 89], ["Further investigation", "TEST", 0, 21]]], ["Therefore, the established BIEC cell lines may serve as a useful model system to study host-pathogen interaction and regulation of immune responses.DiscussionThe ability to generate clones from a single cell is typically a characteristic of stem cell-like cells or tumor cells.", [["BIEC cell lines", "ANATOMY", 27, 42], ["cell", "ANATOMY", 203, 207], ["stem cell-like cells", "ANATOMY", 241, 261], ["tumor cells", "ANATOMY", 265, 276], ["tumor", "DISEASE", 265, 270], ["BIEC cell lines", "CELL", 27, 42], ["clones", "CELL", 182, 188], ["cell", "CELL", 203, 207], ["stem cell-like cells", "CELL", 241, 261], ["tumor cells", "CELL", 265, 276], ["BIEC cell lines", "CELL_LINE", 27, 42], ["stem cell-like cells", "CELL_TYPE", 241, 261], ["tumor cells", "CELL_TYPE", 265, 276], ["the established BIEC cell lines", "TREATMENT", 11, 42], ["stem cell-like cells", "PROBLEM", 241, 261], ["tumor cells", "PROBLEM", 265, 276], ["cell lines", "OBSERVATION", 32, 42], ["stem cell", "OBSERVATION", 241, 250], ["tumor cells", "OBSERVATION", 265, 276]]], ["Using limiting dilution method, we successfully generated a pure BIEC clone from a single cell.", [["cell", "ANATOMY", 90, 94], ["BIEC clone", "CELL", 65, 75], ["cell", "CELL", 90, 94], ["BIEC clone", "CELL_LINE", 65, 75], ["limiting dilution method", "TREATMENT", 6, 30], ["a pure BIEC clone", "TREATMENT", 58, 75]]], ["Immortalization of mixed epithelial-like cells followed by limiting dilution is the usual approach since single cell suspension may fail to generate clones unless those have been immortalized.", [["epithelial-like cells", "ANATOMY", 25, 46], ["cell", "ANATOMY", 112, 116], ["epithelial-like cells", "CELL", 25, 46], ["cell", "CELL", 112, 116], ["clones", "CELL", 149, 155], ["mixed epithelial-like cells", "CELL_TYPE", 19, 46], ["mixed epithelial-like cells", "PROBLEM", 19, 46], ["single cell suspension", "TREATMENT", 105, 127], ["mixed", "OBSERVATION_MODIFIER", 19, 24], ["epithelial", "ANATOMY_MODIFIER", 25, 35], ["like cells", "OBSERVATION", 36, 46]]], ["In a previous study, limiting dilution was first performed to obtain fetal-derived pure BIEC culture.", [["fetal", "ANATOMY", 69, 74], ["fetal", "ANATOMICAL_SYSTEM", 69, 74], ["BIEC culture", "CELL", 88, 100], ["BIEC culture", "CELL_LINE", 88, 100], ["a previous study", "TEST", 3, 19]]], ["However, it was immortalized with SV40 gene after a few passages due to a decline in cell proliferative capacity (Miyazawa et al. 2010) .", [["cell", "ANATOMY", 85, 89], ["SV40", "ORGANISM", 34, 38], ["cell", "CELL", 85, 89], ["SV40 gene", "DNA", 34, 43], ["a decline in cell proliferative capacity", "PROBLEM", 72, 112], ["cell proliferative capacity", "OBSERVATION", 85, 112]]], ["These cells were shown to form tight junctions (Miyazawa et al. 2010) .", [["cells", "ANATOMY", 6, 11], ["tight junctions", "ANATOMY", 31, 46], ["cells", "CELL", 6, 11], ["tight junctions", "CELLULAR_COMPONENT", 31, 46], ["tight junctions", "OBSERVATION", 31, 46]]], ["In this study, we first generated a stable BIEC-c4 clone and then immortalized it with three different methods.", [["BIEC-c4 clone", "ANATOMY", 43, 56], ["BIEC-c4 clone", "CELL", 43, 56], ["BIEC-c4 clone", "CELL_LINE", 43, 56], ["this study", "TEST", 3, 13], ["a stable BIEC-c4 clone", "TREATMENT", 34, 56], ["stable", "OBSERVATION_MODIFIER", 36, 42], ["c4 clone", "OBSERVATION", 48, 56]]], ["All four cell types retained their ability to proliferate and were maintained by continuous culture.", [["cell", "ANATOMY", 9, 13], ["cell", "CELL", 9, 13], ["continuous culture", "TEST", 81, 99], ["four cell types", "OBSERVATION", 4, 19]]], ["The possibility that the BIEC-c4 clone was obtained from a stem cell-like population cannot be ruled out (Peterson and Artis 2014; Potten et al. 1997) .", [["BIEC-c4 clone", "ANATOMY", 25, 38], ["stem cell", "ANATOMY", 59, 68], ["BIEC", "GENE_OR_GENE_PRODUCT", 25, 29], ["stem cell", "CELL", 59, 68], ["BIEC", "DNA", 25, 29], ["c4 clone", "CELL_LINE", 30, 38], ["stem cell", "CELL_TYPE", 59, 68], ["the BIEC-c4 clone", "PROBLEM", 21, 38], ["a stem cell-like population", "PROBLEM", 57, 84], ["stem cell", "OBSERVATION", 59, 68]]], ["For instance, the mixed ileal epithelial-like cells could have been derived from crypt-resident stem cells (Booth and Potten 2000) .", [["ileal epithelial-like cells", "ANATOMY", 24, 51], ["crypt-resident stem cells", "ANATOMY", 81, 106], ["ileal epithelial-like cells", "CELL", 24, 51], ["crypt-resident stem cells", "CELL", 81, 106], ["mixed ileal epithelial-like cells", "CELL_TYPE", 18, 51], ["crypt-resident stem cells", "CELL_TYPE", 81, 106], ["the mixed ileal epithelial-like cells", "PROBLEM", 14, 51], ["mixed", "OBSERVATION_MODIFIER", 18, 23], ["ileal epithelial", "ANATOMY", 24, 40], ["like cells", "OBSERVATION", 41, 51], ["stem cells", "OBSERVATION", 96, 106]]], ["Additionally, we were not able to polarize the BIEC-c4 culture, which may be due to the less differentiated phenotype of the BIEC-c4 cells, suggesting that these are more stem cell-like.", [["BIEC-c4 culture", "ANATOMY", 47, 62], ["BIEC-c4 cells", "ANATOMY", 125, 138], ["stem cell", "ANATOMY", 171, 180], ["BIEC-c4 cells", "CELL", 125, 138], ["stem cell", "CELL", 171, 180], ["BIEC-c4 culture", "CELL_LINE", 47, 62], ["BIEC-c4 cells", "CELL_LINE", 125, 138], ["stem cell", "CELL_TYPE", 171, 180], ["the BIEC-c4 culture", "TEST", 43, 62], ["may be due to", "UNCERTAINTY", 70, 83], ["c4 cells", "ANATOMY", 130, 138], ["stem cell", "OBSERVATION", 171, 180]]], ["The BIEC clone generated by limiting dilution could, however, change to a more differentiated phenotype during passaging and lose its ability to proliferate.", [["BIEC clone", "ANATOMY", 4, 14], ["BIEC clone", "CELL", 4, 14], ["BIEC clone", "CELL_LINE", 4, 14], ["The BIEC clone", "TREATMENT", 0, 14], ["a more differentiated phenotype", "PROBLEM", 72, 103], ["more differentiated", "OBSERVATION_MODIFIER", 74, 93]]], ["Further, it would also be difficult to characterize the pure BIEC clones if those were immortalized prior to limiting dilution as immortalization could change certain phenotypes.", [["BIEC clones", "CELL", 61, 72], ["BIEC clones", "CELL_LINE", 61, 72], ["certain phenotypes", "PROBLEM", 159, 177]]], ["Also, it would be difficult to identify whether the proliferative capacity of BIECs was dependent on or independent of immortalization.", [["BIECs", "ANATOMY", 78, 83], ["BIECs", "CANCER", 78, 83], ["BIECs", "CELL_TYPE", 78, 83], ["the proliferative capacity of BIECs", "PROBLEM", 48, 83], ["proliferative", "OBSERVATION_MODIFIER", 52, 65], ["capacity", "OBSERVATION_MODIFIER", 66, 74]]], ["As a result, we were able to identify the ability of BIECclones to grow in continuous culture to be independent of immortalization.", [["BIECclones", "TREATMENT", 53, 63], ["continuous culture", "TEST", 75, 93]]], ["In the future, immortalized BIEC-c4 clones may be cultured under different culture conditions to differentiate into a more mature phenotype.", [["BIEC-c4 clones", "ANATOMY", 28, 42], ["BIEC-c4 clones", "CELL", 28, 42], ["immortalized BIEC-c4 clones", "CELL_LINE", 15, 42], ["immortalized BIEC-c4 clones", "TREATMENT", 15, 42], ["different culture conditions", "TEST", 65, 93], ["a more mature phenotype", "PROBLEM", 116, 139], ["more mature", "OBSERVATION_MODIFIER", 118, 129]]], ["Due to the trade-off between cell proliferation and differentiation, immortalization may be able to rescue the BIECs from loss of proliferation.DiscussionIn conclusion, the bovine intestinal epithelial cell line, designated as BIEC-c4, and the immortalized BIECs were established and characterized using different immunological and biochemical techniques.", [["cell", "ANATOMY", 29, 33], ["BIECs", "ANATOMY", 111, 116], ["intestinal epithelial cell line", "ANATOMY", 180, 211], ["BIEC-c4", "ANATOMY", 227, 234], ["BIECs", "ANATOMY", 257, 262], ["BIECs", "DISEASE", 111, 116], ["cell", "CELL", 29, 33], ["BIECs", "CANCER", 111, 116], ["bovine", "ORGANISM", 173, 179], ["intestinal epithelial cell line", "CELL", 180, 211], ["BIEC-c4", "CELL", 227, 234], ["BIECs", "CELL", 257, 262], ["bovine intestinal epithelial cell line", "CELL_LINE", 173, 211], ["BIEC-c4", "CELL_LINE", 227, 234], ["immortalized BIECs", "CELL_LINE", 244, 262], ["bovine", "SPECIES", 173, 179], ["bovine", "SPECIES", 173, 179], ["cell proliferation", "TREATMENT", 29, 47], ["loss of proliferation", "PROBLEM", 122, 143], ["the bovine intestinal epithelial cell line", "TREATMENT", 169, 211], ["BIEC", "TEST", 227, 231], ["cell proliferation", "OBSERVATION", 29, 47], ["proliferation", "OBSERVATION", 130, 143], ["intestinal", "ANATOMY", 180, 190], ["epithelial cell line", "OBSERVATION", 191, 211]]], ["The established primary and the immortalized BIECs may be further investigated for TLR mediated immune responses.", [["BIECs", "ANATOMY", 45, 50], ["BIECs", "CELL", 45, 50], ["TLR", "GENE_OR_GENE_PRODUCT", 83, 86], ["immortalized BIECs", "CELL_LINE", 32, 50], ["TLR", "PROTEIN", 83, 86], ["TLR mediated immune responses", "PROBLEM", 83, 112]]], ["Further studies may clarify and justify the effective use of these cells for studying the innate immune responses against enteric pathogens.", [["cells", "ANATOMY", 67, 72], ["enteric pathogens", "DISEASE", 122, 139], ["cells", "CELL", 67, 72], ["Further studies", "TEST", 0, 15], ["these cells", "TREATMENT", 61, 72], ["the innate immune responses", "TREATMENT", 86, 113], ["enteric pathogens", "PROBLEM", 122, 139]]]], "83284b9347ee9b89e6a621525740b95e443c10ee": [["SARS-CoV-2Severe acute respiratory syndrome coronavirus 235Funding: This contemporary review did not receive any specific grant from funding agencies 36 in the public, commercial, or not-for-profit sectors.", [["SARS", "DISEASE", 0, 4], ["acute respiratory syndrome coronavirus 235Funding", "DISEASE", 17, 66], ["SARS-CoV-2Severe acute respiratory", "ORGANISM", 0, 34], ["SARS-CoV-2Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 55], ["SARS", "PROBLEM", 0, 4], ["acute respiratory syndrome coronavirus", "PROBLEM", 17, 55], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["respiratory syndrome", "OBSERVATION", 23, 43]]], ["3756In December 2019, COVID-19 was first described in Wuhan, China, in patients complaining 57 of flu-like symptoms.", [["COVID-19", "CHEMICAL", 22, 30], ["flu", "DISEASE", 98, 101], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["COVID", "TEST", 22, 27], ["flu-like symptoms", "PROBLEM", 98, 115]]], ["1 The virus was isolated and identified as a new strain of coronavirus, 58 now named SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2).", [["coronavirus", "DISEASE", 59, 70], ["Acute Respiratory Syndrome CoronaVirus", "DISEASE", 104, 142], ["coronavirus", "ORGANISM", 59, 70], ["SARS-CoV-2", "ORGANISM", 85, 95], ["coronavirus", "SPECIES", 59, 70], ["SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2", "SPECIES", 85, 144], ["The virus", "PROBLEM", 2, 11], ["a new strain of coronavirus", "PROBLEM", 43, 70], ["SARS", "TEST", 85, 89], ["CoV", "TEST", 90, 93], ["Severe Acute Respiratory Syndrome CoronaVirus", "PROBLEM", 97, 142], ["virus", "OBSERVATION", 6, 11], ["new", "OBSERVATION_MODIFIER", 45, 48], ["Severe", "OBSERVATION_MODIFIER", 97, 103], ["Acute", "OBSERVATION_MODIFIER", 104, 109], ["Respiratory Syndrome", "OBSERVATION", 110, 130]]], ["Mortality 59 rate of COVID-19 is estimated to be below 1%, 2 mainly due to the severe acute respiratory 60 syndrome and multi-organ dysfunction.", [["multi-organ", "ANATOMY", 120, 131], ["respiratory 60 syndrome", "DISEASE", 92, 115], ["multi-organ dysfunction", "DISEASE", 120, 143], ["multi-organ", "ORGAN", 120, 131], ["Mortality", "TEST", 0, 9], ["COVID", "TEST", 21, 26], ["the severe acute respiratory 60 syndrome", "PROBLEM", 75, 115], ["multi-organ dysfunction", "PROBLEM", 120, 143], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["respiratory 60 syndrome", "OBSERVATION", 92, 115], ["multi-organ dysfunction", "OBSERVATION", 120, 143]]], ["Cardiovascular complications of COVID-19 received 61 less medical attention; nevertheless, the first cases of myocarditis in COVID- 19 patients have 62 been reported.", [["Cardiovascular", "ANATOMY", 0, 14], ["Cardiovascular complications", "DISEASE", 0, 28], ["COVID-19", "CHEMICAL", 32, 40], ["myocarditis", "DISEASE", 110, 121], ["COVID-19", "CHEMICAL", 32, 40], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["COVID", "TEST", 32, 37], ["myocarditis", "PROBLEM", 110, 121], ["COVID", "TEST", 125, 130], ["myocarditis", "OBSERVATION", 110, 121]]], ["[3] [4] [5] [6] Moreover, myocarditis was recognized as the cause of death in some 63 COVID-19 patients.", [["myocarditis", "DISEASE", 26, 37], ["death", "DISEASE", 69, 74], ["[3] [4] [5] [6]", "SIMPLE_CHEMICAL", 0, 15], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["myocarditis", "PROBLEM", 26, 37], ["death", "PROBLEM", 69, 74], ["myocarditis", "OBSERVATION", 26, 37]]], ["7 Pathology is usually focal within the myocardium, but there is a risk of 64 arrhythmia, as well as progression to fulminant heart failure and cardiogenic shock.", [["myocardium", "ANATOMY", 40, 50], ["heart", "ANATOMY", 126, 131], ["arrhythmia", "DISEASE", 78, 88], ["heart failure", "DISEASE", 126, 139], ["cardiogenic shock", "DISEASE", 144, 161], ["myocardium", "ORGAN", 40, 50], ["heart", "ORGAN", 126, 131], ["arrhythmia", "PROBLEM", 78, 88], ["fulminant heart failure", "PROBLEM", 116, 139], ["cardiogenic shock", "PROBLEM", 144, 161], ["focal", "OBSERVATION_MODIFIER", 23, 28], ["myocardium", "ANATOMY", 40, 50], ["arrhythmia", "OBSERVATION", 78, 88], ["fulminant", "OBSERVATION_MODIFIER", 116, 125], ["heart", "ANATOMY", 126, 131], ["failure", "OBSERVATION", 132, 139], ["cardiogenic shock", "OBSERVATION", 144, 161]]], ["This 65 article outlines the possible pathophysiology of COVID-19-related myocarditis, its clinical 66 presentation, as well as the associated arrhythmias.", [["COVID-19", "CHEMICAL", 57, 65], ["myocarditis", "DISEASE", 74, 85], ["arrhythmias", "DISEASE", 143, 154], ["COVID-19", "CELL", 57, 65], ["COVID", "TEST", 57, 62], ["myocarditis", "PROBLEM", 74, 85], ["the associated arrhythmias", "PROBLEM", 128, 154], ["possible", "UNCERTAINTY", 29, 37], ["myocarditis", "OBSERVATION", 74, 85], ["arrhythmias", "OBSERVATION", 143, 154]]], ["The criteria for screening and 67 management of myocarditis relating to COVID-19 are also proposed.", [["myocarditis", "DISEASE", 48, 59], ["COVID-19", "CHEMICAL", 72, 80], ["screening", "TEST", 17, 26], ["myocarditis", "PROBLEM", 48, 59], ["COVID", "TEST", 72, 77], ["myocarditis", "OBSERVATION", 48, 59]]], ["Myocarditis is an inflammatory disease of the heart characterized by inflammatory infiltrates 72 and myocardial injury without an ischemic cause.", [["heart", "ANATOMY", 46, 51], ["myocardial", "ANATOMY", 101, 111], ["Myocarditis", "DISEASE", 0, 11], ["myocardial injury", "DISEASE", 101, 118], ["heart", "ORGAN", 46, 51], ["myocardial", "MULTI-TISSUE_STRUCTURE", 101, 111], ["Myocarditis", "PROBLEM", 0, 11], ["an inflammatory disease of the heart", "PROBLEM", 15, 51], ["inflammatory infiltrates", "PROBLEM", 69, 93], ["myocardial injury", "PROBLEM", 101, 118], ["an ischemic cause", "PROBLEM", 127, 144], ["inflammatory", "OBSERVATION", 18, 30], ["heart", "ANATOMY", 46, 51], ["inflammatory", "OBSERVATION_MODIFIER", 69, 81], ["infiltrates", "OBSERVATION", 82, 93], ["myocardial", "ANATOMY", 101, 111], ["injury", "OBSERVATION", 112, 118], ["without", "UNCERTAINTY", 119, 126], ["ischemic", "OBSERVATION", 130, 138]]], ["8 The most commonly identifiable cause of 73 myocarditis in the United States other developed countries is viral.", [["myocarditis", "DISEASE", 45, 56], ["myocarditis", "PROBLEM", 45, 56], ["viral", "PROBLEM", 107, 112], ["most commonly", "OBSERVATION_MODIFIER", 6, 19], ["myocarditis", "OBSERVATION", 45, 56], ["viral", "OBSERVATION", 107, 112]]], ["9 , 10 Esfandiarei and 7456McManus 8 proposed that the pathophysiology of viral myocarditis is a combination of direct 75 cell injury and T-lymphocytes-mediated cytotoxicity which can be augmented by the 76 cytokine storm syndrome.", [["cell", "ANATOMY", 122, 126], ["T-lymphocytes", "ANATOMY", 138, 151], ["viral myocarditis", "DISEASE", 74, 91], ["cell", "CELL", 122, 126], ["T-lymphocytes", "CELL", 138, 151], ["T-lymphocytes", "CELL_TYPE", 138, 151], ["cytokine", "PROTEIN", 207, 215], ["viral myocarditis", "PROBLEM", 74, 91], ["direct 75 cell injury", "PROBLEM", 112, 133], ["T-lymphocytes", "PROBLEM", 138, 151], ["mediated cytotoxicity", "PROBLEM", 152, 173], ["the 76 cytokine storm syndrome", "PROBLEM", 200, 230], ["viral myocarditis", "OBSERVATION", 74, 91], ["cell injury", "OBSERVATION", 122, 133]]], ["Interleukin-6 (IL-6) appears to be the central mediator of cytokine 77 storm where it orchestrates the pro-inflammatory responses from immune cells including the 78 T-lymphocytes.", [["immune cells", "ANATOMY", 135, 147], ["78 T-lymphocytes", "ANATOMY", 162, 178], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 0, 13], ["IL-6", "GENE_OR_GENE_PRODUCT", 15, 19], ["cytokine 77", "GENE_OR_GENE_PRODUCT", 59, 70], ["immune cells", "CELL", 135, 147], ["78 T-lymphocytes", "CELL", 162, 178], ["Interleukin-6 (IL-6", "PROTEIN", 0, 19], ["cytokine", "PROTEIN", 59, 67], ["immune cells", "CELL_TYPE", 135, 147], ["78 T-lymphocytes", "CELL_TYPE", 162, 178], ["Interleukin-6 (IL", "TREATMENT", 0, 17], ["immune cells", "TEST", 135, 147]]], ["11 This causes T-lymphocyte activation and a further release of inflammatory 79 cytokines which stimulate more T-lymphocytes, leading to a positive feedback loop of 80 immune activation and myocardial damage.", [["T-lymphocyte", "ANATOMY", 15, 27], ["T-lymphocytes", "ANATOMY", 111, 124], ["myocardial", "ANATOMY", 190, 200], ["myocardial damage", "DISEASE", 190, 207], ["T-lymphocyte", "CELL", 15, 27], ["T-lymphocytes", "CELL", 111, 124], ["myocardial", "MULTI-TISSUE_STRUCTURE", 190, 200], ["inflammatory 79 cytokines", "PROTEIN", 64, 89], ["T-lymphocytes", "CELL_TYPE", 111, 124], ["T-lymphocyte activation", "PROBLEM", 15, 38], ["inflammatory 79 cytokines", "PROBLEM", 64, 89], ["a positive feedback loop", "PROBLEM", 137, 161], ["myocardial damage", "PROBLEM", 190, 207], ["lymphocyte activation", "OBSERVATION", 17, 38], ["inflammatory", "OBSERVATION_MODIFIER", 64, 76], ["feedback loop", "OBSERVATION", 148, 161], ["myocardial", "ANATOMY", 190, 200], ["damage", "OBSERVATION", 201, 207]]], ["Cardiotropism of the T-lymphocytes is thought 81 to arise from the interaction between the heart-produced hepatocyte growth factor (HGF) and 82 c-Met, a HGF receptor on na\u00efve T-lymphocytes.", [["T-lymphocytes", "ANATOMY", 21, 34], ["heart", "ANATOMY", 91, 96], ["T-lymphocytes", "ANATOMY", 175, 188], ["T-lymphocytes", "CELL", 21, 34], ["heart", "ORGAN", 91, 96], ["hepatocyte growth factor", "GENE_OR_GENE_PRODUCT", 106, 130], ["HGF", "GENE_OR_GENE_PRODUCT", 132, 135], ["c-Met", "GENE_OR_GENE_PRODUCT", 144, 149], ["HGF", "GENE_OR_GENE_PRODUCT", 153, 156], ["na\u00efve T-lymphocytes", "CELL", 169, 188], ["T-lymphocytes", "CELL_TYPE", 21, 34], ["hepatocyte growth factor", "PROTEIN", 106, 130], ["HGF", "PROTEIN", 132, 135], ["82 c-Met", "PROTEIN", 141, 149], ["HGF receptor", "PROTEIN", 153, 165], ["na\u00efve T-lymphocytes", "CELL_TYPE", 169, 188], ["Cardiotropism", "TEST", 0, 13], ["the T-lymphocytes", "TEST", 17, 34], ["the heart", "TEST", 87, 96], ["hepatocyte growth factor", "PROBLEM", 106, 130], ["HGF", "TEST", 132, 135], ["a HGF receptor", "TEST", 151, 165], ["heart", "ANATOMY", 91, 96], ["hepatocyte", "ANATOMY", 106, 116], ["lymphocytes", "ANATOMY", 177, 188]]], ["12 Despite being a minor cause of all viral myocarditis cases, human coronaviruses have been 86 linked to myocarditis in patients of all age groups.", [["viral myocarditis", "DISEASE", 38, 55], ["myocarditis", "DISEASE", 106, 117], ["human", "ORGANISM", 63, 68], ["patients", "ORGANISM", 121, 129], ["human", "SPECIES", 63, 68], ["patients", "SPECIES", 121, 129], ["human coronaviruses", "SPECIES", 63, 82], ["all viral myocarditis cases", "PROBLEM", 34, 61], ["human coronaviruses", "PROBLEM", 63, 82], ["myocarditis", "PROBLEM", 106, 117], ["viral myocarditis", "OBSERVATION", 38, 55], ["myocarditis", "OBSERVATION", 106, 117]]], ["[13] [14] [15] The viral RNAs of MERS-CoV and 87 SARS-CoV, which are close relatives of SARS-CoV-2, were found in the heart tissues of 88 infected animals, suggesting that these coronaviruses possess cardiotropism.", [["heart tissues", "ANATOMY", 118, 131], ["[13] [14] [15]", "SIMPLE_CHEMICAL", 0, 14], ["MERS-CoV", "ORGANISM", 33, 41], ["87 SARS-CoV", "ORGANISM", 46, 57], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["heart tissues", "TISSUE", 118, 131], ["coronaviruses", "ORGANISM", 178, 191], ["viral RNAs", "RNA", 19, 29], ["MERS-CoV", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 49, 57], ["SARS-CoV", "SPECIES", 88, 96], ["The viral RNAs", "TEST", 15, 29], ["MERS", "TEST", 33, 37], ["CoV", "TEST", 38, 41], ["SARS", "TEST", 49, 53], ["CoV", "TEST", 54, 57], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96], ["these coronaviruses possess cardiotropism", "PROBLEM", 172, 213], ["heart tissues", "ANATOMY", 118, 131], ["infected", "OBSERVATION", 138, 146]]], ["16 Possible pathophysiology of SARS-CoV-2-related myocarditis 100 SARS-CoV-2 gains entry into the human cells by binding its spike protein to a membrane 101 protein, Angiotensin-Converting Enzyme 2 (ACE2).", [["cells", "ANATOMY", 104, 109], ["membrane", "ANATOMY", 144, 152], ["SARS", "DISEASE", 31, 35], ["myocarditis", "DISEASE", 50, 61], ["SARS", "DISEASE", 66, 70], ["Angiotensin", "CHEMICAL", 166, 177], ["SARS-CoV-2", "ORGANISM", 31, 41], ["human", "ORGANISM", 98, 103], ["cells", "CELL", 104, 109], ["Angiotensin-Converting Enzyme 2", "GENE_OR_GENE_PRODUCT", 166, 197], ["ACE2", "GENE_OR_GENE_PRODUCT", 199, 203], ["human cells", "CELL_TYPE", 98, 109], ["spike protein", "PROTEIN", 125, 138], ["membrane 101 protein", "PROTEIN", 144, 164], ["Angiotensin-Converting Enzyme 2", "PROTEIN", 166, 197], ["ACE2", "PROTEIN", 199, 203], ["human", "SPECIES", 98, 103], ["SARS-CoV", "SPECIES", 31, 39], ["human", "SPECIES", 98, 103], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["myocarditis", "PROBLEM", 50, 61], ["CoV", "TEST", 71, 74], ["a membrane", "TEST", 142, 152], ["Angiotensin", "TEST", 166, 177], ["Converting Enzyme", "TEST", 178, 195], ["Possible", "UNCERTAINTY", 3, 11], ["SARS", "OBSERVATION", 31, 35], ["myocarditis", "OBSERVATION", 50, 61]]], ["20 However, the spike protein must first 102 be cleaved at the S1/S2 and subsequently at the S2' sites to enable binding to the ACE2.", [["S2", "GENE_OR_GENE_PRODUCT", 66, 68], ["S2' sites", "CELLULAR_COMPONENT", 93, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 128, 132], ["spike protein", "PROTEIN", 16, 29], ["S1", "PROTEIN", 63, 65], ["S2", "PROTEIN", 66, 68], ["S2' sites", "DNA", 93, 102], ["ACE2", "PROTEIN", 128, 132], ["the spike protein", "TEST", 12, 29], ["S2", "ANATOMY", 66, 68]]], ["10356Cleavage at the S1/S2 site appears to be mediated by TMPRSS2, a serine protein.", [["10356", "CHEMICAL", 0, 5], ["serine", "CHEMICAL", 69, 75], ["S2", "GENE_OR_GENE_PRODUCT", 24, 26], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 58, 65], ["serine", "AMINO_ACID", 69, 75], ["S1/S2 site", "DNA", 21, 31], ["TMPRSS2", "PROTEIN", 58, 65], ["serine protein", "PROTEIN", 69, 83], ["10356", "SPECIES", 0, 5], ["Cleavage at the S1/S2 site", "PROBLEM", 5, 31], ["a serine protein", "TEST", 67, 83], ["S1", "ANATOMY", 21, 23], ["S2", "ANATOMY", 24, 26]]], ["20 The 104 ACE2 can be found on the ciliated columnar epithelial cells of the respiratory tract, type II 105 pneumocytes as well as cardiomyocytes.", [["columnar epithelial cells", "ANATOMY", 45, 70], ["respiratory tract", "ANATOMY", 78, 95], ["type II 105 pneumocytes", "ANATOMY", 97, 120], ["cardiomyocytes", "ANATOMY", 132, 146], ["ACE2", "GENE_OR_GENE_PRODUCT", 11, 15], ["ciliated columnar epithelial cells", "CELL", 36, 70], ["tract", "ORGANISM_SUBDIVISION", 90, 95], ["pneumocytes", "CELL", 109, 120], ["cardiomyocytes", "CELL", 132, 146], ["104 ACE2", "PROTEIN", 7, 15], ["ciliated columnar epithelial cells", "CELL_TYPE", 36, 70], ["type II 105 pneumocytes", "CELL_TYPE", 97, 120], ["cardiomyocytes", "CELL_TYPE", 132, 146], ["type II 105 pneumocytes", "PROBLEM", 97, 120], ["cardiomyocytes", "PROBLEM", 132, 146], ["columnar epithelial cells", "OBSERVATION", 45, 70], ["respiratory tract", "ANATOMY", 78, 95], ["pneumocytes", "OBSERVATION", 109, 120], ["cardiomyocytes", "ANATOMY", 132, 146]]], ["21, 22 Therefore, it is plausible that SARS-CoV-2 10656infects the human heart, especially when there is heart failure since ACE2 is upregulated, 23 107 although the presence of viral receptors does not always predict tropism.", [["heart", "ANATOMY", 73, 78], ["heart", "ANATOMY", 105, 110], ["SARS-CoV-2 10656", "CHEMICAL", 39, 55], ["heart failure", "DISEASE", 105, 118], ["SARS-CoV-2 10656", "ORGANISM", 39, 55], ["human", "ORGANISM", 67, 72], ["heart", "ORGAN", 73, 78], ["heart", "ORGAN", 105, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 125, 129], ["ACE2", "PROTEIN", 125, 129], ["viral receptors", "PROTEIN", 178, 193], ["human", "SPECIES", 67, 72], ["SARS-CoV-2 10656", "SPECIES", 39, 55], ["human", "SPECIES", 67, 72], ["CoV", "TEST", 44, 47], ["heart failure", "PROBLEM", 105, 118], ["ACE2", "TEST", 125, 129], ["viral receptors", "PROBLEM", 178, 193], ["human heart", "ANATOMY", 67, 78], ["heart", "ANATOMY", 105, 110], ["failure", "OBSERVATION", 111, 118]]], ["24 10856There are at least 6 known accessory proteins which can be transcribed by the SARS-CoV-2 110 genome.", [["SARS-CoV-2 110", "GENE_OR_GENE_PRODUCT", 86, 100], ["accessory proteins", "PROTEIN", 35, 53], ["SARS-CoV-2 110 genome", "DNA", 86, 107], ["SARS-CoV", "SPECIES", 86, 94], ["6 known accessory proteins", "PROBLEM", 27, 53], ["the SARS", "TEST", 82, 90], ["accessory proteins", "OBSERVATION", 35, 53]]], ["25 It remains to be determined whether any of the accessory proteins do provide 111 infectivity advantage as in MERS-CoV and SARS-CoV.116It is unclear how prevalent myocarditis is among COVID-19 patients.", [["myocarditis", "DISEASE", 165, 176], ["MERS-CoV", "ORGANISM", 112, 120], ["SARS-CoV", "ORGANISM", 125, 133], ["patients", "ORGANISM", 195, 203], ["accessory proteins", "PROTEIN", 50, 68], ["patients", "SPECIES", 195, 203], ["MERS-CoV", "SPECIES", 112, 120], ["SARS-CoV", "SPECIES", 125, 133], ["the accessory proteins", "PROBLEM", 46, 68], ["myocarditis", "PROBLEM", 165, 176]]], ["This is partly because 117 the early reports often lacked the specific diagnostic modalities to assess myocarditis.", [["myocarditis", "DISEASE", 103, 114], ["myocarditis", "PROBLEM", 103, 114], ["myocarditis", "OBSERVATION", 103, 114]]], ["Some 118 argued that up to 7% of the COVID-19-related deaths were attributable to myocarditis; 26 119 however, this was assumed and not based on a confirmatory diagnosis of myocarditis and 120 may be an overestimate.", [["deaths", "DISEASE", 54, 60], ["myocarditis", "DISEASE", 82, 93], ["myocarditis", "DISEASE", 173, 184], ["the COVID", "TEST", 33, 42], ["myocarditis", "PROBLEM", 82, 93], ["myocarditis", "PROBLEM", 173, 184], ["myocarditis", "OBSERVATION", 82, 93], ["myocarditis", "OBSERVATION", 173, 184]]], ["On the other hand, many laboratories are rationing tests and first 121 screening for known pathogens resulting in flu-like symptoms.", [["rationing tests", "TEST", 41, 56], ["first 121 screening", "TEST", 61, 80], ["known pathogens", "PROBLEM", 85, 100], ["flu-like symptoms", "PROBLEM", 114, 131]]], ["If a positive pathogen is 122 identified, then testing for SARS-CoV-2 is not performed.", [["SARS", "DISEASE", 59, 63], ["SARS-CoV-2", "ORGANISM", 59, 69], ["SARS-CoV", "SPECIES", 59, 67], ["a positive pathogen", "PROBLEM", 3, 22], ["testing", "TEST", 47, 54], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67]]], ["This is erroneous and likely to 123 miss the true frequency of SARS-CoV-2 infection as it assumes mutual exclusivity of SARS-124116CoV-2.", [["SARS", "DISEASE", 63, 67], ["infection", "DISEASE", 74, 83], ["SARS", "DISEASE", 120, 124], ["SARS-CoV-2", "ORGANISM", 63, 73], ["SARS-CoV-2", "SPECIES", 63, 73], ["SARS-124116CoV-2", "SPECIES", 120, 136], ["SARS", "PROBLEM", 63, 67], ["CoV-2 infection", "PROBLEM", 68, 83], ["SARS", "TEST", 120, 124], ["infection", "OBSERVATION", 74, 83]]], ["One report has identified 24.5% of COVID-19 patients to have co-infection with 125 other viruses.", [["co-infection", "DISEASE", 61, 73], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["COVID", "TEST", 35, 40], ["co-infection", "PROBLEM", 61, 73], ["co-infection", "OBSERVATION", 61, 73]]], ["27 Hence, it is possible that many cases of COVID-19-related myocarditis were 126 missed due to a lack of SARS-CoV-2 diagnosis.", [["COVID-19", "CHEMICAL", 44, 52], ["myocarditis", "DISEASE", 61, 72], ["COVID-19", "CHEMICAL", 44, 52], ["COVID-19", "ORGANISM", 44, 52], ["COVID", "TEST", 44, 49], ["myocarditis", "PROBLEM", 61, 72], ["SARS", "PROBLEM", 106, 110]]], ["127116Certain ethnic groups may be disproportionately affected by SARS-CoV-2.", [["127116Certain", "CHEMICAL", 0, 13], ["SARS", "DISEASE", 66, 70], ["SARS-CoV-2", "ORGANISM", 66, 76], ["SARS-CoV", "SPECIES", 66, 74]]], ["COVID-19 death 129 rates were shown to be higher among the African-American population than other ethnicities 130 in many American states.", [["death", "DISEASE", 9, 14], ["COVID", "TEST", 0, 5], ["death", "TEST", 9, 14]]], ["28 Whilst this may partially be explained by the higher 131 cardiovascular risk factors or genetic predisposition to poorer cardiac outcomes, 29 Hubei, China reported a 7.3% incidence of heart palpitations among its 137 patients.", [["cardiovascular", "ANATOMY", 60, 74], ["cardiac", "ANATOMY", 124, 131], ["heart", "ANATOMY", 187, 192], ["heart palpitations", "DISEASE", 187, 205], ["cardiac", "ORGAN", 124, 131], ["heart", "ORGAN", 187, 192], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 220, 228], ["the higher 131 cardiovascular risk factors", "PROBLEM", 45, 87], ["heart palpitations", "PROBLEM", 187, 205], ["heart", "ANATOMY", 187, 192], ["palpitations", "OBSERVATION", 193, 205]]], ["30 140116Moreover, Wang et al. 31 reported that arrhythmia was a cause of ICU transfer in 44.4% of 141 COVID-19 patients.", [["arrhythmia", "DISEASE", 48, 58], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["arrhythmia", "PROBLEM", 48, 58], ["COVID", "TEST", 103, 108]]], ["Caution is encouraged when interpreting these data as the sample size 142 tends to be small and hence prone to overestimation.", [["these data", "TEST", 40, 50], ["the sample size", "TEST", 54, 69], ["small", "OBSERVATION_MODIFIER", 86, 91]]], ["The exact nature of the arrhythmias was 143 also not usually reported, rendering it difficult to assess whether they are secondary to other 144 conditions such as electrolyte imbalance or pre-existing arrhythmias.", [["arrhythmias", "DISEASE", 24, 35], ["arrhythmias", "DISEASE", 201, 212], ["the arrhythmias", "PROBLEM", 20, 35], ["other 144 conditions", "PROBLEM", 134, 154], ["electrolyte imbalance", "PROBLEM", 163, 184], ["pre-existing arrhythmias", "PROBLEM", 188, 212], ["arrhythmias", "OBSERVATION", 24, 35], ["arrhythmias", "OBSERVATION", 201, 212]]], ["The actual prevalence 145 of arrhythmias in COVID-19 patients; therefore, remains unknown.", [["arrhythmias", "DISEASE", 29, 40], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["arrhythmias", "PROBLEM", 29, 40]]], ["Nevertheless, 146 arrhythmias could occur in the context of myocarditis.", [["arrhythmias", "DISEASE", 18, 29], ["myocarditis", "DISEASE", 60, 71], ["arrhythmias", "PROBLEM", 18, 29], ["myocarditis", "PROBLEM", 60, 71], ["myocarditis", "OBSERVATION", 60, 71]]], ["Peretto et al. 32 reported in a recent 147 study that 78.7% of myocarditis patients exhibited some forms of ventricular arrhythmias.", [["ventricular", "ANATOMY", 108, 119], ["myocarditis", "DISEASE", 63, 74], ["ventricular arrhythmias", "DISEASE", 108, 131], ["patients", "ORGANISM", 75, 83], ["ventricular", "MULTI-TISSUE_STRUCTURE", 108, 119], ["patients", "SPECIES", 75, 83], ["a recent 147 study", "TEST", 30, 48], ["myocarditis", "PROBLEM", 63, 74], ["ventricular arrhythmias", "PROBLEM", 108, 131], ["myocarditis", "OBSERVATION", 63, 74], ["ventricular", "ANATOMY", 108, 119], ["arrhythmias", "OBSERVATION", 120, 131]]], ["148116The characteristics of arrhythmias also differ between the active and healed myocarditis, 32 149 suggesting that the pathophysiology is dependent on the stage of myocardial injury. shown that pro-inflammatory cytokines, e.g. IL-6, might cause the displacement of 159 plakoglobin, a desmosomal protein, from the cardiomyocyte membrane.", [["myocardial", "ANATOMY", 168, 178], ["desmosomal", "ANATOMY", 288, 298], ["cardiomyocyte membrane", "ANATOMY", 317, 339], ["148116", "CHEMICAL", 0, 6], ["arrhythmias", "DISEASE", 29, 40], ["myocarditis", "DISEASE", 83, 94], ["myocardial injury", "DISEASE", 168, 185], ["myocardial", "MULTI-TISSUE_STRUCTURE", 168, 178], ["IL-6", "GENE_OR_GENE_PRODUCT", 231, 235], ["plakoglobin", "GENE_OR_GENE_PRODUCT", 273, 284], ["desmosomal", "GENE_OR_GENE_PRODUCT", 288, 298], ["cardiomyocyte membrane", "CELLULAR_COMPONENT", 317, 339], ["pro-inflammatory cytokines", "PROTEIN", 198, 224], ["IL-6", "PROTEIN", 231, 235], ["159 plakoglobin", "PROTEIN", 269, 284], ["desmosomal protein", "PROTEIN", 288, 306], ["148116", "SPECIES", 0, 6], ["arrhythmias", "PROBLEM", 29, 40], ["the active and healed myocarditis", "PROBLEM", 61, 94], ["myocardial injury", "PROBLEM", 168, 185], ["pro-inflammatory cytokines", "TEST", 198, 224], ["the displacement of 159 plakoglobin", "PROBLEM", 249, 284], ["a desmosomal protein", "TEST", 286, 306], ["arrhythmias", "OBSERVATION", 29, 40], ["active", "OBSERVATION_MODIFIER", 65, 71], ["healed", "OBSERVATION_MODIFIER", 76, 82], ["myocarditis", "OBSERVATION", 83, 94], ["dependent", "OBSERVATION_MODIFIER", 142, 151], ["myocardial", "ANATOMY", 168, 178], ["injury", "OBSERVATION", 179, 185], ["pro-inflammatory cytokines", "OBSERVATION", 198, 224], ["displacement", "OBSERVATION_MODIFIER", 253, 265], ["cardiomyocyte", "ANATOMY", 317, 330], ["membrane", "ANATOMY_MODIFIER", 331, 339]]], ["35 This could be 160 arrhythmogenic as inadequate cell-to-cell adherence is postulated to damage the cell 161 membrane, leading to cardiac cell death and fibrofatty replacement.", [["cell", "ANATOMY", 50, 54], ["cell", "ANATOMY", 58, 62], ["cell 161 membrane", "ANATOMY", 101, 118], ["cardiac cell", "ANATOMY", 131, 143], ["arrhythmogenic", "DISEASE", 21, 35], ["cardiac cell death", "DISEASE", 131, 149], ["cell", "CELL", 50, 54], ["cell", "CELL", 58, 62], ["cell 161 membrane", "CELLULAR_COMPONENT", 101, 118], ["cardiac cell", "CELL", 131, 143], ["arrhythmogenic", "PROBLEM", 21, 35], ["inadequate cell", "PROBLEM", 39, 54], ["cardiac cell death", "PROBLEM", 131, 149], ["fibrofatty replacement", "TREATMENT", 154, 176], ["cell 161 membrane", "OBSERVATION", 101, 118], ["cardiac", "ANATOMY", 131, 138], ["cell death", "OBSERVATION", 139, 149], ["fibrofatty replacement", "OBSERVATION", 154, 176]]], ["36 Moreover, reduced 162 surface expression of desmosomal proteins is a known etiology of arrhythmogenic 163 cardiomyopathies.", [["surface", "ANATOMY", 25, 32], ["arrhythmogenic 163 cardiomyopathies", "DISEASE", 90, 125], ["desmosomal proteins", "GENE_OR_GENE_PRODUCT", 47, 66], ["desmosomal proteins", "PROTEIN", 47, 66], ["desmosomal proteins", "PROBLEM", 47, 66], ["arrhythmogenic 163 cardiomyopathies", "PROBLEM", 90, 125], ["desmosomal proteins", "OBSERVATION", 47, 66], ["cardiomyopathies", "OBSERVATION", 109, 125]]], ["36 Substantial evidence has now suggested an increase in serum IL-6 in 164 COVID-19 patients, especially in those with severe presentations.", [["serum", "ANATOMY", 57, 62], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["IL-6", "GENE_OR_GENE_PRODUCT", 63, 67], ["patients", "ORGANISM", 84, 92], ["serum IL-6", "PROTEIN", 57, 67], ["patients", "SPECIES", 84, 92], ["serum IL", "TEST", 57, 65], ["increase", "OBSERVATION_MODIFIER", 45, 53], ["serum IL", "OBSERVATION_MODIFIER", 57, 65], ["severe", "OBSERVATION_MODIFIER", 119, 125]]], ["37 It is, therefore, plausible 165 that SARS-CoV-2 infection precipitates arrhythmias in patients with a genetic predisposition. of tachycardia and acute-onset heart failure with cardiogenic shock.", [["heart", "ANATOMY", 160, 165], ["SARS", "DISEASE", 40, 44], ["infection", "DISEASE", 51, 60], ["arrhythmias", "DISEASE", 74, 85], ["tachycardia", "DISEASE", 132, 143], ["heart failure", "DISEASE", 160, 173], ["cardiogenic shock", "DISEASE", 179, 196], ["SARS-CoV-2", "ORGANISM", 40, 50], ["patients", "ORGANISM", 89, 97], ["heart", "ORGAN", 160, 165], ["patients", "SPECIES", 89, 97], ["SARS-CoV", "SPECIES", 40, 48], ["2 infection", "PROBLEM", 49, 60], ["arrhythmias", "PROBLEM", 74, 85], ["tachycardia", "PROBLEM", 132, 143], ["acute-onset heart failure", "PROBLEM", 148, 173], ["cardiogenic shock", "PROBLEM", 179, 196], ["tachycardia", "OBSERVATION", 132, 143], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["onset", "OBSERVATION_MODIFIER", 154, 159], ["heart", "ANATOMY", 160, 165], ["failure", "OBSERVATION", 166, 173], ["cardiogenic shock", "OBSERVATION", 179, 196]]], ["[3] [4] [5] In these severe cases, 176 patients may also present with signs of right-sided heart failure, including raised jugular 177 venous pressure, peripheral edema and right upper quadrant pain.", [["heart", "ANATOMY", 91, 96], ["jugular 177 venous", "ANATOMY", 123, 141], ["peripheral edema", "ANATOMY", 152, 168], ["right upper quadrant", "ANATOMY", 173, 193], ["heart failure", "DISEASE", 91, 104], ["peripheral edema", "DISEASE", 152, 168], ["right upper quadrant pain", "DISEASE", 173, 198], ["[3] [4] [5", "SIMPLE_CHEMICAL", 0, 10], ["patients", "ORGANISM", 39, 47], ["heart", "ORGAN", 91, 96], ["jugular 177 venous", "MULTI-TISSUE_STRUCTURE", 123, 141], ["peripheral edema", "PATHOLOGICAL_FORMATION", 152, 168], ["upper quadrant", "ORGANISM_SUBDIVISION", 179, 193], ["patients", "SPECIES", 39, 47], ["right-sided heart failure", "PROBLEM", 79, 104], ["raised jugular 177 venous pressure", "PROBLEM", 116, 150], ["peripheral edema", "PROBLEM", 152, 168], ["right upper quadrant pain", "PROBLEM", 173, 198], ["right", "ANATOMY_MODIFIER", 79, 84], ["sided", "ANATOMY_MODIFIER", 85, 90], ["heart", "ANATOMY", 91, 96], ["failure", "OBSERVATION", 97, 104], ["jugular", "ANATOMY_MODIFIER", 123, 130], ["177 venous", "ANATOMY", 131, 141], ["pressure", "OBSERVATION_MODIFIER", 142, 150], ["peripheral", "ANATOMY_MODIFIER", 152, 162], ["edema", "OBSERVATION", 163, 168], ["right", "ANATOMY_MODIFIER", 173, 178], ["upper", "ANATOMY_MODIFIER", 179, 184], ["quadrant", "ANATOMY", 185, 193], ["pain", "OBSERVATION", 194, 198]]], ["10 The most emergent 178 presentation is fulminant myocarditis, defined by ventricular dysfunction and heart failure 179 within 2-3 weeks of contracting the virus.", [["ventricular", "ANATOMY", 75, 86], ["heart", "ANATOMY", 103, 108], ["myocarditis", "DISEASE", 51, 62], ["ventricular dysfunction", "DISEASE", 75, 98], ["heart failure", "DISEASE", 103, 116], ["ventricular", "ORGAN", 75, 86], ["heart", "ORGAN", 103, 108], ["fulminant myocarditis", "PROBLEM", 41, 62], ["ventricular dysfunction", "PROBLEM", 75, 98], ["heart failure", "PROBLEM", 103, 116], ["contracting the virus", "PROBLEM", 141, 162], ["fulminant", "OBSERVATION_MODIFIER", 41, 50], ["myocarditis", "OBSERVATION", 51, 62], ["ventricular", "ANATOMY", 75, 86], ["dysfunction", "OBSERVATION", 87, 98], ["heart", "ANATOMY", 103, 108], ["failure", "OBSERVATION", 109, 116], ["virus", "OBSERVATION", 157, 162]]], ["8 The early signs of fulminant myocarditis usually 180 resemble those of sepsis; i.e., a patient often presents febrile with low pulse pressure, cold or 181 mottled periphery and sinus tachycardia.", [["sinus", "ANATOMY", 179, 184], ["myocarditis", "DISEASE", 31, 42], ["sepsis", "DISEASE", 73, 79], ["febrile", "DISEASE", 112, 119], ["sinus tachycardia", "DISEASE", 179, 196], ["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["fulminant myocarditis", "PROBLEM", 21, 42], ["sepsis", "PROBLEM", 73, 79], ["febrile", "PROBLEM", 112, 119], ["low pulse pressure", "PROBLEM", 125, 143], ["cold or 181 mottled periphery", "PROBLEM", 145, 174], ["sinus tachycardia", "PROBLEM", 179, 196], ["fulminant", "OBSERVATION_MODIFIER", 21, 30], ["myocarditis", "OBSERVATION", 31, 42], ["sepsis", "OBSERVATION", 73, 79], ["sinus", "ANATOMY", 179, 184], ["tachycardia", "OBSERVATION", 185, 196]]], ["10 Sepsis-related cardiomyopathy: A case series study showed that 67% of critically-ill 220 COVID-19 patients required vasopressor and that 33% developed cardiomyopathy.", [["Sepsis", "DISEASE", 3, 9], ["cardiomyopathy", "DISEASE", 18, 32], ["critically-ill", "DISEASE", 73, 87], ["cardiomyopathy", "DISEASE", 154, 168], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["Sepsis", "PROBLEM", 3, 9], ["cardiomyopathy", "PROBLEM", 18, 32], ["A case series study", "TEST", 34, 53], ["COVID", "TEST", 92, 97], ["vasopressor", "TREATMENT", 119, 130], ["cardiomyopathy", "PROBLEM", 154, 168], ["Sepsis", "OBSERVATION", 3, 9], ["cardiomyopathy", "OBSERVATION", 18, 32], ["cardiomyopathy", "OBSERVATION", 154, 168]]], ["40 This 221 raises suspicion of sepsis-related cardiomyopathy, a disease characterized by reversible 222 myocardial dysfunction.", [["myocardial", "ANATOMY", 105, 115], ["sepsis", "DISEASE", 32, 38], ["cardiomyopathy", "DISEASE", 47, 61], ["myocardial dysfunction", "DISEASE", 105, 127], ["myocardial", "MULTI-TISSUE_STRUCTURE", 105, 115], ["sepsis", "PROBLEM", 32, 38], ["cardiomyopathy", "PROBLEM", 47, 61], ["a disease", "PROBLEM", 63, 72], ["reversible 222 myocardial dysfunction", "PROBLEM", 90, 127], ["suspicion of", "UNCERTAINTY", 19, 31], ["sepsis", "OBSERVATION", 32, 38], ["cardiomyopathy", "OBSERVATION", 47, 61], ["reversible", "OBSERVATION_MODIFIER", 90, 100], ["222 myocardial dysfunction", "OBSERVATION", 101, 127]]], ["The myocardial injury is thought to arise from raised nitric oxide 223 production which suppresses the cardiomyocyte's response to calcium and downregulates the 224 heart's 1-adrenergic receptors.", [["myocardial", "ANATOMY", 4, 14], ["cardiomyocyte", "ANATOMY", 103, 116], ["heart", "ANATOMY", 165, 170], ["myocardial injury", "DISEASE", 4, 21], ["nitric oxide", "CHEMICAL", 54, 66], ["calcium", "CHEMICAL", 131, 138], ["nitric oxide", "CHEMICAL", 54, 66], ["calcium", "CHEMICAL", 131, 138], ["myocardial", "MULTI-TISSUE_STRUCTURE", 4, 14], ["nitric oxide 223", "SIMPLE_CHEMICAL", 54, 70], ["cardiomyocyte", "CELL", 103, 116], ["calcium", "SIMPLE_CHEMICAL", 131, 138], ["heart", "ORGAN", 165, 170], ["1-adrenergic receptors", "GENE_OR_GENE_PRODUCT", 173, 195], ["224 heart's 1-adrenergic receptors", "PROTEIN", 161, 195], ["The myocardial injury", "PROBLEM", 0, 21], ["raised nitric oxide", "TREATMENT", 47, 66], ["calcium", "TEST", 131, 138], ["myocardial", "ANATOMY", 4, 14], ["injury", "OBSERVATION", 15, 21], ["thought to arise", "UNCERTAINTY", 25, 41], ["cardiomyocyte", "ANATOMY", 103, 116], ["heart", "ANATOMY", 165, 170]]], ["41 The three cardinal signs of sepsis-related cardiomyopathy Takotsubo cardiomyopathy is usually preceded by an emotional or physical stressor.", [["sepsis", "DISEASE", 31, 37], ["cardiomyopathy", "DISEASE", 46, 60], ["Takotsubo cardiomyopathy", "DISEASE", 61, 85], ["sepsis", "PROBLEM", 31, 37], ["cardiomyopathy Takotsubo cardiomyopathy", "PROBLEM", 46, 85], ["sepsis", "OBSERVATION", 31, 37], ["cardiomyopathy", "OBSERVATION", 46, 60], ["Takotsubo cardiomyopathy", "OBSERVATION", 61, 85]]], ["42 Of 233 note, a case report described a COVID-19 patient who initially presented as having reverse 234 an effective alternative, especially when the patient is to undertake the high-resolution CT 255 scan of the chest for assessment of the acute respiratory distress syndrome (Figure 3J) .", [["chest", "ANATOMY", 214, 219], ["respiratory", "ANATOMY", 248, 259], ["acute respiratory distress syndrome", "DISEASE", 242, 277], ["patient", "ORGANISM", 51, 58], ["patient", "ORGANISM", 151, 158], ["chest", "ORGAN", 214, 219], ["patient", "SPECIES", 51, 58], ["patient", "SPECIES", 151, 158], ["the high-resolution CT 255 scan of the chest", "TEST", 175, 219], ["assessment", "TEST", 224, 234], ["the acute respiratory distress syndrome", "PROBLEM", 238, 277], ["chest", "ANATOMY", 214, 219], ["acute", "OBSERVATION_MODIFIER", 242, 247], ["respiratory distress", "OBSERVATION", 248, 268]]], ["256116Contrast-enhanced cardiac CT will add very little scanning time, and it is particularly useful 257 in this situation to perform a test rapidly with minimal requirement for breath-holding.", [["cardiac", "ANATOMY", 24, 31], ["cardiac", "ORGAN", 24, 31], ["cardiac CT", "TEST", 24, 34], ["a test", "TEST", 134, 140], ["breath-holding", "TREATMENT", 178, 192]]], ["44258Without the CMR or contrast-enhanced CT results, it is arduous to distinguish myocarditis 259 from other differential diagnoses. and RNA-DNA extraction performed to test for the presence of viral genomes.", [["myocarditis", "DISEASE", 83, 94], ["DNA", "CELLULAR_COMPONENT", 142, 145], ["viral genomes", "DNA", 195, 208], ["the CMR", "TEST", 13, 20], ["myocarditis", "PROBLEM", 83, 94], ["RNA", "TEST", 138, 141], ["DNA extraction", "TEST", 142, 156], ["viral genomes", "PROBLEM", 195, 208], ["myocarditis", "OBSERVATION", 83, 94], ["viral genomes", "OBSERVATION", 195, 208]]], ["45 Regarding 266258the contagious spread risk, should coronary angiography be deemed necessary, it is 267 reasonable to perform the right heart procedures and/or EMB concomitantly as these will add 268 minimal risk, whilst adding 15-minutes to the procedure time.", [["coronary", "ANATOMY", 54, 62], ["right heart", "ANATOMY", 132, 143], ["coronary", "MULTI-TISSUE_STRUCTURE", 54, 62], ["heart", "ORGAN", 138, 143], ["coronary angiography", "TEST", 54, 74], ["the right heart procedures", "TEST", 128, 154], ["the procedure time", "TREATMENT", 244, 262], ["right", "ANATOMY_MODIFIER", 132, 137], ["heart", "ANATOMY", 138, 143]]], ["It also serves as an opportunity 269 for accurate diagnosis and provides tissues for the development of specific biomarkers which 270 could be useful for developing a diagnostic test for SARS-CoV-2 myocarditis.", [["tissues", "ANATOMY", 73, 80], ["myocarditis", "DISEASE", 198, 209], ["tissues", "TISSUE", 73, 80], ["CoV-2", "ORGANISM", 192, 197], ["SARS-CoV", "SPECIES", 187, 195], ["specific biomarkers", "TEST", 104, 123], ["a diagnostic test", "TEST", 165, 182], ["SARS", "PROBLEM", 187, 191], ["CoV", "PROBLEM", 192, 195], ["myocarditis", "PROBLEM", 198, 209], ["myocarditis", "OBSERVATION", 198, 209]]], ["In the tragic 271 situation where a patient is deceased, we suggest that an autopsy be performed and include 272 the heart as this provides an opportunity to observe its gross and microscopic pathology, are not undergoing clinical testing such as an ECG or cardiac imaging.", [["heart", "ANATOMY", 117, 122], ["cardiac", "ANATOMY", 257, 264], ["patient", "ORGANISM", 36, 43], ["heart", "ORGAN", 117, 122], ["patient", "SPECIES", 36, 43], ["an autopsy", "TEST", 73, 83], ["microscopic pathology", "TEST", 180, 201], ["clinical testing", "TEST", 222, 238], ["an ECG", "TEST", 247, 253], ["cardiac imaging", "TEST", 257, 272], ["heart", "ANATOMY", 117, 122]]], ["As the emphasis is to 282 evaluate and admit patients with severe lower respiratory tract symptoms, many patients with 283 possible myocarditis will never be evaluated.", [["lower respiratory tract", "ANATOMY", 66, 89], ["lower respiratory tract symptoms", "DISEASE", 66, 98], ["myocarditis", "DISEASE", 132, 143], ["patients", "ORGANISM", 45, 53], ["lower", "ORGANISM_SUBDIVISION", 66, 71], ["respiratory tract", "ORGANISM_SUBDIVISION", 72, 89], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 105, 113], ["severe lower respiratory tract symptoms", "PROBLEM", 59, 98], ["myocarditis", "PROBLEM", 132, 143], ["lower", "ANATOMY_MODIFIER", 66, 71], ["respiratory tract", "ANATOMY", 72, 89], ["myocarditis", "OBSERVATION", 132, 143]]], ["Some of these may survive the acute event but 284 may be at risk of subsequent arrhythmias.", [["arrhythmias", "DISEASE", 79, 90], ["subsequent arrhythmias", "PROBLEM", 68, 90], ["arrhythmias", "OBSERVATION", 79, 90]]], ["In a study of patients with active and healed 285 myocarditis, monomorphic ventricular tachycardia and regular ventricular arrhythmias were 286 more frequent in healed than acute myocarditis.", [["ventricular", "ANATOMY", 75, 86], ["ventricular", "ANATOMY", 111, 122], ["myocarditis", "DISEASE", 50, 61], ["ventricular tachycardia", "DISEASE", 75, 98], ["ventricular arrhythmias", "DISEASE", 111, 134], ["myocarditis", "DISEASE", 179, 190], ["patients", "ORGANISM", 14, 22], ["ventricular", "MULTI-TISSUE_STRUCTURE", 75, 86], ["ventricular", "MULTI-TISSUE_STRUCTURE", 111, 122], ["patients", "SPECIES", 14, 22], ["a study", "TEST", 3, 10], ["active and healed 285 myocarditis", "PROBLEM", 28, 61], ["monomorphic ventricular tachycardia", "PROBLEM", 63, 98], ["regular ventricular arrhythmias", "PROBLEM", 103, 134], ["acute myocarditis", "PROBLEM", 173, 190], ["active", "OBSERVATION_MODIFIER", 28, 34], ["healed", "OBSERVATION_MODIFIER", 39, 45], ["myocarditis", "OBSERVATION", 50, 61], ["ventricular", "ANATOMY", 75, 86], ["tachycardia", "OBSERVATION", 87, 98], ["ventricular", "ANATOMY", 111, 122], ["arrhythmias", "OBSERVATION", 123, 134], ["healed", "OBSERVATION_MODIFIER", 161, 167], ["acute", "OBSERVATION_MODIFIER", 173, 178], ["myocarditis", "OBSERVATION", 179, 190]]], ["32 involves mechanical circulatory support such as extracorporeal membrane oxygenation, 297 ventricular assist device, or intra-aortic balloon pump.", [["extracorporeal membrane", "ANATOMY", 51, 74], ["ventricular", "ANATOMY", 92, 103], ["intra-aortic", "ANATOMY", 122, 134], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 51, 74], ["ventricular", "MULTI-TISSUE_STRUCTURE", 92, 103], ["mechanical circulatory support", "TREATMENT", 12, 42], ["extracorporeal membrane oxygenation", "TREATMENT", 51, 86], ["ventricular assist device", "TREATMENT", 92, 117], ["intra-aortic balloon pump", "TREATMENT", 122, 147], ["mechanical circulatory support", "OBSERVATION", 12, 42], ["intra-aortic", "ANATOMY", 122, 134], ["balloon pump", "OBSERVATION", 135, 147]]], ["The ESC did not endorse the use of 298 intravenous immunoglobulin due to a lack of supporting evidence, 9 and discouraged the use 299 of corticosteroids in active-infection myocarditis, citing the ineffectiveness of corticosteroids 300 in a randomized-controlled trial.", [["ESC", "ANATOMY", 4, 7], ["intravenous", "ANATOMY", 39, 50], ["corticosteroids", "CHEMICAL", 137, 152], ["infection myocarditis", "DISEASE", 163, 184], ["corticosteroids 300", "CHEMICAL", 216, 235], ["corticosteroids", "CHEMICAL", 137, 152], ["corticosteroids", "CHEMICAL", 216, 231], ["ESC", "CELL", 4, 7], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 51, 65], ["immunoglobulin", "PROTEIN", 51, 65], ["298 intravenous immunoglobulin", "TREATMENT", 35, 65], ["corticosteroids", "TREATMENT", 137, 152], ["active-infection myocarditis", "PROBLEM", 156, 184], ["corticosteroids", "TREATMENT", 216, 231], ["active", "OBSERVATION_MODIFIER", 156, 162], ["infection myocarditis", "OBSERVATION", 163, 184]]], ["46302Case reports of coronavirus-related myocarditis provide a glimpse into the efficacy of some 303 of the aforementioned treatments.", [["coronavirus", "DISEASE", 21, 32], ["myocarditis", "DISEASE", 41, 52], ["coronavirus", "ORGANISM", 21, 32], ["coronavirus", "PROBLEM", 21, 32], ["myocarditis", "PROBLEM", 41, 52], ["the aforementioned treatments", "TREATMENT", 104, 133], ["coronavirus", "OBSERVATION", 21, 32], ["myocarditis", "OBSERVATION", 41, 52]]], ["Supplemental Table 1 is a summary of 9 case reports on 304 patients with coronavirus-related myocarditis.", [["coronavirus", "DISEASE", 73, 84], ["myocarditis", "DISEASE", 93, 104], ["patients", "ORGANISM", 59, 67], ["coronavirus", "ORGANISM", 73, 84], ["patients", "SPECIES", 59, 67], ["coronavirus", "SPECIES", 73, 84], ["coronavirus", "PROBLEM", 73, 84], ["myocarditis", "PROBLEM", 93, 104], ["myocarditis", "OBSERVATION", 93, 104]]], ["Mechanical circulatory support was deployed 305 in 2/7 cases (where treatment modalities were reported).", [["Mechanical circulatory support", "TREATMENT", 0, 30], ["treatment modalities", "TREATMENT", 68, 88], ["circulatory support", "OBSERVATION", 11, 30]]], ["3, 47 Presumably, in a more 306 hemodynamically stable case, medical treatment consisting of inotropes or vasopressors was 307 sufficient to mitigate the ventricular systolic dysfunction.", [["ventricular", "ANATOMY", 154, 165], ["ventricular systolic dysfunction", "DISEASE", 154, 186], ["ventricular systolic", "MULTI-TISSUE_STRUCTURE", 154, 174], ["medical treatment", "TREATMENT", 61, 78], ["inotropes", "TREATMENT", 93, 102], ["vasopressors", "TREATMENT", 106, 118], ["the ventricular systolic dysfunction", "PROBLEM", 150, 186], ["stable", "OBSERVATION_MODIFIER", 48, 54], ["ventricular systolic", "ANATOMY", 154, 174], ["dysfunction", "OBSERVATION", 175, 186]]], ["4, 13, 48 In some cases, 308 immunomodulatory treatments were given; Zeng et al. (2020) 3 in COVID-19.", [["immunomodulatory treatments", "TREATMENT", 29, 56]]], ["Currently, chloroquine is under a phase IIb clinical trial to assess its efficacy 332 in treating COVID-19 patients with severe respiratory syndrome.", [["chloroquine", "CHEMICAL", 11, 22], ["respiratory syndrome", "DISEASE", 128, 148], ["chloroquine", "CHEMICAL", 11, 22], ["chloroquine", "SIMPLE_CHEMICAL", 11, 22], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["chloroquine", "TREATMENT", 11, 22], ["severe respiratory syndrome", "PROBLEM", 121, 148], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["respiratory syndrome", "OBSERVATION", 128, 148]]], ["52 Both chloroquine and its 333 derivative, hydroxychloroquine, may cause QTc interval prolongation; however, their effects 334 appear to be modest.", [["chloroquine", "CHEMICAL", 8, 19], ["hydroxychloroquine", "CHEMICAL", 44, 62], ["QTc interval prolongation", "DISEASE", 74, 99], ["chloroquine", "CHEMICAL", 8, 19], ["hydroxychloroquine", "CHEMICAL", 44, 62], ["chloroquine", "SIMPLE_CHEMICAL", 8, 19], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 44, 62], ["chloroquine", "TREATMENT", 8, 19], ["hydroxychloroquine", "TREATMENT", 44, 62], ["QTc interval prolongation", "PROBLEM", 74, 99], ["prolongation", "OBSERVATION_MODIFIER", 87, 99], ["modest", "OBSERVATION_MODIFIER", 141, 147]]], ["51 Nevertheless, (hydroxy)chloroquine requires metabolism by the 335 CYP3A4 enzyme 53 whose inhibition might raise the drug's plasma concentration,", [["plasma", "ANATOMY", 126, 132], ["hydroxy", "CHEMICAL", 18, 25], ["chloroquine", "CHEMICAL", 26, 37], ["(hydroxy)chloroquine", "CHEMICAL", 17, 37], ["(hydroxy)chloroquine", "SIMPLE_CHEMICAL", 17, 37], ["CYP3A4 enzyme 53", "GENE_OR_GENE_PRODUCT", 69, 85], ["plasma", "ORGANISM_SUBSTANCE", 126, 132], ["335 CYP3A4 enzyme 53", "PROTEIN", 65, 85], ["chloroquine", "TREATMENT", 26, 37], ["CYP3A4 enzyme", "TEST", 69, 82]]]], "88f9ec841f4b34c3198893e3c13a9c906b0a1bb6": [["Acute urticaria with pyrexia as the first manifestations of a COVID-19 infectionDear Editor,Acute urticaria with pyrexia as the first manifestations of a COVID-19 infectionThe coronavirus disease 2019 (COVID-19) affects principally the respiratory tract but recent studies described that COVID-19 could present a broader clinical spectrum from the absence of any symptoms to heart 1 , digestive 2 or Ear-Nose-Throat (including anosmia and ageusia) 3 manifestations.", [["respiratory tract", "ANATOMY", 236, 253], ["heart", "ANATOMY", 375, 380], ["urticaria", "DISEASE", 6, 15], ["pyrexia", "DISEASE", 21, 28], ["infection", "DISEASE", 71, 80], ["Acute urticaria", "DISEASE", 92, 107], ["pyrexia", "DISEASE", 113, 120], ["infection", "DISEASE", 163, 172], ["coronavirus disease", "DISEASE", 176, 195], ["COVID-19", "CHEMICAL", 202, 210], ["anosmia", "DISEASE", 427, 434], ["ageusia", "DISEASE", 439, 446], ["respiratory tract", "ORGANISM_SUBDIVISION", 236, 253], ["Acute urticaria", "PROBLEM", 0, 15], ["pyrexia", "PROBLEM", 21, 28], ["a COVID", "TEST", 60, 67], ["Acute urticaria", "PROBLEM", 92, 107], ["pyrexia", "PROBLEM", 113, 120], ["a COVID-19 infection", "PROBLEM", 152, 172], ["The coronavirus disease", "PROBLEM", 172, 195], ["COVID", "TEST", 202, 207], ["the respiratory tract", "PROBLEM", 232, 253], ["recent studies", "TEST", 258, 272], ["COVID", "TEST", 288, 293], ["any symptoms to heart 1", "PROBLEM", 359, 382], ["Ear-Nose-Throat (including anosmia and ageusia) 3 manifestations", "PROBLEM", 400, 464], ["urticaria", "OBSERVATION", 6, 15], ["pyrexia", "OBSERVATION", 21, 28], ["Acute", "OBSERVATION_MODIFIER", 92, 97], ["urticaria", "OBSERVATION", 98, 107], ["pyrexia", "OBSERVATION", 113, 120], ["coronavirus disease", "OBSERVATION", 176, 195], ["respiratory tract", "ANATOMY", 236, 253], ["heart", "ANATOMY", 375, 380], ["Throat", "ANATOMY", 409, 415]]], ["Here we report two cases of peculiar skin manifestation.Acute urticaria with pyrexia as the first manifestations of a COVID-19 infectionA 71-year-old man was admitted to the hospital for general weakness, pyrexia and a cutaneous rash, all appearing the day before with strictly no other complaints.", [["skin", "ANATOMY", 37, 41], ["cutaneous", "ANATOMY", 219, 228], ["urticaria", "DISEASE", 62, 71], ["pyrexia", "DISEASE", 77, 84], ["COVID", "DISEASE", 118, 123], ["weakness", "DISEASE", 195, 203], ["pyrexia", "DISEASE", 205, 212], ["rash", "DISEASE", 229, 233], ["skin", "ORGAN", 37, 41], ["man", "ORGANISM", 150, 153], ["man", "SPECIES", 150, 153], ["peculiar skin manifestation", "PROBLEM", 28, 55], ["Acute urticaria", "PROBLEM", 56, 71], ["pyrexia", "PROBLEM", 77, 84], ["a COVID", "TEST", 116, 123], ["general weakness", "PROBLEM", 187, 203], ["pyrexia", "PROBLEM", 205, 212], ["a cutaneous rash", "PROBLEM", 217, 233], ["other complaints", "PROBLEM", 281, 297], ["skin", "ANATOMY", 37, 41], ["manifestation", "OBSERVATION", 42, 55], ["urticaria", "OBSERVATION", 62, 71], ["pyrexia", "OBSERVATION", 77, 84], ["weakness", "OBSERVATION", 195, 203], ["pyrexia", "OBSERVATION", 205, 212], ["cutaneous", "ANATOMY", 219, 228], ["rash", "OBSERVATION", 229, 233]]], ["A dermatologist diagnosed a very extensive acute urticaria.", [["urticaria", "DISEASE", 49, 58], ["a very extensive acute urticaria", "PROBLEM", 26, 58], ["very", "OBSERVATION_MODIFIER", 28, 32], ["extensive", "OBSERVATION_MODIFIER", 33, 42], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["urticaria", "OBSERVATION", 49, 58]]], ["There was no change in the patient's treatment or habits during the previous few weeks.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["no", "UNCERTAINTY", 10, 12], ["change", "OBSERVATION_MODIFIER", 13, 19]]], ["He was allergic to iodine but no contrast agent had been injected before the eruption.", [["allergic", "DISEASE", 7, 15], ["iodine", "CHEMICAL", 19, 25], ["iodine", "CHEMICAL", 19, 25], ["He", "ORGANISM", 0, 2], ["iodine", "SIMPLE_CHEMICAL", 19, 25], ["allergic", "PROBLEM", 7, 15], ["iodine", "TREATMENT", 19, 25], ["contrast agent", "TREATMENT", 33, 47], ["the eruption", "PROBLEM", 73, 85]]], ["His comorbidities included obesity (BMI 32), insulin-dependent diabetes mellitus, hypercholesterolemia, obstructive sleep apnea-hypopnea syndrome, high blood pressure, stroke 18 months ago without further sequelae, and kidney failure on dialysis 3 times a week.", [["blood", "ANATOMY", 152, 157], ["kidney", "ANATOMY", 219, 225], ["obesity", "DISEASE", 27, 34], ["diabetes mellitus", "DISEASE", 63, 80], ["hypercholesterolemia", "DISEASE", 82, 102], ["obstructive sleep apnea-hypopnea syndrome", "DISEASE", 104, 145], ["high blood pressure", "DISEASE", 147, 166], ["stroke", "DISEASE", 168, 174], ["kidney failure", "DISEASE", 219, 233], ["insulin", "GENE_OR_GENE_PRODUCT", 45, 52], ["blood", "ORGANISM_SUBSTANCE", 152, 157], ["kidney", "ORGAN", 219, 225], ["His comorbidities", "PROBLEM", 0, 17], ["obesity", "PROBLEM", 27, 34], ["insulin-dependent diabetes mellitus", "PROBLEM", 45, 80], ["hypercholesterolemia", "PROBLEM", 82, 102], ["obstructive sleep apnea-hypopnea syndrome", "PROBLEM", 104, 145], ["high blood pressure", "PROBLEM", 147, 166], ["stroke", "PROBLEM", 168, 174], ["further sequelae", "PROBLEM", 197, 213], ["kidney failure", "PROBLEM", 219, 233], ["dialysis", "TREATMENT", 237, 245], ["obesity", "OBSERVATION", 27, 34], ["hypercholesterolemia", "OBSERVATION", 82, 102], ["obstructive sleep", "OBSERVATION", 104, 121], ["apnea-hypopnea syndrome", "OBSERVATION", 122, 145], ["sequelae", "OBSERVATION", 205, 213], ["kidney", "ANATOMY", 219, 225], ["failure", "OBSERVATION", 226, 233]]], ["All his parameters, physical examination, two pairs of blood cultures, a PCR research of Influenza A and B on a nasopharyngeal smear and an electrocardiogram were normal.", [["blood cultures", "ANATOMY", 55, 69], ["nasopharyngeal smear", "ANATOMY", 112, 132], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["B", "CANCER", 105, 106], ["nasopharyngeal smear", "CANCER", 112, 132], ["Influenza A", "SPECIES", 89, 100], ["All his parameters", "TEST", 0, 18], ["physical examination", "TEST", 20, 40], ["blood cultures", "TEST", 55, 69], ["a PCR", "TEST", 71, 76], ["Influenza A", "PROBLEM", 89, 100], ["a nasopharyngeal smear", "TEST", 110, 132], ["an electrocardiogram", "TEST", 137, 157], ["nasopharyngeal", "ANATOMY", 112, 126], ["normal", "OBSERVATION", 163, 169]]], ["Blood test revealed a mild lymphopenia (1120/mm\u00b3), a slightly elevated CRP (13.2 mg/L > 5 mg/L) and increased liver enzymes (GOT, GPT, LDH, GGT doubled).", [["Blood", "ANATOMY", 0, 5], ["liver", "ANATOMY", 110, 115], ["lymphopenia", "DISEASE", 27, 38], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["CRP", "GENE_OR_GENE_PRODUCT", 71, 74], ["liver", "ORGAN", 110, 115], ["GOT", "SIMPLE_CHEMICAL", 125, 128], ["GPT", "SIMPLE_CHEMICAL", 130, 133], ["LDH", "SIMPLE_CHEMICAL", 135, 138], ["GGT", "SIMPLE_CHEMICAL", 140, 143], ["CRP", "PROTEIN", 71, 74], ["liver enzymes", "PROTEIN", 110, 123], ["GOT", "PROTEIN", 125, 128], ["GPT", "PROTEIN", 130, 133], ["LDH", "PROTEIN", 135, 138], ["GGT", "PROTEIN", 140, 143], ["Blood test", "TEST", 0, 10], ["a mild lymphopenia", "PROBLEM", 20, 38], ["a slightly elevated CRP", "PROBLEM", 51, 74], ["increased liver enzymes", "PROBLEM", 100, 123], ["GPT", "TEST", 130, 133], ["LDH", "TEST", 135, 138], ["GGT", "TEST", 140, 143], ["mild", "OBSERVATION_MODIFIER", 22, 26], ["lymphopenia", "OBSERVATION", 27, 38], ["slightly", "OBSERVATION_MODIFIER", 53, 61], ["elevated", "OBSERVATION", 62, 70], ["liver", "ANATOMY", 110, 115], ["LDH", "ANATOMY", 135, 138]]], ["Chest x-ray and abdominal CT-scan also failed to identify any infectious site.", [["abdominal", "ANATOMY", 16, 25], ["abdominal", "ORGAN", 16, 25], ["Chest x-ray", "TEST", 0, 11], ["abdominal CT-scan", "TEST", 16, 33], ["any infectious site", "PROBLEM", 58, 77], ["abdominal", "ANATOMY", 16, 25], ["infectious", "OBSERVATION", 62, 72]]], ["A few days after admission, the patient presented clinical deterioration with increased temperature and CRP, hypoxemia, unilateral ankle pain, constipation, chest pain, atrial fibrillation and tachycardia.", [["ankle", "ANATOMY", 131, 136], ["chest", "ANATOMY", 157, 162], ["atrial", "ANATOMY", 169, 175], ["hypoxemia", "DISEASE", 109, 118], ["unilateral ankle pain", "DISEASE", 120, 141], ["constipation", "DISEASE", 143, 155], ["chest pain", "DISEASE", 157, 167], ["atrial fibrillation", "DISEASE", 169, 188], ["tachycardia", "DISEASE", 193, 204], ["patient", "ORGANISM", 32, 39], ["CRP", "GENE_OR_GENE_PRODUCT", 104, 107], ["ankle", "ORGANISM_SUBDIVISION", 131, 136], ["patient", "SPECIES", 32, 39], ["clinical deterioration", "PROBLEM", 50, 72], ["increased temperature", "PROBLEM", 78, 99], ["CRP", "TEST", 104, 107], ["hypoxemia", "PROBLEM", 109, 118], ["unilateral ankle pain", "PROBLEM", 120, 141], ["constipation", "PROBLEM", 143, 155], ["chest pain", "PROBLEM", 157, 167], ["atrial fibrillation", "PROBLEM", 169, 188], ["tachycardia", "PROBLEM", 193, 204], ["hypoxemia", "OBSERVATION", 109, 118], ["unilateral", "ANATOMY_MODIFIER", 120, 130], ["ankle", "ANATOMY", 131, 136], ["pain", "OBSERVATION", 137, 141], ["constipation", "OBSERVATION", 143, 155], ["chest", "ANATOMY", 157, 162], ["atrial", "ANATOMY", 169, 175], ["fibrillation", "OBSERVATION", 176, 188], ["tachycardia", "OBSERVATION", 193, 204]]], ["A nasopharyngeal smear test revealed a COVID-19 infection.", [["nasopharyngeal smear", "ANATOMY", 2, 22], ["infection", "DISEASE", 48, 57], ["nasopharyngeal smear", "CANCER", 2, 22], ["A nasopharyngeal smear test", "TEST", 0, 27], ["a COVID-19 infection", "PROBLEM", 37, 57], ["nasopharyngeal", "ANATOMY", 2, 16], ["infection", "OBSERVATION", 48, 57]]], ["Urticaria improved gradually with bilastine.", [["Urticaria", "DISEASE", 0, 9], ["bilastine", "CHEMICAL", 34, 43], ["bilastine", "CHEMICAL", 34, 43], ["bilastine", "SIMPLE_CHEMICAL", 34, 43], ["Urticaria", "PROBLEM", 0, 9], ["bilastine", "TREATMENT", 34, 43]]], ["Unfortunately, he died 14 days after admission of end-stage respiratory failure following COVID-19 infection.", [["respiratory", "ANATOMY", 60, 71], ["respiratory failure", "DISEASE", 60, 79], ["COVID-19", "CHEMICAL", 90, 98], ["infection", "DISEASE", 99, 108], ["end-stage respiratory failure", "PROBLEM", 50, 79], ["COVID-19 infection", "PROBLEM", 90, 108], ["stage", "OBSERVATION_MODIFIER", 54, 59], ["respiratory", "ANATOMY", 60, 71], ["failure", "OBSERVATION", 72, 79], ["infection", "OBSERVATION", 99, 108]]], ["Alongside that, some nephrologists, caregivers, and dialysis patients were tested positive.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["dialysis", "TREATMENT", 52, 60]]], ["The pandemic hit Belgium in early February 2020 and the first case of COVID-19 was confirmed in our hospital on 9Acute urticaria with pyrexia as the first manifestations of a COVID-19 infectionMarch, when the patient's first symptoms started.", [["urticaria", "DISEASE", 119, 128], ["pyrexia", "DISEASE", 134, 141], ["infection", "DISEASE", 184, 193], ["patient", "ORGANISM", 209, 216], ["patient", "SPECIES", 209, 216], ["COVID", "TEST", 70, 75], ["9Acute urticaria", "PROBLEM", 112, 128], ["pyrexia", "PROBLEM", 134, 141], ["a COVID", "TREATMENT", 173, 180], ["the patient's first symptoms", "PROBLEM", 205, 233], ["infection", "OBSERVATION", 184, 193]]], ["Hygienic protective measures were not yet in place.Acute urticaria with pyrexia as the first manifestations of a COVID-19 infectionA 39-year-old nurse, who works in a rest home, went to the doctor for a generalized, pruritic urticarial rash (Fig. 1a,b) that had started two days ago on her forearms.", [["forearms", "ANATOMY", 290, 298], ["urticaria", "DISEASE", 57, 66], ["pyrexia", "DISEASE", 72, 79], ["rash", "DISEASE", 236, 240], ["forearms", "ORGANISM_SUBDIVISION", 290, 298], ["Hygienic protective measures", "TREATMENT", 0, 28], ["Acute urticaria", "PROBLEM", 51, 66], ["pyrexia", "PROBLEM", 72, 79], ["a generalized, pruritic urticarial rash", "PROBLEM", 201, 240], ["urticaria", "OBSERVATION", 57, 66], ["pyrexia", "OBSERVATION", 72, 79], ["pruritic", "OBSERVATION_MODIFIER", 216, 224], ["forearms", "ANATOMY", 290, 298]]], ["Concomitantly, pyrexia (38.3\u00b0C) with chills, myalgia and headache had appeared.", [["pyrexia", "DISEASE", 15, 22], ["chills", "DISEASE", 37, 43], ["myalgia", "DISEASE", 45, 52], ["headache", "DISEASE", 57, 65], ["pyrexia", "PROBLEM", 15, 22], ["chills", "PROBLEM", 37, 43], ["myalgia", "PROBLEM", 45, 52], ["headache", "PROBLEM", 57, 65], ["pyrexia", "OBSERVATION", 15, 22], ["myalgia", "OBSERVATION", 45, 52]]], ["She also suffered from rhinorrhea, mild Accepted Article dry cough and dyspnea but had no digestive or urinary complaints.", [["digestive", "ANATOMY", 90, 99], ["urinary", "ANATOMY", 103, 110], ["rhinorrhea", "DISEASE", 23, 33], ["dry cough", "DISEASE", 57, 66], ["dyspnea", "DISEASE", 71, 78], ["digestive or urinary complaints", "DISEASE", 90, 121], ["digestive", "ORGANISM_SUBDIVISION", 90, 99], ["urinary", "ORGANISM_SUBDIVISION", 103, 110], ["rhinorrhea", "PROBLEM", 23, 33], ["Article dry cough", "PROBLEM", 49, 66], ["dyspnea", "PROBLEM", 71, 78], ["digestive or urinary complaints", "PROBLEM", 90, 121], ["rhinorrhea", "OBSERVATION", 23, 33], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["dry", "OBSERVATION_MODIFIER", 57, 60], ["cough", "OBSERVATION", 61, 66], ["no", "UNCERTAINTY", 87, 89], ["urinary", "ANATOMY", 103, 110], ["complaints", "OBSERVATION", 111, 121]]], ["There was no change in her daily habits or drugs.", [["no", "UNCERTAINTY", 10, 12], ["change", "OBSERVATION_MODIFIER", 13, 19]]], ["Bilastine gradually improved her rash.", [["Bilastine", "CHEMICAL", 0, 9], ["rash", "DISEASE", 33, 37], ["Bilastine", "CHEMICAL", 0, 9], ["Bilastine", "SIMPLE_CHEMICAL", 0, 9], ["her rash", "PROBLEM", 29, 37], ["gradually", "OBSERVATION_MODIFIER", 10, 19], ["improved", "OBSERVATION_MODIFIER", 20, 28], ["rash", "OBSERVATION", 33, 37]]], ["Anosmia and ageusia occurred five days after and lasted a week.", [["Anosmia", "DISEASE", 0, 7], ["ageusia", "DISEASE", 12, 19], ["Anosmia", "PROBLEM", 0, 7], ["ageusia", "PROBLEM", 12, 19], ["ageusia", "OBSERVATION", 12, 19]]], ["Thereafter, her 8-year-old son developed an urticaria and her husband presented a radiologically confirmed COVID-19 infection.Acute urticaria with pyrexia as the first manifestations of a COVID-19 infectionVery few data are available concerning the association between urticaria and COVID-19.", [["urticaria", "DISEASE", 44, 53], ["infection", "DISEASE", 116, 125], ["urticaria", "DISEASE", 132, 141], ["pyrexia", "DISEASE", 147, 154], ["urticaria", "DISEASE", 269, 278], ["an urticaria", "PROBLEM", 41, 53], ["COVID-19 infection", "PROBLEM", 107, 125], ["Acute urticaria", "PROBLEM", 126, 141], ["pyrexia", "PROBLEM", 147, 154], ["a COVID", "TEST", 186, 193], ["urticaria", "PROBLEM", 269, 278], ["COVID", "TEST", 283, 288], ["urticaria", "OBSERVATION", 44, 53], ["infection", "OBSERVATION", 116, 125], ["urticaria", "OBSERVATION", 132, 141], ["pyrexia", "OBSERVATION", 147, 154]]], ["A medical team of Wuhan 4 has studied 140 patients infected with SARS-CoV-2, among whom they noticed two patients with chronic urticaria but did not mention any acute urticaria.", [["SARS", "DISEASE", 65, 69], ["chronic urticaria", "DISEASE", 119, 136], ["urticaria", "DISEASE", 167, 176], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 105, 113], ["SARS-CoV", "SPECIES", 65, 73], ["chronic urticaria", "PROBLEM", 119, 136], ["any acute urticaria", "PROBLEM", 157, 176], ["chronic", "OBSERVATION_MODIFIER", 119, 126], ["urticaria", "OBSERVATION", 127, 136], ["acute", "OBSERVATION_MODIFIER", 161, 166], ["urticaria", "OBSERVATION", 167, 176]]], ["More recently, an Italian report showed that, among 88 patients with confirmed diagnosis of COVID-19 who had not used any new medicine in the 15 previous days, 20.4% developed skin manifestations, including 3 widespread urticaria 5 .", [["skin", "ANATOMY", 176, 180], ["COVID", "DISEASE", 92, 97], ["urticaria", "DISEASE", 220, 229], ["patients", "ORGANISM", 55, 63], ["skin", "ORGAN", 176, 180], ["patients", "SPECIES", 55, 63], ["skin manifestations", "PROBLEM", 176, 195], ["3 widespread urticaria", "PROBLEM", 207, 229], ["skin", "ANATOMY", 176, 180], ["manifestations", "OBSERVATION", 181, 195], ["widespread", "OBSERVATION_MODIFIER", 209, 219], ["urticaria", "OBSERVATION", 220, 229]]], ["No correlation with the severity of the disease has been established until now.", [["the disease", "PROBLEM", 36, 47], ["disease", "OBSERVATION", 40, 47]]], ["A recent survey of Belgian dermatologists 6 revealed an actual increasing incidence of (giant) urticaria and (urticarial) vasculitis.", [["urticaria", "DISEASE", 95, 104], ["urticarial", "DISEASE", 110, 120], ["vasculitis", "DISEASE", 122, 132], ["Belgian dermatologists", "TEST", 19, 41], ["giant) urticaria and (urticarial) vasculitis", "PROBLEM", 88, 132], ["increasing", "OBSERVATION_MODIFIER", 63, 73], ["giant", "OBSERVATION_MODIFIER", 88, 93], ["urticaria", "OBSERVATION", 95, 104], ["urticarial", "OBSERVATION_MODIFIER", 110, 120], ["vasculitis", "OBSERVATION", 122, 132]]], ["Chinese dermatologists 7 have observed these eruptions in COVID-19 pneumonia patients.Acute urticaria with pyrexia as the first manifestations of a COVID-19 infectionBased on these two case reports, we want to warn clinicians that urticaria with pyrexia in the current context of COVID-19 pandemic can be the first manifestations of this infection, even without any respiratory symptoms, like we observed for the anosmia 3 .", [["respiratory", "ANATOMY", 366, 377], ["pneumonia", "DISEASE", 67, 76], ["urticaria", "DISEASE", 92, 101], ["pyrexia", "DISEASE", 107, 114], ["urticaria", "DISEASE", 231, 240], ["pyrexia", "DISEASE", 246, 253], ["infection", "DISEASE", 338, 347], ["anosmia", "DISEASE", 413, 420], ["patients", "ORGANISM", 77, 85], ["COVID-19", "ORGANISM", 280, 288], ["patients", "SPECIES", 77, 85], ["these eruptions", "PROBLEM", 39, 54], ["pneumonia", "PROBLEM", 67, 76], ["Acute urticaria", "PROBLEM", 86, 101], ["pyrexia", "PROBLEM", 107, 114], ["a COVID-19 infectionBased", "PROBLEM", 146, 171], ["urticaria", "PROBLEM", 231, 240], ["pyrexia", "PROBLEM", 246, 253], ["COVID", "TEST", 280, 285], ["this infection", "PROBLEM", 333, 347], ["any respiratory symptoms", "PROBLEM", 362, 386], ["the anosmia", "PROBLEM", 409, 420], ["eruptions", "OBSERVATION", 45, 54], ["pneumonia", "OBSERVATION", 67, 76], ["urticaria", "OBSERVATION", 92, 101], ["pyrexia", "OBSERVATION", 107, 114], ["pyrexia", "OBSERVATION", 246, 253], ["infection", "OBSERVATION", 338, 347]]], ["These patients can unknowingly infect others and contribute to the spread of the COVID-19 infection, hence their necessary isolation.", [["infection", "DISEASE", 90, 99], ["patients", "ORGANISM", 6, 14], ["COVID-19", "ORGANISM", 81, 89], ["patients", "SPECIES", 6, 14], ["COVID-19", "SPECIES", 81, 89], ["the COVID-19 infection", "PROBLEM", 77, 99], ["their necessary isolation", "TREATMENT", 107, 132], ["infection", "OBSERVATION", 90, 99]]], ["It is evident that urticaria can go with a viral infection and, due to the prevalence of COVID-19, we should consider this as a potential cause when doing our diagnosis.Acute urticaria with pyrexia as the first manifestations of a COVID-19 infectionTherefore we need to have rapidly more available screening tests to counter the underestimation of the number of cases.", [["urticaria", "DISEASE", 19, 28], ["viral infection", "DISEASE", 43, 58], ["urticaria", "DISEASE", 175, 184], ["pyrexia", "DISEASE", 190, 197], ["infection", "DISEASE", 240, 249], ["urticaria", "PROBLEM", 19, 28], ["a viral infection", "PROBLEM", 41, 58], ["COVID", "TEST", 89, 94], ["Acute urticaria", "PROBLEM", 169, 184], ["pyrexia", "PROBLEM", 190, 197], ["a COVID-19 infection", "PROBLEM", 229, 249], ["screening tests", "TEST", 298, 313], ["urticaria", "OBSERVATION", 19, 28], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infection", "OBSERVATION", 49, 58], ["urticaria", "OBSERVATION", 175, 184], ["pyrexia", "OBSERVATION", 190, 197], ["infection", "OBSERVATION", 240, 249]]]], "PMC7125516": [["IntroductionDengue virus is a member of the Flaviviridae family.", [["Dengue virus", "DISEASE", 12, 24], ["Dengue virus", "ORGANISM", 12, 24], ["Dengue virus", "SPECIES", 12, 24], ["Dengue virus", "SPECIES", 12, 24], ["IntroductionDengue virus", "PROBLEM", 0, 24]]], ["This virus causes a disease prevalent between 30th north and 20th south parallels and its incidence has been estimated to 60 million per year, causing 30 000 deaths (Tolou et al., 1997), with appearance of hyper endemic transmission in the Americas (Gubler, 1998).", [["deaths", "DISEASE", 158, 164], ["This virus", "PROBLEM", 0, 10], ["a disease prevalent", "PROBLEM", 18, 37], ["hyper endemic transmission", "PROBLEM", 206, 232], ["disease", "OBSERVATION", 20, 27], ["hyper", "OBSERVATION_MODIFIER", 206, 211], ["endemic", "OBSERVATION_MODIFIER", 212, 219], ["Americas", "ANATOMY_MODIFIER", 240, 248]]], ["It is transmitted among humans by mosquitoes, mainly Aedes aegypti.IntroductionA wide spectrum of symptoms can be encountered, ranging from a benign fever with occasional hemorrhages to a potentially fatal syndrome.", [["fever", "DISEASE", 149, 154], ["hemorrhages", "DISEASE", 171, 182], ["humans", "ORGANISM", 24, 30], ["Aedes aegypti", "ORGANISM", 53, 66], ["humans", "SPECIES", 24, 30], ["Aedes aegypti", "SPECIES", 53, 66], ["humans", "SPECIES", 24, 30], ["Aedes aegypti", "SPECIES", 53, 66], ["symptoms", "PROBLEM", 98, 106], ["a benign fever", "PROBLEM", 140, 154], ["occasional hemorrhages", "PROBLEM", 160, 182], ["a potentially fatal syndrome", "PROBLEM", 186, 214], ["benign", "OBSERVATION_MODIFIER", 142, 148], ["hemorrhages", "OBSERVATION", 171, 182], ["potentially", "UNCERTAINTY", 188, 199], ["fatal syndrome", "OBSERVATION", 200, 214]]], ["Without medical intervention, the case fatality rate of the hemorrhagic and shock syndrome can reach 40\u201350% (Igarashi, 1997).", [["hemorrhagic", "DISEASE", 60, 71], ["shock", "DISEASE", 76, 81], ["medical intervention", "TREATMENT", 8, 28], ["the hemorrhagic and shock syndrome", "PROBLEM", 56, 90], ["hemorrhagic", "OBSERVATION_MODIFIER", 60, 71], ["shock syndrome", "OBSERVATION", 76, 90]]], ["The mechanisms of this syndrome are still under discussion: (i) specific strains could be involved (Murgue et al., 1997); and (ii) preexisting subneutralizing antibodies could enhance the antibody-mediated uptake of the virus by monocytes or macrophages which are designated as host cells of the virus (antibody dependent enhancement: ADE) (Hawkes and Lafferty, 1967; see review in Porterfield, 1986).", [["monocytes", "ANATOMY", 229, 238], ["macrophages", "ANATOMY", 242, 253], ["cells", "ANATOMY", 283, 288], ["monocytes", "CELL", 229, 238], ["macrophages", "CELL", 242, 253], ["host cells", "CELL", 278, 288], ["subneutralizing antibodies", "PROTEIN", 143, 169], ["monocytes", "CELL_TYPE", 229, 238], ["macrophages", "CELL_TYPE", 242, 253], ["host cells", "CELL_TYPE", 278, 288], ["this syndrome", "PROBLEM", 18, 31], ["preexisting subneutralizing antibodies", "PROBLEM", 131, 169], ["the antibody", "TEST", 184, 196], ["the virus", "PROBLEM", 216, 225], ["macrophages", "PROBLEM", 242, 253], ["the virus", "PROBLEM", 292, 301], ["host cells", "OBSERVATION", 278, 288]]], ["The requirement for the Fc region of IgG in ADE has been demonstrated by Halstead and O\u2019Rourke (1977) who compared whole human serum, that had enhancing activity and Fab\u20322 of the same origin that had not.", [["serum", "ANATOMY", 127, 132], ["IgG", "GENE_OR_GENE_PRODUCT", 37, 40], ["human", "ORGANISM", 121, 126], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["Fab\u20322", "GENE_OR_GENE_PRODUCT", 166, 171], ["Fc region", "PROTEIN", 24, 33], ["IgG", "PROTEIN", 37, 40], ["Fab\u20322", "PROTEIN", 166, 171], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["whole human serum", "TEST", 115, 132], ["enhancing activity", "PROBLEM", 143, 161], ["enhancing", "OBSERVATION_MODIFIER", 143, 152], ["activity", "OBSERVATION_MODIFIER", 153, 161]]], ["The requirement for fonctional Fc\u03b3 receptors in ADE has also been shown (Littaua et al., 1996).", [["ADE", "DISEASE", 48, 51], ["Fc\u03b3 receptors", "GENE_OR_GENE_PRODUCT", 31, 44], ["fonctional Fc\u03b3 receptors", "PROTEIN", 20, 44], ["fonctional Fc\u03b3 receptors", "TREATMENT", 20, 44]]], ["These receptors, present at the surface of macrophages, play a major role in the phagocytosis of antibody-coated particles (Paul, 1993) and are dependent on the Fc binding of IgG.IntroductionNo specific prophylactic or therapeutic agent is currently available against dengue disease.", [["surface", "ANATOMY", 32, 39], ["macrophages", "ANATOMY", 43, 54], ["dengue disease", "DISEASE", 268, 282], ["surface", "CELLULAR_COMPONENT", 32, 39], ["macrophages", "CELL", 43, 54], ["Fc", "GENE_OR_GENE_PRODUCT", 161, 163], ["IgG", "GENE_OR_GENE_PRODUCT", 175, 178], ["macrophages", "CELL_TYPE", 43, 54], ["antibody", "PROTEIN", 97, 105], ["IgG", "PROTEIN", 175, 178], ["dengue", "SPECIES", 268, 274], ["therapeutic agent", "TREATMENT", 219, 236], ["dengue disease", "PROBLEM", 268, 282], ["macrophages", "OBSERVATION", 43, 54]]], ["Intravenous infusion to correct hypovolemia and eventually blood transfusion, can reduce the mortality rate.", [["blood", "ANATOMY", 59, 64], ["hypovolemia", "DISEASE", 32, 43], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["Intravenous infusion", "TREATMENT", 0, 20], ["hypovolemia", "PROBLEM", 32, 43], ["eventually blood transfusion", "TREATMENT", 48, 76], ["the mortality rate", "TEST", 89, 107], ["hypovolemia", "OBSERVATION", 32, 43]]], ["Monoclonal antibodies passively transferred to mice challenged with a lethal intracerebral dose of dengue 2 virus have been shown to be protective (Kaufman et al., 1987).", [["intracerebral", "ANATOMY", 77, 90], ["dengue", "DISEASE", 99, 105], ["mice", "ORGANISM", 47, 51], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 90], ["dengue 2 virus", "ORGANISM", 99, 113], ["Monoclonal antibodies", "PROTEIN", 0, 21], ["mice", "SPECIES", 47, 51], ["dengue 2 virus", "SPECIES", 99, 113], ["mice", "SPECIES", 47, 51], ["dengue 2 virus", "SPECIES", 99, 113], ["Monoclonal antibodies", "TREATMENT", 0, 21], ["a lethal intracerebral dose of dengue 2 virus", "TREATMENT", 68, 113]]], ["In the case of another virus (vesicular stomatitis virus) protection against lethal infection has been shown to be mediated by neutralizing antibodies (Zinkernagel, 1997).", [["vesicular stomatitis virus", "DISEASE", 30, 56], ["lethal infection", "DISEASE", 77, 93], ["vesicular stomatitis virus", "ORGANISM", 30, 56], ["neutralizing antibodies", "PROTEIN", 127, 150], ["another virus (vesicular stomatitis virus", "PROBLEM", 15, 56], ["lethal infection", "PROBLEM", 77, 93]]], ["Immunotherapy of dengue, as prophylaxis or treatment, could thus be of interest.", [["dengue", "DISEASE", 17, 23], ["dengue", "SPECIES", 17, 23], ["Immunotherapy", "TREATMENT", 0, 13], ["dengue", "PROBLEM", 17, 23], ["prophylaxis", "TREATMENT", 28, 39], ["treatment", "TREATMENT", 43, 52], ["dengue", "OBSERVATION", 17, 23]]], ["IgG fragments lacking Fc (scFv or Fab) should be used so that they do not participate in any enhancing effects (ADE).", [["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["Fc", "GENE_OR_GENE_PRODUCT", 22, 24], ["scFv", "GENE_OR_GENE_PRODUCT", 26, 30], ["Fab", "GENE_OR_GENE_PRODUCT", 34, 37], ["IgG fragments", "PROTEIN", 0, 13], ["Fc", "PROTEIN", 22, 24], ["scFv", "PROTEIN", 26, 30], ["Fab", "PROTEIN", 34, 37], ["IgG fragments", "PROBLEM", 0, 13]]], ["For this work, Fab were prefered to scFv because they have a better stability, resulting in a longer half-life.", [["Fab", "GENE_OR_GENE_PRODUCT", 15, 18], ["Fab", "PROTEIN", 15, 18], ["scFv", "PROTEIN", 36, 40]]], ["A Fab has recently been shown to have a 55-fold greater half-life than its corresponding scFv (Lamarre et al., 1997).IntroductionRecombinant IgG fragments have already been obtained against influenza virus (Caton and Koprowski, 1990, Stark and Caton, 1991), HIV virus (Burton et al., 1991), rabies virus (Cheung et al., 1992, Muller et al., 1997), respiratory syncitial virus (Tempest et al., 1991, Barbas et al., 1992), hepatitis B virus (Zebedee et al., 1992), hantaan virus (Liang et al., 1996), coronavirus (Lamarre and Talbot, 1995) and against such flaviviruses as looping ill and tick-borne encephalitis (Jiang et al., 1993) but not against dengue virus.IntroductionIn this study, we have cloned in a phagemidic vector the Fab region of the murine monoclonal antibody (mAb) 4E11, raised against dengue virus.", [["influenza virus", "DISEASE", 190, 205], ["HIV virus", "DISEASE", 258, 267], ["rabies virus", "DISEASE", 291, 303], ["respiratory syncitial virus", "DISEASE", 348, 375], ["hepatitis B", "DISEASE", 421, 432], ["looping ill", "DISEASE", 571, 582], ["tick-borne encephalitis", "DISEASE", 587, 610], ["dengue virus", "DISEASE", 648, 660], ["dengue", "DISEASE", 802, 808], ["Fab", "GENE_OR_GENE_PRODUCT", 2, 5], ["IgG", "GENE_OR_GENE_PRODUCT", 141, 144], ["influenza virus", "ORGANISM", 190, 205], ["HIV virus", "ORGANISM", 258, 267], ["rabies virus", "ORGANISM", 291, 303], ["respiratory syncitial virus", "ORGANISM", 348, 375], ["hepatitis B virus", "ORGANISM", 421, 438], ["hantaan virus", "ORGANISM", 463, 476], ["coronavirus", "ORGANISM", 499, 510], ["dengue virus", "ORGANISM", 648, 660], ["Fab", "GENE_OR_GENE_PRODUCT", 730, 733], ["murine", "ORGANISM", 748, 754], ["dengue virus", "ORGANISM", 802, 814], ["Fab", "PROTEIN", 2, 5], ["scFv", "PROTEIN", 89, 93], ["IgG fragments", "DNA", 141, 154], ["Fab region", "PROTEIN", 730, 740], ["murine monoclonal antibody (mAb) 4E11", "PROTEIN", 748, 785], ["influenza virus", "SPECIES", 190, 205], ["HIV virus", "SPECIES", 258, 267], ["rabies virus", "SPECIES", 291, 303], ["hepatitis B virus", "SPECIES", 421, 438], ["hantaan virus", "SPECIES", 463, 476], ["coronavirus", "SPECIES", 499, 510], ["tick-borne encephalitis", "SPECIES", 587, 610], ["murine", "SPECIES", 748, 754], ["HIV virus", "SPECIES", 258, 267], ["rabies virus", "SPECIES", 291, 303], ["hepatitis B virus", "SPECIES", 421, 438], ["hantaan virus", "SPECIES", 463, 476], ["tick-borne encephalitis", "SPECIES", 587, 610], ["dengue virus", "SPECIES", 648, 660], ["dengue virus", "SPECIES", 802, 814], ["IntroductionRecombinant IgG fragments", "PROBLEM", 117, 154], ["influenza virus", "PROBLEM", 190, 205], ["HIV virus", "PROBLEM", 258, 267], ["rabies virus", "PROBLEM", 291, 303], ["respiratory syncitial virus", "PROBLEM", 348, 375], ["Barbas et al.", "TEST", 399, 412], ["hepatitis B virus", "TEST", 421, 438], ["hantaan virus", "PROBLEM", 463, 476], ["coronavirus", "PROBLEM", 499, 510], ["such flaviviruses", "PROBLEM", 550, 567], ["looping ill", "PROBLEM", 571, 582], ["tick-borne encephalitis", "PROBLEM", 587, 610], ["dengue virus", "PROBLEM", 648, 660], ["this study", "TEST", 676, 686], ["a phagemidic vector", "TREATMENT", 706, 725], ["the murine monoclonal antibody", "TEST", 744, 774], ["dengue virus", "PROBLEM", 802, 814], ["IgG fragments", "OBSERVATION", 141, 154], ["respiratory", "ANATOMY", 348, 359]]], ["Immunochemical and serological properties of the mAb and the Fab were compared.Preparation and characterization of the hybridoma ::: Materials and methodsHybridoma cells producing a murine monoclonal antibody 4E11, recognizing dengue virus, serotype 1 envelope protein, were prepared according to protocols published previously (Morens et al., 1987).", [["Hybridoma cells", "ANATOMY", 154, 169], ["dengue", "DISEASE", 227, 233], ["mAb", "GENE_OR_GENE_PRODUCT", 49, 52], ["Fab", "GENE_OR_GENE_PRODUCT", 61, 64], ["Hybridoma cells", "CELL", 154, 169], ["murine", "ORGANISM", 182, 188], ["4E11", "GENE_OR_GENE_PRODUCT", 209, 213], ["dengue virus", "ORGANISM", 227, 239], ["serotype 1 envelope protein", "GENE_OR_GENE_PRODUCT", 241, 268], ["mAb", "PROTEIN", 49, 52], ["Fab", "PROTEIN", 61, 64], ["hybridoma", "CELL_LINE", 119, 128], ["Hybridoma cells", "CELL_LINE", 154, 169], ["murine monoclonal antibody 4E11", "PROTEIN", 182, 213], ["serotype 1 envelope protein", "PROTEIN", 241, 268], ["murine", "SPECIES", 182, 188], ["dengue virus", "SPECIES", 227, 239], ["dengue virus", "SPECIES", 227, 239], ["Immunochemical", "TEST", 0, 14], ["the mAb", "TREATMENT", 45, 52], ["the Fab", "TEST", 57, 64], ["methodsHybridoma cells", "TEST", 147, 169], ["a murine monoclonal antibody", "TEST", 180, 208], ["recognizing dengue virus", "PROBLEM", 215, 239], ["serotype 1 envelope protein", "TREATMENT", 241, 268], ["Hybridoma cells", "OBSERVATION", 154, 169]]], ["These cells were a generous gift from Dr D.M. Morens.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11]]], ["The mAb is of the IgG2a, k, isotype and is protective in vivo against dengue virus, serotype 1: 0.4 mg protected all 3 weeks-old BALB/c mice challenged with 100 DL50 (data not shown).Production of phage-displayed Fab fragments ::: Materials and methodsTotal RNAs were isolated from 5\u00d7106 cells of the mouse 4E11 hybridoma (RNAxel\u00ae, Eurobio, Les Ulis, France). cDNA was synthetized using random hexanucleotides (Lafaye et al., 1995) and MLV enzyme (Eurobio), then PCR-amplified (Saiki et al., 1985).", [["5\u00d7106 cells", "ANATOMY", 282, 293], ["4E11 hybridoma", "ANATOMY", 307, 321], ["dengue", "DISEASE", 70, 76], ["mAb", "GENE_OR_GENE_PRODUCT", 4, 7], ["IgG2a", "GENE_OR_GENE_PRODUCT", 18, 23], ["dengue virus", "ORGANISM", 70, 82], ["serotype 1", "ORGANISM", 84, 94], ["BALB/c mice", "ORGANISM", 129, 140], ["Fab", "GENE_OR_GENE_PRODUCT", 213, 216], ["5\u00d7106 cells", "CELL", 282, 293], ["mouse", "ORGANISM", 301, 306], ["4E11 hybridoma", "CELL", 307, 321], ["RNAxel\u00ae", "CELL", 323, 330], ["MLV enzyme", "GENE_OR_GENE_PRODUCT", 436, 446], ["mAb", "PROTEIN", 4, 7], ["IgG2a, k, isotype", "PROTEIN", 18, 35], ["Fab fragments", "DNA", 213, 226], ["5\u00d7106 cells", "CELL_LINE", 282, 293], ["mouse 4E11 hybridoma", "CELL_LINE", 301, 321], ["cDNA", "DNA", 360, 364], ["MLV enzyme", "PROTEIN", 436, 446], ["dengue virus", "SPECIES", 70, 82], ["mice", "SPECIES", 136, 140], ["mouse", "SPECIES", 301, 306], ["dengue virus", "SPECIES", 70, 82], ["mice", "SPECIES", 136, 140], ["mouse", "SPECIES", 301, 306], ["The mAb", "TREATMENT", 0, 7], ["dengue virus", "PROBLEM", 70, 82], ["Total RNAs", "TEST", 252, 262], ["RNAxel\u00ae", "TEST", 323, 330], ["Eurobio", "TEST", 332, 339], ["random hexanucleotides", "TREATMENT", 387, 409], ["MLV enzyme", "TEST", 436, 446], ["Eurobio", "TEST", 448, 455], ["PCR", "TEST", 463, 466], ["Fab fragments", "OBSERVATION", 213, 226]]], ["The PCR primers harboured a restriction site that enabled the double-stranded PCR products to be cloned into the vector.", [["PCR primers", "DNA", 4, 15], ["restriction site", "DNA", 28, 44], ["The PCR primers", "TREATMENT", 0, 15], ["a restriction site", "PROBLEM", 26, 44], ["the double-stranded PCR products", "TREATMENT", 58, 90]]], ["The 5\u2032 primers were designed to hybridize to partially conserved sequences coding for the N-terminus of variable regions.", [["N", "CHEMICAL", 90, 91], ["5\u2032 primers", "DNA", 4, 14], ["N-terminus", "PROTEIN", 90, 100], ["variable regions", "PROTEIN", 104, 120], ["The 5\u2032 primers", "TREATMENT", 0, 14]]], ["Four 5\u2032 primers for light chain and eight 5\u2032 primers for Fd had to be tested, depending on the family to which belonged the template.", [["Fd", "GENE_OR_GENE_PRODUCT", 57, 59], ["5\u2032 primers", "DNA", 5, 15], ["5\u2032 primers", "DNA", 42, 52], ["Fd", "PROTEIN", 57, 59], ["light chain and eight 5\u2032 primers", "TREATMENT", 20, 52]]], ["The 3\u2032 primers hybridize in the region corresponding to the light chain C-terminus and to the hinge region of Fd (Kang et al., 1991).", [["3\u2032 primers", "DNA", 4, 14], ["light chain C-terminus", "PROTEIN", 60, 82], ["hinge region", "PROTEIN", 94, 106], ["Fd", "PROTEIN", 110, 112], ["The 3\u2032 primers hybridize", "TREATMENT", 0, 24], ["region", "ANATOMY_MODIFIER", 32, 38], ["light", "OBSERVATION_MODIFIER", 60, 65], ["chain", "OBSERVATION_MODIFIER", 66, 71], ["-terminus", "ANATOMY_MODIFIER", 73, 82], ["hinge", "ANATOMY_MODIFIER", 94, 99]]], ["PCR conditions were described elsewhere (Lafaye et al., 1995).", [["PCR conditions", "TEST", 0, 14]]], ["After digestion by SacI and XbaI (Gibco, Gaithersburg, MD), the light chain gene was cloned into the phagemidic expression vector pMad (kindly given to us by G. Orfanoudakis, E.S.B.S., Strasbourg).", [["SacI", "GENE_OR_GENE_PRODUCT", 19, 23], ["XbaI", "GENE_OR_GENE_PRODUCT", 28, 32], ["light chain", "GENE_OR_GENE_PRODUCT", 64, 75], ["SacI", "DNA", 19, 23], ["XbaI", "DNA", 28, 32], ["light chain gene", "DNA", 64, 80], ["phagemidic expression vector pMad", "DNA", 101, 134], ["the light chain gene", "TREATMENT", 60, 80]]], ["After digestion with XhoI and SpeI (Boehringer, Mannheim, Germany), the Fd gene was cloned in frame with the gene for minor coat protein III (PIII) of filamentous phages, in the vector having already received the light chain gene (for a schematic drawing of the construct, see Barbas et al., 1991).E. coli expression and purification of phages-Fab ::: Materials and methodsThe phagemid was then introduced into competent E. coli cells by CaCl2 transformation (Sambrook et al., 1989) at an efficiency rate of 2\u00d7105 transformants per mg phagemid.", [["cells", "ANATOMY", 429, 434], ["CaCl2", "CHEMICAL", 438, 443], ["CaCl2", "CHEMICAL", 438, 443], ["XhoI", "GENE_OR_GENE_PRODUCT", 21, 25], ["SpeI", "GENE_OR_GENE_PRODUCT", 30, 34], ["Fd", "GENE_OR_GENE_PRODUCT", 72, 74], ["minor coat protein III", "GENE_OR_GENE_PRODUCT", 118, 140], ["E. coli", "ORGANISM", 298, 305], ["phagemid", "GENE_OR_GENE_PRODUCT", 377, 385], ["E. coli cells", "CELL", 421, 434], ["CaCl2", "SIMPLE_CHEMICAL", 438, 443], ["transformants", "CELL", 514, 527], ["XhoI", "DNA", 21, 25], ["SpeI", "DNA", 30, 34], ["Fd gene", "DNA", 72, 79], ["minor coat protein III", "PROTEIN", 118, 140], ["PIII", "PROTEIN", 142, 146], ["light chain gene", "DNA", 213, 229], ["Fab", "PROTEIN", 344, 347], ["E. coli cells", "CELL_LINE", 421, 434], ["E. coli", "SPECIES", 298, 305], ["E. coli", "SPECIES", 421, 428], ["E. coli", "SPECIES", 298, 305], ["E. coli", "SPECIES", 421, 428], ["XhoI", "TREATMENT", 21, 25], ["minor coat protein III (PIII", "TREATMENT", 118, 146], ["filamentous phages", "TREATMENT", 151, 169], ["E. coli expression", "PROBLEM", 298, 316], ["The phagemid", "TREATMENT", 373, 385], ["filamentous phages", "OBSERVATION", 151, 169], ["coli expression", "OBSERVATION", 301, 316], ["coli cells", "OBSERVATION", 424, 434], ["CaCl2 transformation", "OBSERVATION", 438, 458]]], ["The phage-Fab was obtained as described elsewhere (Lafaye et al., 1995), then it was titrated (Parmley and Smith, 1988) and analysed by ELISA, as described below.Production of Fab fragments ::: Materials and methodsThe selected phagemid was digested with NheI and SpeI (Boehringer) to remove the gene coding for PIII, then ligated and transformed (Barbas et al., 1991).", [["Fab", "GENE_OR_GENE_PRODUCT", 10, 13], ["Fab", "GENE_OR_GENE_PRODUCT", 176, 179], ["phagemid", "GENE_OR_GENE_PRODUCT", 228, 236], ["NheI", "GENE_OR_GENE_PRODUCT", 255, 259], ["SpeI", "GENE_OR_GENE_PRODUCT", 264, 268], ["PIII", "GENE_OR_GENE_PRODUCT", 312, 316], ["phage-Fab", "PROTEIN", 4, 13], ["Fab fragments", "PROTEIN", 176, 189], ["NheI", "DNA", 255, 259], ["PIII", "DNA", 312, 316], ["The selected phagemid", "TREATMENT", 215, 236], ["NheI", "TREATMENT", 255, 259], ["SpeI (Boehringer", "TREATMENT", 264, 280], ["Fab fragments", "OBSERVATION", 176, 189], ["phagemid", "OBSERVATION", 228, 236]]], ["This clone was cultivated in 2YT/ampicillin at 37\u00b0C until a OD600 of 1.8 was reached.", [["clone", "ANATOMY", 5, 10], ["2YT", "CHEMICAL", 29, 32], ["ampicillin", "CHEMICAL", 33, 43], ["2YT", "CHEMICAL", 29, 32], ["ampicillin", "CHEMICAL", 33, 43], ["clone", "CELL", 5, 10], ["2YT", "SIMPLE_CHEMICAL", 29, 32], ["ampicillin", "SIMPLE_CHEMICAL", 33, 43], ["This clone", "TREATMENT", 0, 10], ["ampicillin", "TREATMENT", 33, 43]]], ["IPTG was added at a concentration of 1 mM and the culture was grown overnight at 30\u00b0C, with stirring.", [["IPTG", "CHEMICAL", 0, 4], ["IPTG", "CHEMICAL", 0, 4], ["IPTG", "SIMPLE_CHEMICAL", 0, 4], ["IPTG", "TREATMENT", 0, 4], ["the culture", "TEST", 46, 57]]], ["Cells were pelleted by centrifugation and soluble Fab were recovered from the periplasm by osmotic shock.", [["Cells", "ANATOMY", 0, 5], ["periplasm", "ANATOMY", 78, 87], ["shock", "DISEASE", 99, 104], ["Cells", "CELL", 0, 5], ["Fab", "GENE_OR_GENE_PRODUCT", 50, 53], ["soluble Fab", "PROTEIN", 42, 53], ["soluble Fab", "TREATMENT", 42, 53], ["osmotic shock", "PROBLEM", 91, 104], ["osmotic shock", "OBSERVATION", 91, 104]]], ["One ml of buffer (8.6 g saccharose, 100 \u03bcl EDTA 0.5M pH 8.0, 10 ml Tris 1 M pH 8.0, milli-Q purified water for a total volume of 50 ml) was used for the extraction of Fab expressed in 70 ml culture.", [["saccharose", "CHEMICAL", 24, 34], ["saccharose", "CHEMICAL", 24, 34], ["EDTA", "CHEMICAL", 43, 47], ["Fab", "GENE_OR_GENE_PRODUCT", 167, 170], ["Fab", "PROTEIN", 167, 170], ["saccharose", "TEST", 24, 34], ["EDTA", "TEST", 43, 47], ["pH", "TEST", 53, 55], ["Tris", "TEST", 67, 71], ["pH", "TEST", 76, 78], ["milli", "TEST", 84, 89], ["a total volume", "TREATMENT", 111, 125], ["the extraction of Fab", "TREATMENT", 149, 170], ["ml culture", "TEST", 187, 197]]], ["The periplasmic fraction was cleared by centrifugation (10 000\u00d7g, 4\u00b0C, 20 min) and Fab were purified with an affinity column prepared by covalently coupling anti-mouse Fab antibodies (Sigma, St. Louis, MO) to protein G-sepharose 4B (Sigma) with 20 mM dimethylpimelimidate (Sigma) (Harlow and Lane, 1988).", [["periplasmic", "ANATOMY", 4, 15], ["dimethylpimelimidate", "CHEMICAL", 251, 271], ["dimethylpimelimidate", "CHEMICAL", 251, 271], ["Fab", "GENE_OR_GENE_PRODUCT", 83, 86], ["St. Louis", "ORGANISM", 191, 200], ["G-sepharose 4B", "GENE_OR_GENE_PRODUCT", 217, 231], ["Sigma", "SIMPLE_CHEMICAL", 233, 238], ["dimethylpimelimidate", "SIMPLE_CHEMICAL", 251, 271], ["Fab", "PROTEIN", 83, 86], ["anti-mouse Fab antibodies", "PROTEIN", 157, 182], ["Sigma, St. Louis, MO) to protein G", "PROTEIN", 184, 218], ["sepharose 4B", "PROTEIN", 219, 231], ["anti-mouse", "SPECIES", 157, 167], ["The periplasmic fraction", "TEST", 0, 24], ["Fab", "TEST", 83, 86], ["an affinity column", "TREATMENT", 106, 124], ["anti-mouse Fab antibodies", "TEST", 157, 182], ["protein G", "TEST", 209, 218]]], ["The Fab were eluted with 100 mM glycine pH 2.5, neutralized by adding 3M Tris\u2013HCl pH 9.0, dialysed agaist PBS and filtered (Millex-GP 0.22 \u03bcm, Millipore, Bedford, MA).ELISA ::: Materials and methodsA protein E fragment of dengue virus, strain FGA/89 (Despr\u00e9s et al., 1993), located between residues 296 and 400 (E(296\u2013400)), was cloned as a MalE fusion protein in p-MALc plasmid (Biolabs, Beverly, MA) following the procedure described previously (Megret et al., 1992).", [["glycine", "CHEMICAL", 32, 39], ["dengue", "DISEASE", 222, 228], ["glycine", "CHEMICAL", 32, 39], ["Fab", "GENE_OR_GENE_PRODUCT", 4, 7], ["dengue virus", "ORGANISM", 222, 234], ["MalE", "GENE_OR_GENE_PRODUCT", 341, 345], ["Fab", "PROTEIN", 4, 7], ["MalE fusion protein", "PROTEIN", 341, 360], ["p-MALc plasmid", "DNA", 364, 378], ["dengue virus", "SPECIES", 222, 234], ["dengue virus", "SPECIES", 222, 234], ["The Fab", "TEST", 0, 7], ["100 mM glycine pH", "TREATMENT", 25, 42], ["Tris\u2013HCl pH", "TEST", 73, 84], ["PBS", "TEST", 106, 109], ["Millex", "TEST", 124, 130], ["Materials", "TEST", 177, 186], ["methodsA protein E fragment", "TEST", 191, 218], ["dengue virus", "PROBLEM", 222, 234], ["strain FGA", "TEST", 236, 246], ["a MalE fusion protein", "TEST", 339, 360], ["the procedure", "TREATMENT", 412, 425]]], ["The protein was produced in E. coli and purified on a maltodextrin column according to the manufacturer procedures (Biolabs).", [["maltodextrin", "CHEMICAL", 54, 66], ["E. coli", "ORGANISM", 28, 35], ["maltodextrin", "SIMPLE_CHEMICAL", 54, 66], ["Biolabs", "GENE_OR_GENE_PRODUCT", 116, 123], ["E. coli", "SPECIES", 28, 35], ["E. coli", "SPECIES", 28, 35], ["The protein", "TEST", 0, 11], ["E. coli", "PROBLEM", 28, 35], ["a maltodextrin column", "TREATMENT", 52, 73], ["the manufacturer procedures", "TREATMENT", 87, 114], ["E. coli", "OBSERVATION", 28, 35]]], ["This protein at a concentration of 1 \u03bcg ml\u22121 in PBS was coated for 2 h at 37\u00b0C on microtiter plates (Nunc, Roskilde, Denmark).", [["PBS", "SIMPLE_CHEMICAL", 48, 51]]], ["Plates were washed six times in PBS/0.5% gelatin/0.1% Tween (PGT), then non specific binding was blocked for 1 h at 37\u00b0C with PGT.", [["gelatin", "CHEMICAL", 41, 48], ["PGT", "CHEMICAL", 126, 129], ["Tween", "CHEMICAL", 54, 59], ["PGT", "CHEMICAL", 126, 129], ["Tween (PGT", "SIMPLE_CHEMICAL", 54, 64], ["PGT", "SIMPLE_CHEMICAL", 126, 129], ["Plates", "TREATMENT", 0, 6], ["PGT", "TREATMENT", 126, 129]]], ["Two-fold dilutions of 100 \u03bcl of phage-Fab, starting with 1012 Transforming Units per ml were distributed in the wells.", [["Two-fold dilutions", "TREATMENT", 0, 18], ["phage-Fab", "TREATMENT", 32, 41]]], ["The negative control was a non recombinant phage.", [["a non recombinant phage", "TREATMENT", 25, 48], ["negative", "OBSERVATION", 4, 12]]], ["After 2 h at 37\u00b0C, plates were washed and each well was incubated with 100 \u03bcl of an anti-phage M13 horse radish peroxydase (HRP) conjugate (Pharmacia, Uppsala, Sweden) and revealed with orthophenylenediamine dihydrochloride (Dako, Glostrup, Denmark).", [["orthophenylenediamine dihydrochloride", "CHEMICAL", 186, 223], ["orthophenylenediamine dihydrochloride", "CHEMICAL", 186, 223], ["horse", "ORGANISM", 99, 104], ["radish peroxydase", "SIMPLE_CHEMICAL", 105, 122], ["HRP", "SIMPLE_CHEMICAL", 124, 127], ["orthophenylenediamine dihydrochloride", "SIMPLE_CHEMICAL", 186, 223], ["Dako", "SIMPLE_CHEMICAL", 225, 229], ["HRP", "PROTEIN", 124, 127], ["horse", "SPECIES", 99, 104], ["radish", "SPECIES", 105, 111], ["radish", "SPECIES", 105, 111], ["an anti-phage M13", "TREATMENT", 81, 98], ["orthophenylenediamine dihydrochloride", "TREATMENT", 186, 223]]], ["The 490 nm absorbance was measured on an ELISA reader (Dynatech, Guernsey).", [["The 490 nm absorbance", "TEST", 0, 21], ["490 nm", "OBSERVATION_MODIFIER", 4, 10]]], ["Concentration of soluble Fab in periplasmic extract were ELISA assayed using a rat anti-mouse chain (Immunotech, Marseille, France) that was coated and a goat anti-mouse Fab HRP conjugate (Sigma) for revelation.", [["extract", "ANATOMY", 44, 51], ["Fab", "GENE_OR_GENE_PRODUCT", 25, 28], ["periplasmic extract", "ORGANISM_SUBSTANCE", 32, 51], ["rat", "ORGANISM", 79, 82], ["goat", "ORGANISM", 154, 158], ["HRP", "GENE_OR_GENE_PRODUCT", 174, 177], ["soluble Fab", "PROTEIN", 17, 28], ["rat anti-mouse chain", "PROTEIN", 79, 99], ["goat anti-mouse Fab HRP conjugate", "PROTEIN", 154, 187], ["rat", "SPECIES", 79, 82], ["goat", "SPECIES", 154, 158], ["anti-mouse", "SPECIES", 159, 169], ["rat", "SPECIES", 79, 82], ["goat", "SPECIES", 154, 158], ["Concentration of soluble Fab in periplasmic extract", "TREATMENT", 0, 51], ["ELISA", "TEST", 57, 62], ["a rat anti-mouse chain", "TREATMENT", 77, 99], ["a goat anti-mouse Fab", "TREATMENT", 152, 173]]], ["The result was established by comparison with the purified recombinant Fab.Affinity measurements ::: Materials and methodsAffinity was measured in solution (Friguet et al., 1985).", [["Fab", "GENE_OR_GENE_PRODUCT", 71, 74], ["purified recombinant Fab", "PROTEIN", 50, 74]]], ["Samples of Fab 4E11 (as periplasmic extract diluted 1/640 in PGT) or mAb 4E11 (5 ng ml\u22121) were incubated overnight with increasing amounts of MalE-E(296\u2013400), at concentrations ranging from 10\u221211 to 10\u22127 M. The remaining free antigen-binding sites were then quantified by ELISA, using an anti-mouse \u03b2-galactosidase conjugate (J. Gregoire, Pasteur Institute, Paris) and 4-methylumbelliferyl \u03b2-d galactoside (Sigma).", [["Samples", "ANATOMY", 0, 7], ["MalE-E", "CHEMICAL", 142, 148], ["4-methylumbelliferyl \u03b2-d galactoside", "CHEMICAL", 369, 405], ["MalE-E", "CHEMICAL", 142, 148], ["4-methylumbelliferyl \u03b2-d galactoside", "CHEMICAL", 369, 405], ["Fab 4E11", "GENE_OR_GENE_PRODUCT", 11, 19], ["PGT", "SIMPLE_CHEMICAL", 61, 64], ["mAb 4E11", "SIMPLE_CHEMICAL", 69, 77], ["MalE-E", "SIMPLE_CHEMICAL", 142, 148], ["4-methylumbelliferyl \u03b2-d galactoside", "SIMPLE_CHEMICAL", 369, 405], ["Sigma", "SIMPLE_CHEMICAL", 407, 412], ["Fab 4E11", "PROTEIN", 11, 19], ["PGT", "PROTEIN", 61, 64], ["mAb 4E11", "PROTEIN", 69, 77], ["Samples of Fab", "TEST", 0, 14], ["periplasmic extract", "TEST", 24, 43], ["mAb", "TEST", 69, 72], ["ELISA", "TEST", 272, 277], ["an anti-mouse \u03b2-galactosidase conjugate", "TREATMENT", 285, 324]]], ["Fluorescence was read (Fluoroskan, Labsystem, Finland) at 460 nm, after excitation at 355 nm.Sequencing, analysis and modeling of the Fab-DNA fragment ::: Materials and methodsAutomatized sequencing was performed by Genome Express S.A. (Grenoble, France), using P13 (5\u2032 GCC GCT GGA TTG TTA TTA CTC 3\u2032) and P21 (5\u2032 CAC CCT CAG AGC CAC CAC CCT 3\u2032) for Fd sequencing and KEF (5\u2032 GAA TTC TAA ACT AGC TAG TCG 3\u2032) and Universal Primer (5\u2032 TGA CCG GCA GCA AAA TG 3\u2032) for light chain sequencing.Sequencing, analysis and modeling of the Fab-DNA fragment ::: Materials and methodsThe DNA sequences in the Genbank/EMBL nucleotide sequence data base were compared using Genetics Computer Group software (University of Wisconsin, WI).", [["nucleotide", "CHEMICAL", 608, 618], ["DNA", "CELLULAR_COMPONENT", 138, 141], ["DNA", "CELLULAR_COMPONENT", 532, 535], ["DNA", "CELLULAR_COMPONENT", 574, 577], ["Fab-DNA fragment", "DNA", 134, 150], ["P21", "DNA", 306, 309], ["Fd sequencing", "DNA", 350, 363], ["KEF", "DNA", 368, 371], ["Universal Primer", "DNA", 412, 428], ["Fab-DNA fragment", "DNA", 528, 544], ["DNA sequences", "DNA", 574, 587], ["Genbank/EMBL nucleotide sequence", "DNA", 595, 627], ["Fluorescence", "TEST", 0, 12], ["Sequencing", "TEST", 93, 103], ["analysis", "TEST", 105, 113], ["methodsAutomatized sequencing", "TEST", 169, 198], ["P13", "TEST", 262, 265], ["GCC GCT", "TEST", 270, 277], ["TTG", "TEST", 282, 285], ["CTC", "TEST", 294, 297], ["P21", "TEST", 306, 309], ["CAC", "TEST", 314, 317], ["CCT", "TEST", 318, 321], ["CAG", "TEST", 322, 325], ["AGC", "TEST", 326, 329], ["CAC", "TEST", 330, 333], ["CAC", "TEST", 334, 337], ["CCT", "TEST", 338, 341], ["Fd sequencing", "TEST", 350, 363], ["KEF", "TEST", 368, 371], ["GAA", "TEST", 376, 379], ["TTC", "TEST", 380, 383], ["AGC", "TEST", 392, 395], ["TCG", "TEST", 400, 403], ["Universal Primer", "TEST", 412, 428], ["TGA", "TEST", 433, 436], ["GCA", "TEST", 441, 444], ["GCA", "TEST", 445, 448], ["AAA", "TEST", 449, 452], ["TG", "TEST", 453, 455], ["light chain sequencing", "TEST", 464, 486], ["Sequencing", "TEST", 487, 497], ["analysis", "TEST", 499, 507], ["The DNA sequences", "TEST", 570, 587]]], ["The DNA sequences of the Fab heavy and light chains are accessible in Genbank under the following numbers, respectively, AJ131288 and AJ131289.Plaque-reduction neutralization tests ::: Materials and methodsNeutralization tests were performed on Vero cells, in 24-wells culture plates with prototype dengue viruses of the four serotypes.", [["Plaque", "ANATOMY", 143, 149], ["Vero cells", "ANATOMY", 245, 255], ["AJ131289", "CHEMICAL", 134, 142], ["dengue", "DISEASE", 299, 305], ["AJ131288", "CHEMICAL", 121, 129], ["AJ131289", "CHEMICAL", 134, 142], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["Vero cells", "CELL", 245, 255], ["DNA sequences", "DNA", 4, 17], ["Fab heavy and light chains", "PROTEIN", 25, 51], ["Vero cells", "CELL_LINE", 245, 255], ["dengue viruses", "SPECIES", 299, 313], ["The DNA sequences", "TEST", 0, 17], ["Plaque-reduction neutralization tests", "TEST", 143, 180], ["methodsNeutralization tests", "TEST", 199, 226], ["Vero cells", "TEST", 245, 255], ["prototype dengue viruses", "PROBLEM", 289, 313], ["light chains", "OBSERVATION_MODIFIER", 39, 51], ["reduction", "OBSERVATION_MODIFIER", 150, 159], ["neutralization", "OBSERVATION", 160, 174]]], ["Dengue virus strains were the following: Hawaii 1944 for serotype 1, New Guinea C 1944 for serotype 2, H 87 for serotype 3, H 241 for serotype 4.", [["Dengue", "DISEASE", 0, 6], ["Dengue virus", "ORGANISM", 0, 12], ["Dengue virus", "SPECIES", 0, 12], ["Dengue virus", "SPECIES", 0, 12], ["Dengue virus strains", "PROBLEM", 0, 20], ["serotype", "TREATMENT", 57, 65], ["serotype", "PROBLEM", 134, 142]]], ["Periplasmic extract containing Fab 4E11, periplasmic extract of non-transformed TG1, purified Fab 4E11 (all stored at \u221220\u00b0C) and parental mAb (stored at high concentration at 4\u00b0C) were incubated in two-fold serial dilutions with 100 Focus Forming Units (FFU) of virus overnight at 4\u00b0C (Despr\u00e9s et al., 1993).", [["extract", "ANATOMY", 12, 19], ["extract", "ANATOMY", 53, 60], ["TG1", "ANATOMY", 80, 83], ["Fab 4E11", "GENE_OR_GENE_PRODUCT", 31, 39], ["TG1", "CELL", 80, 83], ["Fab 4E11", "ORGANISM", 94, 102], ["mAb", "GENE_OR_GENE_PRODUCT", 138, 141], ["Fab 4E11", "PROTEIN", 31, 39], ["non-transformed TG1", "CELL_LINE", 64, 83], ["Fab 4E11", "PROTEIN", 94, 102], ["\u221220\u00b0C", "PROTEIN", 118, 123], ["parental mAb", "PROTEIN", 129, 141], ["Periplasmic extract containing Fab", "TEST", 0, 34], ["purified Fab", "TEST", 85, 97], ["parental mAb", "TREATMENT", 129, 141], ["virus", "PROBLEM", 262, 267]]], ["The mixture was then incubated, in duplicate, on Vero cells for 2 h at 37\u00b0C with Iscov-carboxycellulose 1.6% and then re-incubated at 37\u00b0C in a 5% CO2 incubator during 5 days for serotypes 2 and 4 and 6 days for serotypes 1 and 3.", [["Vero cells", "ANATOMY", 49, 59], ["Iscov-carboxycellulose", "CHEMICAL", 81, 103], ["CO2", "CHEMICAL", 147, 150], ["Iscov-carboxycellulose", "CHEMICAL", 81, 103], ["CO2", "CHEMICAL", 147, 150], ["Vero cells", "CELL", 49, 59], ["Iscov-carboxycellulose", "SIMPLE_CHEMICAL", 81, 103], ["CO2", "SIMPLE_CHEMICAL", 147, 150], ["Vero cells", "CELL_LINE", 49, 59], ["Vero cells", "TREATMENT", 49, 59], ["Iscov-carboxycellulose", "TREATMENT", 81, 103], ["a 5% CO2 incubator", "TREATMENT", 142, 160], ["serotypes", "TREATMENT", 179, 188], ["serotypes", "PROBLEM", 212, 221]]], ["After fixation, plaques were revealed with anti-dengue virus specific hyperimmunized mouse ascitic fluids, then with an anti-mouse HRP conjugate.", [["plaques", "ANATOMY", 16, 23], ["ascitic fluids", "ANATOMY", 91, 105], ["plaques", "PATHOLOGICAL_FORMATION", 16, 23], ["anti-dengue virus", "ORGANISM", 43, 60], ["mouse", "ORGANISM", 85, 90], ["ascitic fluids", "ORGANISM_SUBSTANCE", 91, 105], ["HRP", "GENE_OR_GENE_PRODUCT", 131, 134], ["anti-mouse HRP conjugate", "PROTEIN", 120, 144], ["mouse", "SPECIES", 85, 90], ["anti-dengue virus", "SPECIES", 43, 60], ["mouse", "SPECIES", 85, 90], ["fixation", "TREATMENT", 6, 14], ["plaques", "PROBLEM", 16, 23], ["anti-dengue virus specific hyperimmunized mouse ascitic fluids", "PROBLEM", 43, 105], ["an anti-mouse HRP conjugate", "TREATMENT", 117, 144], ["fixation", "OBSERVATION", 6, 14], ["plaques", "OBSERVATION", 16, 23], ["ascitic fluids", "OBSERVATION", 91, 105]]], ["The neutralization capacity was estimated as the mAb or Fab concentration causing 50% reduction of FFU.Isolation of Fab cDNA ::: Results and discussionmRNA was extracted from a culture of hybridoma cells 4E11 and utilized as a template for RT-PCR to obtain cDNA.", [["hybridoma cells", "ANATOMY", 188, 203], ["FFU", "CHEMICAL", 99, 102], ["Fab", "GENE_OR_GENE_PRODUCT", 56, 59], ["FFU", "SIMPLE_CHEMICAL", 99, 102], ["Fab", "GENE_OR_GENE_PRODUCT", 116, 119], ["hybridoma cells 4E11", "CELL", 188, 208], ["mAb", "PROTEIN", 49, 52], ["Fab cDNA", "DNA", 116, 124], ["hybridoma cells", "CELL_LINE", 188, 203], ["4E11", "CELL_LINE", 204, 208], ["cDNA", "DNA", 257, 261], ["The neutralization capacity", "TEST", 0, 27], ["the mAb", "TREATMENT", 45, 52], ["Fab concentration", "TREATMENT", 56, 73], ["50% reduction of FFU", "PROBLEM", 82, 102], ["a culture", "TEST", 175, 184], ["hybridoma cells", "PROBLEM", 188, 203], ["RT-PCR", "TEST", 240, 246], ["cDNA", "TEST", 257, 261], ["neutralization capacity", "OBSERVATION", 4, 27], ["hybridoma cells", "OBSERVATION", 188, 203]]], ["The 3\u2032 primer CkDNA and the 5\u2032 primer LC7 allowed the amplification of a DNA fragment of a length of 650 bp, which is the size for a DNA fragment coding for a light chain.", [["DNA", "CELLULAR_COMPONENT", 73, 76], ["DNA", "CELLULAR_COMPONENT", 133, 136], ["3\u2032 primer CkDNA", "DNA", 4, 19], ["5\u2032 primer LC7", "DNA", 28, 41], ["DNA fragment", "DNA", 73, 85], ["DNA fragment", "DNA", 133, 145], ["light chain", "PROTEIN", 159, 170], ["the 5\u2032 primer LC7", "TREATMENT", 24, 41], ["a DNA fragment", "PROBLEM", 71, 85], ["bp", "TEST", 105, 107], ["a DNA fragment", "PROBLEM", 131, 145], ["size", "OBSERVATION_MODIFIER", 122, 126], ["DNA fragment", "OBSERVATION", 133, 145]]], ["The 3\u2032 primer IgG2a and the 5\u2032 primer VHIIC allowed the amplification of DNA coding for Fd.", [["IgG2a", "GENE_OR_GENE_PRODUCT", 14, 19], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["3\u2032 primer IgG2a and the 5\u2032 primer VHIIC", "DNA", 4, 43], ["The 3\u2032 primer IgG2a", "TREATMENT", 0, 19], ["the 5\u2032 primer VHIIC", "TREATMENT", 24, 43]]], ["The DNA fragment coding for the light chain was inserted first in the pMad phagemidic vector and then the fragment coding for the heavy chain.Isolation of Fab cDNA ::: Results and discussionOne clone constructed with the light chain and Fd genes from 4E11 was ELISA tested for binding to MalE-E(296\u2013400) fusion protein and compared to a phage having incorporated no heterologous gene.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["Fab", "GENE_OR_GENE_PRODUCT", 155, 158], ["clone", "CELL", 194, 199], ["Fd", "GENE_OR_GENE_PRODUCT", 237, 239], ["4E11", "GENE_OR_GENE_PRODUCT", 251, 255], ["MalE-E", "GENE_OR_GENE_PRODUCT", 288, 294], ["light chain", "PROTEIN", 32, 43], ["pMad phagemidic vector", "DNA", 70, 92], ["heavy chain", "PROTEIN", 130, 141], ["Fab cDNA", "DNA", 155, 163], ["light chain and Fd genes", "DNA", 221, 245], ["4E11", "DNA", 251, 255], ["MalE-E(296\u2013400) fusion protein", "PROTEIN", 288, 318], ["heterologous gene", "DNA", 366, 383], ["The DNA fragment", "PROBLEM", 0, 16], ["the light chain", "TREATMENT", 28, 43], ["the pMad phagemidic vector", "TREATMENT", 66, 92], ["ELISA", "TEST", 260, 265], ["fusion protein", "TREATMENT", 304, 318], ["a phage", "TREATMENT", 335, 342], ["fragment", "OBSERVATION_MODIFIER", 8, 16], ["fragment", "OBSERVATION", 106, 114]]], ["The signal obtained with the phage-Fab was constantly above the negative phage and linearly dependent on the phage-Fab concentration (data not shown).", [["Fab", "GENE_OR_GENE_PRODUCT", 35, 38], ["Fab", "GENE_OR_GENE_PRODUCT", 115, 118], ["phage-Fab", "PROTEIN", 29, 38], ["Fab", "PROTEIN", 115, 118]]], ["For soluble Fab production, the gene coding for minor coat protein III was removed by NheI and SpeI digestion.DNA sequence analysis ::: Results and discussionWhen compared to the data base, Fd belonged to the VH14 family consisting of four members: X62705 (Moncharmont et al., 1982) with which most identity (90%) was shared, X07144 (Rocca-Serra et al., 1983), M13068 (Roth et al., 1985) and Z22138 (Tillman et al., 1992).", [["Fab", "GENE_OR_GENE_PRODUCT", 12, 15], ["minor coat protein III", "GENE_OR_GENE_PRODUCT", 48, 70], ["NheI", "GENE_OR_GENE_PRODUCT", 86, 90], ["SpeI", "GENE_OR_GENE_PRODUCT", 95, 99], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["Fd", "GENE_OR_GENE_PRODUCT", 190, 192], ["VH14", "GENE_OR_GENE_PRODUCT", 209, 213], ["Fab", "PROTEIN", 12, 15], ["minor coat protein III", "PROTEIN", 48, 70], ["Fd", "PROTEIN", 190, 192], ["VH14 family", "PROTEIN", 209, 220], ["soluble Fab production", "TREATMENT", 4, 26], ["minor coat protein III", "TREATMENT", 48, 70], ["DNA sequence analysis", "TEST", 110, 131]]], ["These antibodies were directed against an oestrogen receptor (X62705), against an hapten (GAT) (X07144 and M13068) and against DNA (Z22138).", [["oestrogen", "CHEMICAL", 42, 51], ["oestrogen receptor", "GENE_OR_GENE_PRODUCT", 42, 60], ["X62705", "SIMPLE_CHEMICAL", 62, 68], ["GAT", "GENE_OR_GENE_PRODUCT", 90, 93], ["DNA", "CELLULAR_COMPONENT", 127, 130], ["antibodies", "PROTEIN", 6, 16], ["oestrogen receptor", "PROTEIN", 42, 60], ["These antibodies", "TEST", 0, 16], ["an oestrogen receptor", "TREATMENT", 39, 60], ["DNA", "PROBLEM", 127, 130]]], ["The D segment of Fd corresponded to the DQ52 genetic element and the junction segment corresponded to the JH3 genetic element.DNA sequence analysis ::: Results and discussionThe sequence of the light chain of 4E11 belonged to the VK 21 group III subgroup.", [["Fd", "GENE_OR_GENE_PRODUCT", 17, 19], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["4E11", "GENE_OR_GENE_PRODUCT", 209, 213], ["D segment", "DNA", 4, 13], ["Fd", "PROTEIN", 17, 19], ["DQ52 genetic element", "DNA", 40, 60], ["JH3 genetic element", "DNA", 106, 125], ["light chain", "PROTEIN", 194, 205], ["4E11", "PROTEIN", 209, 213], ["VK 21 group III subgroup", "PROTEIN", 230, 254], ["The D segment of Fd", "PROBLEM", 0, 19], ["the JH3 genetic element", "PROBLEM", 102, 125], ["DNA sequence analysis", "TEST", 126, 147], ["the light chain", "TEST", 190, 205], ["D segment", "OBSERVATION_MODIFIER", 4, 13], ["junction", "ANATOMY_MODIFIER", 69, 77], ["segment", "ANATOMY_MODIFIER", 78, 85], ["genetic element", "OBSERVATION", 110, 125]]], ["When compared with sequences of other light chain coding genes, two of the three genes presenting most homologies were from anti-viral IgG.", [["IgG", "GENE_OR_GENE_PRODUCT", 135, 138], ["light chain coding genes", "DNA", 38, 62], ["anti-viral IgG", "PROTEIN", 124, 138], ["anti-viral IgG", "TREATMENT", 124, 138]]], ["The non anti-viral IgG was directed against CD 18 (95.2% identity).", [["IgG", "GENE_OR_GENE_PRODUCT", 19, 22], ["anti-viral IgG", "PROTEIN", 8, 22], ["CD 18", "PROTEIN", 44, 49], ["The non anti-viral IgG", "TREATMENT", 0, 22]]], ["The anti-viral IgG were directed against influenza virus (X59209, Stark and Caton, 1991) (96% identity) and Hantaan virus (L46814, Liang et al., 1996) (95.2% identity); the identity between CDRs being 77 and 95%, respectively.", [["influenza virus", "DISEASE", 41, 56], ["IgG", "GENE_OR_GENE_PRODUCT", 15, 18], ["influenza virus", "ORGANISM", 41, 56], ["Hantaan virus", "ORGANISM", 108, 121], ["anti-viral IgG", "PROTEIN", 4, 18], ["influenza virus", "SPECIES", 41, 56], ["Hantaan virus", "SPECIES", 108, 121], ["Hantaan virus", "SPECIES", 108, 121], ["The anti-viral IgG", "TREATMENT", 0, 18], ["influenza virus", "PROBLEM", 41, 56], ["Hantaan virus", "PROBLEM", 108, 121], ["CDRs", "TEST", 190, 194]]], ["Because the third light chain CDR (L3) plays a significant role in antigen recognition, the conservation of six of its nine residues is noteworthy.", [["third light chain CDR", "PROTEIN", 12, 33], ["L3", "PROTEIN", 35, 37], ["L3", "ANATOMY", 35, 37], ["significant", "OBSERVATION_MODIFIER", 47, 58]]], ["Identities between the Fd of these IgG were less remarquable, though 40% of the CDR 2 (H2) was identical.DNA sequence analysis ::: Results and discussionThe fine mapping of 4E11 epitope could provide clues to test the hypothesis that the use of variants of this light chain among three antiviral antibodies could eventually signal the presence of comparable epitopes at the surface of the three different viruses.Affinity measurements ::: Immunochemical and serological properties ::: Results and discussionThe affinity of the mAb and the Fab for MalE-E(296\u2013400) binding were, respectively, measured as 3.77\u00d710\u22129 and 1.7\u00d710\u22129 M and can be considered as equivalent due to experimental variations and precision of the method.Quantification and purification of the soluble Fab ::: Immunochemical and serological properties ::: Results and discussionThe Fab was harvested in periplasmic extract, purified and electrophoresed on a 10% SDS-PAGE gel.", [["surface", "ANATOMY", 374, 381], ["extract", "ANATOMY", 883, 890], ["MalE-E", "CHEMICAL", 547, 553], ["Fd", "GENE_OR_GENE_PRODUCT", 23, 25], ["IgG", "GENE_OR_GENE_PRODUCT", 35, 38], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["4E11 epitope", "GENE_OR_GENE_PRODUCT", 173, 185], ["surface", "CELLULAR_COMPONENT", 374, 381], ["mAb", "GENE_OR_GENE_PRODUCT", 527, 530], ["Fab", "GENE_OR_GENE_PRODUCT", 539, 542], ["MalE-E", "SIMPLE_CHEMICAL", 547, 553], ["Fab", "GENE_OR_GENE_PRODUCT", 850, 853], ["periplasmic extract", "ORGANISM_SUBSTANCE", 871, 890], ["Fd", "PROTEIN", 23, 25], ["IgG", "PROTEIN", 35, 38], ["4E11 epitope", "PROTEIN", 173, 185], ["light chain", "PROTEIN", 262, 273], ["antiviral antibodies", "PROTEIN", 286, 306], ["epitopes", "PROTEIN", 358, 366], ["mAb", "PROTEIN", 527, 530], ["Fab", "PROTEIN", 539, 542], ["soluble Fab", "PROTEIN", 762, 773], ["Fab", "PROTEIN", 850, 853], ["these IgG", "TEST", 29, 38], ["the CDR", "TEST", 76, 83], ["DNA sequence analysis", "TEST", 105, 126], ["this light chain", "TREATMENT", 257, 273], ["three antiviral antibodies", "TREATMENT", 280, 306], ["the mAb", "TEST", 523, 530], ["experimental variations", "PROBLEM", 671, 694], ["the method", "TREATMENT", 712, 722], ["a 10% SDS", "TREATMENT", 924, 933], ["IgG", "OBSERVATION", 35, 38], ["three different", "OBSERVATION_MODIFIER", 389, 404], ["viruses", "OBSERVATION", 405, 412]]], ["Two narrowly separated bands of approximately 25 kD were shown, corresponding to light chain and Fd present in similar quantities (Fig. 1).", [["Fd", "GENE_OR_GENE_PRODUCT", 97, 99], ["light chain", "PROTEIN", 81, 92], ["Fd", "PROTEIN", 97, 99], ["Two narrowly separated bands", "PROBLEM", 0, 28], ["light chain and Fd", "PROBLEM", 81, 99], ["narrowly", "OBSERVATION_MODIFIER", 4, 12], ["separated", "OBSERVATION_MODIFIER", 13, 22], ["bands", "OBSERVATION_MODIFIER", 23, 28], ["approximately", "OBSERVATION_MODIFIER", 32, 45], ["25 kD", "OBSERVATION_MODIFIER", 46, 51], ["light chain", "OBSERVATION_MODIFIER", 81, 92]]], ["No contaminant was present and the concentration was measured as 9 \u03bcg ml\u22121 by Bradford\u2019s method.PRNT ::: Immunochemical and serological properties ::: Results and discussionPRNT (50% inhibition) were performed for the four serotypes during the same experiment in order to allow comparisons to be made between Fab (purified Fab and Fab in periplasmic extract) and mAb and between serotypes.", [["extract", "ANATOMY", 350, 357], ["Fab", "GENE_OR_GENE_PRODUCT", 309, 312], ["Fab", "GENE_OR_GENE_PRODUCT", 323, 326], ["Fab", "GENE_OR_GENE_PRODUCT", 331, 334], ["mAb", "GENE_OR_GENE_PRODUCT", 363, 366], ["Fab", "PROTEIN", 309, 312], ["purified Fab", "PROTEIN", 314, 326], ["Fab", "PROTEIN", 331, 334], ["mAb", "PROTEIN", 363, 366], ["contaminant", "PROBLEM", 3, 14], ["discussionPRNT (50% inhibition)", "TREATMENT", 163, 194], ["the four serotypes", "PROBLEM", 214, 232], ["Fab (purified Fab", "TREATMENT", 309, 326], ["Fab in periplasmic extract", "TREATMENT", 331, 357], ["mAb", "TREATMENT", 363, 366], ["contaminant", "OBSERVATION", 3, 14]]], ["This experiment was preceded by preliminary experiments, whose results are in accordance with those given in Table 1(data not shown). mAb concentration which neutralized serotype 1 (0.28 \u03bcg ml\u22121) (Fig. 2) was lower than that neutralizing serotypes 2 and 3 (2.25 \u03bcg ml\u22121) and serotype 4 (>2.25 \u03bcg ml\u22121) (Table 1).", [["mAb", "GENE_OR_GENE_PRODUCT", 134, 137], ["mAb", "PROTEIN", 134, 137], ["serotype 1", "SPECIES", 170, 180], ["mAb concentration", "TREATMENT", 134, 151], ["neutralized serotype", "TREATMENT", 158, 178], ["neutralizing serotypes", "TREATMENT", 225, 247], ["serotype", "TREATMENT", 275, 283]]], ["Periplasmic extract without Fab did not show any neutralizing properties.", [["extract", "ANATOMY", 12, 19], ["Fab", "GENE_OR_GENE_PRODUCT", 28, 31], ["Fab", "PROTEIN", 28, 31], ["Periplasmic extract", "TEST", 0, 19], ["neutralizing", "OBSERVATION", 49, 61]]], ["Fab neutralization capacity could be estimated as 8 times (serotypes 1 and 2) to four times (serotype 3) and four times or less (serotype 4) lower than that of mAb 4E11.PRNT ::: Immunochemical and serological properties ::: Results and discussionDespite experimental variations observed between the tested serotypes, some reduction of Fab neutralizing capacity when compared with the parental mAb was observed.", [["Fab", "GENE_OR_GENE_PRODUCT", 0, 3], ["mAb 4E11", "GENE_OR_GENE_PRODUCT", 160, 168], ["Fab", "GENE_OR_GENE_PRODUCT", 335, 338], ["mAb", "GENE_OR_GENE_PRODUCT", 393, 396], ["mAb 4E11", "PROTEIN", 160, 168], ["Fab", "PROTEIN", 335, 338], ["parental mAb", "PROTEIN", 384, 396], ["Fab neutralization capacity", "TEST", 0, 27], ["experimental variations", "PROBLEM", 254, 277], ["the tested serotypes", "TREATMENT", 295, 315], ["Fab neutralizing capacity", "PROBLEM", 335, 360], ["reduction", "OBSERVATION_MODIFIER", 322, 331]]], ["It has already been reported that neutralization by a Fab is usually reduced by at least one order of magnitude compared with its parental IgG (Schofield et al., 1997), but the observed reduction was not in agreement with the conserved affinity.", [["Fab", "GENE_OR_GENE_PRODUCT", 54, 57], ["IgG", "GENE_OR_GENE_PRODUCT", 139, 142], ["Fab", "PROTEIN", 54, 57], ["parental IgG", "PROTEIN", 130, 142], ["neutralization", "OBSERVATION", 34, 48]]], ["Technical reasons for this appearent loss of activity, such as alterations during freeze-thaw, or defects in the association of the light chain and Fd could not be ruled out despite the taken precautions.", [["Fd", "GENE_OR_GENE_PRODUCT", 148, 150], ["light chain", "PROTEIN", 132, 143], ["Fd", "PROTEIN", 148, 150], ["this appearent loss of activity", "PROBLEM", 22, 53], ["freeze-thaw", "TREATMENT", 82, 93], ["defects", "PROBLEM", 98, 105], ["the taken precautions", "TREATMENT", 182, 203], ["defects", "OBSERVATION", 98, 105]]], ["These reasons would not have hampered the affinity measurements, which were not dependent on the quantity of active Fab present in the tested solution, but only on the linearity of the signal with respect to the dilution.", [["Fab", "GENE_OR_GENE_PRODUCT", 116, 119], ["Fab", "PROTEIN", 116, 119], ["the affinity measurements", "TEST", 38, 63], ["active Fab", "TREATMENT", 109, 119], ["active", "OBSERVATION_MODIFIER", 109, 115], ["Fab", "OBSERVATION", 116, 119]]], ["Reasons based on the mechanism of neutralization could also be proposed.", [["neutralization", "TREATMENT", 34, 48], ["neutralization", "OBSERVATION", 34, 48]]], ["Because Fab 4E11 bound to the envelope protein of the virus, it should block the attachment of the virus to the host cell, by binding close to the attachment site (see review in Dimmock, 1993).", [["cell", "ANATOMY", 117, 121], ["Fab 4E11", "GENE_OR_GENE_PRODUCT", 8, 16], ["host cell", "CELL", 112, 121], ["Fab 4E11", "PROTEIN", 8, 16], ["envelope protein", "PROTEIN", 30, 46], ["attachment site", "DNA", 147, 162], ["the virus", "PROBLEM", 50, 59], ["virus", "OBSERVATION", 54, 59], ["virus", "OBSERVATION", 99, 104], ["host cell", "OBSERVATION", 112, 121]]], ["This blocking could be less complete by the Fab than by the Mab, due to reduction in Fab steric hindrance.", [["Fab", "GENE_OR_GENE_PRODUCT", 44, 47], ["Mab", "GENE_OR_GENE_PRODUCT", 60, 63], ["Fab", "PROTEIN", 44, 47], ["Mab", "PROTEIN", 60, 63], ["the Mab", "TREATMENT", 56, 63], ["reduction in Fab steric hindrance", "PROBLEM", 72, 105], ["Fab steric hindrance", "OBSERVATION", 85, 105]]], ["Because no effector for Fc is present in the in vitro neutralization essay, the fact that the lack of Fc seems to cause a reduction of neutralization properties can be mostly explained by this reduction of Fab steric hindrance.PRNT ::: Immunochemical and serological properties ::: Results and discussionOur in vitro neutralization experiments by recombinant Fab 4E11 proved that Fc and divalence of the parental mAb were not necessary to the neutralization process.", [["Fc", "GENE_OR_GENE_PRODUCT", 24, 26], ["Fc", "GENE_OR_GENE_PRODUCT", 102, 104], ["Fab", "GENE_OR_GENE_PRODUCT", 206, 209], ["Fab 4E11", "GENE_OR_GENE_PRODUCT", 359, 367], ["Fc", "GENE_OR_GENE_PRODUCT", 380, 382], ["mAb", "GENE_OR_GENE_PRODUCT", 413, 416], ["Fc", "PROTEIN", 24, 26], ["Fc", "PROTEIN", 102, 104], ["recombinant Fab 4E11", "PROTEIN", 347, 367], ["Fc", "PROTEIN", 380, 382], ["parental mAb", "PROTEIN", 404, 416], ["a reduction of neutralization properties", "PROBLEM", 120, 160], ["this reduction of Fab steric hindrance", "TREATMENT", 188, 226], ["the parental mAb", "TREATMENT", 400, 416], ["reduction", "OBSERVATION_MODIFIER", 122, 131], ["neutralization", "OBSERVATION", 135, 149]]], ["Such results have already been established by Fab obtained by papain digestion, but could be subject to caution due to incomplete digestion (Dimmock, 1993).", [["Fab", "GENE_OR_GENE_PRODUCT", 46, 49], ["papain", "GENE_OR_GENE_PRODUCT", 62, 68], ["Fab", "PROTEIN", 46, 49], ["incomplete digestion", "PROBLEM", 119, 139]]], ["These results cannot be generalised to all monoclonal antibodies (Ubol et al., 1995).PRNT ::: Immunochemical and serological properties ::: Results and discussionIn a medical perspective, more work could be done to improve the production of Fab 4E11 and to test it in vivo.", [["Fab 4E11", "GENE_OR_GENE_PRODUCT", 241, 249], ["monoclonal antibodies", "PROTEIN", 43, 64], ["Fab 4E11", "PROTEIN", 241, 249]]], ["The humanization of Fab 4E11, or the search for an antibody of similar properties but of human origin, that would be better tolerated in medical use, can also be pursued.", [["Fab 4E11", "GENE_OR_GENE_PRODUCT", 20, 28], ["human", "ORGANISM", 89, 94], ["Fab 4E11", "PROTEIN", 20, 28], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["an antibody", "TEST", 48, 59]]], ["Recent availability for medical practice of a recombinant mouse-human chimera Fab (Abciximab\u00ae used as an anti-aggregant) gives ground for hope that long-pursued antiviral seroprophylaxis or serotherapy may some day become reality.", [["Abciximab\u00ae", "CHEMICAL", 83, 93], ["mouse", "ORGANISM", 58, 63], ["human", "ORGANISM", 64, 69], ["Fab", "GENE_OR_GENE_PRODUCT", 78, 81], ["recombinant mouse-human chimera Fab", "PROTEIN", 46, 81], ["Abciximab\u00ae", "PROTEIN", 83, 93], ["mouse", "SPECIES", 58, 63], ["human", "SPECIES", 64, 69], ["mouse", "SPECIES", 58, 63], ["human", "SPECIES", 64, 69], ["medical practice", "TREATMENT", 24, 40], ["a recombinant mouse-human chimera Fab (Abciximab\u00ae", "TREATMENT", 44, 93], ["an anti-aggregant)", "TREATMENT", 102, 120], ["antiviral seroprophylaxis", "TREATMENT", 161, 186], ["serotherapy", "TREATMENT", 190, 201]]]], "PMC7255246": [], "b1c95fc0ea9e1ab3de0a2adde0097bc7ba70c005": [["IntroductionPneumonia is a common illness that continues to be the major killer of young children in developing countries and elderly people in developed countries.", [["IntroductionPneumonia", "DISEASE", 0, 21], ["children", "ORGANISM", 89, 97], ["people", "ORGANISM", 134, 140], ["children", "SPECIES", 89, 97], ["people", "SPECIES", 134, 140]]], ["Many microorganisms are associated with pneumonia, and now attention is turning to the importance of viruses as pathogens.", [["pneumonia", "DISEASE", 40, 49], ["Many microorganisms", "PROBLEM", 0, 19], ["pneumonia", "PROBLEM", 40, 49], ["viruses", "PROBLEM", 101, 108], ["pathogens", "PROBLEM", 112, 121], ["microorganisms", "OBSERVATION", 5, 19], ["associated with", "UNCERTAINTY", 24, 39], ["pneumonia", "OBSERVATION", 40, 49], ["viruses", "OBSERVATION", 101, 108]]], ["Widespread introduction of Haemophilus infl uenzae type b and pneumococcal conjugate vaccines into immunisation programmes has led to speculation about the growing predominance of viruses as causes of childhood pneumonia.", [["pneumonia", "DISEASE", 211, 220], ["Haemophilus infl uenzae type b", "ORGANISM", 27, 57], ["pneumococcal conjugate", "ORGANISM", 62, 84], ["Haemophilus infl uenzae", "SPECIES", 27, 50], ["Haemophilus infl uenzae", "SPECIES", 27, 50], ["pneumococcal", "SPECIES", 62, 74], ["Haemophilus infl uenzae type b", "TREATMENT", 27, 57], ["pneumococcal conjugate vaccines", "TREATMENT", 62, 93], ["immunisation programmes", "TREATMENT", 99, 122], ["viruses", "PROBLEM", 180, 187], ["childhood pneumonia", "PROBLEM", 201, 220], ["Haemophilus", "OBSERVATION", 27, 38], ["viruses", "OBSERVATION", 180, 187], ["childhood", "OBSERVATION_MODIFIER", 201, 210], ["pneumonia", "OBSERVATION", 211, 220]]], ["The emergence of severe acute respiratory syndrome (SARS), avian infl uenza A (H5N1) virus, and the 2009 pandemic infl uenza A (H1N1) virus has re-emphasised the important role of respiratory viruses as causes of severe pneumonia.", [["acute respiratory syndrome", "DISEASE", 24, 50], ["SARS", "DISEASE", 52, 56], ["avian infl uenza A (H5N1) virus", "DISEASE", 59, 90], ["respiratory viruses", "DISEASE", 180, 199], ["pneumonia", "DISEASE", 220, 229], ["avian", "ORGANISM", 59, 64], ["infl uenza A (H5N1) virus", "ORGANISM", 65, 90], ["2009 pandemic", "ORGANISM", 100, 113], ["infl uenza A (H1N1) virus", "ORGANISM", 114, 139], ["H5N1) virus", "SPECIES", 79, 90], ["H1N1) virus", "SPECIES", 128, 139], ["infl uenza A (H5N1) virus", "SPECIES", 65, 90], ["infl uenza A (H1N1) virus", "SPECIES", 114, 139], ["severe acute respiratory syndrome", "PROBLEM", 17, 50], ["SARS", "PROBLEM", 52, 56], ["avian infl uenza A (H5N1) virus", "PROBLEM", 59, 90], ["A (H1N1) virus", "PROBLEM", 125, 139], ["respiratory viruses", "PROBLEM", 180, 199], ["severe pneumonia", "PROBLEM", 213, 229], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["respiratory syndrome", "OBSERVATION", 30, 50], ["respiratory viruses", "OBSERVATION", 180, 199], ["severe", "OBSERVATION_MODIFIER", 213, 219], ["pneumonia", "OBSERVATION", 220, 229]]], ["New respiratory viruses-such as human metapneumovirus, coronaviruses NL63 and HKU1, and human bocavirus-have been discovered during the past decade.", [["respiratory viruses", "DISEASE", 4, 23], ["human metapneumovirus", "DISEASE", 32, 53], ["human", "ORGANISM", 32, 37], ["metapneumovirus", "ORGANISM", 38, 53], ["coronaviruses NL63", "ORGANISM", 55, 73], ["HKU1", "GENE_OR_GENE_PRODUCT", 78, 82], ["human", "ORGANISM", 88, 93], ["bocavirus", "GENE_OR_GENE_PRODUCT", 94, 103], ["human", "SPECIES", 32, 37], ["metapneumovirus", "SPECIES", 38, 53], ["human", "SPECIES", 88, 93], ["human metapneumovirus", "SPECIES", 32, 53], ["human", "SPECIES", 88, 93], ["New respiratory viruses", "PROBLEM", 0, 23], ["human metapneumovirus", "PROBLEM", 32, 53], ["coronaviruses", "PROBLEM", 55, 68], ["HKU1", "TREATMENT", 78, 82], ["human bocavirus", "PROBLEM", 88, 103], ["respiratory viruses", "OBSERVATION", 4, 23], ["metapneumovirus", "OBSERVATION", 38, 53]]], ["Importantly, the availability of molecular diagnostic assays (such as PCR) has greatly increased our ability to detect and characterise the epidemiology of respiratory virus infections.", [["respiratory virus infections", "DISEASE", 156, 184], ["respiratory virus", "ORGANISM", 156, 173], ["respiratory virus", "SPECIES", 156, 173], ["molecular diagnostic assays", "TEST", 33, 60], ["PCR", "TEST", 70, 73], ["respiratory virus infections", "PROBLEM", 156, 184], ["respiratory virus", "OBSERVATION", 156, 173]]], ["Findings of previous studies, in which conventional virological diagnostic techniques were used, have most likely underestimated the role of viruses as pneumonia pathogens.", [["pneumonia", "DISEASE", 152, 161], ["previous studies", "TEST", 12, 28], ["pneumonia pathogens", "PROBLEM", 152, 171], ["most likely", "UNCERTAINTY", 102, 113], ["viruses", "OBSERVATION", 141, 148], ["pneumonia", "OBSERVATION", 152, 161]]], ["[1] [2] [3] [4] [5] In this Seminar, we review viral communityacquired pneumonia in immunocompetent children and adults, focusing on studies that have used modern molecular diagnostic techniques.Epidemiology of pneumoniaAccording to WHO estimates, 450 million cases of pneumonia are recorded every year; about 4 million people die from this illness, accounting for 7% of total mortality of 57 million people.", [["pneumonia", "DISEASE", 71, 80], ["pneumonia", "DISEASE", 269, 278], ["[1] [2] [3] [4] [5", "SIMPLE_CHEMICAL", 0, 18], ["children", "ORGANISM", 100, 108], ["people", "ORGANISM", 320, 326], ["people", "ORGANISM", 401, 407], ["children", "SPECIES", 100, 108], ["people", "SPECIES", 320, 326], ["people", "SPECIES", 401, 407], ["viral communityacquired pneumonia", "PROBLEM", 47, 80], ["studies", "TEST", 133, 140], ["pneumonia", "PROBLEM", 269, 278], ["pneumonia", "OBSERVATION", 71, 80], ["pneumonia", "OBSERVATION", 269, 278]]], ["6, 7 The highest incidences arise in children younger than 5 years and in adults older than 75 years (fi gure 1).", [["children", "ORGANISM", 37, 45], ["children", "SPECIES", 37, 45]]], ["In children, 156 million episodes of pneumonia are recorded annually, of which 151 million are present in developing countries.", [["pneumonia", "DISEASE", 37, 46], ["children", "ORGANISM", 3, 11], ["children", "SPECIES", 3, 11], ["pneumonia", "PROBLEM", 37, 46], ["pneumonia", "OBSERVATION", 37, 46]]], ["6, 7 In 2008, 1\u00b76 million children younger than 5 years died from pneumonia.", [["pneumonia", "DISEASE", 66, 75], ["children", "ORGANISM", 26, 34], ["children", "SPECIES", 26, 34], ["pneumonia", "PROBLEM", 66, 75], ["pneumonia", "OBSERVATION", 66, 75]]], ["9 5 million cases of childhood community-acquired pneumonia are reported yearly in developed countries, but mortality has declined strikingly and is now very rare.", [["pneumonia", "DISEASE", 50, 59], ["acquired pneumonia", "PROBLEM", 41, 59], ["pneumonia", "OBSERVATION", 50, 59]]], ["In a Canadian study, 25 319 admissions for childhood pneumonia took place during the 9-year study period; 11 deaths were recorded and only one death did not have a comorbid condition.", [["pneumonia", "DISEASE", 53, 62], ["deaths", "DISEASE", 109, 115], ["death", "DISEASE", 143, 148], ["childhood pneumonia", "PROBLEM", 43, 62], ["a comorbid condition", "PROBLEM", 162, 182], ["pneumonia", "OBSERVATION", 53, 62]]], ["10 Mortality of 1\u00b72 per million previously healthy young adults has been recorded in the UK.", [["adults", "ORGANISM", 57, 63]]], ["11 In the USA alone, the economic burden of community-acquired pneumonia has been estimated to be more than US$17 billion annually.", [["pneumonia", "DISEASE", 63, 72], ["community-acquired pneumonia", "PROBLEM", 44, 72], ["economic", "OBSERVATION_MODIFIER", 25, 33], ["burden", "OBSERVATION_MODIFIER", 34, 40], ["pneumonia", "OBSERVATION", 63, 72]]], ["12Diagnosis of viral pneumoniaLaboratory diagnosis of viral pneumonia has relied on detection of virus or viral antigen in upper-respiratory specimens (eg, nasopharyngeal aspirates) and lowerrespiratory samples (eg, induced sputum) by culture or immunofl uorescence microscopy, and on measurementSearch strategy and selection criteriaWe searched PubMed for original research, reviews, and commentaries, with the terms \"pneumonia and children/ adults\", \"pneumonia and aetiology\", \"viral pneumonia\", \"pneumonia and viruses\", and names of specifi c respiratory viruses and pneumonia.", [["upper-respiratory specimens", "ANATOMY", 123, 150], ["nasopharyngeal aspirates", "ANATOMY", 156, 180], ["lowerrespiratory samples", "ANATOMY", 186, 210], ["sputum", "ANATOMY", 224, 230], ["viral pneumonia", "DISEASE", 54, 69], ["pneumonia", "DISEASE", 419, 428], ["pneumonia", "DISEASE", 453, 462], ["viral pneumonia", "DISEASE", 480, 495], ["pneumonia", "DISEASE", 499, 508], ["respiratory viruses", "DISEASE", 546, 565], ["pneumonia", "DISEASE", 570, 579], ["upper-respiratory specimens", "CANCER", 123, 150], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 156, 180], ["children", "ORGANISM", 433, 441], ["specifi c respiratory viruses", "ORGANISM", 536, 565], ["viral antigen", "PROTEIN", 106, 119], ["children", "SPECIES", 433, 441], ["viral pneumonia", "PROBLEM", 54, 69], ["virus", "PROBLEM", 97, 102], ["viral antigen in upper-respiratory specimens", "PROBLEM", 106, 150], ["nasopharyngeal aspirates", "TEST", 156, 180], ["lowerrespiratory samples (eg, induced sputum", "PROBLEM", 186, 230], ["culture", "TEST", 235, 242], ["immunofl uorescence microscopy", "TEST", 246, 276], ["pneumonia", "PROBLEM", 419, 428], ["pneumonia", "PROBLEM", 453, 462], ["viral pneumonia\"", "PROBLEM", 480, 496], ["pneumonia", "PROBLEM", 499, 508], ["viruses", "PROBLEM", 513, 520], ["specifi c respiratory viruses", "PROBLEM", 536, 565], ["pneumonia", "PROBLEM", 570, 579], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["viral", "OBSERVATION_MODIFIER", 54, 59], ["pneumonia", "OBSERVATION", 60, 69], ["nasopharyngeal", "ANATOMY", 156, 170], ["pneumonia", "OBSERVATION", 419, 428], ["pneumonia", "OBSERVATION", 453, 462], ["viral", "OBSERVATION_MODIFIER", 480, 485], ["pneumonia", "OBSERVATION", 486, 495], ["pneumonia", "OBSERVATION", 499, 508], ["respiratory viruses", "OBSERVATION", 546, 565], ["pneumonia", "OBSERVATION", 570, 579]]], ["We also searched our personal database of references gathered over the past 15 years and manually scanned references from selected reports and from selected authors. of antibodies in paired serum samples.", [["serum samples", "ANATOMY", 190, 203], ["serum samples", "ORGANISM_SUBSTANCE", 190, 203], ["antibodies", "PROTEIN", 169, 179], ["antibodies in paired serum samples", "TEST", 169, 203]]], ["Introduction of PCR has increased the ability to detect respiratory viruses, including those that are diffi cult to culture.", [["respiratory viruses", "DISEASE", 56, 75], ["Introduction of PCR", "TREATMENT", 0, 19], ["respiratory viruses", "PROBLEM", 56, 75], ["culture", "TEST", 116, 123], ["respiratory", "ANATOMY", 56, 67], ["viruses", "OBSERVATION", 68, 75]]], ["At least 26 viruses have now been associated with communityacquired pneumonia (panel).Search strategy and selection criteriaDespite technological advances, establishing the cause of pneumonia remains challenging.", [["pneumonia", "DISEASE", 68, 77], ["pneumonia", "DISEASE", 182, 191], ["communityacquired pneumonia", "PROBLEM", 50, 77], ["pneumonia", "PROBLEM", 182, 191], ["viruses", "OBSERVATION", 12, 19], ["pneumonia", "OBSERVATION", 68, 77], ["pneumonia", "OBSERVATION", 182, 191]]], ["13 Specimens from the lower-respiratory tract can be hard to obtain, and distinguishing possible prolonged shedding or colonisation from infection can be diffi cult.", [["lower-respiratory tract", "ANATOMY", 22, 45], ["infection", "DISEASE", 137, 146], ["lower-", "ORGANISM_SUBDIVISION", 22, 28], ["respiratory tract", "ORGANISM_SUBDIVISION", 28, 45], ["Specimens", "TEST", 3, 12], ["prolonged shedding", "PROBLEM", 97, 115], ["colonisation from infection", "PROBLEM", 119, 146], ["cult", "TEST", 160, 164], ["lower", "ANATOMY_MODIFIER", 22, 27], ["respiratory tract", "ANATOMY", 28, 45], ["possible", "UNCERTAINTY", 88, 96], ["prolonged", "OBSERVATION_MODIFIER", 97, 106], ["shedding", "OBSERVATION", 107, 115], ["colonisation", "OBSERVATION", 119, 131], ["infection", "OBSERVATION", 137, 146]]], ["For diagnosis of viral pneumonia, reliance on testing of nasopharyngeal specimens presents its own challenges; detection of a virus in the nasopharynx could represent coincidental upper-respiratory infection or a pneumonia pathogen.", [["nasopharyngeal specimens", "ANATOMY", 57, 81], ["nasopharynx", "ANATOMY", 139, 150], ["upper-respiratory", "ANATOMY", 180, 197], ["viral pneumonia", "DISEASE", 17, 32], ["infection", "DISEASE", 198, 207], ["pneumonia", "DISEASE", 213, 222], ["nasopharyngeal specimens", "CANCER", 57, 81], ["nasopharynx", "ORGAN", 139, 150], ["viral pneumonia", "PROBLEM", 17, 32], ["testing of nasopharyngeal specimens", "TEST", 46, 81], ["a virus in the nasopharynx", "PROBLEM", 124, 150], ["coincidental upper-respiratory infection", "PROBLEM", 167, 207], ["a pneumonia pathogen", "PROBLEM", 211, 231], ["viral", "OBSERVATION_MODIFIER", 17, 22], ["pneumonia", "OBSERVATION", 23, 32], ["nasopharyngeal", "ANATOMY", 57, 71], ["virus", "OBSERVATION", 126, 131], ["nasopharynx", "ANATOMY", 139, 150], ["could represent", "UNCERTAINTY", 151, 166], ["upper-respiratory", "OBSERVATION_MODIFIER", 180, 197], ["infection", "OBSERVATION", 198, 207], ["pneumonia", "OBSERVATION", 213, 222]]], ["Measurement of background prevalence of asymptomatic nasopharyngeal viral infection in a control group might help to clarify the size of this diagnostic issue at a population level, but this approach has been used only rarely in aetiological studies.", [["nasopharyngeal", "ANATOMY", 53, 67], ["nasopharyngeal viral infection", "DISEASE", 53, 83], ["nasopharyngeal viral", "ORGANISM", 53, 73], ["asymptomatic nasopharyngeal viral infection", "PROBLEM", 40, 83], ["aetiological studies", "TEST", 229, 249], ["asymptomatic", "OBSERVATION_MODIFIER", 40, 52], ["nasopharyngeal", "ANATOMY", 53, 67], ["viral infection", "OBSERVATION", 68, 83], ["size", "OBSERVATION_MODIFIER", 129, 133]]], ["Furthermore, most research has focused on patients admitted to hospital and, therefore, fi ndings might not be representative of mildto-moderate disease.Search strategy and selection criteriaSeveral diff erent types of specimen from the upper and lower airway have been used in aetiological studies of community-acquired pneumonia, including: nasopharyngeal aspirates or washes; swabs from the nasopharynx, nose, or throat; combined nasopharygeal and throat swabs; expectorated and induced sputum; tracheal aspirates; bronchoalveolar lavage; and lung puncture.", [["specimen", "ANATOMY", 219, 227], ["lower airway", "ANATOMY", 247, 259], ["nasopharyngeal aspirates", "ANATOMY", 343, 367], ["swabs", "ANATOMY", 379, 384], ["nasopharynx", "ANATOMY", 394, 405], ["nose", "ANATOMY", 407, 411], ["throat", "ANATOMY", 416, 422], ["nasopharygeal", "ANATOMY", 433, 446], ["throat swabs", "ANATOMY", 451, 463], ["sputum", "ANATOMY", 490, 496], ["tracheal aspirates", "ANATOMY", 498, 516], ["bronchoalveolar lavage", "ANATOMY", 518, 540], ["lung", "ANATOMY", 546, 550], ["pneumonia", "DISEASE", 321, 330], ["patients", "ORGANISM", 42, 50], ["upper", "ORGANISM_SUBDIVISION", 237, 242], ["airway", "MULTI-TISSUE_STRUCTURE", 253, 259], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 343, 367], ["nasopharynx", "ORGAN", 394, 405], ["nose", "ORGAN", 407, 411], ["throat", "ORGANISM_SUBDIVISION", 416, 422], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 498, 516], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 518, 540], ["lung", "ORGAN", 546, 550], ["patients", "SPECIES", 42, 50], ["mildto-moderate disease", "PROBLEM", 129, 152], ["Search strategy", "TEST", 153, 168], ["selection criteriaSeveral diff", "TEST", 173, 203], ["specimen from the upper and lower airway", "PROBLEM", 219, 259], ["aetiological studies", "TEST", 278, 298], ["community-acquired pneumonia", "PROBLEM", 302, 330], ["nasopharyngeal aspirates", "PROBLEM", 343, 367], ["washes", "TREATMENT", 371, 377], ["swabs from the nasopharynx, nose", "TEST", 379, 411], ["throat", "PROBLEM", 416, 422], ["combined nasopharygeal and throat swabs", "PROBLEM", 424, 463], ["expectorated and induced sputum", "PROBLEM", 465, 496], ["tracheal aspirates", "TEST", 498, 516], ["bronchoalveolar lavage", "TEST", 518, 540], ["lung puncture", "TEST", 546, 559], ["moderate", "OBSERVATION_MODIFIER", 136, 144], ["disease", "OBSERVATION", 145, 152], ["upper", "ANATOMY_MODIFIER", 237, 242], ["lower", "ANATOMY_MODIFIER", 247, 252], ["airway", "ANATOMY", 253, 259], ["pneumonia", "OBSERVATION", 321, 330], ["nasopharyngeal", "ANATOMY", 343, 357], ["aspirates", "OBSERVATION", 358, 367], ["nasopharynx", "ANATOMY", 394, 405], ["nose", "ANATOMY", 407, 411], ["throat", "ANATOMY", 416, 422], ["throat", "ANATOMY", 451, 457], ["tracheal", "ANATOMY", 498, 506], ["aspirates", "OBSERVATION", 507, 516], ["bronchoalveolar lavage", "OBSERVATION", 518, 540], ["lung", "ANATOMY", 546, 550], ["puncture", "OBSERVATION", 551, 559]]], ["14, 15 Recovery of virus fl uctuates according to specimen type, which probably accounts for some of the variability of fi ndings between studies.Search strategy and selection criteriaMost studies of the cause of viral pneumonia have used upper-respiratory specimens to test for viruses.", [["upper-respiratory specimens", "ANATOMY", 239, 266], ["pneumonia", "DISEASE", 219, 228], ["virus fl uctuates", "TEST", 19, 36], ["studies", "TEST", 138, 145], ["selection criteria", "TEST", 166, 184], ["viral pneumonia", "PROBLEM", 213, 228], ["upper-respiratory specimens", "TEST", 239, 266], ["viruses", "PROBLEM", 279, 286], ["virus fl", "OBSERVATION", 19, 27], ["specimen type", "OBSERVATION_MODIFIER", 50, 63], ["probably accounts for", "UNCERTAINTY", 71, 92], ["viral", "OBSERVATION_MODIFIER", 213, 218], ["pneumonia", "OBSERVATION", 219, 228]]], ["In children, nasopharyngeal aspirates are generally deemed the specimen of choice because both nasal and nasopharyngeal mucus samples are gathered.", [["nasopharyngeal aspirates", "ANATOMY", 13, 37], ["nasal", "ANATOMY", 95, 100], ["nasopharyngeal mucus samples", "ANATOMY", 105, 133], ["children", "ORGANISM", 3, 11], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 13, 37], ["nasal", "ORGANISM_SUBDIVISION", 95, 100], ["nasopharyngeal mucus samples", "CANCER", 105, 133], ["children", "SPECIES", 3, 11], ["nasopharyngeal aspirates", "TEST", 13, 37], ["both nasal and nasopharyngeal mucus samples", "PROBLEM", 90, 133], ["nasopharyngeal", "ANATOMY", 13, 27], ["aspirates", "OBSERVATION", 28, 37], ["nasal", "ANATOMY", 95, 100], ["nasopharyngeal mucus", "ANATOMY", 105, 125]]], ["Respiratory viruses have been noted in 95% of mucus samples obtained by nasopharyngeal aspiration from children with respiratory infection.", [["mucus samples", "ANATOMY", 46, 59], ["nasopharyngeal", "ANATOMY", 72, 86], ["respiratory", "ANATOMY", 117, 128], ["Respiratory viruses", "DISEASE", 0, 19], ["respiratory infection", "DISEASE", 117, 138], ["mucus samples", "TISSUE", 46, 59], ["nasopharyngeal aspiration", "MULTI-TISSUE_STRUCTURE", 72, 97], ["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["Respiratory viruses", "PROBLEM", 0, 19], ["mucus samples", "TEST", 46, 59], ["nasopharyngeal aspiration", "PROBLEM", 72, 97], ["respiratory infection", "PROBLEM", 117, 138], ["viruses", "OBSERVATION", 12, 19], ["nasopharyngeal", "ANATOMY", 72, 86], ["aspiration", "OBSERVATION", 87, 97], ["respiratory", "ANATOMY", 117, 128], ["infection", "OBSERVATION", 129, 138]]], ["16 Obtaining an aspirate is, however, unpleasant and requires a suction device.", [["an aspirate", "TEST", 13, 24], ["a suction device", "TREATMENT", 62, 78], ["aspirate", "OBSERVATION", 16, 24]]], ["Nasal swabs taken with a sterile cotton swab from a depth of 2-3 cm have comparable sensitivity to nasopharyngeal aspirates for culture of all major respiratory viruses, except respiratory syncytial virus.", [["Nasal swabs", "ANATOMY", 0, 11], ["nasopharyngeal aspirates", "ANATOMY", 99, 123], ["respiratory viruses", "DISEASE", 149, 168], ["respiratory syncytial virus", "DISEASE", 177, 204], ["Nasal swabs", "ORGANISM_SUBSTANCE", 0, 11], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 99, 123], ["respiratory syncytial virus", "ORGANISM", 177, 204], ["respiratory syncytial virus", "SPECIES", 177, 204], ["cotton", "SPECIES", 33, 39], ["respiratory syncytial virus", "SPECIES", 177, 204], ["Nasal swabs", "TEST", 0, 11], ["a sterile cotton swab", "TREATMENT", 23, 44], ["nasopharyngeal aspirates", "TEST", 99, 123], ["culture", "TEST", 128, 135], ["all major respiratory viruses", "PROBLEM", 139, 168], ["respiratory syncytial virus", "PROBLEM", 177, 204], ["nasopharyngeal", "ANATOMY", 99, 113], ["aspirates", "OBSERVATION", 114, 123], ["respiratory viruses", "OBSERVATION", 149, 168], ["respiratory syncytial virus", "OBSERVATION", 177, 204]]], ["17 Flocked swabs with nylon fi bres in a perpendicular fashion are now preferred by many clinicians because they are convenient to use and have a similar sensitivity to nasopharyngeal aspirates for detection by PCR of respiratory viruses.", [["swabs", "ANATOMY", 11, 16], ["nasopharyngeal aspirates", "ANATOMY", 169, 193], ["respiratory viruses", "DISEASE", 218, 237], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 169, 193], ["nylon fi bres", "TREATMENT", 22, 35], ["nasopharyngeal aspirates", "TEST", 169, 193], ["respiratory viruses", "PROBLEM", 218, 237], ["nasopharyngeal", "ANATOMY", 169, 183], ["aspirates", "OBSERVATION", 184, 193], ["respiratory viruses", "OBSERVATION", 218, 237]]], ["15, 17, 18 In adults, nasopharyngeal swabs have a higher sensitivity than throat swabs, but they can be less sensitive than nasopharyngeal washes.", [["nasopharyngeal swabs", "ANATOMY", 22, 42], ["throat swabs", "ANATOMY", 74, 86], ["nasopharyngeal", "ANATOMY", 124, 138], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 22, 42], ["nasopharyngeal", "ORGANISM_SUBDIVISION", 124, 138], ["nasopharyngeal swabs", "TEST", 22, 42], ["throat swabs", "TEST", 74, 86], ["nasopharyngeal washes", "TREATMENT", 124, 145], ["nasopharyngeal", "ANATOMY", 22, 36]]], ["14 Transnasal nasopharyngeal fl ocked swabs also have high virus detection rates in adults.", [["swabs", "ANATOMY", 38, 43], ["Transnasal nasopharyngeal fl ocked swabs", "TEST", 3, 43], ["high virus detection rates", "PROBLEM", 54, 80], ["nasopharyngeal", "ANATOMY", 14, 28]]], ["19, 20 Lower-respiratory specimens have obvious advantages for establishing the cause of pneumonia because they come from the site of infection.", [["specimens", "ANATOMY", 25, 34], ["pneumonia", "DISEASE", 89, 98], ["infection", "DISEASE", 134, 143], ["pneumonia", "PROBLEM", 89, 98], ["infection", "PROBLEM", 134, 143], ["pneumonia", "OBSERVATION", 89, 98], ["infection", "OBSERVATION", 134, 143]]], ["However, obtaining reliable specimens that are not contaminated by fl ora from the upper airway is diffi cult.", [["specimens", "ANATOMY", 28, 37], ["upper airway", "ANATOMY", 83, 95], ["specimens", "CANCER", 28, 37], ["fl ora", "GENE_OR_GENE_PRODUCT", 67, 73], ["upper airway", "MULTI-TISSUE_STRUCTURE", 83, 95], ["reliable specimens", "TEST", 19, 37], ["upper", "ANATOMY_MODIFIER", 83, 88], ["airway", "ANATOMY", 89, 95]]], ["Induced sputum specimens have been used in paediatric pneumonia studies, although assuring that the specimens are representative of the lower-respiratory tract can be challenging.", [["sputum specimens", "ANATOMY", 8, 24], ["specimens", "ANATOMY", 100, 109], ["lower-respiratory tract", "ANATOMY", 136, 159], ["pneumonia", "DISEASE", 54, 63], ["sputum specimens", "CANCER", 8, 24], ["specimens", "CANCER", 100, 109], ["lower-", "ORGANISM_SUBDIVISION", 136, 142], ["respiratory tract", "ORGANISM_SUBDIVISION", 142, 159], ["Induced sputum specimens", "TEST", 0, 24], ["paediatric pneumonia studies", "TEST", 43, 71], ["the specimens", "TEST", 96, 109], ["the lower-respiratory tract", "PROBLEM", 132, 159], ["pneumonia", "OBSERVATION", 54, 63], ["lower", "ANATOMY_MODIFIER", 136, 141], ["respiratory tract", "ANATOMY", 142, 159]]], ["21 High-quality specimens can be obtained by thoracic needle aspiration, but this technique has not been adopted widely because of safety concerns, despite a low complication rate.", [["specimens", "ANATOMY", 16, 25], ["thoracic", "ANATOMY", 45, 53], ["thoracic needle", "MULTI-TISSUE_STRUCTURE", 45, 60], ["thoracic needle aspiration", "TEST", 45, 71], ["a low complication rate", "PROBLEM", 156, 179], ["thoracic", "ANATOMY", 45, 53], ["aspiration", "OBSERVATION", 61, 71]]], ["22, 23 In general, PCR-based methods are between two and fi ve times more sensitive than conventional virus diagnostic methods (culture, antigen detection, and serological assays) for detection of respiratory viruses.", [["respiratory viruses", "DISEASE", 197, 216], ["PCR", "TEST", 19, 22], ["conventional virus diagnostic methods", "TEST", 89, 126], ["culture", "TEST", 128, 135], ["antigen detection", "TEST", 137, 154], ["serological assays", "TEST", 160, 178], ["respiratory viruses", "PROBLEM", 197, 216], ["respiratory viruses", "OBSERVATION", 197, 216]]], ["This benefi t applies particularly to adults and elderly people, who might have a smaller nasopharyngeal viral load than children.", [["nasopharyngeal", "ANATOMY", 90, 104], ["people", "ORGANISM", 57, 63], ["nasopharyngeal", "CANCER", 90, 104], ["children", "ORGANISM", 121, 129], ["people", "SPECIES", 57, 63], ["children", "SPECIES", 121, 129], ["a smaller nasopharyngeal viral load", "PROBLEM", 80, 115], ["smaller", "OBSERVATION_MODIFIER", 82, 89], ["nasopharyngeal", "ANATOMY", 90, 104], ["viral load", "OBSERVATION", 105, 115]]], ["24, 25 Moreover, some respiratory viruses can only be detected readily by PCR.", [["respiratory viruses", "DISEASE", 22, 41], ["some respiratory viruses", "PROBLEM", 17, 41], ["PCR", "TEST", 74, 77], ["respiratory viruses", "OBSERVATION", 22, 41]]], ["Development of several multiplex assays has enabled simultaneous detection of up to 15 diff erent viruses, and use of these tests is becoming standard for identifi cation of respiratory viruses.", [["respiratory viruses", "DISEASE", 174, 193], ["cation", "SIMPLE_CHEMICAL", 164, 170], ["several multiplex assays", "TEST", 15, 39], ["simultaneous detection", "TEST", 52, 74], ["15 diff erent viruses", "PROBLEM", 84, 105], ["these tests", "TEST", 118, 129], ["respiratory viruses", "PROBLEM", 174, 193], ["several", "OBSERVATION_MODIFIER", 15, 22], ["viruses", "OBSERVATION", 98, 105], ["respiratory viruses", "OBSERVATION", 174, 193]]], ["26, 27 The ability to diff erentiate viral from bacterial pneumonia could have important management implications.", [["pneumonia", "DISEASE", 58, 67], ["viral from bacterial pneumonia", "PROBLEM", 37, 67], ["bacterial", "OBSERVATION_MODIFIER", 48, 57], ["pneumonia", "OBSERVATION", 58, 67]]], ["Despite advances, diagnostic tests still fail to identify causative agents in many aff ected individuals.", [["diagnostic tests", "TEST", 18, 34], ["causative agents", "TREATMENT", 58, 74]]], ["28 As a result, other variables have been used to distinguish viral from bacterial pneumonia (table 1) .", [["pneumonia", "DISEASE", 83, 92], ["viral from bacterial pneumonia", "PROBLEM", 62, 92], ["bacterial", "OBSERVATION_MODIFIER", 73, 82], ["pneumonia", "OBSERVATION", 83, 92]]], ["However, no clinical algorithm exists to discern clearly the cause of pneumonia.", [["pneumonia", "DISEASE", 70, 79], ["clinical algorithm", "TEST", 12, 30], ["pneumonia", "PROBLEM", 70, 79], ["pneumonia", "OBSERVATION", 70, 79]]], ["This absence is perhaps not surprising in view of the probable important interaction between viruses and bacteria in pathogenesis of pneumonia.Search strategy and selection criteriaRespiratory viruses usually follow seasonal patterns of activity and are most likely to cause pneumonia during those times.", [["pneumonia", "DISEASE", 133, 142], ["pneumonia", "DISEASE", 275, 284], ["viruses", "PROBLEM", 93, 100], ["bacteria", "PROBLEM", 105, 113], ["pneumonia", "PROBLEM", 133, 142], ["Search strategy", "TREATMENT", 143, 158], ["selection criteriaRespiratory viruses", "PROBLEM", 163, 200], ["pneumonia", "PROBLEM", 275, 284], ["perhaps not", "UNCERTAINTY", 16, 27], ["probable", "UNCERTAINTY", 54, 62], ["viruses", "OBSERVATION", 93, 100], ["pneumonia", "OBSERVATION", 133, 142], ["most likely", "UNCERTAINTY", 254, 265], ["pneumonia", "OBSERVATION", 275, 284]]], ["Epidemics of respiratory syncytial virus typically happen every or every other year in late autumn, rhinovirus epidemics arise in autumn and spring, whereas infl uenza peaks are seen during late autumn and early winter.", [["respiratory syncytial virus", "DISEASE", 13, 40], ["rhinovirus epidemics", "DISEASE", 100, 120], ["respiratory syncytial virus", "ORGANISM", 13, 40], ["rhinovirus", "ORGANISM", 100, 110], ["respiratory syncytial virus", "SPECIES", 13, 40], ["respiratory syncytial virus", "SPECIES", 13, 40], ["respiratory syncytial virus", "PROBLEM", 13, 40], ["rhinovirus epidemics", "PROBLEM", 100, 120], ["respiratory", "OBSERVATION", 13, 24], ["syncytial virus", "OBSERVATION", 25, 40], ["rhinovirus", "OBSERVATION", 100, 110]]], ["Several viruses can be co-circulating at specifi c times of the year, even during the highest epidemic peaks of one virus.", [["Several viruses", "PROBLEM", 0, 15], ["one virus", "PROBLEM", 112, 121], ["viruses", "OBSERVATION", 8, 15]]], ["29 Although viral pneumonia is being recognised increasingly in adults, it still seems to be most typical in children, especially in infants younger than 2 years.", [["viral pneumonia", "DISEASE", 12, 27], ["children", "ORGANISM", 109, 117], ["infants", "ORGANISM", 133, 140], ["children", "SPECIES", 109, 117], ["infants", "SPECIES", 133, 140], ["viral pneumonia", "PROBLEM", 12, 27], ["viral", "OBSERVATION_MODIFIER", 12, 17], ["pneumonia", "OBSERVATION", 18, 27]]], ["30 According to the British Thoracic Society, fever higher than 38\u00b75\u00b0C, a respiratory rate greater than 50 breaths per min, and chest recession are suggestive of bacterial rather than viral pneumonia; by comparison, young age, wheezing, fever less than 38\u00b75\u00b0C, and striking chest recession are suggestive of a viral cause.", [["respiratory", "ANATOMY", 74, 85], ["chest", "ANATOMY", 128, 133], ["chest", "ANATOMY", 274, 279], ["fever", "DISEASE", 46, 51], ["pneumonia", "DISEASE", 190, 199], ["wheezing", "DISEASE", 227, 235], ["fever", "DISEASE", 237, 242], ["chest recession", "DISEASE", 274, 289], ["chest", "ORGANISM_SUBDIVISION", 128, 133], ["chest", "ORGAN", 274, 279], ["fever", "PROBLEM", 46, 51], ["a respiratory rate", "TEST", 72, 90], ["chest recession", "PROBLEM", 128, 143], ["bacterial", "PROBLEM", 162, 171], ["viral pneumonia", "PROBLEM", 184, 199], ["wheezing", "PROBLEM", 227, 235], ["fever", "PROBLEM", 237, 242], ["striking chest recession", "PROBLEM", 265, 289], ["a viral cause", "PROBLEM", 308, 321], ["Thoracic", "ANATOMY", 28, 36], ["Society", "OBSERVATION", 37, 44], ["chest", "ANATOMY", 128, 133], ["suggestive of", "UNCERTAINTY", 148, 161], ["bacterial", "OBSERVATION_MODIFIER", 162, 171], ["viral", "OBSERVATION_MODIFIER", 184, 189], ["pneumonia", "OBSERVATION", 190, 199], ["chest", "ANATOMY", 274, 279], ["suggestive of", "UNCERTAINTY", 294, 307], ["viral", "OBSERVATION", 310, 315]]], ["1 However, clinical signs and symptoms of viral and bacterial pneumonia are highly variable and overlap; there fore, they cannot be relied on.", [["pneumonia", "DISEASE", 62, 71], ["clinical signs", "TEST", 11, 25], ["symptoms", "PROBLEM", 30, 38], ["viral and bacterial pneumonia", "PROBLEM", 42, 71], ["viral", "OBSERVATION_MODIFIER", 42, 47], ["bacterial", "OBSERVATION_MODIFIER", 52, 61], ["pneumonia", "OBSERVATION", 62, 71]]], ["Importantly, typical pneumococcal pneumonia (sudden onset, high fever, chills, pleuritic chest pain, lobar infi ltrates, leucocytosis) is only one part of the range of bacterial pneumonia.", [["chest", "ANATOMY", 89, 94], ["pneumonia", "DISEASE", 34, 43], ["fever", "DISEASE", 64, 69], ["chills", "DISEASE", 71, 77], ["chest pain", "DISEASE", 89, 99], ["leucocytosis", "DISEASE", 121, 133], ["pneumonia", "DISEASE", 178, 187], ["pneumococcal", "SPECIES", 21, 33], ["typical pneumococcal pneumonia", "PROBLEM", 13, 43], ["high fever", "PROBLEM", 59, 69], ["chills", "PROBLEM", 71, 77], ["pleuritic chest pain", "PROBLEM", 79, 99], ["lobar infi ltrates", "PROBLEM", 101, 119], ["leucocytosis", "PROBLEM", 121, 133], ["bacterial pneumonia", "PROBLEM", 168, 187], ["typical", "OBSERVATION_MODIFIER", 13, 20], ["pneumococcal", "OBSERVATION_MODIFIER", 21, 33], ["pneumonia", "OBSERVATION", 34, 43], ["high", "OBSERVATION_MODIFIER", 59, 63], ["fever", "OBSERVATION_MODIFIER", 64, 69], ["pleuritic", "OBSERVATION_MODIFIER", 79, 88], ["chest", "ANATOMY", 89, 94], ["lobar", "ANATOMY_MODIFIER", 101, 106], ["leucocytosis", "OBSERVATION", 121, 133], ["only one part", "OBSERVATION_MODIFIER", 138, 151], ["bacterial", "OBSERVATION_MODIFIER", 168, 177], ["pneumonia", "OBSERVATION", 178, 187]]], ["31 White-blood-cell count and concentrations in serum of C-reactive protein and procalcitonin are variables studied widely in children and adults with community-acquired pneumonia.", [["blood-cell", "ANATOMY", 9, 19], ["serum", "ANATOMY", 48, 53], ["pneumonia", "DISEASE", 170, 179], ["White-blood-cell", "CELL", 3, 19], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 57, 75], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 80, 93], ["children", "ORGANISM", 126, 134], ["C-reactive protein", "PROTEIN", 57, 75], ["procalcitonin", "PROTEIN", 80, 93], ["children", "SPECIES", 126, 134], ["White-blood-cell count", "TEST", 3, 25], ["concentrations", "TEST", 30, 44], ["serum", "TEST", 48, 53], ["C", "TEST", 57, 58], ["procalcitonin", "TEST", 80, 93], ["community-acquired pneumonia", "PROBLEM", 151, 179], ["cell count", "OBSERVATION", 15, 25], ["reactive protein", "OBSERVATION", 59, 75], ["pneumonia", "OBSERVATION", 170, 179]]], ["In general, these biomarkers are raised signifi cantly in individuals with bacterial pneumonia compared with patients with viral pneumonia (table 1), 19,32-35 although none has suffi cient sensitivity or specifi city to be used in isolation.", [["bacterial pneumonia", "DISEASE", 75, 94], ["viral pneumonia", "DISEASE", 123, 138], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["these biomarkers", "TEST", 12, 28], ["bacterial pneumonia", "PROBLEM", 75, 94], ["viral pneumonia", "PROBLEM", 123, 138], ["bacterial", "OBSERVATION_MODIFIER", 75, 84], ["pneumonia", "OBSERVATION", 85, 94], ["viral", "OBSERVATION_MODIFIER", 123, 128], ["pneumonia", "OBSERVATION", 129, 138]]], ["Use of procalcitonin in clinical practice to identify bacterial infection and help guide antimicrobial treatment has been the focus of many studies.", [["bacterial infection", "DISEASE", 54, 73], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 7, 20], ["procalcitonin", "TREATMENT", 7, 20], ["bacterial infection", "PROBLEM", 54, 73], ["antimicrobial treatment", "TREATMENT", 89, 112], ["many studies", "TEST", 135, 147], ["bacterial", "OBSERVATION_MODIFIER", 54, 63], ["infection", "OBSERVATION", 64, 73]]], ["This substance increases within 6-12 h after onset of bacterial infection and halves daily when infection is controlled.", [["bacterial infection", "DISEASE", 54, 73], ["infection", "DISEASE", 96, 105], ["bacterial infection", "PROBLEM", 54, 73], ["infection", "PROBLEM", 96, 105], ["bacterial", "OBSERVATION_MODIFIER", 54, 63], ["infection", "OBSERVATION", 64, 73], ["infection", "OBSERVATION", 96, 105]]], ["34 In the context of pneumonia, concentrations of procalcitonin greater than 0\u00b75 \u03bcg/L support bacterial infection, whereas repeatedly low amounts suggest that bacterial infection is unlikely.", [["pneumonia", "DISEASE", 21, 30], ["bacterial infection", "DISEASE", 94, 113], ["bacterial infection", "DISEASE", 159, 178], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 50, 63], ["procalcitonin", "PROTEIN", 50, 63], ["pneumonia", "PROBLEM", 21, 30], ["procalcitonin", "TEST", 50, 63], ["bacterial infection", "PROBLEM", 94, 113], ["bacterial infection", "PROBLEM", 159, 178], ["pneumonia", "OBSERVATION", 21, 30], ["bacterial", "OBSERVATION_MODIFIER", 94, 103], ["infection", "OBSERVATION", 104, 113], ["bacterial", "OBSERVATION_MODIFIER", 159, 168], ["infection", "OBSERVATION", 169, 178]]], ["However, the exact role of procalcitonin in management of pneumonia is still the subject of ongoing discussion and debate.", [["pneumonia", "DISEASE", 58, 67], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 27, 40], ["procalcitonin in management", "TREATMENT", 27, 54], ["pneumonia", "PROBLEM", 58, 67], ["pneumonia", "OBSERVATION", 58, 67]]], ["35 Recommendations from the American Thoracic Society are that diagnosis of pneumonia should be made on the basis of chest radiography.", [["chest", "ANATOMY", 117, 122], ["pneumonia", "DISEASE", 76, 85], ["chest", "ORGANISM_SUBDIVISION", 117, 122], ["pneumonia", "PROBLEM", 76, 85], ["chest radiography", "TEST", 117, 134], ["Thoracic", "ANATOMY", 37, 45], ["pneumonia", "OBSERVATION", 76, 85], ["chest", "ANATOMY", 117, 122]]], ["36 Interstitial infi ltrates on chest radiographs are generally believed to suggest a viral cause of pneumonia and alveolar infi ltrates to indicate a bacterial cause (fi gure 2).", [["chest", "ANATOMY", 32, 37], ["alveolar", "ANATOMY", 115, 123], ["pneumonia", "DISEASE", 101, 110], ["Interstitial infi ltrates", "PROBLEM", 3, 28], ["chest radiographs", "TEST", 32, 49], ["pneumonia", "PROBLEM", 101, 110], ["alveolar infi ltrates", "PROBLEM", 115, 136], ["a bacterial cause", "PROBLEM", 149, 166], ["Interstitial", "ANATOMY_MODIFIER", 3, 15], ["chest", "ANATOMY", 32, 37], ["viral", "OBSERVATION", 86, 91], ["pneumonia", "OBSERVATION", 101, 110], ["alveolar", "ANATOMY_MODIFIER", 115, 123], ["bacterial", "OBSERVATION_MODIFIER", 151, 160]]], ["However, bacteria and viruses alone or together can induce a broad range of chest radiographic changes, and alterations are only helpful in specifi c cases to confi rm a microbial cause of pneumonia.", [["chest", "ANATOMY", 76, 81], ["pneumonia", "DISEASE", 189, 198], ["chest", "ORGAN", 76, 81], ["bacteria", "PROBLEM", 9, 17], ["viruses", "PROBLEM", 22, 29], ["chest radiographic changes", "PROBLEM", 76, 102], ["pneumonia", "PROBLEM", 189, 198], ["bacteria", "OBSERVATION", 9, 17], ["chest", "ANATOMY", 76, 81], ["pneumonia", "OBSERVATION", 189, 198]]], ["In one study, bacterial infection was noted in 97 (71%) of 137 children with alveolar infi ltrates, whereas 97 (72%) of 134 with bacterial pneumonia had alveolar infi ltrates.", [["alveolar", "ANATOMY", 77, 85], ["alveolar", "ANATOMY", 153, 161], ["bacterial infection", "DISEASE", 14, 33], ["alveolar infi ltrates", "DISEASE", 77, 98], ["pneumonia", "DISEASE", 139, 148], ["children", "ORGANISM", 63, 71], ["children", "SPECIES", 63, 71], ["one study", "TEST", 3, 12], ["bacterial infection", "PROBLEM", 14, 33], ["alveolar infi ltrates", "TEST", 77, 98], ["bacterial pneumonia", "PROBLEM", 129, 148], ["alveolar infi ltrates", "PROBLEM", 153, 174], ["bacterial", "OBSERVATION_MODIFIER", 14, 23], ["infection", "OBSERVATION", 24, 33], ["alveolar", "ANATOMY_MODIFIER", 77, 85], ["bacterial", "OBSERVATION_MODIFIER", 129, 138], ["pneumonia", "OBSERVATION", 139, 148], ["alveolar", "ANATOMY_MODIFIER", 153, 161], ["infi ltrates", "OBSERVATION", 162, 174]]], ["33 In children with viral pneumonia, 40 (49%) had alveolar changes.", [["alveolar", "ANATOMY", 50, 58], ["viral pneumonia", "DISEASE", 20, 35], ["children", "ORGANISM", 6, 14], ["alveolar", "MULTI-TISSUE_STRUCTURE", 50, 58], ["children", "SPECIES", 6, 14], ["viral pneumonia", "PROBLEM", 20, 35], ["alveolar changes", "PROBLEM", 50, 66], ["viral", "OBSERVATION_MODIFIER", 20, 25], ["pneumonia", "OBSERVATION", 26, 35], ["alveolar", "ANATOMY_MODIFIER", 50, 58]]], ["Of 85 children with bacteraemic pneumococcal pneumonia, alveolar infi ltrates were recorded in 77 (91%) and interstitial infi ltrates alone in eight (9%).", [["alveolar", "ANATOMY", 56, 64], ["pneumococcal pneumonia", "DISEASE", 32, 54], ["children", "ORGANISM", 6, 14], ["children", "SPECIES", 6, 14], ["pneumococcal", "SPECIES", 32, 44], ["bacteraemic pneumococcal pneumonia", "PROBLEM", 20, 54], ["alveolar infi ltrates", "PROBLEM", 56, 77], ["interstitial infi ltrates", "PROBLEM", 108, 133], ["bacteraemic", "OBSERVATION_MODIFIER", 20, 31], ["pneumococcal", "OBSERVATION_MODIFIER", 32, 44], ["pneumonia", "OBSERVATION", 45, 54], ["alveolar", "ANATOMY_MODIFIER", 56, 64], ["interstitial", "ANATOMY_MODIFIER", 108, 120]]], ["37 Multilobe disease in various cases of viral pneumonia was reported in half of 88 adults with community-acquired pneumonia.", [["Multilobe disease", "DISEASE", 3, 20], ["viral pneumonia", "DISEASE", 41, 56], ["pneumonia", "DISEASE", 115, 124], ["Multilobe disease", "PROBLEM", 3, 20], ["viral pneumonia", "PROBLEM", 41, 56], ["community-acquired pneumonia", "PROBLEM", 96, 124], ["disease", "OBSERVATION", 13, 20], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["pneumonia", "OBSERVATION", 47, 56], ["pneumonia", "OBSERVATION", 115, 124]]], ["19 Thoracic CT indicated tree-bud opacities, multifocal consolidations, and ground-glass opacities in adults with viral pneumonia without any evidence of possible concomitant bacterial infection; however, a viral cause was never suggested by the radiologists.", [["bud", "ANATOMY", 30, 33], ["consolidations", "DISEASE", 56, 70], ["viral pneumonia", "DISEASE", 114, 129], ["bacterial infection", "DISEASE", 175, 194], ["Thoracic CT", "TEST", 3, 14], ["tree-bud opacities", "PROBLEM", 25, 43], ["multifocal consolidations", "PROBLEM", 45, 70], ["ground-glass opacities", "PROBLEM", 76, 98], ["viral pneumonia", "PROBLEM", 114, 129], ["concomitant bacterial infection", "PROBLEM", 163, 194], ["a viral cause", "PROBLEM", 205, 218], ["Thoracic", "ANATOMY", 3, 11], ["tree", "OBSERVATION_MODIFIER", 25, 29], ["bud", "ANATOMY_MODIFIER", 30, 33], ["opacities", "OBSERVATION", 34, 43], ["multifocal", "OBSERVATION_MODIFIER", 45, 55], ["consolidations", "OBSERVATION", 56, 70], ["ground", "OBSERVATION_MODIFIER", 76, 82], ["glass opacities", "OBSERVATION", 83, 98], ["viral", "OBSERVATION_MODIFIER", 114, 119], ["pneumonia", "OBSERVATION", 120, 129], ["without any evidence of", "UNCERTAINTY", 130, 153], ["possible", "UNCERTAINTY", 154, 162], ["concomitant", "OBSERVATION_MODIFIER", 163, 174], ["bacterial", "OBSERVATION_MODIFIER", 175, 184], ["infection", "OBSERVATION", 185, 194]]], ["38 Intuitively, bacterial pneumonia should respond to appropriate antibacterial treatment but viral pneumonia should not.", [["pneumonia", "DISEASE", 26, 35], ["pneumonia", "DISEASE", 100, 109], ["bacterial pneumonia", "PROBLEM", 16, 35], ["appropriate antibacterial treatment", "TREATMENT", 54, 89], ["viral pneumonia", "PROBLEM", 94, 109], ["bacterial", "OBSERVATION_MODIFIER", 16, 25], ["pneumonia", "OBSERVATION", 26, 35], ["pneumonia", "OBSERVATION", 100, 109]]], ["In a study of 153 children admitted with community-acquired pneumonia, median duration of fever was 14 h after onset of antibiotic treatment.", [["pneumonia", "DISEASE", 60, 69], ["fever", "DISEASE", 90, 95], ["children", "ORGANISM", 18, 26], ["children", "SPECIES", 18, 26], ["community-acquired pneumonia", "PROBLEM", 41, 69], ["fever", "PROBLEM", 90, 95], ["antibiotic treatment", "TREATMENT", 120, 140], ["pneumonia", "OBSERVATION", 60, 69]]], ["39 No diff erence was recorded between those diagnosed with viral and bacterial pneumonia.", [["viral and bacterial pneumonia", "DISEASE", 60, 89], ["diff erence", "PROBLEM", 6, 17], ["viral and bacterial pneumonia", "PROBLEM", 60, 89], ["viral", "OBSERVATION", 60, 65], ["bacterial", "OBSERVATION_MODIFIER", 70, 79], ["pneumonia", "OBSERVATION", 80, 89]]], ["However, children with mixed viral and bacterial infections became afebrile over a longer period.", [["viral and bacterial infections", "DISEASE", 29, 59], ["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17], ["mixed viral and bacterial infections", "PROBLEM", 23, 59], ["afebrile", "PROBLEM", 67, 75], ["bacterial", "OBSERVATION_MODIFIER", 39, 48], ["infections", "OBSERVATION", 49, 59]]], ["Undetected bacterial co-infection probably accounts for the response to antibacterial treatment in patients with apparent viral pneumonia.Search strategy and selection criteriaCommunity-acquired pneumonia is a dynamic situation.", [["bacterial co-infection", "DISEASE", 11, 33], ["viral pneumonia", "DISEASE", 122, 137], ["pneumonia", "DISEASE", 195, 204], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["Undetected bacterial co-infection", "PROBLEM", 0, 33], ["antibacterial treatment", "TREATMENT", 72, 95], ["apparent viral pneumonia", "PROBLEM", 113, 137], ["selection criteriaCommunity", "TEST", 158, 185], ["acquired pneumonia", "PROBLEM", 186, 204], ["bacterial co-infection", "OBSERVATION", 11, 33], ["probably accounts for", "UNCERTAINTY", 34, 55], ["viral", "OBSERVATION_MODIFIER", 122, 127], ["pneumonia", "OBSERVATION", 128, 137], ["pneumonia", "OBSERVATION", 195, 204]]], ["Biomarkers and infi ltrates on chest radiographs are only snapshots of this active state.", [["chest", "ANATOMY", 31, 36], ["Biomarkers", "TEST", 0, 10], ["infi ltrates", "TEST", 15, 27], ["chest radiographs", "TEST", 31, 48], ["chest", "ANATOMY", 31, 36]]], ["Findings of follow-up studies, after 12-24 h, might be totally diff erent.Causes of viral pneumonia Paediatric studiesWe identifi ed nine studies of community-acquired pneumonia (n=4279 episodes) in which the viral cause had been searched for by PCR.", [["pneumonia", "DISEASE", 90, 99], ["pneumonia", "DISEASE", 168, 177], ["follow-up studies", "TEST", 12, 29], ["totally diff erent", "PROBLEM", 55, 73], ["viral pneumonia", "PROBLEM", 84, 99], ["community-acquired pneumonia", "PROBLEM", 149, 177], ["the viral cause", "PROBLEM", 205, 220], ["viral", "OBSERVATION_MODIFIER", 84, 89], ["pneumonia", "OBSERVATION", 90, 99], ["pneumonia", "OBSERVATION", 168, 177]]], ["In most of these investigations, virus culture and antigen detection were also used.", [["these investigations", "TEST", 11, 31], ["virus culture", "TEST", 33, 46], ["antigen detection", "TEST", 51, 68]]], ["21, 30, [40] [41] [42] [43] [44] [45] [46] Seven studies were undertaken in developed countries and two in developing countries.", [["21, 30, [40] [41] [42] [43", "CHEMICAL", 0, 26], ["21, 30, [40] [41] [42] [43] [44] [45]", "CHEMICAL", 0, 37], ["[40] [41] [42] [43] [44] [45] [46", "SIMPLE_CHEMICAL", 8, 41], ["Seven studies", "TEST", 43, 56]]], ["Evidence of viral infection was recorded in 49% (range 43-67) of cases.", [["viral infection", "DISEASE", 12, 27], ["viral infection", "PROBLEM", 12, 27], ["viral", "OBSERVATION_MODIFIER", 12, 17], ["infection", "OBSERVATION", 18, 27]]], ["Prevalence of community-acquired pneumonia associated with respiratory syncytial virus (11%), infl uenza viruses (10%), parainfl uenza viruses (8%), and adenovirus (3%) was similar to that reported in studies in which only conventional diagnostic approaches were used.", [["pneumonia", "DISEASE", 33, 42], ["respiratory syncytial virus", "DISEASE", 59, 86], ["infl uenza viruses", "DISEASE", 94, 112], ["parainfl uenza viruses", "DISEASE", 120, 142], ["respiratory syncytial virus", "ORGANISM", 59, 86], ["infl uenza viruses", "ORGANISM", 94, 112], ["parainfl uenza viruses", "ORGANISM", 120, 142], ["adenovirus", "ORGANISM", 153, 163], ["respiratory syncytial virus", "SPECIES", 59, 86], ["parainfl uenza viruses", "SPECIES", 120, 142], ["respiratory syncytial virus", "SPECIES", 59, 86], ["infl uenza viruses", "SPECIES", 94, 112], ["parainfl uenza viruses", "SPECIES", 120, 142], ["adenovirus", "SPECIES", 153, 163], ["community-acquired pneumonia", "PROBLEM", 14, 42], ["respiratory syncytial virus", "PROBLEM", 59, 86], ["infl uenza viruses", "PROBLEM", 94, 112], ["parainfl uenza viruses", "PROBLEM", 120, 142], ["adenovirus", "PROBLEM", 153, 163], ["pneumonia", "OBSERVATION", 33, 42], ["respiratory syncytial", "ANATOMY", 59, 80]]], ["1,2 Exact numbers of diff erent viruses are diffi cult to compare from one study to another because several techniques were applied.", [["diff erent viruses", "PROBLEM", 21, 39], ["one study", "TEST", 71, 80]]], ["When serological assays alone were used, evidence of a viral cause was obtained in 20-43% of children with community-acquired pneumonia, and respiratory syncytial virus was dominant.", [["pneumonia", "DISEASE", 126, 135], ["respiratory syncytial virus", "DISEASE", 141, 168], ["children", "ORGANISM", 93, 101], ["respiratory syncytial virus", "ORGANISM", 141, 168], ["children", "SPECIES", 93, 101], ["respiratory syncytial virus", "SPECIES", 141, 168], ["serological assays", "TEST", 5, 23], ["a viral cause", "PROBLEM", 53, 66], ["community-acquired pneumonia", "PROBLEM", 107, 135], ["respiratory syncytial virus", "PROBLEM", 141, 168], ["pneumonia", "OBSERVATION", 126, 135], ["respiratory", "ANATOMY", 141, 152], ["syncytial virus", "OBSERVATION", 153, 168]]], ["47-50 PCR has increased detection of rhinoviruses (18%) and enteroviruses (7%).", [["rhinoviruses", "DISEASE", 37, 49], ["enteroviruses", "DISEASE", 60, 73], ["rhinoviruses", "ORGANISM", 37, 49], ["PCR", "TEST", 6, 9], ["rhinoviruses", "PROBLEM", 37, 49], ["enteroviruses", "PROBLEM", 60, 73], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["rhinoviruses", "OBSERVATION", 37, 49]]], ["Of newly described viruses, human bocavirus was recorded in 5% of cases and human metapneumovirus in 8%.", [["human metapneumovirus", "DISEASE", 76, 97], ["human", "ORGANISM", 28, 33], ["bocavirus", "CANCER", 34, 43], ["human", "ORGANISM", 76, 81], ["metapneumovirus", "ORGANISM", 82, 97], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 76, 81], ["metapneumovirus", "SPECIES", 82, 97], ["human", "SPECIES", 28, 33], ["human metapneumovirus", "SPECIES", 76, 97], ["newly described viruses", "PROBLEM", 3, 26], ["human bocavirus", "PROBLEM", 28, 43], ["human metapneumovirus", "PROBLEM", 76, 97], ["viruses", "OBSERVATION", 19, 26], ["metapneumovirus", "OBSERVATION", 82, 97]]], ["Coronaviruses were seen in 22 (7%) of 338 children in one study.", [["children", "ORGANISM", 42, 50], ["children", "SPECIES", 42, 50], ["Coronaviruses", "PROBLEM", 0, 13], ["one study", "TEST", 54, 63]]], ["41 In a 3-year prospective study in Finland, the overall probable cause of pneumonia was recorded in 85% of children, with bacterial infection in 53% and viral infection in 62%.", [["pneumonia", "DISEASE", 75, 84], ["bacterial infection", "DISEASE", 123, 142], ["viral infection", "DISEASE", 154, 169], ["children", "ORGANISM", 108, 116], ["children", "SPECIES", 108, 116], ["prospective study", "TEST", 15, 32], ["pneumonia", "PROBLEM", 75, 84], ["bacterial infection", "PROBLEM", 123, 142], ["viral infection", "PROBLEM", 154, 169], ["probable cause of", "UNCERTAINTY", 57, 74], ["pneumonia", "OBSERVATION", 75, 84], ["bacterial", "OBSERVATION_MODIFIER", 123, 132], ["infection", "OBSERVATION", 133, 142], ["viral", "OBSERVATION_MODIFIER", 154, 159], ["infection", "OBSERVATION", 160, 169]]], ["30 The most comprehensive study from a virological perspective searched for 14 viruses in 338 children with pneumonia over a 2-year period.", [["pneumonia", "DISEASE", 108, 117], ["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102], ["The most comprehensive study", "TEST", 3, 31], ["pneumonia", "PROBLEM", 108, 117], ["pneumonia", "OBSERVATION", 108, 117]]], ["41 Prevalence of viral infection was 67%, with respiratory syncytial virus, rhinoviruses, human bocavirus, human meta pneumo virus, and parainfl uenza viruses being the most common agents.Causes of viral pneumonia Paediatric studiesMany researchers have focused on the role of single respiratory viruses as a cause of childhood communityacquired pneumonia or have studied sole virus infections and looked for pneumonia in their clinical profi les (table 2) .", [["viral infection", "DISEASE", 17, 32], ["respiratory syncytial virus", "DISEASE", 47, 74], ["rhinoviruses", "DISEASE", 76, 88], ["viral pneumonia", "DISEASE", 198, 213], ["respiratory viruses", "DISEASE", 284, 303], ["pneumonia", "DISEASE", 346, 355], ["infections", "DISEASE", 383, 393], ["pneumonia", "DISEASE", 409, 418], ["respiratory syncytial virus", "ORGANISM", 47, 74], ["rhinoviruses", "ORGANISM", 76, 88], ["human", "ORGANISM", 90, 95], ["human meta pneumo virus", "ORGANISM", 107, 130], ["parainfl uenza viruses", "ORGANISM", 136, 158], ["single respiratory viruses", "ORGANISM", 277, 303], ["respiratory syncytial virus", "SPECIES", 47, 74], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 107, 112], ["pneumo virus", "SPECIES", 118, 130], ["respiratory syncytial virus", "SPECIES", 47, 74], ["human", "SPECIES", 90, 95], ["human meta pneumo virus", "SPECIES", 107, 130], ["parainfl uenza viruses", "SPECIES", 136, 158], ["viral infection", "PROBLEM", 17, 32], ["respiratory syncytial virus", "PROBLEM", 47, 74], ["rhinoviruses", "PROBLEM", 76, 88], ["human bocavirus", "PROBLEM", 90, 105], ["human meta pneumo virus", "PROBLEM", 107, 130], ["parainfl uenza viruses", "PROBLEM", 136, 158], ["viral pneumonia", "PROBLEM", 198, 213], ["Paediatric studies", "TEST", 214, 232], ["single respiratory viruses", "PROBLEM", 277, 303], ["childhood communityacquired pneumonia", "PROBLEM", 318, 355], ["studied sole virus infections", "PROBLEM", 364, 393], ["pneumonia", "PROBLEM", 409, 418], ["viral", "OBSERVATION_MODIFIER", 17, 22], ["infection", "OBSERVATION", 23, 32], ["syncytial virus", "OBSERVATION", 59, 74], ["viral", "OBSERVATION_MODIFIER", 198, 203], ["pneumonia", "OBSERVATION", 204, 213], ["viruses", "OBSERVATION", 296, 303], ["pneumonia", "OBSERVATION", 346, 355]]], ["Globally, respiratory syncytial virus continues to be the major causative viral agent of pneumonia in children and could be the predominant viral cause of severe pneumonia in this population.", [["respiratory syncytial virus", "DISEASE", 10, 37], ["pneumonia", "DISEASE", 89, 98], ["pneumonia", "DISEASE", 162, 171], ["respiratory syncytial virus", "ORGANISM", 10, 37], ["children", "ORGANISM", 102, 110], ["children", "SPECIES", 102, 110], ["respiratory syncytial virus", "SPECIES", 10, 37], ["Globally, respiratory syncytial virus", "PROBLEM", 0, 37], ["pneumonia", "PROBLEM", 89, 98], ["severe pneumonia", "PROBLEM", 155, 171], ["respiratory", "OBSERVATION", 10, 21], ["syncytial virus", "OBSERVATION", 22, 37], ["viral agent", "OBSERVATION", 74, 85], ["pneumonia", "OBSERVATION", 89, 98], ["predominant", "OBSERVATION_MODIFIER", 128, 139], ["viral", "OBSERVATION", 140, 145], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["pneumonia", "OBSERVATION", 162, 171]]], ["52, 53 With the advent of PCR techniques, rhinoviruses have been detected increasingly in childhood pneumonia.", [["pneumonia", "DISEASE", 100, 109], ["rhinoviruses", "ORGANISM", 42, 54], ["PCR techniques", "TEST", 26, 40], ["rhinoviruses", "PROBLEM", 42, 54], ["childhood pneumonia", "PROBLEM", 90, 109], ["rhinoviruses", "OBSERVATION", 42, 54], ["childhood", "OBSERVATION_MODIFIER", 90, 99], ["pneumonia", "OBSERVATION", 100, 109]]], ["54 infections in children admitted to hospital has been reported in seven studies, 55-61 and 11-53% had pneumonia.", [["infections", "DISEASE", 3, 13], ["pneumonia", "DISEASE", 104, 113], ["children", "ORGANISM", 17, 25], ["children", "SPECIES", 17, 25], ["pneumonia", "PROBLEM", 104, 113], ["infections", "OBSERVATION", 3, 13], ["pneumonia", "OBSERVATION", 104, 113]]], ["However, the role of rhinoviruses in pneumonia is still questioned because of the frequent detection of rhinoviruses in asymptomatic individuals (mean prevalence 15%), strikingly more than for other respiratory viruses (prevalence 1-5%).", [["rhinoviruses", "DISEASE", 21, 33], ["pneumonia", "DISEASE", 37, 46], ["rhinoviruses", "DISEASE", 104, 116], ["respiratory viruses", "DISEASE", 199, 218], ["rhinoviruses", "ORGANISM", 21, 33], ["rhinoviruses", "ORGANISM", 104, 116], ["rhinoviruses", "PROBLEM", 21, 33], ["pneumonia", "PROBLEM", 37, 46], ["rhinoviruses", "PROBLEM", 104, 116], ["asymptomatic individuals", "PROBLEM", 120, 144], ["mean prevalence", "TEST", 146, 161], ["other respiratory viruses", "PROBLEM", 193, 218], ["rhinoviruses", "OBSERVATION", 21, 33], ["pneumonia", "OBSERVATION", 37, 46], ["rhinoviruses", "OBSERVATION", 104, 116], ["respiratory", "ANATOMY", 199, 210], ["viruses", "OBSERVATION", 211, 218]]], ["62 Jartti and colleagues suggested that PCR is likely to detect a true but asymptomatic infection.", [["infection", "DISEASE", 88, 97], ["PCR", "TEST", 40, 43], ["asymptomatic infection", "PROBLEM", 75, 97], ["asymptomatic", "OBSERVATION_MODIFIER", 75, 87], ["infection", "OBSERVATION", 88, 97]]], ["62 A diffi culty with rhinoviruses is the paucity of serological tests to verify acute infection.", [["rhinoviruses", "DISEASE", 22, 34], ["acute infection", "DISEASE", 81, 96], ["rhinoviruses", "ORGANISM", 22, 34], ["A diffi culty", "PROBLEM", 3, 16], ["rhinoviruses", "PROBLEM", 22, 34], ["serological tests", "TEST", 53, 70], ["acute infection", "PROBLEM", 81, 96], ["rhinoviruses", "OBSERVATION", 22, 34], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["infection", "OBSERVATION", 87, 96]]], ["In immunocompetent individuals, rhinoviral clearance after symptomatic infection is rapid (average 1-3 weeks).", [["rhinoviral", "ANATOMY", 32, 42], ["infection", "DISEASE", 71, 80], ["individuals", "ORGANISM", 19, 30], ["rhinoviral", "CANCER", 32, 42], ["rhinoviral clearance", "TREATMENT", 32, 52], ["symptomatic infection", "PROBLEM", 59, 80], ["symptomatic", "OBSERVATION_MODIFIER", 59, 70], ["infection", "OBSERVATION", 71, 80]]], ["18 Pneumonia was diagnosed in 10% of children admitted with acute human metapneumovirus respiratory infection, [63] [64] [65] [66] with the highest prevalence (44%) in infants younger than 12 months.", [["respiratory", "ANATOMY", 88, 99], ["Pneumonia", "DISEASE", 3, 12], ["metapneumovirus respiratory infection", "DISEASE", 72, 109], ["children", "ORGANISM", 37, 45], ["human", "ORGANISM", 66, 71], ["metapneumovirus", "ORGANISM", 72, 87], ["infants", "ORGANISM", 168, 175], ["children", "SPECIES", 37, 45], ["human", "SPECIES", 66, 71], ["infants", "SPECIES", 168, 175], ["human metapneumovirus", "SPECIES", 66, 87], ["Pneumonia", "PROBLEM", 3, 12], ["acute human metapneumovirus respiratory infection", "PROBLEM", 60, 109], ["Pneumonia", "OBSERVATION", 3, 12], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["metapneumovirus respiratory infection", "OBSERVATION", 72, 109]]], ["66 It has also been recorded in 11-75% of children with human bocavirus infection.", [["bocavirus infection", "DISEASE", 62, 81], ["children", "ORGANISM", 42, 50], ["human", "ORGANISM", 56, 61], ["bocavirus", "CANCER", 62, 71], ["children", "SPECIES", 42, 50], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["human bocavirus infection", "PROBLEM", 56, 81], ["bocavirus infection", "OBSERVATION", 62, 81]]], ["67 In a study from Thailand of infants younger than 5 years admitted with pneumonia, human bocavirus was the third most prevalent agent detected, after rhinovirus and respiratory syncytial virus, accounting for 12% of all cases.", [["pneumonia", "DISEASE", 74, 83], ["respiratory syncytial virus", "DISEASE", 167, 194], ["infants", "ORGANISM", 31, 38], ["human", "ORGANISM", 85, 90], ["bocavirus", "CANCER", 91, 100], ["rhinovirus", "ORGANISM", 152, 162], ["respiratory syncytial virus", "ORGANISM", 167, 194], ["infants", "SPECIES", 31, 38], ["human", "SPECIES", 85, 90], ["respiratory syncytial virus", "SPECIES", 167, 194], ["human", "SPECIES", 85, 90], ["respiratory syncytial virus", "SPECIES", 167, 194], ["a study", "TEST", 6, 13], ["pneumonia", "PROBLEM", 74, 83], ["human bocavirus", "PROBLEM", 85, 100], ["rhinovirus", "PROBLEM", 152, 162], ["respiratory syncytial virus", "PROBLEM", 167, 194], ["pneumonia", "OBSERVATION", 74, 83], ["syncytial virus", "OBSERVATION", 179, 194]]], ["68 Although the role of human bocavirus in pneumonia is still being clarifi ed, serological evidence suggests it is a cause of human infection.", [["pneumonia", "DISEASE", 43, 52], ["infection", "DISEASE", 133, 142], ["human", "ORGANISM", 24, 29], ["bocavirus", "ORGANISM", 30, 39], ["human", "ORGANISM", 127, 132], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 127, 132], ["human bocavirus", "PROBLEM", 24, 39], ["pneumonia", "PROBLEM", 43, 52], ["human infection", "PROBLEM", 127, 142], ["pneumonia", "OBSERVATION", 43, 52], ["infection", "OBSERVATION", 133, 142]]], ["With a novel IgM and IgG enzyme immunoassay, 96% of children with a high load of human bocavirus in nasopharyngeal aspirates and 92% of wheezy children with viraemia had diagnostic seroresponses.", [["nasopharyngeal aspirates", "ANATOMY", 100, 124], ["wheezy", "DISEASE", 136, 142], ["viraemia", "DISEASE", 157, 165], ["IgM", "GENE_OR_GENE_PRODUCT", 13, 16], ["IgG", "GENE_OR_GENE_PRODUCT", 21, 24], ["children", "ORGANISM", 52, 60], ["human", "ORGANISM", 81, 86], ["bocavirus", "CANCER", 87, 96], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 100, 124], ["children", "ORGANISM", 143, 151], ["IgM", "PROTEIN", 13, 16], ["IgG enzyme", "PROTEIN", 21, 31], ["children", "SPECIES", 52, 60], ["human", "SPECIES", 81, 86], ["children", "SPECIES", 143, 151], ["human", "SPECIES", 81, 86], ["a novel IgM", "TEST", 5, 16], ["IgG enzyme immunoassay", "TEST", 21, 43], ["a high load of human bocavirus", "PROBLEM", 66, 96], ["nasopharyngeal aspirates", "TEST", 100, 124], ["viraemia", "PROBLEM", 157, 165], ["human bocavirus", "ANATOMY", 81, 96], ["nasopharyngeal", "ANATOMY", 100, 114], ["aspirates", "OBSERVATION", 115, 124]]], ["69 Human bocavirus was identifi ed serologically in 12 (12%) of 101 children with community-acquired pneumonia in Italy.", [["pneumonia", "DISEASE", 101, 110], ["Human", "ORGANISM", 3, 8], ["bocavirus", "CANCER", 9, 18], ["children", "ORGANISM", 68, 76], ["Human", "SPECIES", 3, 8], ["children", "SPECIES", 68, 76], ["Human bocavirus", "SPECIES", 3, 18], ["Human bocavirus", "TEST", 3, 18], ["community-acquired pneumonia", "PROBLEM", 82, 110], ["bocavirus", "OBSERVATION", 9, 18], ["pneumonia", "OBSERVATION", 101, 110]]], ["70 Although prevalence of adenovirus-associated pneumonia is fairly low (range 2-12%), this type of infection is important to recognise because it might induce severe and fatal necrotising pneumonia (especially serotypes 3, 7, and 14).", [["pneumonia", "DISEASE", 48, 57], ["infection", "DISEASE", 100, 109], ["pneumonia", "DISEASE", 189, 198], ["adenovirus", "ORGANISM", 26, 36], ["adenovirus", "PROBLEM", 26, 36], ["pneumonia", "PROBLEM", 48, 57], ["infection", "PROBLEM", 100, 109], ["severe and fatal necrotising pneumonia", "PROBLEM", 160, 198], ["adenovirus", "OBSERVATION", 26, 36], ["pneumonia", "OBSERVATION", 48, 57], ["fairly", "OBSERVATION_MODIFIER", 61, 67], ["low", "OBSERVATION_MODIFIER", 68, 71], ["infection", "OBSERVATION", 100, 109], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["fatal", "OBSERVATION_MODIFIER", 171, 176], ["necrotising", "OBSERVATION_MODIFIER", 177, 188], ["pneumonia", "OBSERVATION", 189, 198]]], ["30, [40] [41] [42] [43] [44] [45] [46] 71 In China, adenovirus DNA was detected in 9% of post-mortem pulmonary tissue specimens from 175 children with fatal pneumonia.", [["pulmonary tissue specimens", "ANATOMY", 101, 127], ["30, [40] [41] [42] [43] [44] [45", "CHEMICAL", 0, 32], ["pneumonia", "DISEASE", 157, 166], ["[40] [41] [42] [43] [44] [45] [46] 71", "SIMPLE_CHEMICAL", 4, 41], ["adenovirus", "ORGANISM", 52, 62], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["pulmonary tissue specimens", "TISSUE", 101, 127], ["children", "ORGANISM", 137, 145], ["children", "SPECIES", 137, 145], ["adenovirus", "SPECIES", 52, 62], ["adenovirus DNA", "PROBLEM", 52, 66], ["post-mortem pulmonary tissue specimens", "PROBLEM", 89, 127], ["fatal pneumonia", "PROBLEM", 151, 166], ["pulmonary tissue", "ANATOMY", 101, 117], ["fatal", "OBSERVATION_MODIFIER", 151, 156], ["pneumonia", "OBSERVATION", 157, 166]]], ["72 Of note, PCR is substantially more sensitive for identifi cation of adenovirus than is antigen detection.", [["cation", "SIMPLE_CHEMICAL", 61, 67], ["adenovirus", "ORGANISM", 71, 81], ["PCR", "TEST", 12, 15], ["adenovirus", "PROBLEM", 71, 81], ["antigen detection", "TEST", 90, 107]]], ["73 Human coronaviruses 229E and OC43, and newly discovered types NL63 and HKU1, have been linked to community-acquired pneumonia in children.", [["pneumonia", "DISEASE", 119, 128], ["Human coronaviruses 229E", "ORGANISM", 3, 27], ["OC43", "GENE_OR_GENE_PRODUCT", 32, 36], ["NL63", "GENE_OR_GENE_PRODUCT", 65, 69], ["HKU1", "GENE_OR_GENE_PRODUCT", 74, 78], ["children", "ORGANISM", 132, 140], ["HKU1", "PROTEIN", 74, 78], ["Human", "SPECIES", 3, 8], ["children", "SPECIES", 132, 140], ["Human coronaviruses 229E", "SPECIES", 3, 27], ["Human coronaviruses", "TEST", 3, 22], ["OC43", "TEST", 32, 36], ["acquired pneumonia in children", "PROBLEM", 110, 140], ["pneumonia", "OBSERVATION", 119, 128]]], ["74, 75 Infection with human coronavirus was detected in 3% of children and adolescents in a large pneumonia study in Thailand.", [["human coronavirus", "DISEASE", 22, 39], ["pneumonia", "DISEASE", 98, 107], ["human", "ORGANISM", 22, 27], ["coronavirus", "ORGANISM", 28, 39], ["children", "ORGANISM", 62, 70], ["human", "SPECIES", 22, 27], ["children", "SPECIES", 62, 70], ["adolescents", "SPECIES", 75, 86], ["human coronavirus", "SPECIES", 22, 39], ["human coronavirus", "PROBLEM", 22, 39], ["a large pneumonia study", "PROBLEM", 90, 113], ["Infection", "OBSERVATION", 7, 16], ["large", "OBSERVATION_MODIFIER", 92, 97], ["pneumonia", "OBSERVATION", 98, 107]]], ["76Research in adultsWe identifi ed ten studies of adults with communityacquired pneumonia (n=2910 episodes) in which PCR was used to test for respiratory viruses.", [["pneumonia", "DISEASE", 80, 89], ["respiratory viruses", "DISEASE", 142, 161], ["adults", "ORGANISM", 50, 56], ["communityacquired pneumonia", "PROBLEM", 62, 89], ["PCR", "TEST", 117, 120], ["respiratory viruses", "PROBLEM", 142, 161], ["pneumonia", "OBSERVATION", 80, 89], ["respiratory", "ANATOMY", 142, 153], ["viruses", "OBSERVATION", 154, 161]]], ["Evidence of viral infection was detected in 22% of cases.", [["viral infection", "DISEASE", 12, 27], ["viral infection", "PROBLEM", 12, 27], ["viral", "OBSERVATION_MODIFIER", 12, 17], ["infection", "OBSERVATION", 18, 27]]], ["19, 20, [77] [78] [79] [80] [81] [82] [83] [84] [85] In most of these studies, a comprehensive array of conventional virological methods were also implemented to better defi ne the role of viruses in adults with communityacquired pneumonia.", [["pneumonia", "DISEASE", 230, 239], ["19, 20, [77] [78] [79] [80] [81] [82] [83] [84]", "CHEMICAL", 0, 47], ["[77] [78] [79] [80] [81] [82] [83] [84] [85", "SIMPLE_CHEMICAL", 8, 51], ["these studies", "TEST", 64, 77], ["conventional virological methods", "TREATMENT", 104, 136], ["communityacquired pneumonia", "PROBLEM", 212, 239], ["viruses", "OBSERVATION", 189, 196], ["pneumonia", "OBSERVATION", 230, 239]]], ["Similar to fi ndings of paediatric studies, prevalence of infection with infl uenza viruses (8%), respiratory syncytial virus (3%), parainfl uenza viruses (2%), and adenovirus (2%) is comparable with values recorded with conventional diagnostic methods alone.", [["infection", "DISEASE", 58, 67], ["infl uenza viruses", "DISEASE", 73, 91], ["respiratory syncytial virus", "DISEASE", 98, 125], ["parainfl uenza viruses", "DISEASE", 132, 154], ["infl uenza viruses", "ORGANISM", 73, 91], ["respiratory syncytial virus", "ORGANISM", 98, 125], ["parainfl uenza viruses", "ORGANISM", 132, 154], ["adenovirus", "ORGANISM", 165, 175], ["respiratory syncytial virus", "SPECIES", 98, 125], ["parainfl uenza viruses", "SPECIES", 132, 154], ["infl uenza viruses", "SPECIES", 73, 91], ["respiratory syncytial virus", "SPECIES", 98, 125], ["parainfl uenza viruses", "SPECIES", 132, 154], ["adenovirus", "SPECIES", 165, 175], ["paediatric studies", "TEST", 24, 42], ["infection", "PROBLEM", 58, 67], ["infl uenza viruses", "PROBLEM", 73, 91], ["respiratory syncytial virus", "TEST", 98, 125], ["parainfl uenza viruses", "PROBLEM", 132, 154], ["adenovirus", "PROBLEM", 165, 175], ["infection", "OBSERVATION", 58, 67], ["respiratory syncytial", "ANATOMY", 98, 119]]], ["5, 36 Serological techniques only were used in four studies; evidence of viral community-acquired pneumonia was noted in 10-23% of patients.", [["pneumonia", "DISEASE", 98, 107], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["Serological techniques", "TEST", 6, 28], ["four studies", "TEST", 47, 59], ["viral community-acquired pneumonia", "PROBLEM", 73, 107], ["viral", "OBSERVATION_MODIFIER", 73, 78], ["community", "OBSERVATION_MODIFIER", 79, 88], ["pneumonia", "OBSERVATION", 98, 107]]], ["[86] [87] [88] [89] Use of PCR has augmented detection of viruses that are diffi cult to identify with conventional methods, including rhinoviruses (6%), human coronaviruses (5%), and human metapneumovirus (1%).", [["human coronaviruses", "DISEASE", 154, 173], ["human metapneumovirus", "DISEASE", 184, 205], ["rhinoviruses", "ORGANISM", 135, 147], ["human", "ORGANISM", 154, 159], ["coronaviruses", "ORGANISM", 160, 173], ["human", "ORGANISM", 184, 189], ["metapneumovirus", "ORGANISM", 190, 205], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 184, 189], ["metapneumovirus", "SPECIES", 190, 205], ["human coronaviruses", "SPECIES", 154, 173], ["human metapneumovirus", "SPECIES", 184, 205], ["PCR", "TEST", 27, 30], ["viruses", "PROBLEM", 58, 65], ["conventional methods", "PROBLEM", 103, 123], ["rhinoviruses", "PROBLEM", 135, 147], ["human coronaviruses", "PROBLEM", 154, 173], ["human metapneumovirus", "TREATMENT", 184, 205], ["viruses", "OBSERVATION", 58, 65], ["rhinoviruses", "OBSERVATION", 135, 147]]], ["As a result, overall prevalence of respiratory viral infection in PCR studies (15-56%) is generally higher than for studies in which PCR was not implemented.", [["respiratory viral infection", "DISEASE", 35, 62], ["respiratory viral infection", "PROBLEM", 35, 62], ["PCR studies", "TEST", 66, 77], ["studies", "TEST", 116, 123], ["PCR", "TEST", 133, 136], ["respiratory", "ANATOMY", 35, 46], ["viral infection", "OBSERVATION", 47, 62]]], ["With a full set of tests, fi ndings of three reports suggest that a third of adult cases of community-acquired pneumonia are associated with viral infection.", [["pneumonia", "DISEASE", 111, 120], ["viral infection", "DISEASE", 141, 156], ["tests", "TEST", 19, 24], ["community-acquired pneumonia", "PROBLEM", 92, 120], ["viral infection", "PROBLEM", 141, 156], ["pneumonia", "OBSERVATION", 111, 120], ["associated with", "UNCERTAINTY", 125, 140], ["viral", "OBSERVATION_MODIFIER", 141, 146], ["infection", "OBSERVATION", 147, 156]]], ["19, 20, 85 Other researchers have focused on the role of specifi c respiratory viruses in adults with community-acquired pneumonia.", [["pneumonia", "DISEASE", 121, 130], ["specifi c respiratory viruses", "ORGANISM", 57, 86], ["specifi c respiratory viruses", "PROBLEM", 57, 86], ["community-acquired pneumonia", "PROBLEM", 102, 130], ["respiratory", "ANATOMY", 67, 78], ["viruses", "OBSERVATION", 79, 86], ["pneumonia", "OBSERVATION", 121, 130]]], ["Respiratory syncytial virus is recognised increasingly as a cause of illness in adults, 90 and roughly 2-9% of elderly patients admitted with pneumonia in the USA have infection associated with this virus.", [["Respiratory syncytial virus", "DISEASE", 0, 27], ["illness", "DISEASE", 69, 76], ["pneumonia", "DISEASE", 142, 151], ["infection", "DISEASE", 168, 177], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["patients", "ORGANISM", 119, 127], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["patients", "SPECIES", 119, 127], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["Respiratory syncytial virus", "PROBLEM", 0, 27], ["illness", "PROBLEM", 69, 76], ["pneumonia", "PROBLEM", 142, 151], ["infection", "PROBLEM", 168, 177], ["this virus", "PROBLEM", 194, 204], ["syncytial virus", "OBSERVATION", 12, 27], ["pneumonia", "OBSERVATION", 142, 151], ["infection", "OBSERVATION", 168, 177]]], ["91 Infections with respiratory syncytial virus are linked to substantial mortality.", [["Infections", "DISEASE", 3, 13], ["respiratory syncytial virus", "DISEASE", 19, 46], ["respiratory syncytial virus", "ORGANISM", 19, 46], ["respiratory syncytial virus", "SPECIES", 19, 46], ["respiratory syncytial virus", "PROBLEM", 19, 46], ["respiratory syncytial virus", "OBSERVATION", 19, 46], ["substantial", "OBSERVATION_MODIFIER", 61, 72], ["mortality", "OBSERVATION", 73, 82]]], ["92 Several outbreaks of severe respiratory disease (including fatal pneumonia) in elderly residents of nursing homes have been associated with rhinoviruses.", [["respiratory", "ANATOMY", 31, 42], ["respiratory disease", "DISEASE", 31, 50], ["pneumonia", "DISEASE", 68, 77], ["rhinoviruses", "DISEASE", 143, 155], ["rhinoviruses", "ORGANISM", 143, 155], ["severe respiratory disease", "PROBLEM", 24, 50], ["fatal pneumonia", "PROBLEM", 62, 77], ["rhinoviruses", "PROBLEM", 143, 155], ["outbreaks", "OBSERVATION_MODIFIER", 11, 20], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["respiratory disease", "OBSERVATION", 31, 50], ["fatal", "OBSERVATION_MODIFIER", 62, 67], ["pneumonia", "OBSERVATION", 68, 77], ["rhinoviruses", "OBSERVATION", 143, 155]]], ["93, 94 Adenoviruses have been implicated in 90% of pneumoniarelated admissions in basic military trainees.", [["Adenoviruses", "GENE_OR_GENE_PRODUCT", 7, 19]]], ["95 An outbreak of pneumonia associated with adenovirus serotype 14 has been reported.", [["pneumonia", "DISEASE", 18, 27], ["adenovirus serotype 14", "ORGANISM", 44, 66], ["pneumonia", "PROBLEM", 18, 27], ["adenovirus serotype", "PROBLEM", 44, 63], ["outbreak", "OBSERVATION_MODIFIER", 6, 14], ["pneumonia", "OBSERVATION", 18, 27]]], ["96 When searched for systematically, coronaviruses have been detected in samples from a small proportion (2-6%) of adults with pneumonia.", [["samples", "ANATOMY", 73, 80], ["pneumonia", "DISEASE", 127, 136], ["coronaviruses", "ORGANISM", 37, 50], ["adults", "ORGANISM", 115, 121], ["coronaviruses", "PROBLEM", 37, 50], ["pneumonia", "PROBLEM", 127, 136], ["small", "OBSERVATION_MODIFIER", 88, 93], ["pneumonia", "OBSERVATION", 127, 136]]], ["76, 97 These patients had clinical illnesses indistinguishable from those in individuals with community-acquired pneumonia associated with other micro organisms.", [["pneumonia", "DISEASE", 113, 122], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["clinical illnesses", "PROBLEM", 26, 44], ["community-acquired pneumonia", "PROBLEM", 94, 122], ["other micro organisms", "PROBLEM", 139, 160], ["pneumonia", "OBSERVATION", 113, 122]]], ["2% of asymptomatic controls also had human coronavirus infection.", [["coronavirus infection", "DISEASE", 43, 64], ["controls", "ORGANISM", 19, 27], ["human", "ORGANISM", 37, 42], ["coronavirus", "ORGANISM", 43, 54], ["human", "SPECIES", 37, 42], ["human coronavirus", "SPECIES", 37, 54], ["asymptomatic controls", "PROBLEM", 6, 27], ["human coronavirus infection", "PROBLEM", 37, 64], ["coronavirus infection", "OBSERVATION", 43, 64]]], ["76 Infections with human metapneumovirus arise throughout adulthood.", [["Infections", "DISEASE", 3, 13], ["human metapneumovirus", "DISEASE", 19, 40], ["human", "ORGANISM", 19, 24], ["metapneumovirus", "ORGANISM", 25, 40], ["human", "SPECIES", 19, 24], ["metapneumovirus", "SPECIES", 25, 40], ["human metapneumovirus", "SPECIES", 19, 40], ["human metapneumovirus", "PROBLEM", 19, 40], ["metapneumovirus", "OBSERVATION", 25, 40]]], ["Outbreaks of this viral infection associated with fatal outcome have been reported from long-term care facilities.", [["viral infection", "DISEASE", 18, 33], ["this viral infection", "PROBLEM", 13, 33], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["infection", "OBSERVATION", 24, 33]]], ["98, 99 Of patients admitted with human metapneumovirus infection, 27% had chest radiographic infi ltrates, 12% required ventilatory support, and 7% died.", [["chest", "ANATOMY", 74, 79], ["human metapneumovirus infection", "DISEASE", 33, 64], ["patients", "ORGANISM", 10, 18], ["human", "ORGANISM", 33, 38], ["metapneumovirus", "ORGANISM", 39, 54], ["chest", "ORGANISM_SUBDIVISION", 74, 79], ["patients", "SPECIES", 10, 18], ["human", "SPECIES", 33, 38], ["human metapneumovirus", "SPECIES", 33, 54], ["human metapneumovirus infection", "PROBLEM", 33, 64], ["chest radiographic infi ltrates", "TEST", 74, 105], ["ventilatory support", "TREATMENT", 120, 139], ["metapneumovirus infection", "OBSERVATION", 39, 64], ["chest", "ANATOMY", 74, 79]]], ["100 Human bocavirus is an uncommon cause of pneumonia in adults.", [["pneumonia", "DISEASE", 44, 53], ["Human", "ORGANISM", 4, 9], ["Human", "SPECIES", 4, 9], ["Human bocavirus", "SPECIES", 4, 19], ["pneumonia", "PROBLEM", 44, 53], ["bocavirus", "OBSERVATION", 10, 19], ["pneumonia", "OBSERVATION", 44, 53]]], ["As part of a surveillance project in Thailand, this virus was detected in fi ve (1%) of 667 adults (age 20 years or older) admitted with pneumonia and in one of 126 (1%) controls without febrile or respiratory illness.", [["respiratory", "ANATOMY", 198, 209], ["pneumonia", "DISEASE", 137, 146], ["febrile", "DISEASE", 187, 194], ["respiratory illness", "DISEASE", 198, 217], ["this virus", "PROBLEM", 47, 57], ["pneumonia", "PROBLEM", 137, 146], ["febrile or respiratory illness", "PROBLEM", 187, 217], ["pneumonia", "OBSERVATION", 137, 146], ["without", "UNCERTAINTY", 179, 186], ["febrile", "OBSERVATION_MODIFIER", 187, 194], ["respiratory", "ANATOMY", 198, 209], ["illness", "OBSERVATION", 210, 217]]], ["68Pneumonia associated with SARS, avian infl uenza, and 2009 pandemic infl uenzaDuring 2002 and 2003, the SARS coronavirus caused severe respiratory infection in more than 8000 people and led to 774 deaths.", [["respiratory", "ANATOMY", 137, 148], ["68Pneumonia", "CHEMICAL", 0, 11], ["SARS", "DISEASE", 28, 32], ["avian infl uenza", "DISEASE", 34, 50], ["SARS coronavirus", "DISEASE", 106, 122], ["respiratory infection", "DISEASE", 137, 158], ["deaths", "DISEASE", 199, 205], ["SARS coronavirus", "ORGANISM", 106, 122], ["people", "ORGANISM", 177, 183], ["coronavirus", "SPECIES", 111, 122], ["people", "SPECIES", 177, 183], ["SARS coronavirus", "SPECIES", 106, 122], ["68Pneumonia", "PROBLEM", 0, 11], ["SARS", "PROBLEM", 28, 32], ["the SARS coronavirus", "PROBLEM", 102, 122], ["severe respiratory infection", "PROBLEM", 130, 158], ["severe", "OBSERVATION_MODIFIER", 130, 136], ["respiratory", "ANATOMY", 137, 148], ["infection", "OBSERVATION", 149, 158]]], ["Up to a third of patients with SARS became critically ill.", [["SARS", "DISEASE", 31, 35], ["critically ill", "DISEASE", 43, 57], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["critically ill", "PROBLEM", 43, 57]]], ["Pneumonia with lung injury arose in about 16% of all individuals infected with the virus and in 80% of critically ill patients.", [["lung", "ANATOMY", 15, 19], ["Pneumonia", "DISEASE", 0, 9], ["lung injury", "DISEASE", 15, 26], ["critically ill", "DISEASE", 103, 117], ["lung", "ORGAN", 15, 19], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["Pneumonia", "PROBLEM", 0, 9], ["lung injury", "PROBLEM", 15, 26], ["the virus", "PROBLEM", 79, 88], ["lung", "ANATOMY", 15, 19], ["injury", "OBSERVATION", 20, 26], ["infected", "OBSERVATION", 65, 73]]], ["By contrast with other viral pneumonias, children were fairly well protected from severe illness.", [["viral pneumonias", "DISEASE", 23, 39], ["illness", "DISEASE", 89, 96], ["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["other viral pneumonias", "PROBLEM", 17, 39], ["severe illness", "PROBLEM", 82, 96], ["viral", "OBSERVATION_MODIFIER", 23, 28], ["pneumonias", "OBSERVATION", 29, 39], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["illness", "OBSERVATION", 89, 96]]], ["101 Since November, 2003, avian infl uenza A (H5N1) virus has caused more than 450 human infections, with a case-fatality proportion of about 60%.", [["infections", "DISEASE", 89, 99], ["avian", "ORGANISM", 26, 31], ["infl uenza A (H5N1) virus", "ORGANISM", 32, 57], ["human", "ORGANISM", 83, 88], ["human", "SPECIES", 83, 88], ["infl uenza A (H5N1) virus", "SPECIES", 32, 57], ["human", "SPECIES", 83, 88], ["A (H5N1) virus", "PROBLEM", 43, 57], ["450 human infections", "PROBLEM", 79, 99], ["infections", "OBSERVATION", 89, 99]]], ["Multiorgan failure usually develops within 1 week from onset of illness, with lymphopenia, thrombocytopenia, and raised concentrations of aminotransferase and creatinine.", [["Multiorgan", "ANATOMY", 0, 10], ["Multiorgan failure", "DISEASE", 0, 18], ["illness", "DISEASE", 64, 71], ["lymphopenia", "DISEASE", 78, 89], ["thrombocytopenia", "DISEASE", 91, 107], ["creatinine", "CHEMICAL", 159, 169], ["creatinine", "CHEMICAL", 159, 169], ["aminotransferase", "SIMPLE_CHEMICAL", 138, 154], ["creatinine", "SIMPLE_CHEMICAL", 159, 169], ["aminotransferase", "PROTEIN", 138, 154], ["Multiorgan failure", "PROBLEM", 0, 18], ["illness", "PROBLEM", 64, 71], ["lymphopenia", "PROBLEM", 78, 89], ["thrombocytopenia", "PROBLEM", 91, 107], ["aminotransferase", "TEST", 138, 154], ["creatinine", "TEST", 159, 169], ["failure", "OBSERVATION", 11, 18], ["illness", "OBSERVATION", 64, 71], ["lymphopenia", "OBSERVATION", 78, 89], ["thrombocytopenia", "OBSERVATION", 91, 107]]], ["Almost all patients with avian infl uenza develop pneumonia.", [["avian infl uenza", "DISEASE", 25, 41], ["pneumonia", "DISEASE", 50, 59], ["patients", "ORGANISM", 11, 19], ["infl uenza", "ORGANISM", 31, 41], ["patients", "SPECIES", 11, 19], ["pneumonia", "PROBLEM", 50, 59], ["pneumonia", "OBSERVATION", 50, 59]]], ["Cause of death is most typically progressive respiratory failure.", [["respiratory", "ANATOMY", 45, 56], ["death", "DISEASE", 9, 14], ["respiratory failure", "DISEASE", 45, 64], ["death", "PROBLEM", 9, 14], ["typically progressive respiratory failure", "PROBLEM", 23, 64], ["death", "OBSERVATION", 9, 14], ["most typically", "OBSERVATION_MODIFIER", 18, 32], ["progressive", "OBSERVATION_MODIFIER", 33, 44], ["respiratory failure", "OBSERVATION", 45, 64]]], ["102 Since March, 2009, pandemic infl uenza A (H1N1) virus has spread in more than 200 countries over the world, causing about 18 000 deaths.", [["deaths", "DISEASE", 133, 139], ["infl uenza A (H1N1) virus", "ORGANISM", 32, 57], ["H1N1) virus", "SPECIES", 46, 57], ["infl uenza A (H1N1) virus", "SPECIES", 32, 57], ["A (H1N1) virus", "PROBLEM", 43, 57]]], ["In the USA alone, more than 59 million people have been infected.", [["people", "ORGANISM", 39, 45], ["people", "SPECIES", 39, 45], ["infected", "PROBLEM", 56, 64], ["infected", "OBSERVATION", 56, 64]]], ["Critical illness arose most commonly in adults with a median age of 40 years and has been rare in those older than 65 years.", [["Critical illness", "DISEASE", 0, 16], ["Critical illness", "PROBLEM", 0, 16], ["illness", "OBSERVATION", 9, 16]]], ["[103] [104] [105] Half of patients with critical illness had viral pneumonitis or acute respiratory distress syndrome.", [["respiratory", "ANATOMY", 88, 99], ["critical illness", "DISEASE", 40, 56], ["viral pneumonitis", "DISEASE", 61, 78], ["acute respiratory distress syndrome", "DISEASE", 82, 117], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["critical illness", "PROBLEM", 40, 56], ["viral pneumonitis", "PROBLEM", 61, 78], ["acute respiratory distress syndrome", "PROBLEM", 82, 117], ["viral pneumonitis", "OBSERVATION", 61, 78], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["respiratory distress", "OBSERVATION", 88, 108], ["syndrome", "OBSERVATION", 109, 117]]], ["103, 106 In Germany, pneumonia was diagnosed in 275 (0\u00b77%) of 40 729 patients with pandemic H1N1 virus infection; half of these were admitted.", [["pneumonia", "DISEASE", 21, 30], ["H1N1 virus infection", "DISEASE", 92, 112], ["patients", "ORGANISM", 69, 77], ["pandemic H1N1 virus", "ORGANISM", 83, 102], ["patients", "SPECIES", 69, 77], ["pandemic H1N1 virus", "SPECIES", 83, 102], ["pandemic H1N1 virus", "SPECIES", 83, 102], ["pneumonia", "PROBLEM", 21, 30], ["pandemic H1N1 virus infection", "PROBLEM", 83, 112], ["pneumonia", "OBSERVATION", 21, 30], ["H1N1 virus", "OBSERVATION", 92, 102]]], ["107 In the UK, 102 (29%) of 349 patients with chest radiographs had fi ndings consistent with pneumonia.", [["chest", "ANATOMY", 46, 51], ["pneumonia", "DISEASE", 94, 103], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["chest radiographs", "TEST", 46, 63], ["fi ndings", "PROBLEM", 68, 77], ["pneumonia", "PROBLEM", 94, 103], ["chest", "ANATOMY", 46, 51], ["consistent with", "UNCERTAINTY", 78, 93], ["pneumonia", "OBSERVATION", 94, 103]]], ["Median age of patients with pneumonia was 26 years.", [["pneumonia", "DISEASE", 28, 37], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["pneumonia", "PROBLEM", 28, 37], ["pneumonia", "OBSERVATION", 28, 37]]], ["108 Poor outcomes from H1N1 virus infection have been recorded in pregnant women, indigenous populations, and individuals with substantial obesity or serious comorbidities.Pneumonia associated with SARS, avian infl uenza, and 2009 pandemic infl uenzaChest radiographic infi ltrates in SARS, H5N1, and H1N1 infections were most usually interstitial, patchy, and bilateral.", [["interstitial", "ANATOMY", 335, 347], ["H1N1 virus infection", "DISEASE", 23, 43], ["obesity", "DISEASE", 139, 146], ["Pneumonia", "DISEASE", 172, 181], ["SARS", "DISEASE", 198, 202], ["SARS", "DISEASE", 285, 289], ["H5N1", "DISEASE", 291, 295], ["infections", "DISEASE", 306, 316], ["H1N1 virus", "ORGANISM", 23, 33], ["women", "ORGANISM", 75, 80], ["H1N1 virus", "SPECIES", 23, 33], ["women", "SPECIES", 75, 80], ["H1N1 virus", "SPECIES", 23, 33], ["H1N1 virus infection", "PROBLEM", 23, 43], ["substantial obesity", "PROBLEM", 127, 146], ["serious comorbidities", "PROBLEM", 150, 171], ["Pneumonia", "PROBLEM", 172, 181], ["SARS", "PROBLEM", 198, 202], ["SARS", "PROBLEM", 285, 289], ["H5N1", "PROBLEM", 291, 295], ["H1N1 infections", "PROBLEM", 301, 316], ["substantial", "OBSERVATION_MODIFIER", 127, 138], ["obesity", "OBSERVATION", 139, 146], ["SARS", "OBSERVATION", 198, 202], ["interstitial", "OBSERVATION_MODIFIER", 335, 347], ["patchy", "OBSERVATION_MODIFIER", 349, 355], ["bilateral", "ANATOMY_MODIFIER", 361, 370]]], ["109Detection of several virusesIn 1997, Drews and colleagues 110 reviewed eight studies of a total of 1341 cases of respiratory viral infection detected mostly with conventional techniques.", [["respiratory viral infection", "DISEASE", 116, 143], ["respiratory viral infection", "PROBLEM", 116, 143], ["respiratory", "OBSERVATION", 116, 127], ["viral infection", "OBSERVATION", 128, 143]]], ["These researchers noted dual viral infection in 67 (5%) cases.", [["viral infection", "DISEASE", 29, 44], ["dual viral infection", "PROBLEM", 24, 44], ["viral", "OBSERVATION_MODIFIER", 29, 34], ["infection", "OBSERVATION", 35, 44]]], ["Detection of several viruses in a fairly high proportion of cases has been a feature of pneumonia aetiological studies in which PCR was used.", [["pneumonia", "DISEASE", 88, 97], ["several viruses", "PROBLEM", 13, 28], ["pneumonia aetiological studies", "PROBLEM", 88, 118], ["PCR", "TEST", 128, 131], ["several", "OBSERVATION_MODIFIER", 13, 20], ["viruses", "OBSERVATION", 21, 28], ["pneumonia", "OBSERVATION", 88, 97]]], ["In particular, for childhood pneumonia, two or three viruses have been detected in 10-20% of children.", [["pneumonia", "DISEASE", 29, 38], ["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101], ["childhood pneumonia", "PROBLEM", 19, 38], ["pneumonia", "OBSERVATION", 29, 38]]], ["21, 30, [40] [41] [42] [43] [44] [45] [46] Specifi cally, human bocavirus is detected frequently in association with other respiratory viruses.", [["21, 30, [40] [41] [42] [43] [44] [45] [46", "CHEMICAL", 0, 41], ["respiratory viruses", "DISEASE", 123, 142], ["21, 30, [40] [41] [42] [43] [44] [45]", "CHEMICAL", 0, 37], ["[40] [41] [42] [43] [44] [45] [46] Specifi cally", "SIMPLE_CHEMICAL", 8, 56], ["human", "ORGANISM", 58, 63], ["bocavirus", "CANCER", 64, 73], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["Specifi cally", "TEST", 43, 56], ["human bocavirus", "PROBLEM", 58, 73], ["other respiratory viruses", "PROBLEM", 117, 142], ["respiratory", "ANATOMY", 123, 134], ["viruses", "OBSERVATION", 135, 142]]], ["[67] [68] [69] In a Thai pneumonia study, 40 (91%) of 44 children younger than 5 years with human bocavirus infections had co-infection with other viruses.", [["pneumonia", "DISEASE", 25, 34], ["bocavirus infections", "DISEASE", 98, 118], ["co-infection", "DISEASE", 123, 135], ["children", "ORGANISM", 57, 65], ["human", "ORGANISM", 92, 97], ["children", "SPECIES", 57, 65], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["a Thai pneumonia study", "TEST", 18, 40], ["human bocavirus infections", "PROBLEM", 92, 118], ["co-infection", "PROBLEM", 123, 135], ["other viruses", "PROBLEM", 141, 154], ["pneumonia", "OBSERVATION", 25, 34], ["bocavirus infections", "OBSERVATION", 98, 118]]], ["68 The combination of human bocavirus and rhinovirus was the most typical dual infection.", [["infection", "DISEASE", 79, 88], ["human", "ORGANISM", 22, 27], ["bocavirus", "CANCER", 28, 37], ["rhinovirus", "ORGANISM", 42, 52], ["human", "SPECIES", 22, 27], ["human bocavirus", "SPECIES", 22, 37], ["human bocavirus", "PROBLEM", 22, 37], ["rhinovirus", "PROBLEM", 42, 52], ["the most typical dual infection", "PROBLEM", 57, 88], ["human bocavirus", "OBSERVATION", 22, 37], ["rhinovirus", "OBSERVATION", 42, 52], ["most typical", "OBSERVATION_MODIFIER", 61, 73], ["dual", "OBSERVATION_MODIFIER", 74, 78], ["infection", "OBSERVATION", 79, 88]]], ["In a comprehensive virological study of childhood pneumonia, two or more viruses were detected in 61 (18%) of 338 pneumonia episodes, and three viruses were recorded in nine cases.", [["pneumonia", "DISEASE", 50, 59], ["pneumonia", "DISEASE", 114, 123], ["a comprehensive virological study", "TEST", 3, 36], ["childhood pneumonia", "PROBLEM", 40, 59], ["more viruses", "PROBLEM", 68, 80], ["pneumonia episodes", "PROBLEM", 114, 132], ["three viruses", "PROBLEM", 138, 151], ["pneumonia", "OBSERVATION", 50, 59], ["pneumonia", "OBSERVATION", 114, 123]]], ["41 Human bocavirus was associated with other viruses in 33 (69%) of 48 episodes, followed by infl uenza viruses (13/25; 52%) and respiratory syncytial virus (34/67; 51%).", [["infl uenza viruses", "DISEASE", 93, 111], ["respiratory syncytial virus", "DISEASE", 129, 156], ["Human", "ORGANISM", 3, 8], ["bocavirus", "CANCER", 9, 18], ["infl uenza viruses", "ORGANISM", 93, 111], ["respiratory syncytial virus", "ORGANISM", 129, 156], ["Human", "SPECIES", 3, 8], ["respiratory syncytial virus", "SPECIES", 129, 156], ["Human bocavirus", "SPECIES", 3, 18], ["infl uenza viruses", "SPECIES", 93, 111], ["respiratory syncytial virus", "SPECIES", 129, 156], ["Human bocavirus", "PROBLEM", 3, 18], ["other viruses", "PROBLEM", 39, 52], ["infl uenza viruses", "PROBLEM", 93, 111], ["respiratory syncytial virus", "PROBLEM", 129, 156], ["bocavirus", "OBSERVATION", 9, 18], ["viruses", "OBSERVATION", 45, 52], ["respiratory syncytial", "ANATOMY", 129, 150]]], ["In another study, 64% of children with human bocavirus infection and co-infection with another virus had serological evidence of acute human bocavirus infection.", [["bocavirus infection", "DISEASE", 45, 64], ["co-infection", "DISEASE", 69, 81], ["bocavirus infection", "DISEASE", 141, 160], ["children", "ORGANISM", 25, 33], ["human", "ORGANISM", 39, 44], ["human", "ORGANISM", 135, 140], ["children", "SPECIES", 25, 33], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 135, 140], ["another study", "TEST", 3, 16], ["human bocavirus infection", "PROBLEM", 39, 64], ["co-infection", "PROBLEM", 69, 81], ["another virus", "PROBLEM", 87, 100], ["acute human bocavirus infection", "PROBLEM", 129, 160], ["bocavirus infection", "OBSERVATION", 45, 64], ["co-infection", "OBSERVATION", 69, 81], ["evidence of", "UNCERTAINTY", 117, 128], ["acute", "OBSERVATION_MODIFIER", 129, 134], ["human bocavirus infection", "OBSERVATION", 135, 160]]], ["69 The clinical relevance of detection of several viruses in pneumonia, and the association with severe illness, is uncertain.", [["pneumonia", "DISEASE", 61, 70], ["illness", "DISEASE", 104, 111], ["several viruses", "PROBLEM", 42, 57], ["pneumonia", "PROBLEM", 61, 70], ["severe illness", "PROBLEM", 97, 111], ["several", "OBSERVATION_MODIFIER", 42, 49], ["viruses", "OBSERVATION", 50, 57], ["pneumonia", "OBSERVATION", 61, 70], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["illness", "OBSERVATION", 104, 111]]], ["Viruses might interact indirectly or directly, resulting in complementation or inhibition.", [["Viruses", "PROBLEM", 0, 7]]], ["Children with pneumonia caused by co-infection with human bocavirus and other viruses have more wheezing than with viral pneumonia associated with a sole pathogen.", [["pneumonia", "DISEASE", 14, 23], ["co-infection", "DISEASE", 34, 46], ["wheezing", "DISEASE", 96, 104], ["viral pneumonia", "DISEASE", 115, 130], ["Children", "ORGANISM", 0, 8], ["human", "ORGANISM", 52, 57], ["Children", "SPECIES", 0, 8], ["human", "SPECIES", 52, 57], ["human bocavirus", "SPECIES", 52, 67], ["pneumonia", "PROBLEM", 14, 23], ["co-infection", "PROBLEM", 34, 46], ["human bocavirus", "PROBLEM", 52, 67], ["other viruses", "PROBLEM", 72, 85], ["wheezing", "PROBLEM", 96, 104], ["viral pneumonia", "PROBLEM", 115, 130], ["a sole pathogen", "PROBLEM", 147, 162], ["pneumonia", "OBSERVATION", 14, 23], ["co-infection", "OBSERVATION", 34, 46], ["pneumonia", "OBSERVATION", 121, 130], ["pathogen", "OBSERVATION", 154, 162]]], ["69 In one study, viral co-infections were associated with more severe pneumonia than were single infections, when rates of admission were looked at.", [["viral co-infections", "DISEASE", 17, 36], ["pneumonia", "DISEASE", 70, 79], ["infections", "DISEASE", 97, 107], ["one study", "TEST", 6, 15], ["viral co-infections", "PROBLEM", 17, 36], ["more severe pneumonia", "PROBLEM", 58, 79], ["single infections", "PROBLEM", 90, 107], ["co-infections", "OBSERVATION", 23, 36], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["pneumonia", "OBSERVATION", 70, 79], ["infections", "OBSERVATION", 97, 107]]], ["41Viral-bacterial co-infectionInterest has grown with respect to the interaction of bacteria and viruses in the pathogenesis of pneumonia.", [["pneumonia", "DISEASE", 128, 137], ["bacterial co-infection", "PROBLEM", 8, 30], ["bacteria", "PROBLEM", 84, 92], ["viruses", "PROBLEM", 97, 104], ["pneumonia", "PROBLEM", 128, 137], ["bacterial co-infection", "OBSERVATION", 8, 30], ["pneumonia", "OBSERVATION", 128, 137]]], ["Evidence from cell culture, ecological, post-mortem, and clinical studies support this area of interest.", [["cell culture", "ANATOMY", 14, 26], ["cell", "CELL", 14, 18], ["cell culture", "TEST", 14, 26], ["clinical studies", "TEST", 57, 73], ["cell culture", "OBSERVATION", 14, 26]]], ["A favoured hypothesis is that viral infection is followed by secondary bacterial infection.", [["viral infection", "DISEASE", 30, 45], ["bacterial infection", "DISEASE", 71, 90], ["A favoured hypothesis", "PROBLEM", 0, 21], ["viral infection", "PROBLEM", 30, 45], ["secondary bacterial infection", "PROBLEM", 61, 90], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["infection", "OBSERVATION", 36, 45], ["bacterial", "OBSERVATION_MODIFIER", 71, 80], ["infection", "OBSERVATION", 81, 90]]], ["Researchers who reassessed data from the infl uenza pandemics of 1918, 1957, and 1968 have suggested that most deaths during these periods probably resulted from secondary bacterial pneumonia.", [["deaths", "DISEASE", 111, 117], ["pneumonia", "DISEASE", 182, 191], ["infl uenza", "ORGANISM", 41, 51], ["secondary bacterial pneumonia", "PROBLEM", 162, 191], ["secondary", "OBSERVATION_MODIFIER", 162, 171], ["bacterial", "OBSERVATION_MODIFIER", 172, 181], ["pneumonia", "OBSERVATION", 182, 191]]], ["114 This fi nding contrasts with avian H5N1-associated pneumonia, which seems to be a primarily viral infection.", [["H5N1", "DISEASE", 39, 43], ["pneumonia", "DISEASE", 55, 64], ["viral infection", "DISEASE", 96, 111], ["avian H5N1", "ORGANISM", 33, 43], ["avian H5N1", "SPECIES", 33, 43], ["avian H5N1", "TREATMENT", 33, 43], ["pneumonia", "PROBLEM", 55, 64], ["a primarily viral infection", "PROBLEM", 84, 111], ["H5N1", "OBSERVATION", 39, 43], ["pneumonia", "OBSERVATION", 55, 64], ["seems to be", "UNCERTAINTY", 72, 83], ["primarily", "OBSERVATION_MODIFIER", 86, 95], ["viral", "OBSERVATION_MODIFIER", 96, 101], ["infection", "OBSERVATION", 102, 111]]], ["102 In patients with 2009 pandemic H1N1 infection, secondary bacterial infection developed in 4-24% of cases.", [["H1N1 infection", "DISEASE", 35, 49], ["bacterial infection", "DISEASE", 61, 80], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["pandemic H1N1", "SPECIES", 26, 39], ["2009 pandemic H1N1 infection", "PROBLEM", 21, 49], ["secondary bacterial infection", "PROBLEM", 51, 80], ["pandemic", "OBSERVATION_MODIFIER", 26, 34], ["H1N1", "OBSERVATION_MODIFIER", 35, 39], ["infection", "OBSERVATION", 40, 49], ["bacterial", "OBSERVATION_MODIFIER", 61, 70], ["infection", "OBSERVATION", 71, 80]]], ["103, 106, 115 Evidence of probable mixed viral-bacterial infection has been recorded in up to 45% of cases of communityacquired pneumonia in children.", [["viral-bacterial infection", "DISEASE", 41, 66], ["pneumonia", "DISEASE", 128, 137], ["children", "ORGANISM", 141, 149], ["children", "SPECIES", 141, 149], ["mixed viral-bacterial infection", "PROBLEM", 35, 66], ["communityacquired pneumonia", "PROBLEM", 110, 137], ["probable", "UNCERTAINTY", 26, 34], ["mixed", "OBSERVATION_MODIFIER", 35, 40], ["viral", "OBSERVATION", 41, 46], ["bacterial", "OBSERVATION_MODIFIER", 47, 56], ["infection", "OBSERVATION", 57, 66], ["pneumonia", "OBSERVATION", 128, 137]]], ["21, 30, [40] [41] [42] [43] [44] [45] [46] Not surprisingly, the most typical combination is Streptococcus pneumoniae with various respiratory viruses.", [["21, 30, [40] [41] [42] [43] [44] [45", "CHEMICAL", 0, 36], ["Streptococcus pneumoniae", "DISEASE", 93, 117], ["respiratory viruses", "DISEASE", 131, 150], ["21, 30, [40] [41] [42] [43] [44] [45]", "CHEMICAL", 0, 37], ["[40] [41] [42] [43] [44] [45] [46", "SIMPLE_CHEMICAL", 8, 41], ["Streptococcus pneumoniae", "ORGANISM", 93, 117], ["Streptococcus pneumoniae", "SPECIES", 93, 117], ["Streptococcus pneumoniae", "SPECIES", 93, 117], ["Streptococcus pneumoniae", "PROBLEM", 93, 117], ["various respiratory viruses", "PROBLEM", 123, 150], ["Streptococcus pneumoniae", "OBSERVATION", 93, 117], ["respiratory viruses", "OBSERVATION", 131, 150]]], ["In developing countries, both viruses and bacteria have been detected directly in lung aspirate samples from children with pneumonia.", [["lung aspirate samples", "ANATOMY", 82, 103], ["pneumonia", "DISEASE", 123, 132], ["lung aspirate samples", "ORGANISM_SUBSTANCE", 82, 103], ["children", "ORGANISM", 109, 117], ["children", "SPECIES", 109, 117], ["both viruses", "PROBLEM", 25, 37], ["bacteria", "PROBLEM", 42, 50], ["pneumonia", "PROBLEM", 123, 132], ["viruses", "OBSERVATION", 30, 37], ["lung", "ANATOMY", 82, 86], ["aspirate", "OBSERVATION", 87, 95], ["pneumonia", "OBSERVATION", 123, 132]]], ["22 In a study from The Gambia, 45 of 74 children had evidence of pneumococcal communityacquired pneumonia and 15 (33%) of these also had evidence of a respiratory virus infection, shown by virus culture or serological tests.", [["pneumococcal communityacquired pneumonia", "DISEASE", 65, 105], ["respiratory virus infection", "DISEASE", 151, 178], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["pneumococcal", "SPECIES", 65, 77], ["a study", "TEST", 6, 13], ["pneumococcal communityacquired pneumonia", "PROBLEM", 65, 105], ["a respiratory virus infection", "PROBLEM", 149, 178], ["virus culture", "TEST", 189, 202], ["serological tests", "TEST", 206, 223], ["evidence of", "UNCERTAINTY", 53, 64], ["pneumococcal", "OBSERVATION_MODIFIER", 65, 77], ["communityacquired", "OBSERVATION_MODIFIER", 78, 95], ["pneumonia", "OBSERVATION", 96, 105], ["evidence of", "UNCERTAINTY", 137, 148], ["respiratory virus infection", "OBSERVATION", 151, 178]]], ["116 In a study from Nigeria, 117 virological analysis was done in 122 children with community-acquired pneumonia.", [["pneumonia", "DISEASE", 103, 112], ["children", "ORGANISM", 70, 78], ["children", "SPECIES", 70, 78], ["a study", "TEST", 7, 14], ["virological analysis", "TEST", 33, 53], ["community-acquired pneumonia", "PROBLEM", 84, 112], ["pneumonia", "OBSERVATION", 103, 112]]], ["61 (50%) had evidence of viral infection and, of those, ten (16%) also had blood cultures positive for bacteria, most usually Staphylococcus aureus.", [["blood cultures", "ANATOMY", 75, 89], ["viral infection", "DISEASE", 25, 40], ["Staphylococcus aureus", "DISEASE", 126, 147], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["Staphylococcus aureus", "ORGANISM", 126, 147], ["Staphylococcus aureus", "SPECIES", 126, 147], ["Staphylococcus aureus", "SPECIES", 126, 147], ["viral infection", "PROBLEM", 25, 40], ["blood cultures", "TEST", 75, 89], ["bacteria", "PROBLEM", 103, 111], ["Staphylococcus aureus", "PROBLEM", 126, 147], ["evidence of", "UNCERTAINTY", 13, 24], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40], ["Staphylococcus aureus", "OBSERVATION", 126, 147]]], ["Furthermore, ten (16%) of 62 cases with measles-associated community-acquired pneumonia had bacteraemia.", [["measles", "DISEASE", 40, 47], ["pneumonia", "DISEASE", 78, 87], ["bacteraemia", "DISEASE", 92, 103], ["measles", "PROBLEM", 40, 47], ["acquired pneumonia", "PROBLEM", 69, 87], ["bacteraemia", "PROBLEM", 92, 103], ["pneumonia", "OBSERVATION", 78, 87], ["bacteraemia", "OBSERVATION", 92, 103]]], ["117 Mixed viral-bacterial infections in adults with community-acquired pneumonia seem to be reported less frequently than those in children.", [["viral-bacterial infections", "DISEASE", 10, 36], ["pneumonia", "DISEASE", 71, 80], ["children", "ORGANISM", 131, 139], ["children", "SPECIES", 131, 139], ["Mixed viral-bacterial infections", "PROBLEM", 4, 36], ["community-acquired pneumonia", "PROBLEM", 52, 80], ["Mixed", "OBSERVATION_MODIFIER", 4, 9], ["viral", "OBSERVATION_MODIFIER", 10, 15], ["bacterial", "OBSERVATION_MODIFIER", 16, 25], ["infections", "OBSERVATION", 26, 36], ["pneumonia", "OBSERVATION", 71, 80]]], ["19, 20, [77] [78] [79] [80] [81] [82] [83] [84] [85] In one study, both viral and bacterial pathogens were noted in 35 (14%) of 242 cases.", [["19, 20, [77] [78] [79] [80] [81] [82] [83] [84]", "CHEMICAL", 0, 47], ["[77] [78] [79] [80] [81] [82] [83] [84] [85", "SIMPLE_CHEMICAL", 8, 51], ["one study", "TEST", 56, 65], ["both viral and bacterial pathogens", "TEST", 67, 101]]], ["84 In another investigation, evidence of mixed viral and bacterial infections was reported in 45 (15%) of 304 patients (median age 70 years).", [["viral and bacterial infections", "DISEASE", 47, 77], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["another investigation", "TEST", 6, 27], ["mixed viral and bacterial infections", "PROBLEM", 41, 77], ["evidence of", "UNCERTAINTY", 29, 40], ["mixed", "OBSERVATION_MODIFIER", 41, 46], ["viral", "OBSERVATION", 47, 52], ["bacterial", "OBSERVATION_MODIFIER", 57, 66], ["infections", "OBSERVATION", 67, 77]]], ["The most frequent combinations were rhinovirus plus Strep pneumoniae and infl uenza A plus Strep pneumoniae.", [["rhinovirus plus Strep pneumoniae", "DISEASE", 36, 68], ["Strep pneumoniae", "DISEASE", 91, 107], ["rhinovirus", "ORGANISM", 36, 46], ["Strep pneumoniae", "ORGANISM", 52, 68], ["infl uenza A", "ORGANISM", 73, 85], ["Strep pneumoniae", "ORGANISM", 91, 107], ["Strep pneumoniae", "SPECIES", 52, 68], ["Strep pneumoniae", "SPECIES", 91, 107], ["Strep pneumoniae", "SPECIES", 52, 68], ["Strep pneumoniae", "SPECIES", 91, 107], ["rhinovirus", "PROBLEM", 36, 46], ["Strep pneumoniae", "PROBLEM", 52, 68], ["infl uenza A plus Strep pneumoniae", "PROBLEM", 73, 107], ["Strep pneumoniae", "OBSERVATION", 91, 107]]], ["19 Undoubtedly, detection of several pathogens will be noted more frequently as more elaborate diagnostic tests are used as part of pneumonia aetiological studies.", [["pneumonia", "DISEASE", 132, 141], ["several pathogens", "PROBLEM", 29, 46], ["diagnostic tests", "TEST", 95, 111], ["pneumonia aetiological studies", "PROBLEM", 132, 162], ["several", "OBSERVATION_MODIFIER", 29, 36], ["pathogens", "OBSERVATION", 37, 46], ["pneumonia", "OBSERVATION", 132, 141]]], ["Presuming that viral infection precedes bacterial infection, we are likely to continue underestimating the true incidence of viralbacterial co-infection because of diffi culties detecting the earlier infection.Viral-bacterial co-infectionEvidence, albeit sparse, suggests that mixed infections could induce a more severe infl ammatory and clinical disease than individual bacterial or viral infections.", [["viral infection", "DISEASE", 15, 30], ["bacterial infection", "DISEASE", 40, 59], ["co-infection", "DISEASE", 140, 152], ["infection", "DISEASE", 200, 209], ["Viral-bacterial co-infection", "DISEASE", 210, 238], ["infections", "DISEASE", 283, 293], ["viral infections", "DISEASE", 385, 401], ["viralbacterial", "CANCER", 125, 139], ["Viral-bacterial", "ORGANISM", 210, 225], ["viral infection", "PROBLEM", 15, 30], ["bacterial infection", "PROBLEM", 40, 59], ["viralbacterial co-infection", "PROBLEM", 125, 152], ["diffi culties", "PROBLEM", 164, 177], ["the earlier infection", "PROBLEM", 188, 209], ["Viral-bacterial co-infection", "PROBLEM", 210, 238], ["mixed infections", "PROBLEM", 277, 293], ["a more severe infl ammatory", "PROBLEM", 307, 334], ["clinical disease", "PROBLEM", 339, 355], ["individual bacterial or viral infections", "PROBLEM", 361, 401], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30], ["bacterial", "OBSERVATION_MODIFIER", 40, 49], ["infection", "OBSERVATION", 50, 59], ["viralbacterial co-infection", "OBSERVATION", 125, 152], ["infection", "OBSERVATION", 200, 209], ["bacterial co-infection", "OBSERVATION", 216, 238], ["mixed", "OBSERVATION_MODIFIER", 277, 282], ["infections", "OBSERVATION", 283, 293], ["severe", "OBSERVATION_MODIFIER", 314, 320], ["viral", "OBSERVATION_MODIFIER", 385, 390], ["infections", "OBSERVATION", 391, 401]]], ["19, 84, 118 Concomitant infl uenza virus and Staph aureus infection can cause severe fatal pneumonia in children and adults.", [["Staph aureus infection", "DISEASE", 45, 67], ["pneumonia", "DISEASE", 91, 100], ["infl uenza virus", "ORGANISM", 24, 40], ["Staph aureus", "ORGANISM", 45, 57], ["children", "ORGANISM", 104, 112], ["Staph aureus", "SPECIES", 45, 57], ["children", "SPECIES", 104, 112], ["infl uenza virus", "SPECIES", 24, 40], ["Staph aureus", "SPECIES", 45, 57], ["Concomitant infl uenza virus", "PROBLEM", 12, 40], ["Staph aureus infection", "PROBLEM", 45, 67], ["severe fatal pneumonia", "PROBLEM", 78, 100], ["Staph aureus", "OBSERVATION", 45, 57], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["fatal", "OBSERVATION_MODIFIER", 85, 90], ["pneumonia", "OBSERVATION", 91, 100]]], ["[119] [120] [121] Moreover, in one pneumonia study, half of children with treatment failure had evidence of mixed viral-bacterial infection.", [["pneumonia", "DISEASE", 35, 44], ["viral-bacterial infection", "DISEASE", 114, 139], ["children", "ORGANISM", 60, 68], ["children", "SPECIES", 60, 68], ["one pneumonia study", "PROBLEM", 31, 50], ["treatment failure", "PROBLEM", 74, 91], ["mixed viral-bacterial infection", "PROBLEM", 108, 139], ["pneumonia", "OBSERVATION", 35, 44], ["mixed", "OBSERVATION_MODIFIER", 108, 113], ["viral", "OBSERVATION", 114, 119], ["bacterial", "OBSERVATION_MODIFIER", 120, 129], ["infection", "OBSERVATION", 130, 139]]], ["39 Similarly, in adults, rhinoviruspneumococcal and infl uenza-bacterial pneumonia co-infections are associated with severe pneumonia and raised mortality.", [["pneumonia", "DISEASE", 73, 82], ["pneumonia", "DISEASE", 124, 133], ["adults", "ORGANISM", 17, 23], ["rhinoviruspneumococcal", "ORGANISM", 25, 47], ["infl uenza-bacterial", "ORGANISM", 52, 72], ["rhinoviruspneumococcal", "TREATMENT", 25, 47], ["infl uenza-bacterial pneumonia co-infections", "PROBLEM", 52, 96], ["severe pneumonia", "PROBLEM", 117, 133], ["raised mortality", "PROBLEM", 138, 154], ["uenza-bacterial pneumonia", "OBSERVATION", 57, 82], ["associated with", "UNCERTAINTY", 101, 116], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["pneumonia", "OBSERVATION", 124, 133]]], ["19, 84, 121 Detection of Strep pneumoniae in the nasopharynx of patients with 2009 pandemic H1N1 infection predicted severe disease outcome.", [["nasopharynx", "ANATOMY", 49, 60], ["Strep pneumoniae", "DISEASE", 25, 41], ["H1N1 infection", "DISEASE", 92, 106], ["Strep pneumoniae", "ORGANISM", 25, 41], ["nasopharynx", "ORGAN", 49, 60], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["pandemic H1N1", "SPECIES", 83, 96], ["Strep pneumoniae", "SPECIES", 25, 41], ["Strep pneumoniae in the nasopharynx", "PROBLEM", 25, 60], ["2009 pandemic H1N1 infection", "PROBLEM", 78, 106], ["severe disease outcome", "PROBLEM", 117, 139], ["Strep pneumoniae", "OBSERVATION", 25, 41], ["nasopharynx", "ANATOMY", 49, 60], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["disease", "OBSERVATION", 124, 131]]], ["122PathologyPost-mortem studies provide direct evidence for a viral cause of pneumonia and descriptions of characteristics of lung histopathology.", [["lung", "ANATOMY", 126, 130], ["pneumonia", "DISEASE", 77, 86], ["lung", "ORGAN", 126, 130], ["mortem studies", "TEST", 17, 31], ["a viral cause", "PROBLEM", 60, 73], ["pneumonia", "PROBLEM", 77, 86], ["lung histopathology", "PROBLEM", 126, 145], ["pneumonia", "OBSERVATION", 77, 86], ["lung", "ANATOMY", 126, 130], ["histopathology", "OBSERVATION", 131, 145]]], ["Many diff erent respiratory viruses have been detected in lung tissue in case reports or in larger series.PathologyIn 200 children who died from serious respiratory infections in Brazil, use of immunohistochemical techniques aided detection of viruses in lung tissue from 53 (34%) with bronchopneumonia and 18 (42%) with interstitial pneumonitis, predominantly respiratory syncytial virus, infl uenza A and B viruses, adenovirus, and parainfl uenza viruses types 1, 2, and 3.", [["lung tissue", "ANATOMY", 58, 69], ["respiratory", "ANATOMY", 153, 164], ["lung tissue", "ANATOMY", 255, 266], ["interstitial", "ANATOMY", 321, 333], ["respiratory infections", "DISEASE", 153, 175], ["bronchopneumonia", "DISEASE", 286, 302], ["interstitial pneumonitis", "DISEASE", 321, 345], ["respiratory syncytial virus", "DISEASE", 361, 388], ["lung tissue", "TISSUE", 58, 69], ["children", "ORGANISM", 122, 130], ["lung tissue", "TISSUE", 255, 266], ["respiratory syncytial virus", "ORGANISM", 361, 388], ["infl uenza A", "ORGANISM", 390, 402], ["B viruses", "ORGANISM", 407, 416], ["adenovirus", "ORGANISM", 418, 428], ["parainfl uenza viruses", "ORGANISM", 434, 456], ["3", "GENE_OR_GENE_PRODUCT", 473, 474], ["children", "SPECIES", 122, 130], ["respiratory syncytial virus", "SPECIES", 361, 388], ["infl uenza A", "SPECIES", 390, 402], ["B viruses", "SPECIES", 407, 416], ["parainfl uenza viruses", "SPECIES", 434, 456], ["Many diff erent respiratory viruses", "PROBLEM", 0, 35], ["serious respiratory infections", "PROBLEM", 145, 175], ["immunohistochemical techniques", "TEST", 194, 224], ["viruses in lung tissue", "PROBLEM", 244, 266], ["bronchopneumonia", "PROBLEM", 286, 302], ["interstitial pneumonitis", "PROBLEM", 321, 345], ["predominantly respiratory syncytial virus", "PROBLEM", 347, 388], ["infl uenza A and B viruses", "PROBLEM", 390, 416], ["adenovirus", "PROBLEM", 418, 428], ["parainfl uenza viruses types", "PROBLEM", 434, 462], ["respiratory viruses", "OBSERVATION", 16, 35], ["lung", "ANATOMY", 58, 62], ["serious", "OBSERVATION_MODIFIER", 145, 152], ["respiratory", "ANATOMY", 153, 164], ["infections", "OBSERVATION", 165, 175], ["viruses", "OBSERVATION", 244, 251], ["lung", "ANATOMY", 255, 259], ["bronchopneumonia", "OBSERVATION", 286, 302], ["interstitial", "ANATOMY_MODIFIER", 321, 333], ["pneumonitis", "OBSERVATION", 334, 345], ["predominantly", "OBSERVATION_MODIFIER", 347, 360], ["respiratory syncytial virus", "OBSERVATION", 361, 388], ["parainfl uenza", "ANATOMY", 434, 448]]], ["123 In another study from Mexico, PCR detected respiratory syncytial virus in lung tissue from 29 (30%) of 98 children who died from pneumonia.", [["lung tissue", "ANATOMY", 78, 89], ["respiratory syncytial virus", "DISEASE", 47, 74], ["pneumonia", "DISEASE", 133, 142], ["respiratory syncytial virus", "ORGANISM", 47, 74], ["lung tissue", "TISSUE", 78, 89], ["children", "ORGANISM", 110, 118], ["children", "SPECIES", 110, 118], ["respiratory syncytial virus", "SPECIES", 47, 74], ["another study", "TEST", 7, 20], ["Mexico, PCR", "TEST", 26, 37], ["respiratory syncytial virus in lung tissue", "PROBLEM", 47, 89], ["pneumonia", "PROBLEM", 133, 142], ["respiratory syncytial virus", "OBSERVATION", 47, 74], ["lung", "ANATOMY", 78, 82], ["pneumonia", "OBSERVATION", 133, 142]]], ["124 Of archived lung tissue from 175 children who died of pneumonia in south China, 20 samples had adenovirus detected by PCR or by immunohistochemistry.", [["lung tissue", "ANATOMY", 16, 27], ["samples", "ANATOMY", 87, 94], ["pneumonia", "DISEASE", 58, 67], ["lung tissue", "TISSUE", 16, 27], ["children", "ORGANISM", 37, 45], ["samples", "CANCER", 87, 94], ["adenovirus", "ORGANISM", 99, 109], ["children", "SPECIES", 37, 45], ["adenovirus", "SPECIES", 99, 109], ["archived lung tissue", "PROBLEM", 7, 27], ["pneumonia", "PROBLEM", 58, 67], ["adenovirus", "PROBLEM", 99, 109], ["lung", "ANATOMY", 16, 20], ["tissue", "OBSERVATION", 21, 27], ["pneumonia", "OBSERVATION", 58, 67]]], ["72 Rhinovirus infection of the lung has also been shown by histopathology.", [["lung", "ANATOMY", 31, 35], ["infection", "DISEASE", 14, 23], ["lung", "ORGAN", 31, 35], ["Rhinovirus infection of the lung", "PROBLEM", 3, 35], ["Rhinovirus", "OBSERVATION", 3, 13], ["lung", "ANATOMY", 31, 35], ["histopathology", "OBSERVATION", 59, 73]]], ["125 The nature of histopathological changes in viral pneumonia varies, possibly an indication of diff erences in viral infections and comorbidity.", [["pneumonia", "DISEASE", 53, 62], ["viral infections", "DISEASE", 113, 129], ["histopathological changes", "PROBLEM", 18, 43], ["viral pneumonia varies", "PROBLEM", 47, 69], ["diff erences", "PROBLEM", 97, 109], ["viral infections", "PROBLEM", 113, 129], ["comorbidity", "PROBLEM", 134, 145], ["histopathological", "OBSERVATION", 18, 35], ["viral", "OBSERVATION_MODIFIER", 47, 52], ["pneumonia", "OBSERVATION", 53, 62], ["viral", "OBSERVATION_MODIFIER", 113, 118], ["infections", "OBSERVATION", 119, 129]]], ["Generally, interstitial pneumonitis with lymphocytic infi ltrations is seen in viral pneumonitis.", [["interstitial", "ANATOMY", 11, 23], ["interstitial pneumonitis", "DISEASE", 11, 35], ["lymphocytic infi ltrations", "DISEASE", 41, 67], ["pneumonitis", "DISEASE", 85, 96], ["interstitial pneumonitis", "PATHOLOGICAL_FORMATION", 11, 35], ["interstitial pneumonitis", "PROBLEM", 11, 35], ["lymphocytic infi ltrations", "PROBLEM", 41, 67], ["viral pneumonitis", "PROBLEM", 79, 96], ["interstitial", "ANATOMY_MODIFIER", 11, 23], ["pneumonitis", "OBSERVATION", 24, 35], ["lymphocytic infi ltrations", "OBSERVATION", 41, 67], ["viral", "OBSERVATION_MODIFIER", 79, 84], ["pneumonitis", "OBSERVATION", 85, 96]]], ["123 In fatal cases of pneumonia caused by respiratory syncytial virus infection, post-mortem evidence shows infection of both bronchial and alveolar epithelium.", [["bronchial", "ANATOMY", 126, 135], ["alveolar epithelium", "ANATOMY", 140, 159], ["pneumonia", "DISEASE", 22, 31], ["respiratory syncytial virus infection", "DISEASE", 42, 79], ["infection", "DISEASE", 108, 117], ["respiratory syncytial virus", "ORGANISM", 42, 69], ["bronchial", "MULTI-TISSUE_STRUCTURE", 126, 135], ["alveolar epithelium", "TISSUE", 140, 159], ["respiratory syncytial virus", "SPECIES", 42, 69], ["respiratory syncytial virus", "SPECIES", 42, 69], ["pneumonia", "PROBLEM", 22, 31], ["respiratory syncytial virus infection", "PROBLEM", 42, 79], ["post-mortem evidence", "TEST", 81, 101], ["infection of both bronchial and alveolar epithelium", "PROBLEM", 108, 159], ["fatal", "OBSERVATION_MODIFIER", 7, 12], ["pneumonia", "OBSERVATION", 22, 31], ["respiratory syncytial virus infection", "OBSERVATION", 42, 79], ["infection", "OBSERVATION", 108, 117], ["both", "ANATOMY_MODIFIER", 121, 125], ["bronchial", "ANATOMY", 126, 135], ["alveolar", "ANATOMY_MODIFIER", 140, 148], ["epithelium", "ANATOMY_MODIFIER", 149, 159]]], ["126 Most cells around the bronchioles and in the alveolar interstitium were alveolar macrophages and monocytes, and CD3positive lymphocytes were also seen frequently around bronchioles.", [["cells", "ANATOMY", 9, 14], ["bronchioles", "ANATOMY", 26, 37], ["alveolar interstitium", "ANATOMY", 49, 70], ["alveolar macrophages", "ANATOMY", 76, 96], ["monocytes", "ANATOMY", 101, 110], ["CD3positive lymphocytes", "ANATOMY", 116, 139], ["bronchioles", "ANATOMY", 173, 184], ["cells", "CELL", 9, 14], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 26, 37], ["alveolar interstitium", "MULTI-TISSUE_STRUCTURE", 49, 70], ["alveolar macrophages", "CELL", 76, 96], ["monocytes", "CELL", 101, 110], ["CD3positive lymphocytes", "CELL", 116, 139], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 173, 184], ["alveolar macrophages", "CELL_TYPE", 76, 96], ["monocytes", "CELL_TYPE", 101, 110], ["CD3positive lymphocytes", "CELL_TYPE", 116, 139], ["alveolar macrophages", "PROBLEM", 76, 96], ["monocytes", "TEST", 101, 110], ["CD3positive lymphocytes", "PROBLEM", 116, 139], ["bronchioles", "ANATOMY", 26, 37], ["alveolar", "ANATOMY_MODIFIER", 49, 57], ["interstitium", "ANATOMY_MODIFIER", 58, 70], ["alveolar macrophages", "OBSERVATION", 76, 96], ["monocytes", "OBSERVATION_MODIFIER", 101, 110], ["CD3positive lymphocytes", "OBSERVATION", 116, 139], ["bronchioles", "ANATOMY", 173, 184]]], ["In rhinovirus pneumonia, hyperplasia and desquamation of alveolar-lining cells and immunohistochemical localisation of rhinoviral antigen in alveolar epithelial cells and macrophages were seen.", [["alveolar-lining cells", "ANATOMY", 57, 78], ["alveolar epithelial cells", "ANATOMY", 141, 166], ["macrophages", "ANATOMY", 171, 182], ["rhinovirus pneumonia", "DISEASE", 3, 23], ["hyperplasia", "DISEASE", 25, 36], ["rhinovirus", "ORGANISM", 3, 13], ["alveolar-lining cells", "CELL", 57, 78], ["rhinoviral antigen", "GENE_OR_GENE_PRODUCT", 119, 137], ["alveolar epithelial cells", "CELL", 141, 166], ["macrophages", "CELL", 171, 182], ["alveolar-lining cells", "CELL_TYPE", 57, 78], ["rhinoviral antigen", "PROTEIN", 119, 137], ["alveolar epithelial cells", "CELL_TYPE", 141, 166], ["macrophages", "CELL_TYPE", 171, 182], ["rhinovirus pneumonia", "PROBLEM", 3, 23], ["hyperplasia", "PROBLEM", 25, 36], ["desquamation of alveolar-lining cells", "PROBLEM", 41, 78], ["immunohistochemical localisation", "TEST", 83, 115], ["rhinoviral antigen in alveolar epithelial cells", "PROBLEM", 119, 166], ["macrophages", "PROBLEM", 171, 182], ["rhinovirus", "OBSERVATION_MODIFIER", 3, 13], ["pneumonia", "OBSERVATION", 14, 23], ["hyperplasia", "OBSERVATION", 25, 36], ["desquamation", "OBSERVATION_MODIFIER", 41, 53], ["alveolar", "ANATOMY_MODIFIER", 57, 65], ["lining cells", "OBSERVATION", 66, 78], ["rhinoviral antigen", "OBSERVATION", 119, 137], ["alveolar epithelial cells", "OBSERVATION", 141, 166], ["macrophages", "OBSERVATION", 171, 182]]], ["125 In fatal cases of human metapneumovirus pneumonia, pathological analysis indicated bilateral haemorrhagic bronchopneumonia.", [["metapneumovirus pneumonia", "DISEASE", 28, 53], ["bronchopneumonia", "DISEASE", 110, 126], ["human", "ORGANISM", 22, 27], ["metapneumovirus", "ORGANISM", 28, 43], ["human", "SPECIES", 22, 27], ["metapneumovirus", "SPECIES", 28, 43], ["human metapneumovirus", "SPECIES", 22, 43], ["human metapneumovirus pneumonia", "PROBLEM", 22, 53], ["pathological analysis", "TEST", 55, 76], ["bilateral haemorrhagic bronchopneumonia", "PROBLEM", 87, 126], ["fatal", "OBSERVATION_MODIFIER", 7, 12], ["metapneumovirus pneumonia", "OBSERVATION", 28, 53], ["bilateral", "ANATOMY_MODIFIER", 87, 96], ["haemorrhagic", "OBSERVATION_MODIFIER", 97, 109], ["bronchopneumonia", "OBSERVATION", 110, 126]]], ["127 Histopathological fi ndings in fatal cases of SARS and avian H5N1 infection are quite similar and have been characterised by diff use alveolar damage, desquamation of pneumocytes, oedema, and hyaline-membrane formation.", [["alveolar", "ANATOMY", 138, 146], ["pneumocytes", "ANATOMY", 171, 182], ["hyaline-membrane", "ANATOMY", 196, 212], ["SARS", "DISEASE", 50, 54], ["H5N1 infection", "DISEASE", 65, 79], ["alveolar damage", "DISEASE", 138, 153], ["oedema", "DISEASE", 184, 190], ["avian H5N1", "ORGANISM", 59, 69], ["alveolar", "TISSUE", 138, 146], ["pneumocytes", "CELL", 171, 182], ["hyaline-membrane", "CELLULAR_COMPONENT", 196, 212], ["avian H5N1", "SPECIES", 59, 69], ["Histopathological fi", "TEST", 4, 24], ["SARS", "PROBLEM", 50, 54], ["avian H5N1 infection", "PROBLEM", 59, 79], ["alveolar damage", "PROBLEM", 138, 153], ["desquamation of pneumocytes", "PROBLEM", 155, 182], ["oedema", "PROBLEM", 184, 190], ["hyaline-membrane formation", "PROBLEM", 196, 222], ["alveolar damage", "OBSERVATION", 138, 153], ["pneumocytes", "OBSERVATION", 171, 182], ["oedema", "OBSERVATION", 184, 190], ["hyaline", "OBSERVATION_MODIFIER", 196, 203], ["membrane formation", "OBSERVATION", 204, 222]]], ["128, 129 Diff use alveolar damage has also been recorded in the lungs of people who died of 2009 pandemic H1N1 infections (fi gure 3).", [["alveolar", "ANATOMY", 18, 26], ["lungs", "ANATOMY", 64, 69], ["Diff", "CHEMICAL", 9, 13], ["alveolar damage", "DISEASE", 18, 33], ["H1N1 infections", "DISEASE", 106, 121], ["alveolar", "TISSUE", 18, 26], ["lungs", "ORGAN", 64, 69], ["people", "ORGANISM", 73, 79], ["people", "SPECIES", 73, 79], ["alveolar damage", "PROBLEM", 18, 33], ["pandemic H1N1 infections", "PROBLEM", 97, 121], ["alveolar damage", "OBSERVATION", 18, 33], ["lungs", "ANATOMY", 64, 69]]], ["Furthermore, necrotising bronchiolitis, diff use alveolar damage with alveolar haemorrhage, alveolar septal oedema, hyaline membranes, hyperplasia of type 2 pneumocytes, and necrosis of bronchiolar walls have been noted.", [["alveolar", "ANATOMY", 49, 57], ["alveolar", "ANATOMY", 70, 78], ["alveolar septal", "ANATOMY", 92, 107], ["hyaline membranes", "ANATOMY", 116, 133], ["type 2 pneumocytes", "ANATOMY", 150, 168], ["bronchiolar walls", "ANATOMY", 186, 203], ["bronchiolitis", "DISEASE", 25, 38], ["alveolar damage", "DISEASE", 49, 64], ["alveolar haemorrhage", "DISEASE", 70, 90], ["alveolar septal oedema", "DISEASE", 92, 114], ["necrosis", "DISEASE", 174, 182], ["alveolar", "TISSUE", 49, 57], ["alveolar", "MULTI-TISSUE_STRUCTURE", 70, 78], ["alveolar septal", "PATHOLOGICAL_FORMATION", 92, 107], ["hyaline membranes", "CELLULAR_COMPONENT", 116, 133], ["bronchiolar walls", "TISSUE", 186, 203], ["necrotising bronchiolitis", "PROBLEM", 13, 38], ["alveolar damage", "PROBLEM", 49, 64], ["alveolar haemorrhage", "PROBLEM", 70, 90], ["alveolar septal oedema", "PROBLEM", 92, 114], ["hyaline membranes", "PROBLEM", 116, 133], ["hyperplasia", "PROBLEM", 135, 146], ["type 2 pneumocytes", "PROBLEM", 150, 168], ["necrosis of bronchiolar walls", "PROBLEM", 174, 203], ["necrotising", "OBSERVATION_MODIFIER", 13, 24], ["bronchiolitis", "OBSERVATION", 25, 38], ["alveolar", "ANATOMY_MODIFIER", 49, 57], ["alveolar", "ANATOMY_MODIFIER", 70, 78], ["haemorrhage", "OBSERVATION", 79, 90], ["alveolar", "ANATOMY_MODIFIER", 92, 100], ["septal", "ANATOMY_MODIFIER", 101, 107], ["oedema", "OBSERVATION", 108, 114], ["hyaline membranes", "OBSERVATION", 116, 133], ["hyperplasia", "OBSERVATION", 135, 146], ["type 2", "OBSERVATION_MODIFIER", 150, 156], ["pneumocytes", "OBSERVATION", 157, 168], ["necrosis", "OBSERVATION", 174, 182], ["bronchiolar", "ANATOMY_MODIFIER", 186, 197], ["walls", "ANATOMY_MODIFIER", 198, 203]]], ["130, 131 Histopathological evidence of bacterial co-infection was reported in 29 of 100 fatal H1N1 cases.", [["bacterial co-infection", "DISEASE", 39, 61], ["H1N1", "DISEASE", 94, 98], ["bacterial co-infection", "PROBLEM", 39, 61], ["evidence of", "UNCERTAINTY", 27, 38], ["bacterial co-infection", "OBSERVATION", 39, 61]]], ["132ManagementDo all patients with community-acquired pneumonia, including those with evidence of viral infection, need to be treated with antibiotics?", [["pneumonia", "DISEASE", 53, 62], ["viral infection", "DISEASE", 97, 112], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["community-acquired pneumonia", "PROBLEM", 34, 62], ["viral infection", "PROBLEM", 97, 112], ["antibiotics", "TREATMENT", 138, 149], ["pneumonia", "OBSERVATION", 53, 62], ["viral", "OBSERVATION_MODIFIER", 97, 102], ["infection", "OBSERVATION", 103, 112]]], ["Some experts recommend that all patients with pneumonia should receive antibiotic treatment, because exclusion of the presence of bacterial infection is impossible.", [["pneumonia", "DISEASE", 46, 55], ["bacterial infection", "DISEASE", 130, 149], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["pneumonia", "PROBLEM", 46, 55], ["antibiotic treatment", "TREATMENT", 71, 91], ["bacterial infection", "PROBLEM", 130, 149], ["pneumonia", "OBSERVATION", 46, 55], ["bacterial", "OBSERVATION_MODIFIER", 130, 139], ["infection", "OBSERVATION", 140, 149]]], ["Recommendations of the British Thoracic Society are that antibiotic treatment can be withheld in young children with mild illness in whom viral infection is likely.", [["viral infection", "DISEASE", 138, 153], ["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["antibiotic treatment", "TREATMENT", 57, 77], ["mild illness", "PROBLEM", 117, 129], ["viral infection", "PROBLEM", 138, 153], ["Thoracic", "ANATOMY", 31, 39], ["infection", "OBSERVATION", 144, 153]]], ["1 As far as we know, only one randomised placebo-controlled study has been done to investigate the need for antibiotic treatment in childhood community-acquired pneumonia.", [["pneumonia", "DISEASE", 161, 170], ["antibiotic treatment", "TREATMENT", 108, 128], ["acquired pneumonia", "PROBLEM", 152, 170], ["pneumonia", "OBSERVATION", 161, 170]]], ["133 In 136 children, no clinically signifi cant effi cacy of antibiotics was recorded.", [["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19], ["antibiotics", "TREATMENT", 61, 72]]], ["Most study children had fairly mild disease and the investigation was undertaken during an epidemic of respiratory syncytial virus, so most participants probably had pneumonia caused by this virus.", [["respiratory syncytial virus", "DISEASE", 103, 130], ["pneumonia", "DISEASE", 166, 175], ["children", "ORGANISM", 11, 19], ["respiratory syncytial virus", "ORGANISM", 103, 130], ["participants", "ORGANISM", 140, 152], ["children", "SPECIES", 11, 19], ["participants", "SPECIES", 140, 152], ["respiratory syncytial virus", "SPECIES", 103, 130], ["fairly mild disease", "PROBLEM", 24, 43], ["the investigation", "TEST", 48, 65], ["respiratory syncytial virus", "PROBLEM", 103, 130], ["pneumonia", "PROBLEM", 166, 175], ["this virus", "PROBLEM", 186, 196], ["mild", "OBSERVATION_MODIFIER", 31, 35], ["disease", "OBSERVATION", 36, 43], ["respiratory syncytial virus", "OBSERVATION", 103, 130], ["pneumonia", "OBSERVATION", 166, 175]]], ["Further randomised placebo-controlled trials of antibiotic treatment for pneumonia are unlikely to happen because of ethical concerns.ManagementOpportunities are currently limited in clinical practice for use of antivirals in the treatment of pneumonia (table 3) .", [["pneumonia", "DISEASE", 73, 82], ["pneumonia", "DISEASE", 243, 252], ["Further randomised placebo", "TREATMENT", 0, 26], ["antibiotic treatment", "TREATMENT", 48, 68], ["pneumonia", "PROBLEM", 73, 82], ["ethical concerns", "PROBLEM", 117, 133], ["ManagementOpportunities", "TREATMENT", 134, 157], ["antivirals", "TREATMENT", 212, 222], ["pneumonia", "PROBLEM", 243, 252], ["pneumonia", "OBSERVATION", 73, 82], ["pneumonia", "OBSERVATION", 243, 252]]], ["134 Neuraminidase inhibitors, such as oseltamivir and zanamivir, were developed during the 1990s and now have established roles in early treatment of infl uenza A and B infections.", [["oseltamivir", "CHEMICAL", 38, 49], ["zanamivir", "CHEMICAL", 54, 63], ["infections", "DISEASE", 169, 179], ["oseltamivir", "CHEMICAL", 38, 49], ["zanamivir", "CHEMICAL", 54, 63], ["oseltamivir", "SIMPLE_CHEMICAL", 38, 49], ["zanamivir", "SIMPLE_CHEMICAL", 54, 63], ["infl uenza", "ORGANISM", 150, 160], ["B", "GENE_OR_GENE_PRODUCT", 167, 168], ["infl uenza A", "SPECIES", 150, 162], ["Neuraminidase inhibitors", "TREATMENT", 4, 28], ["oseltamivir", "TREATMENT", 38, 49], ["zanamivir", "TREATMENT", 54, 63], ["infl uenza A", "PROBLEM", 150, 162], ["B infections", "PROBLEM", 167, 179], ["infections", "OBSERVATION", 169, 179]]], ["In children and adults, neuraminidase inhibitors reduce median time to resolution of symptoms by 0\u00b75-2\u00b75 days when administered within 48 h of onset of symptoms.", [["children", "ORGANISM", 3, 11], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 24, 37], ["children", "SPECIES", 3, 11], ["neuraminidase inhibitors", "TREATMENT", 24, 48], ["symptoms", "PROBLEM", 85, 93], ["symptoms", "PROBLEM", 152, 160]]], ["135 Importantly, early use of neuraminidase inhibitors can reduce development of complications such as pneumonia.", [["pneumonia", "DISEASE", 103, 112], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 30, 43], ["neuraminidase inhibitors", "TREATMENT", 30, 54], ["complications", "PROBLEM", 81, 94], ["pneumonia", "PROBLEM", 103, 112], ["complications", "OBSERVATION", 81, 94], ["pneumonia", "OBSERVATION", 103, 112]]], ["136 The Infectious Diseases Society of America extends treatment with neuraminidase inhibitors to admitted infl uenza patients whose onset of symptoms is more than 48 h before presentation.", [["Infectious Diseases", "DISEASE", 8, 27], ["uenza", "DISEASE", 112, 117], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["neuraminidase inhibitors", "TREATMENT", 70, 94], ["symptoms", "PROBLEM", 142, 150], ["Infectious", "OBSERVATION_MODIFIER", 8, 18]]], ["137 Selection of the most appropriate antiviral to treat infl uenza should be made on the basis of relevant susceptibility data.", [["infl uenza", "TREATMENT", 57, 67]]], ["Before emergence of the 2009 pandemic H1N1 virus, the seasonal H1N1 virus developed resistance to oseltamivir, and treatment with either zanamivir or amantadine or rimantidine was recommended, whereas the seasonal H3N2 virus was resistant to amantadine and rimantidine.", [["oseltamivir", "CHEMICAL", 98, 109], ["zanamivir", "CHEMICAL", 137, 146], ["amantadine", "CHEMICAL", 150, 160], ["rimantidine", "CHEMICAL", 164, 175], ["amantadine", "CHEMICAL", 242, 252], ["rimantidine", "CHEMICAL", 257, 268], ["oseltamivir", "CHEMICAL", 98, 109], ["zanamivir", "CHEMICAL", 137, 146], ["amantadine", "CHEMICAL", 150, 160], ["rimantidine", "CHEMICAL", 164, 175], ["amantadine", "CHEMICAL", 242, 252], ["rimantidine", "CHEMICAL", 257, 268], ["H1N1 virus", "ORGANISM", 38, 48], ["oseltamivir", "SIMPLE_CHEMICAL", 98, 109], ["zanamivir", "SIMPLE_CHEMICAL", 137, 146], ["amantadine", "SIMPLE_CHEMICAL", 150, 160], ["rimantidine", "SIMPLE_CHEMICAL", 164, 175], ["seasonal H3N2 virus", "ORGANISM", 205, 224], ["amantadine", "SIMPLE_CHEMICAL", 242, 252], ["rimantidine", "SIMPLE_CHEMICAL", 257, 268], ["pandemic H1N1 virus", "SPECIES", 29, 48], ["seasonal H1N1 virus", "SPECIES", 54, 73], ["seasonal H3N2 virus", "SPECIES", 205, 224], ["2009 pandemic H1N1 virus", "SPECIES", 24, 48], ["seasonal H1N1 virus", "SPECIES", 54, 73], ["seasonal H3N2 virus", "SPECIES", 205, 224], ["the 2009 pandemic H1N1 virus", "PROBLEM", 20, 48], ["the seasonal H1N1 virus", "PROBLEM", 50, 73], ["oseltamivir", "TREATMENT", 98, 109], ["treatment", "TREATMENT", 115, 124], ["zanamivir", "TREATMENT", 137, 146], ["amantadine", "TREATMENT", 150, 160], ["rimantidine", "TREATMENT", 164, 175], ["the seasonal H3N2 virus", "PROBLEM", 201, 224], ["amantadine", "TREATMENT", 242, 252], ["rimantidine", "TREATMENT", 257, 268]]], ["If subtype information is unavailable, zanamivir or a combination of oseltamivir and rimantadine is recommended.", [["zanamivir", "CHEMICAL", 39, 48], ["oseltamivir", "CHEMICAL", 69, 80], ["rimantadine", "CHEMICAL", 85, 96], ["zanamivir", "CHEMICAL", 39, 48], ["oseltamivir", "CHEMICAL", 69, 80], ["rimantadine", "CHEMICAL", 85, 96], ["zanamivir", "SIMPLE_CHEMICAL", 39, 48], ["oseltamivir", "SIMPLE_CHEMICAL", 69, 80], ["rimantadine", "SIMPLE_CHEMICAL", 85, 96], ["zanamivir", "TREATMENT", 39, 48], ["oseltamivir", "TREATMENT", 69, 80], ["rimantadine", "TREATMENT", 85, 96]]], ["137 The 2009 pandemic H1N1 virus remains susceptible to neuraminidase inhibitors, and oseltamivir has been used widely for treatment of pneumonia caused by this virus.", [["pandemic H1N1 virus", "DISEASE", 13, 32], ["oseltamivir", "CHEMICAL", 86, 97], ["pneumonia", "DISEASE", 136, 145], ["oseltamivir", "CHEMICAL", 86, 97], ["pandemic H1N1 virus", "ORGANISM", 13, 32], ["oseltamivir", "SIMPLE_CHEMICAL", 86, 97], ["pandemic H1N1 virus", "SPECIES", 13, 32], ["2009 pandemic H1N1 virus", "SPECIES", 8, 32], ["pandemic H1N1 virus", "PROBLEM", 13, 32], ["neuraminidase inhibitors", "TREATMENT", 56, 80], ["oseltamivir", "TREATMENT", 86, 97], ["pneumonia", "PROBLEM", 136, 145], ["this virus", "PROBLEM", 156, 166], ["pneumonia", "OBSERVATION", 136, 145]]], ["Although resistance to oseltamivir has been reported in people with 2009 pandemic H1N1 virus infection, it has been largely restricted to immunocompromised individuals.", [["oseltamivir", "CHEMICAL", 23, 34], ["H1N1 virus infection", "DISEASE", 82, 102], ["oseltamivir", "CHEMICAL", 23, 34], ["oseltamivir", "SIMPLE_CHEMICAL", 23, 34], ["people", "ORGANISM", 56, 62], ["2009 pandemic H1N1 virus", "ORGANISM", 68, 92], ["people", "SPECIES", 56, 62], ["pandemic H1N1 virus", "SPECIES", 73, 92], ["2009 pandemic H1N1 virus", "SPECIES", 68, 92], ["oseltamivir", "TREATMENT", 23, 34], ["2009 pandemic H1N1 virus infection", "PROBLEM", 68, 102], ["immunocompromised individuals", "PROBLEM", 138, 167], ["immunocompromised", "OBSERVATION", 138, 155]]], ["103 All isolates are still susceptible to zanamivir.", [["zanamivir", "CHEMICAL", 42, 51], ["zanamivir", "CHEMICAL", 42, 51], ["zanamivir", "SIMPLE_CHEMICAL", 42, 51], ["All isolates", "TREATMENT", 4, 16], ["zanamivir", "TREATMENT", 42, 51]]], ["Intravenous use of peramivir or zanamivir could be lifesaving in critically ill patients with infl uenza.", [["peramivir", "CHEMICAL", 19, 28], ["zanamivir", "CHEMICAL", 32, 41], ["critically ill", "DISEASE", 65, 79], ["peramivir", "CHEMICAL", 19, 28], ["zanamivir", "CHEMICAL", 32, 41], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["peramivir", "SIMPLE_CHEMICAL", 19, 28], ["zanamivir", "SIMPLE_CHEMICAL", 32, 41], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["peramivir", "TREATMENT", 19, 28], ["zanamivir", "TREATMENT", 32, 41], ["infl uenza", "TREATMENT", 94, 104]]], ["138, 139 Experience with antivirals for community-acquired pneumonia caused by viruses other than infl uenza is scarce, with existing knowledge mainly from case reports and some treatment studies in immunosuppressed patients.", [["pneumonia", "DISEASE", 59, 68], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["antivirals", "TREATMENT", 25, 35], ["community-acquired pneumonia", "PROBLEM", 40, 68], ["viruses", "PROBLEM", 79, 86], ["some treatment studies", "TEST", 173, 195], ["immunosuppressed patients", "TREATMENT", 199, 224], ["pneumonia", "OBSERVATION", 59, 68], ["viruses", "OBSERVATION", 79, 86]]], ["Ribavirin has a broad antiviral range, including respiratory syncytial virus, human metapneumovirus, and parainfl uenza and infl uenza viruses.", [["Ribavirin", "CHEMICAL", 0, 9], ["respiratory syncytial virus", "DISEASE", 49, 76], ["human metapneumovirus", "DISEASE", 78, 99], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["respiratory syncytial virus", "ORGANISM", 49, 76], ["human", "ORGANISM", 78, 83], ["metapneumovirus", "ORGANISM", 84, 99], ["parainfl uenza", "ORGANISM", 105, 119], ["infl uenza viruses", "ORGANISM", 124, 142], ["respiratory syncytial virus", "SPECIES", 49, 76], ["human", "SPECIES", 78, 83], ["metapneumovirus", "SPECIES", 84, 99], ["respiratory syncytial virus", "SPECIES", 49, 76], ["human metapneumovirus", "SPECIES", 78, 99], ["Ribavirin", "TREATMENT", 0, 9], ["a broad antiviral range", "TREATMENT", 14, 37], ["respiratory syncytial virus", "PROBLEM", 49, 76], ["human metapneumovirus", "PROBLEM", 78, 99], ["parainfl uenza", "TREATMENT", 105, 119], ["infl uenza viruses", "PROBLEM", 124, 142], ["respiratory", "ANATOMY", 49, 60], ["syncytial virus", "OBSERVATION", 61, 76], ["metapneumovirus", "OBSERVATION", 84, 99], ["uenza viruses", "OBSERVATION", 129, 142]]], ["140 Effi cacy of ribavirin aerosol treatment for bronchiolitis and pneumonia caused by respiratory syncytial virus infection is modest at best.", [["ribavirin", "CHEMICAL", 17, 26], ["bronchiolitis", "DISEASE", 49, 62], ["pneumonia", "DISEASE", 67, 76], ["respiratory syncytial virus infection", "DISEASE", 87, 124], ["ribavirin", "CHEMICAL", 17, 26], ["ribavirin", "SIMPLE_CHEMICAL", 17, 26], ["respiratory syncytial virus", "ORGANISM", 87, 114], ["respiratory syncytial virus", "SPECIES", 87, 114], ["respiratory syncytial virus", "SPECIES", 87, 114], ["ribavirin aerosol treatment", "TREATMENT", 17, 44], ["bronchiolitis", "PROBLEM", 49, 62], ["pneumonia", "PROBLEM", 67, 76], ["respiratory syncytial virus infection", "PROBLEM", 87, 124], ["ribavirin aerosol", "OBSERVATION", 17, 34], ["bronchiolitis", "OBSERVATION", 49, 62], ["pneumonia", "OBSERVATION", 67, 76], ["respiratory", "OBSERVATION", 87, 98], ["syncytial virus", "OBSERVATION", 99, 114], ["modest", "OBSERVATION_MODIFIER", 128, 134]]], ["Intravenous ribavirin could be considered for treatment of severe pneumonia caused by infection with respiratory syncytial virus, human metapneumovirus, or parainfl uenza virus, on the basis of experience in immunosuppressed patients.", [["ribavirin", "CHEMICAL", 12, 21], ["pneumonia", "DISEASE", 66, 75], ["infection", "DISEASE", 86, 95], ["respiratory syncytial virus", "DISEASE", 101, 128], ["human metapneumovirus", "DISEASE", 130, 151], ["ribavirin", "CHEMICAL", 12, 21], ["ribavirin", "SIMPLE_CHEMICAL", 12, 21], ["respiratory syncytial virus", "ORGANISM", 101, 128], ["human", "ORGANISM", 130, 135], ["metapneumovirus", "ORGANISM", 136, 151], ["parainfl uenza virus", "ORGANISM", 156, 176], ["patients", "ORGANISM", 225, 233], ["respiratory syncytial virus", "SPECIES", 101, 128], ["human", "SPECIES", 130, 135], ["metapneumovirus", "SPECIES", 136, 151], ["patients", "SPECIES", 225, 233], ["respiratory syncytial virus", "SPECIES", 101, 128], ["human metapneumovirus", "SPECIES", 130, 151], ["parainfl uenza virus", "SPECIES", 156, 176], ["Intravenous ribavirin", "TREATMENT", 0, 21], ["severe pneumonia", "PROBLEM", 59, 75], ["infection", "PROBLEM", 86, 95], ["respiratory syncytial virus", "PROBLEM", 101, 128], ["human metapneumovirus", "PROBLEM", 130, 151], ["parainfl uenza virus", "PROBLEM", 156, 176], ["immunosuppressed patients", "TREATMENT", 208, 233], ["ribavirin", "OBSERVATION", 12, 21], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["pneumonia", "OBSERVATION", 66, 75], ["infection", "OBSERVATION", 86, 95], ["respiratory syncytial virus", "OBSERVATION", 101, 128]]], ["141 New antiviral agents are in development for respiratory syncytial virus infection, including small interfering RNAs.", [["respiratory syncytial virus infection", "DISEASE", 48, 85], ["respiratory syncytial virus", "ORGANISM", 48, 75], ["small interfering RNAs", "RNA", 97, 119], ["respiratory syncytial virus", "SPECIES", 48, 75], ["respiratory syncytial virus", "SPECIES", 48, 75], ["New antiviral agents", "TREATMENT", 4, 24], ["respiratory syncytial virus infection", "PROBLEM", 48, 85], ["small interfering RNAs", "PROBLEM", 97, 119], ["antiviral agents", "OBSERVATION", 8, 24], ["respiratory", "ANATOMY", 48, 59], ["syncytial virus", "OBSERVATION", 60, 75], ["small", "OBSERVATION_MODIFIER", 97, 102], ["interfering RNAs", "OBSERVATION", 103, 119]]], ["142 In several case studies of immunocompromised patients, clinical effi cacy of cidofovir has been shown for severe adenovirus pneumonia.", [["cidofovir", "CHEMICAL", 81, 90], ["adenovirus pneumonia", "DISEASE", 117, 137], ["cidofovir", "CHEMICAL", 81, 90], ["patients", "ORGANISM", 49, 57], ["cidofovir", "SIMPLE_CHEMICAL", 81, 90], ["adenovirus", "ORGANISM", 117, 127], ["patients", "SPECIES", 49, 57], ["immunocompromised patients", "PROBLEM", 31, 57], ["cidofovir", "TREATMENT", 81, 90], ["severe adenovirus pneumonia", "PROBLEM", 110, 137], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["adenovirus", "OBSERVATION", 117, 127], ["pneumonia", "OBSERVATION", 128, 137]]], ["143 Cidofovir should be considered for treatment of new adenovirus subtype 14 pneumonia.", [["Cidofovir", "CHEMICAL", 4, 13], ["pneumonia", "DISEASE", 78, 87], ["Cidofovir", "CHEMICAL", 4, 13], ["Cidofovir", "SIMPLE_CHEMICAL", 4, 13], ["adenovirus subtype 14", "ORGANISM", 56, 77], ["Cidofovir", "TREATMENT", 4, 13], ["treatment", "TREATMENT", 39, 48], ["new adenovirus subtype 14 pneumonia", "PROBLEM", 52, 87], ["new", "OBSERVATION_MODIFIER", 52, 55], ["adenovirus", "OBSERVATION", 56, 66], ["pneumonia", "OBSERVATION", 78, 87]]], ["Researchers reported successful manage ment of human metapneumovirus pneumonia with a combination of intravenous ribavirin and immuno globulin.", [["intravenous", "ANATOMY", 101, 112], ["human metapneumovirus pneumonia", "DISEASE", 47, 78], ["ribavirin", "CHEMICAL", 113, 122], ["ribavirin", "CHEMICAL", 113, 122], ["human", "ORGANISM", 47, 52], ["metapneumovirus", "ORGANISM", 53, 68], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 112], ["ribavirin", "SIMPLE_CHEMICAL", 113, 122], ["immuno globulin", "GENE_OR_GENE_PRODUCT", 127, 142], ["immuno globulin", "PROTEIN", 127, 142], ["human", "SPECIES", 47, 52], ["metapneumovirus", "SPECIES", 53, 68], ["human metapneumovirus", "SPECIES", 47, 68], ["human metapneumovirus pneumonia", "PROBLEM", 47, 78], ["intravenous ribavirin", "TREATMENT", 101, 122], ["immuno globulin", "TREATMENT", 127, 142], ["metapneumovirus pneumonia", "OBSERVATION", 53, 78]]], ["144 Varicella pneumonia should be treated with aciclovir.", [["Varicella pneumonia", "DISEASE", 4, 23], ["aciclovir", "CHEMICAL", 47, 56], ["aciclovir", "CHEMICAL", 47, 56], ["Varicella", "ORGANISM", 4, 13], ["aciclovir", "SIMPLE_CHEMICAL", 47, 56], ["Varicella pneumonia", "PROBLEM", 4, 23], ["aciclovir", "TREATMENT", 47, 56], ["Varicella", "OBSERVATION_MODIFIER", 4, 13], ["pneumonia", "OBSERVATION", 14, 23]]], ["145 Use of corticosteroids for treatment of viral communityacquired pneumonia is controversial and can vary according to the causative virus.", [["corticosteroids", "CHEMICAL", 11, 26], ["viral communityacquired pneumonia", "DISEASE", 44, 77], ["corticosteroids", "CHEMICAL", 11, 26], ["corticosteroids", "TREATMENT", 11, 26], ["treatment", "TREATMENT", 31, 40], ["viral communityacquired pneumonia", "PROBLEM", 44, 77], ["the causative virus", "PROBLEM", 121, 140], ["viral", "OBSERVATION_MODIFIER", 44, 49], ["communityacquired", "OBSERVATION_MODIFIER", 50, 67], ["pneumonia", "OBSERVATION", 68, 77]]], ["The ineff ectiveness of these agents for treatment of respiratory syncytial virus infections is well established.", [["respiratory syncytial virus infections", "DISEASE", 54, 92], ["respiratory syncytial virus", "ORGANISM", 54, 81], ["respiratory syncytial virus", "SPECIES", 54, 81], ["these agents", "TREATMENT", 24, 36], ["treatment", "TREATMENT", 41, 50], ["respiratory syncytial virus infections", "PROBLEM", 54, 92], ["respiratory", "ANATOMY", 54, 65], ["syncytial virus", "OBSERVATION", 66, 81]]], ["146 For management of SARS, inconclusive results were reported in 26 treatment studies, and possible harm was indicated in four trials.", [["SARS", "DISEASE", 22, 26], ["management", "TREATMENT", 8, 18], ["SARS", "PROBLEM", 22, 26], ["treatment studies", "TEST", 69, 86], ["harm", "PROBLEM", 101, 105]]], ["147 High-dose corticosteroids were administered to a third of patients with 2009 pandemic H1N1 virus infection, 148 but use of these agents is not recommended because of prolonged viral shedding in seasonal infl uenza and increased mortality in avian H5N1 and, possibly, 2009 pandemic H1N1 virus infections.", [["corticosteroids", "CHEMICAL", 14, 29], ["H1N1 virus infection", "DISEASE", 90, 110], ["H5N1", "DISEASE", 251, 255], ["H1N1 virus infections", "DISEASE", 285, 306], ["corticosteroids", "CHEMICAL", 14, 29], ["patients", "ORGANISM", 62, 70], ["2009 pandemic H1N1 virus", "ORGANISM", 76, 100], ["infl uenza", "ORGANISM", 207, 217], ["avian H5N1", "ORGANISM", 245, 255], ["pandemic H1N1 virus", "ORGANISM", 276, 295], ["patients", "SPECIES", 62, 70], ["pandemic H1N1 virus", "SPECIES", 81, 100], ["avian H5N1", "SPECIES", 245, 255], ["pandemic H1N1 virus", "SPECIES", 276, 295], ["2009 pandemic H1N1 virus", "SPECIES", 76, 100], ["H1N1 virus", "SPECIES", 285, 295], ["High-dose corticosteroids", "TREATMENT", 4, 29], ["2009 pandemic H1N1 virus infection", "PROBLEM", 76, 110], ["these agents", "TREATMENT", 127, 139], ["prolonged viral shedding", "PROBLEM", 170, 194], ["seasonal infl uenza", "PROBLEM", 198, 217], ["increased mortality in avian H5N1", "PROBLEM", 222, 255], ["pandemic H1N1 virus infections", "PROBLEM", 276, 306], ["increased", "OBSERVATION_MODIFIER", 222, 231], ["mortality", "OBSERVATION", 232, 241]]], ["103 On the other hand, some data suggest that corticosteroids can augment outcome of pneumonia caused by infection with varicella-zoster virus (in combination with aciclovir) and hantavirus.", [["corticosteroids", "CHEMICAL", 46, 61], ["pneumonia", "DISEASE", 85, 94], ["infection", "DISEASE", 105, 114], ["varicella-zoster virus", "DISEASE", 120, 142], ["aciclovir", "CHEMICAL", 164, 173], ["hantavirus", "DISEASE", 179, 189], ["corticosteroids", "CHEMICAL", 46, 61], ["aciclovir", "CHEMICAL", 164, 173], ["corticosteroids", "SIMPLE_CHEMICAL", 46, 61], ["varicella-zoster virus", "ORGANISM", 120, 142], ["aciclovir", "SIMPLE_CHEMICAL", 164, 173], ["varicella-zoster virus", "SPECIES", 120, 142], ["varicella-zoster virus", "SPECIES", 120, 142], ["corticosteroids", "TREATMENT", 46, 61], ["pneumonia", "PROBLEM", 85, 94], ["infection", "PROBLEM", 105, 114], ["varicella", "PROBLEM", 120, 129], ["zoster virus", "PROBLEM", 130, 142], ["aciclovir", "TREATMENT", 164, 173], ["hantavirus", "PROBLEM", 179, 189], ["pneumonia", "OBSERVATION", 85, 94], ["infection", "OBSERVATION", 105, 114], ["zoster virus", "OBSERVATION", 130, 142], ["hantavirus", "OBSERVATION", 179, 189]]], ["149PreventionPossibilities to prevent viral community-acquired pneumonia are limited.", [["pneumonia", "DISEASE", 63, 72], ["viral community-acquired pneumonia", "PROBLEM", 38, 72], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["pneumonia", "OBSERVATION", 63, 72]]], ["Infl uenza vaccines have been used since the mid 1940s and they now have an established role in prevention of infl uenza A and B virus infections.", [["infections", "DISEASE", 135, 145], ["infl uenza A", "ORGANISM", 110, 122], ["B virus", "ORGANISM", 127, 134], ["infl uenza A", "SPECIES", 110, 122], ["B virus", "SPECIES", 127, 134], ["Infl uenza vaccines", "TREATMENT", 0, 19], ["infl uenza A and B virus infections", "PROBLEM", 110, 145]]], ["Importantly, inactivated infl uenza vaccine is eff ective in young children, including those younger than 2 years.", [["infl uenza", "ORGANISM", 25, 35], ["children", "ORGANISM", 67, 75], ["children", "SPECIES", 67, 75], ["inactivated infl uenza vaccine", "TREATMENT", 13, 43]]], ["150 During the 2009 H1N1 pandemic, a monovalent vaccine against the virus was developed.", [["H1N1 pandemic", "DISEASE", 20, 33], ["a monovalent vaccine", "TREATMENT", 35, 55], ["the virus", "PROBLEM", 64, 73], ["virus", "OBSERVATION", 68, 73]]], ["103 Its active use could have played a part in the course of the initial pandemic wave in some countries-eg, in Finland, only 44 fatal cases were recorded.", [["pandemic", "DISEASE", 73, 81], ["active", "OBSERVATION_MODIFIER", 8, 14]]], ["In addition to vaccines, infl uenza A and B virus infections can be prevented by prophylactic use of neuraminidase inhibitors.", [["infections", "DISEASE", 50, 60], ["infl uenza A", "ORGANISM", 25, 37], ["B virus", "ORGANISM", 42, 49], ["neuraminidase inhibitors", "SIMPLE_CHEMICAL", 101, 125], ["B virus", "SPECIES", 42, 49], ["infl uenza A", "SPECIES", 25, 37], ["B virus", "SPECIES", 42, 49], ["vaccines", "TREATMENT", 15, 23], ["infl", "TREATMENT", 25, 29], ["A and B virus infections", "PROBLEM", 36, 60], ["neuraminidase inhibitors", "TREATMENT", 101, 125]]], ["137 Severe respiratory syncytial virus infections in high-risk neonates have been prevented successfully with palivizumab, a humanised monoclonal antibody, which is administered during a respiratory syncytial virus epidemic.", [["respiratory syncytial virus infections", "DISEASE", 11, 49], ["palivizumab", "CHEMICAL", 110, 121], ["respiratory syncytial virus", "DISEASE", 187, 214], ["respiratory syncytial virus", "ORGANISM", 11, 38], ["neonates", "ORGANISM", 63, 71], ["palivizumab", "SIMPLE_CHEMICAL", 110, 121], ["respiratory syncytial virus", "ORGANISM", 187, 214], ["humanised monoclonal antibody", "PROTEIN", 125, 154], ["Severe respiratory syncytial virus", "SPECIES", 4, 38], ["Severe respiratory syncytial virus infections", "PROBLEM", 4, 49], ["palivizumab", "TREATMENT", 110, 121], ["a humanised monoclonal antibody", "TREATMENT", 123, 154], ["a respiratory syncytial virus epidemic", "PROBLEM", 185, 223], ["respiratory", "ANATOMY", 11, 22], ["syncytial virus", "OBSERVATION", 23, 38], ["syncytial virus", "OBSERVATION", 199, 214]]], ["151 This agent has been shown to prevent admissions related to respiratory syncytial virus by 50% in premature infants.", [["respiratory syncytial virus", "DISEASE", 63, 90], ["respiratory syncytial virus", "ORGANISM", 63, 90], ["infants", "ORGANISM", 111, 118], ["infants", "SPECIES", 111, 118], ["respiratory syncytial virus", "SPECIES", 63, 90], ["respiratory syncytial virus", "PROBLEM", 63, 90], ["respiratory syncytial", "ANATOMY", 63, 84]]], ["Since the 1960s, several types of vaccines for respiratory syncytial virus have been developed without success.", [["respiratory syncytial virus", "DISEASE", 47, 74], ["respiratory syncytial virus", "ORGANISM", 47, 74], ["respiratory syncytial virus", "SPECIES", 47, 74], ["respiratory syncytial virus", "SPECIES", 47, 74], ["vaccines", "TREATMENT", 34, 42], ["respiratory syncytial virus", "PROBLEM", 47, 74], ["syncytial virus", "OBSERVATION", 59, 74]]], ["Live-attenuated vaccines produced by reverse genetics are now in clinical studies.", [["Live-attenuated vaccines", "TREATMENT", 0, 24], ["clinical studies", "TEST", 65, 81]]], ["142 Pneumonia caused by adenovirus types 4 and 7 has been prevented in military trainees by an oral vaccine, with 95% effi cacy.", [["oral", "ANATOMY", 95, 99], ["Pneumonia", "DISEASE", 4, 13], ["adenovirus", "ORGANISM", 24, 34], ["oral", "ORGANISM_SUBDIVISION", 95, 99], ["Pneumonia", "PROBLEM", 4, 13], ["adenovirus types", "PROBLEM", 24, 40], ["an oral vaccine", "TREATMENT", 92, 107], ["Pneumonia", "OBSERVATION", 4, 13], ["adenovirus", "OBSERVATION", 24, 34]]], ["95 Pneumococcal conjugate vaccine was shown to prevent a third of viral pneumonia cases in a study in South Africa, most probably by prevention of superimposed bacterial co-infections.", [["pneumonia", "DISEASE", 72, 81], ["bacterial co-infections", "DISEASE", 160, 183], ["Pneumococcal conjugate vaccine", "TREATMENT", 3, 33], ["viral pneumonia cases", "PROBLEM", 66, 87], ["a study", "TEST", 91, 98], ["superimposed bacterial co-infections", "PROBLEM", 147, 183], ["viral", "OBSERVATION_MODIFIER", 66, 71], ["pneumonia", "OBSERVATION", 72, 81], ["most probably", "UNCERTAINTY", 116, 129], ["superimposed", "OBSERVATION_MODIFIER", 147, 159], ["bacterial", "OBSERVATION_MODIFIER", 160, 169], ["co-infections", "OBSERVATION", 170, 183]]], ["152Future researchDespite many advances, further studies are still needed to better understand the role of viruses in the cause and pathogenesis of community-acquired pneumonia.", [["pneumonia", "DISEASE", 167, 176], ["further studies", "TEST", 41, 56], ["viruses", "PROBLEM", 107, 114], ["community-acquired pneumonia", "PROBLEM", 148, 176], ["viruses", "OBSERVATION", 107, 114], ["pneumonia", "OBSERVATION", 167, 176]]], ["Increased availability of molecular diagnostic methods enables us to evaluate our understanding of viral pneumonia and to reassess all existing dogma.", [["pneumonia", "DISEASE", 105, 114], ["viral pneumonia", "PROBLEM", 99, 114], ["viral", "OBSERVATION_MODIFIER", 99, 104], ["pneumonia", "OBSERVATION", 105, 114]]], ["Further clarifi cation is needed of the role of bacterial-viral interaction in the pathogenesis of pneumonia and of the importance of viruses as pneumonia pathogens in the world after widespread implementation of H infl uenzae type b and pneumococcal conjugate vaccines.", [["pneumonia", "DISEASE", 99, 108], ["pneumonia", "DISEASE", 145, 154], ["H infl uenzae type b", "ORGANISM", 213, 233], ["pneumococcal conjugate vaccines", "ORGANISM", 238, 269], ["H infl uenzae", "SPECIES", 213, 226], ["pneumococcal", "SPECIES", 238, 250], ["Further clarifi cation", "TREATMENT", 0, 22], ["bacterial-viral interaction", "PROBLEM", 48, 75], ["pneumonia", "PROBLEM", 99, 108], ["viruses", "PROBLEM", 134, 141], ["pneumonia pathogens", "PROBLEM", 145, 164], ["H infl uenzae type b", "TREATMENT", 213, 233], ["pneumococcal conjugate vaccines", "TREATMENT", 238, 269], ["bacterial", "OBSERVATION_MODIFIER", 48, 57], ["viral interaction", "OBSERVATION", 58, 75], ["pneumonia", "OBSERVATION", 99, 108], ["viruses", "OBSERVATION", 134, 141], ["pneumonia", "OBSERVATION", 145, 154]]], ["Also, examination of regional diff erences in causes of pneumonia is needed urgently, particularly to obtain additional data from developing countries.", [["pneumonia", "DISEASE", 56, 65], ["examination", "TEST", 6, 17], ["regional diff erences", "PROBLEM", 21, 42], ["pneumonia", "PROBLEM", 56, 65], ["pneumonia", "OBSERVATION", 56, 65]]], ["Detailed understanding of the viral cause of community-acquired pneumonia will guide antiviral drug and vaccine developments.", [["pneumonia", "DISEASE", 64, 73], ["community-acquired pneumonia", "PROBLEM", 45, 73], ["antiviral drug", "TREATMENT", 85, 99], ["vaccine developments", "TREATMENT", 104, 124], ["pneumonia", "OBSERVATION", 64, 73]]]], "PMC7538843": [["BackgroundExercise adherence is the extent to which a person\u2019s behavior corresponds with agreed recommendations from health care providers [1].", [["person", "SPECIES", 54, 60]]], ["The benefits of exercise can only be obtained when a person is adhering to the prescribed exercises.", [["person", "SPECIES", 53, 59]]], ["Multiple factors are associated with exercise adherence such as sociocultural factors, knowledge towards exercise, self-efficacy, ethnicity, and economic status of an individual [2].", [["Multiple factors", "PROBLEM", 0, 16]]], ["There is no gold standard outcome tool to measure the exercise adherence rate in the Nepalese cultural context and background.", [["no", "UNCERTAINTY", 9, 11], ["gold", "OBSERVATION_MODIFIER", 12, 16]]], ["People commonly use self-reported diaries to reflect exercise adherence; however, they lack standardization, accuracy, and possess self-presentation bias that limits their validity [4].", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["The Exercise Adherence Rating Scale (EARS) is one of the commonly used outcome tools, which helps to identify the adherence rate of exercises and reasons for adherence and non-adherence [5].BackgroundThe original English version of the EARS is a 16-item, self-reported questionnaire, which assesses the adherence of prescribed exercises [6].", [["EARS", "ANATOMY", 236, 240]]], ["The EARS consist of 3 sections.", [["sections", "ANATOMY", 22, 30], ["EARS", "DNA", 4, 8], ["EARS", "ANATOMY", 4, 8]]], ["This section consists of 5 items, which are related to the way of doing activities and exercise that people often do to improve their physical quality of life.", [["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107]]], ["A possible summed score of section \u2018B\u2019 and \u2018C\u2019 range from 0 to 64.", [["section", "TEST", 27, 34]]], ["A higher overall score indicates better exercise adherence [5].BackgroundThe internal consistency (0.81), test\u2013retest reliability (0.94), constructs validity (70%) and face validity of the original version of the EARS have been established [5, 6].", [["A higher overall score", "PROBLEM", 0, 22], ["test\u2013retest reliability", "TEST", 106, 129], ["constructs validity", "TEST", 138, 157], ["face validity", "TEST", 168, 181], ["internal", "ANATOMY_MODIFIER", 77, 85], ["EARS", "ANATOMY", 213, 217]]], ["Acknowledged with good validity and reliability, the EARS scale has been established as an appropriate and feasible tool to assess exercise adherence.BackgroundThe \u201ccross-cultural adaptation\u201d is a process that looks at both language (translation) and cultural adaptation issues for a questionnaire to use in another setting [7].", [["the EARS scale", "TEST", 49, 63]]], ["Cross-cultural adaptation is important when an instrument has to be used in a different language, setting and time because of the diversified context of geography, ethnicity, economic status, culture, and diseases [2, 8].", [["culture", "TEST", 192, 199], ["diseases", "PROBLEM", 205, 213]]], ["When there is no tool available to assess exercise adherence in Nepal, a tool that is valid and reliable in measuring exercise adherence of Nepali-speaking individuals was required.", [["individuals", "ORGANISM", 156, 167], ["no", "UNCERTAINTY", 14, 16]]], ["Following cross-cultural adaptation, it is mandatory to establish psychometric properties such as validity, reliability, sensitivity and specificity of the adopted tool to use it in the clinical practice and research.", [["cross-cultural adaptation", "TREATMENT", 10, 35]]], ["Therefore, this study aimed to conduct the cross-cultural adaptation of the EARS to the Nepali language and investigate its reliability and validity.Cross-cultural adaptation ::: Methods and materialsBeaton Guidelines is one of the commonly used guidelines for the translation and cross-cultural adaptation of measurement tools [7].", [["this study", "TEST", 11, 21], ["Methods and materialsBeaton Guidelines", "TREATMENT", 179, 217], ["the translation", "TREATMENT", 261, 276], ["measurement tools", "TEST", 310, 327]]], ["As per the suggestion from the developer of the tool, Dr. Emma L Godfrey, we considered (a) Beaton guidelines and (b) evidence of cross-cultural adaptation process followed in a study by Takasaki et al., in 2017 [7, 9] to cross-culturally adapt the EARS into Nepali language.", [["cross-cultural adaptation process", "PROBLEM", 130, 163], ["a study", "TEST", 176, 183]]], ["The five steps of cross-cultural adaptation were; forward translation, synthesis, back translation, expert committee review, and pre-testing, which are described in Fig. 1.Cross-cultural adaptation ::: Methods and materialsTwo independent non-medical translators, who were bilingual in English and Nepali language, translated the original English EARS into the Nepali language and developed two forward translated versions (FT1 and FT2).", [["FT1", "DNA", 424, 427], ["cross-cultural adaptation", "TREATMENT", 18, 43]]], ["A meeting was held among two translators and investigators of the present study to reach a consensus objectively.", [["the present study", "TEST", 62, 79]]], ["All minor issues encountered were addressed and resolved, as there were no major issues.", [["All minor issues", "PROBLEM", 0, 16], ["major issues", "PROBLEM", 75, 87], ["minor", "OBSERVATION_MODIFIER", 4, 9], ["issues", "OBSERVATION", 10, 16], ["no", "UNCERTAINTY", 72, 74], ["major", "OBSERVATION_MODIFIER", 75, 80]]], ["Through consensus, a common forward translation (FT12) was synthesized.", [["FT12", "DNA", 49, 53]]], ["Two Physiotherapists who were bilingual in English and Nepali language then back-translated the FT12 version into English.", [["FT12", "DNA", 96, 100]]], ["The purpose of the back translation was for validity checking to make sure that the adapted version was reflecting the same item content as the original version [10].", [["the back translation", "TREATMENT", 15, 35], ["validity checking", "TEST", 44, 61]]], ["The back-translated versions were reviewed, and a consensus version was developed [7, 9].Cross-cultural adaptation ::: Methods and materialsPretesting was done on 10 individuals with pre-diabetic conditions (who were not included in the reliability and validity testing) to explore clarity, understandability, comprehensibility, and feasibility of the adapted version of the EARS using a visual analog scale; ranging from 0 (not clear at all and difficult to understand) to 10 (clear and easy to understand).", [["a consensus version", "TEST", 48, 67], ["validity testing", "TEST", 253, 269], ["a visual analog scale", "TEST", 386, 407], ["back", "ANATOMY", 4, 8]]], ["The average score of 8.1 indicated that the adapted version was clear, comprehensible, and understandable.", [["The average score", "TEST", 0, 17]]], ["No ambiguity of meaning on any item was reported.", [["ambiguity", "PROBLEM", 3, 12], ["ambiguity", "OBSERVATION", 3, 12]]], ["Thus, the pre-testing version was considered as a final version without any modification in the original English version.", [["the pre-testing version", "TEST", 6, 29]]], ["Thus, a Nepali version of EARS (N-EARS) was cross-culturally adapted (see Additional file 1).", [["a Nepali version of EARS (N-EARS)", "TREATMENT", 6, 39], ["EARS", "ANATOMY", 26, 30]]], ["The Nepali version of the EARS was submitted to the developer of the tool and an appreciation email response was received.Validation of N-EARS ::: Methods and materialsIndividuals at the pre-diabetic stage (who were not included during the pre-testing phase of cross-cultural adaptation) as well as patients with various conditions were screened.", [["patients", "ORGANISM", 299, 307], ["N-EARS", "PROTEIN", 136, 142], ["patients", "SPECIES", 299, 307], ["EARS", "ANATOMY", 26, 30]]], ["Patients were eligible if they satisfied the following inclusion criteria: (1) individuals with pre-diabetes (HbA1c level from 5.7 to 6.4%) [12] or any patients with a confirmed diagnosis of any disease who were prescribed with home exercises by the physiotherapists, and (2) aged 18 years or older and (3) those who were called for follow-up at the clinic after two weeks of the exercise prescription.", [["pre-diabetes", "DISEASE", 96, 108], ["Patients", "ORGANISM", 0, 8], ["individuals", "ORGANISM", 79, 90], ["patients", "ORGANISM", 152, 160], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 152, 160], ["pre-diabetes", "PROBLEM", 96, 108], ["HbA1c level", "TEST", 110, 121], ["any disease", "PROBLEM", 191, 202], ["the exercise prescription", "TREATMENT", 376, 401], ["disease", "OBSERVATION", 195, 202]]], ["Any disease or conditions like recent surgery that limited participants from doing exercises were excluded from the study.Procedure ::: Methods and materialsIndividuals were screened at a clinic of the Dhulikhel Hospital, Nepal from November 2019 to February 2020.", [["participants", "SPECIES", 59, 71], ["Any disease or conditions", "PROBLEM", 0, 25], ["recent surgery", "TREATMENT", 31, 45], ["the study", "TEST", 112, 121], ["disease", "OBSERVATION", 4, 11], ["surgery", "OBSERVATION", 38, 45]]], ["During the follow-up visit after two weeks, participants\u2019 consent was obtained, demographic information was taken, and they were asked to fill the adapted version of the EARS at the same clinic.", [["participants", "SPECIES", 44, 56]]], ["The assessor instructed the participants who rated their level of exercise adherence and reasons for adherence/non-adherence by re-calling their exercise performance level in the previous two weeks.", [["participants", "SPECIES", 28, 40]]], ["Pre-diabetic participants were purposively included in this study because all the participants were staff of the hospital and educated, which is required for any self-administered tool.", [["participants", "ORGANISM", 13, 25], ["participants", "SPECIES", 13, 25], ["participants", "SPECIES", 82, 94], ["this study", "TEST", 55, 65]]], ["Besides, we recruited participants with various conditions from the outpatient department of the hospital intending to increase the generalizability of the outcome.", [["participants", "SPECIES", 22, 34]]], ["However, the number of participants with various conditions was small due to the literacy factor.Statistical analysis ::: Methods and materialsThe mean with standard deviation and number with percentage were described during demographic and clinical data analysis.", [["participants", "SPECIES", 23, 35], ["various conditions", "PROBLEM", 41, 59], ["clinical data analysis", "TEST", 241, 263], ["mean", "OBSERVATION_MODIFIER", 147, 151], ["standard deviation", "OBSERVATION", 157, 175]]], ["Cronbach\u2019s alpha (\u03b1) was calculated to determine internal consistency.", [["Cronbach\u2019s alpha", "GENE_OR_GENE_PRODUCT", 0, 16], ["Cronbach\u2019s alpha", "TEST", 0, 16]]], ["Exploratory Factor Analysis (EFA) was performed in the study by Newman-Beinart et al., to determine factors in the original English tool [5].", [["Exploratory Factor Analysis", "TEST", 0, 27], ["EFA", "TEST", 29, 32]]], ["To compare the findings with the study, we performed EFA to explore construct validity.", [["the study", "TEST", 29, 38], ["EFA", "TEST", 53, 56]]], ["Kaiser\u2013Meyer\u2013Olkin (KMO) test and Bartlett\u2019s test were used to check for sampling adequacy and sphericity, respectively.", [["Bartlett\u2019s test", "TEST", 34, 49], ["sampling adequacy", "TEST", 73, 90], ["sphericity", "TEST", 95, 105]]], ["The minimum recommended value of 0.60 was considered for sampling adequacy [13].", [["sampling adequacy", "TEST", 57, 74]]], ["The Varimax rotation was used during the analysis.", [["The Varimax rotation", "TREATMENT", 0, 20], ["the analysis", "TEST", 37, 49]]], ["Eigenvalues were calculated to select the number of components in EFA [5].", [["EFA", "CHEMICAL", 66, 69], ["Eigenvalues", "TEST", 0, 11]]], ["Receiver Operating Characteristic (ROC) curve was analyzed to identify cutoff score, sensitivity and specificity of N-EARS.", [["cutoff score", "TEST", 71, 83], ["sensitivity", "TEST", 85, 96]]], ["Data were analyzed using SPSS (version 21.00).", [["SPSS (version", "TEST", 25, 38]]], ["The significant level was considered at p < 0.05.Test of reliability ::: ResultsAs shown in Table 2, the Cronbach\u2019s alpha was 0.94 for adherence behavior.", [["Cronbach\u2019s alpha", "GENE_OR_GENE_PRODUCT", 105, 121], ["ResultsAs", "TEST", 73, 82], ["the Cronbach\u2019s alpha", "TEST", 101, 121], ["adherence behavior", "PROBLEM", 135, 153], ["significant", "OBSERVATION_MODIFIER", 4, 15]]], ["The Cronbach\u2019s alpha if item deleted ranged from 0.91 to 0.93 for 6-item adherence behavior.", [["Cronbach\u2019s alpha", "GENE_OR_GENE_PRODUCT", 4, 20], ["The Cronbach\u2019s alpha", "TEST", 0, 20]]], ["Removal of any item would result in lower Cronbach\u2019s alpha, and therefore each item has to be retained.Test of validity ::: ResultsConstruct validity of 6-items of Section \u2018B\u201d was explored using an EFA.", [["Cronbach\u2019s alpha", "GENE_OR_GENE_PRODUCT", 42, 58], ["Removal", "TREATMENT", 0, 7], ["any item", "PROBLEM", 11, 19], ["ResultsConstruct validity", "TEST", 124, 149], ["EFA", "OBSERVATION", 198, 201]]], ["The KMO value for 6-items adherence behavior was 0.7, exceeding the recommended minimum value of 0.60 which verified sampling adequacy for the analysis.", [["The KMO value", "TEST", 0, 13], ["the analysis", "TEST", 139, 151]]], ["Bartlett\u2019s test for sphericity indicated that correlations between items were sufficiently large (Chi-square: 110.2, p < 0.001) for factor analysis.", [["Bartlett\u2019s test", "TEST", 0, 15], ["sphericity", "TEST", 20, 30], ["Chi-square", "TEST", 98, 108], ["factor analysis", "TEST", 132, 147], ["large", "OBSERVATION_MODIFIER", 91, 96]]], ["Thus, the criteria for sampling adequacy and sphericity for the 6-items adherence behavior scale was achieved.", [["sampling adequacy", "TEST", 23, 40], ["sphericity", "TEST", 45, 55]]], ["As depicted in Table 3, the EFA of 6-items adherence behavior revealed the presence of one factor with an Eigen value exceeding one.", [["EFA", "CHEMICAL", 28, 31], ["the EFA", "TEST", 24, 31]]], ["The scree-plot suggested for extraction of only one factor with strong loading (75.8%).Test of validity ::: ResultsThe ROC curve for the 6-items adherence behavior scale, as shown in Fig. 2, demonstrated that Area Under the Curve (AUC) was 0.9 with a 95% confidence interval 0.8\u20131.00 at p = 0.004.", [["The scree-plot", "TEST", 0, 14], ["extraction", "TREATMENT", 29, 39], ["The ROC curve", "TEST", 115, 128], ["behavior scale", "TEST", 155, 169]]], ["The cutoff score was found 17.5 with 89% sensitivity and 78% specificity.Correlation ::: ResultsAs a means of validating 6-item adherence behavior, the correlation analysis was done between 6-item adherence behavior with 10-item reasons for adherence/non-adherence scale, which demonstrated significant correlation (Pearson\u2019s Coefficient, PC: 0.8, p < 0.001).", [["The cutoff score", "TEST", 0, 16], ["the correlation analysis", "TEST", 148, 172], ["adherence/non-adherence scale", "TEST", 241, 270], ["PC", "TEST", 339, 341]]], ["The 6-items adherence scale demonstrated significant correlation with item 1 (PC = 0.7, p = 0.002), item 2 (PC = 0.6, p = 0.02), item 4 (PC = 0.8, p < 0.001), item 6 (PC = 0.8, p < 0.001), item 7 (PC = 0.7, p = 0.001) and with item 10 (PC = 0.8, p < 0.001), but there was no significant correlation with items 3, 5, 8 and 9 (p > 0.05) of 10-item reasons for adherence/non-adherence.Cross-cultural adaptation ::: DiscussionThe EARS was cross-culturally adapted to the Nepali language based on Beaton guidelines [7].", [["EARS", "DNA", 426, 430], ["item", "TEST", 70, 74], ["PC", "TEST", 78, 80], ["p", "TEST", 88, 89], ["item", "TEST", 100, 104], ["PC", "TEST", 108, 110], ["p", "TEST", 118, 119], ["item", "TEST", 129, 133], ["PC", "TEST", 137, 139], ["p", "TEST", 147, 148], ["item", "TEST", 159, 163], ["PC", "TEST", 167, 169], ["p", "TEST", 177, 178], ["item", "TEST", 189, 193], ["PC", "TEST", 197, 199], ["p", "TEST", 207, 208], ["item", "TEST", 227, 231], ["PC", "TEST", 236, 238], ["non-adherence", "PROBLEM", 368, 381]]], ["The forward and back translation as well as adaptation procedure revealed no content or language-related issues.", [["The forward and back translation", "TREATMENT", 0, 32], ["adaptation procedure", "TREATMENT", 44, 64], ["language-related issues", "PROBLEM", 88, 111], ["back", "ANATOMY", 16, 20]]], ["Through pre-testing, good clarity and understandability of the N-EARS were demonstrated.", [["EARS", "DNA", 65, 69], ["good", "OBSERVATION_MODIFIER", 21, 25], ["clarity", "OBSERVATION", 26, 33]]], ["In contrast to the findings of a study by Meade et al., where re-framing for some items was required [6], there was no need of refining or redefining any item or words while adapting to the Nepali language.", [["a study", "TEST", 31, 38]]], ["The N-EARS was formatted in such a way so that it is concise, short, easy to administer, and looks attractive.", [["N-EARS", "PROTEIN", 4, 10]]], ["In section \u2018A\u2019 of the tool, participants did not have any issues in understanding the questions.", [["participants", "SPECIES", 28, 40]]], ["However, in agreement with the findings from the study by Meade et al., they had difficulty in completing the answers of the questions when exercises were not prescribed in appropriate dosage or, when prescribed dosage was not understood [6].Reliability of N-EARS ::: DiscussionThe internal consistency was assessed to evaluate the degree of the interrelatedness among the items [14].", [["the study", "TEST", 45, 54]]], ["The internal consistency of N-EARS was excellent (\u03b1 = 0.94) for 6-item adherence behavior [14, 15].", [["N-EARS", "TEST", 28, 34], ["internal", "ANATOMY_MODIFIER", 4, 12]]], ["The internal consistency of the original English versions was 0.8 and that of the Brazilian version was 0.88 for 6-item adherence behavior [5, 11].", [["internal", "OBSERVATION_MODIFIER", 4, 12], ["consistency", "OBSERVATION_MODIFIER", 13, 24]]], ["The present study demonstrated higher internal consistency (\u03b1 = 0.94) of N-EARS than both English and Brazilian versions.", [["The present study", "TEST", 0, 17], ["higher", "OBSERVATION_MODIFIER", 31, 37], ["internal", "OBSERVATION_MODIFIER", 38, 46], ["consistency", "OBSERVATION_MODIFIER", 47, 58]]], ["An \u03b1 value of 0.70\u20130.95 were considered acceptable values [16].", [["An \u03b1 value", "TEST", 0, 10]]], ["Therefore, the internal consistency of N-EARS of 6-item adherence behavior was comparable with the values of English as well as Brazilian versions and it was within acceptable range.Reliability of N-EARS ::: DiscussionSince the recommendation was against adding up of items to calculate a final score in 10-items for reasons of adherence/non-adherence, we did not determine the internal consistency of the 10-items [5].", [["N-EARS", "PROTEIN", 197, 203]]], ["This was not established even in the original English version by Naomi et al. [5] and the Brazilian version by De Lira et al. [11].Validity of N-EARS ::: DiscussionThe EFA demonstrated adequate construct validity of the 6-item adherence behavior scale of N-EARS.", [["The EFA", "TEST", 164, 171]]], ["The factor loading was higher than that of the original version which demonstrated 71% factor loading [5] and other self-reported outcome measures [17].", [["The factor loading", "TEST", 0, 18]]], ["We could not perform EFA on 10-item reasons for adherence/non-adherence as it could not fulfill the criteria of sampling adequacy (KMO < 0.60) [13], which was in contrast with the Brazilian version (KMO = 0.64) [11].Validity of N-EARS ::: DiscussionThe ROC curve was used to analyze the predictive effect of the 6-item adherence scale [18].", [["EFA", "CHEMICAL", 21, 24], ["EFA", "TEST", 21, 24], ["adherence/non-adherence", "PROBLEM", 48, 71], ["sampling adequacy", "TEST", 112, 129], ["KMO", "TEST", 131, 134], ["The ROC curve", "TEST", 249, 262]]], ["The AUC of the total score of the 6-item adherence behavior scale was 0.91 which was statistically significant and suggested a predictive validity which is in line with literature evidence [18, 19].", [["The AUC", "TEST", 0, 7], ["behavior scale", "TEST", 51, 65], ["a predictive validity", "PROBLEM", 125, 146]]], ["The cutoff score of the tool was 17.5 with a sensitivity of 89% and specificity of 78% that discriminates adherent and non-adherent participants with respect to exercises.", [["participants", "SPECIES", 132, 144], ["The cutoff score", "TEST", 0, 16], ["the tool", "TEST", 20, 28], ["a sensitivity", "TEST", 43, 56], ["specificity", "TEST", 68, 79], ["adherent", "OBSERVATION_MODIFIER", 106, 114]]], ["A study by De Lira et al., in the Brazilian version demonstrated a cutoff score of 17 with sensitivity and specificity higher than 80% [11]; findings that are comparable to the present study.", [["A study", "TEST", 0, 7], ["a cutoff score", "TEST", 65, 79], ["sensitivity", "TEST", 91, 102], ["specificity", "TEST", 107, 118], ["the present study", "TEST", 173, 190]]], ["We also compared our findings with a study by Wang et al., in which a similar scale for exercise adherence was used.", [["a study", "TEST", 35, 42], ["exercise adherence", "TREATMENT", 88, 106]]], ["The sensitivity of 87.2% and specificity of 76.3% reported in the study was similar to the findings of our study [18].Validity of N-EARS ::: DiscussionThe cutoff score of 17.5 indicated that any individual obtaining score > 17.5 out of 24 on the 6-item adherence scale is said to be adherent to the prescribed exercises.", [["The sensitivity", "TEST", 0, 15], ["specificity", "TEST", 29, 40], ["the study", "TEST", 62, 71], ["our study", "TEST", 103, 112], ["The cutoff score", "TEST", 151, 167], ["any individual obtaining score", "TEST", 191, 221]]], ["However, the cutoff score has to be cautiously used during interpretation because without knowing the level of exercise that is necessary for treatment to be effective, a cutoff score in assessing exercise adherence may not be useful [5, 19].", [["the cutoff score", "TEST", 9, 25], ["treatment", "TREATMENT", 142, 151], ["a cutoff score", "TEST", 169, 183]]], ["The cutoff score, sensitivity, and specificity reflected a preliminary predictive validity, which was not established even in the original version of the EARS and was a limitation [5].", [["The cutoff score", "TEST", 0, 16], ["sensitivity", "TEST", 18, 29]]], ["On the other hand, completely relying on the established guidelines with the back translation reflecting the same item content as the original version supported good face validity of the N-EARS [7, 10, 20].Validity of N-EARS ::: DiscussionThe correlation between the total score of 6-item adherence behavior and 10-item reasons for adherence/non-adherence demonstrated the validity of the N-EARS.", [["N-EARS", "CHEMICAL", 187, 193], ["N-EARS", "PROTEIN", 389, 395], ["the back translation", "PROBLEM", 73, 93], ["the total score", "TEST", 263, 278], ["adherence/non-adherence", "PROBLEM", 332, 355]]], ["The strength of correlation has been used in describing validity in patient-reported outcome measures [6, 21].", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75]]], ["The 6-item adherence scale demonstrated a strong correlation (0.6\u20130.8) with items 1, 2, 4, 6, 7, and 10 of 10-item reasons for adherence/non-adherence in the present study.", [["items", "TEST", 76, 81], ["adherence/non-adherence", "PROBLEM", 127, 150], ["the present study", "TEST", 154, 171], ["non-adherence", "OBSERVATION_MODIFIER", 137, 150]]], ["The reasons for adherence/non-adherence in the participants of a study by Newan-Beinart et al. were item numbers 1, 2, 3, 4, 7, and 9 [5].", [["participants", "SPECIES", 47, 59], ["a study", "TEST", 63, 70], ["item numbers", "TEST", 100, 112]]], ["Thus, the 10-items adherence/non-adherence gives clear information on reasons for adherence/non-adherence to exercise on one-to-one analysis, which may vary from one participant to another.Strengths and limitations ::: DiscussionThe strengths of this study include: (1) the method of cross-cultural adaptation that followed the established guidelines giving a methodological strength; (2) the reliability and validity were established on pre-diabetic who were healthy during the recruitment and on patients with various other health conditions as well.", [["patients", "ORGANISM", 498, 506], ["patients", "SPECIES", 498, 506], ["this study", "TEST", 246, 256], ["cross-cultural adaptation", "TREATMENT", 284, 309]]], ["We could evaluate the feasibility of the N-EARS on healthy individuals who were recommended for exercises to prevent disease or remain fit and on patients who were prescribed exercises to treat their impairments or, activity limitations.", [["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["exercises", "TREATMENT", 96, 105], ["disease", "PROBLEM", 117, 124], ["exercises", "TREATMENT", 175, 184], ["their impairments", "PROBLEM", 194, 211]]], ["Therefore, the reliability and validity were demonstrated in the heterogeneous group of participants; and (3) the N-EARS yielded identical psychometric properties as original EARS.Strengths and limitations ::: DiscussionOur study also has some limitations.", [["participants", "SPECIES", 88, 100], ["DiscussionOur study", "TEST", 210, 229], ["heterogeneous", "OBSERVATION_MODIFIER", 65, 78]]], ["First, the study had a small sample size.", [["the study", "TEST", 7, 16], ["a small sample size", "PROBLEM", 21, 40], ["small", "OBSERVATION_MODIFIER", 23, 28], ["sample", "OBSERVATION_MODIFIER", 29, 35], ["size", "OBSERVATION_MODIFIER", 36, 40]]], ["Due to the COVID-19 pandemic, the data collection was stopped, and a preliminary analysis was done with the sample that we had collected before the study was halted in March 2020.", [["the COVID", "TEST", 7, 16], ["pandemic", "PROBLEM", 20, 28], ["the data collection", "TEST", 30, 49], ["a preliminary analysis", "TEST", 67, 89], ["the study", "TEST", 144, 153]]], ["Since preliminary analysis met the criteria for sample adequacy, the final analysis was performed with the current sample.", [["preliminary analysis", "TEST", 6, 26], ["the final analysis", "TEST", 65, 83], ["the current sample", "TEST", 103, 121]]], ["Second, participants had to recall how much they adhered to the prescribed exercises during the last two weeks while scoring exercise adherence level.", [["participants", "SPECIES", 8, 20]]], ["Hence, there might be a possibility of recall bias during scoring.", [["might be a possibility", "UNCERTAINTY", 13, 35]]], ["Finally, participants had to be literate in order to respond to the EARS.", [["participants", "SPECIES", 9, 21], ["EARS", "ANATOMY", 68, 72]]], ["An oral response version of the scale would probably be of interest for future research.ConclusionsThe EARS has been cross-culturally adapted to the Nepali language.", [["oral", "ANATOMY", 3, 7], ["oral", "ORGANISM_SUBDIVISION", 3, 7], ["EARS", "DNA", 103, 107], ["the scale", "TREATMENT", 28, 37], ["EARS", "ANATOMY", 103, 107]]], ["This study provided excellent internal consistency and adequate face, construct as well as predictive validity of the N-EARS.", [["N-EARS", "PROTEIN", 118, 124], ["This study", "TEST", 0, 10]]], ["The N-EARS yielded identical psychometric properties as the original EARS.", [["N-EARS", "PROTEIN", 4, 10], ["The N-EARS", "TEST", 0, 10], ["EARS", "ANATOMY", 69, 73]]], ["A cutoff score of 17.5 was found with good sensitivity and specificity.", [["A cutoff score", "TEST", 0, 14]]], ["The findings of the present study provided evidence to use N-EARS in research and clinical practice that might facilitate the evaluation of exercise-related interventions.", [["the present study", "TEST", 16, 33], ["the evaluation", "TEST", 122, 136], ["exercise-related interventions", "TREATMENT", 140, 170]]], ["Further studies are recommended to investigate other psychometric properties of the N-EARS with a larger sample including various diseases.", [["Further studies", "TEST", 0, 15], ["a larger sample", "PROBLEM", 96, 111], ["various diseases", "PROBLEM", 122, 138], ["diseases", "OBSERVATION", 130, 138]]]], "PMC7472679": [["IntroductionThe post-resuscitation state is often characterized by hypotension that is refractory to pressors [1].", [["hypotension", "DISEASE", 67, 78], ["hypotension", "PROBLEM", 67, 78], ["pressors", "TREATMENT", 101, 109], ["hypotension", "OBSERVATION", 67, 78]]], ["While it is likely that the myocardial and vasomotor processes are multifactorial, it has been proposed that disordered calcium homeostasis is a central factor [2, 3], as ionized calcium plays an important role in both inotropy and vasomotor tone [4].IntroductionNieman et al. previously reported that ionized hypocalcemia occurs post return of spontaneous circulation (ROSC) in their swine model of ventricular fibrillation [2, 3], and that administration of intravenous (IV) calcium gluconate is associated with a transient improvement in hemodynamics.IntroductionHistorically, clinical cardiac arrest has been classified into two broad categories that include ventricular fibrillation and pulseless electrical activity (PEA).", [["myocardial", "ANATOMY", 28, 38], ["ventricular", "ANATOMY", 400, 411], ["intravenous", "ANATOMY", 460, 471], ["cardiac", "ANATOMY", 589, 596], ["ventricular", "ANATOMY", 663, 674], ["calcium", "CHEMICAL", 120, 127], ["calcium", "CHEMICAL", 179, 186], ["hypocalcemia", "DISEASE", 310, 322], ["ventricular fibrillation", "DISEASE", 400, 424], ["calcium gluconate", "CHEMICAL", 477, 494], ["cardiac arrest", "DISEASE", 589, 603], ["ventricular fibrillation", "DISEASE", 663, 687], ["PEA", "CHEMICAL", 723, 726], ["calcium", "CHEMICAL", 120, 127], ["calcium", "CHEMICAL", 179, 186], ["calcium gluconate", "CHEMICAL", 477, 494], ["myocardial", "MULTI-TISSUE_STRUCTURE", 28, 38], ["calcium", "SIMPLE_CHEMICAL", 120, 127], ["ionized calcium", "SIMPLE_CHEMICAL", 171, 186], ["ventricular", "ORGAN", 400, 411], ["intravenous (IV) calcium gluconate", "SIMPLE_CHEMICAL", 460, 494], ["ventricular", "MULTI-TISSUE_STRUCTURE", 663, 674], ["swine", "SPECIES", 385, 390], ["the myocardial and vasomotor processes", "PROBLEM", 24, 62], ["disordered calcium homeostasis", "PROBLEM", 109, 139], ["ionized calcium", "TEST", 171, 186], ["vasomotor tone", "TEST", 232, 246], ["ionized hypocalcemia", "PROBLEM", 302, 322], ["spontaneous circulation", "PROBLEM", 345, 368], ["ventricular fibrillation", "PROBLEM", 400, 424], ["intravenous (IV) calcium gluconate", "TREATMENT", 460, 494], ["clinical cardiac arrest", "PROBLEM", 580, 603], ["ventricular fibrillation", "PROBLEM", 663, 687], ["pulseless electrical activity", "PROBLEM", 692, 721], ["is likely", "UNCERTAINTY", 9, 18], ["myocardial", "ANATOMY", 28, 38], ["ionized hypocalcemia", "OBSERVATION", 302, 322], ["ventricular", "ANATOMY", 400, 411], ["fibrillation", "OBSERVATION", 412, 424], ["transient", "OBSERVATION_MODIFIER", 516, 525], ["improvement", "OBSERVATION", 526, 537], ["cardiac", "ANATOMY", 589, 596], ["arrest", "OBSERVATION", 597, 603], ["ventricular", "ANATOMY", 663, 674], ["fibrillation", "OBSERVATION", 675, 687], ["electrical activity", "OBSERVATION", 702, 721]]], ["The latter category was first called electromechanical dissociation (EMD), but underwent a name change when studies revealed that in a substantial fraction of patients, pulse pressures and ventricular mechanical function were detectible [5, 6].", [["ventricular", "ANATOMY", 189, 200], ["patients", "ORGANISM", 159, 167], ["ventricular mechanical", "MULTI-TISSUE_STRUCTURE", 189, 211], ["patients", "SPECIES", 159, 167], ["pulse pressures", "TEST", 169, 184], ["ventricular mechanical function", "TEST", 189, 220], ["ventricular", "ANATOMY", 189, 200], ["mechanical function", "OBSERVATION", 201, 220]]], ["The detection of pulses with advanced technology renders PEA an imprecise descriptor, and we now refer to the cardiovascular state of subjective clinical cardiac arrest with detectable hemodynamics as \u201cpseudo-PEA.\u201d", [["cardiovascular", "ANATOMY", 110, 124], ["cardiac", "ANATOMY", 154, 161], ["PEA", "CHEMICAL", 57, 60], ["cardiac arrest", "DISEASE", 154, 168], ["PEA", "CHEMICAL", 57, 60], ["pseudo-PEA", "CHEMICAL", 202, 212], ["PEA", "SIMPLE_CHEMICAL", 57, 60], ["cardiac", "ORGAN", 154, 161], ["subjective clinical cardiac arrest", "PROBLEM", 134, 168], ["PEA", "PROBLEM", 209, 212]]], ["Specifically, pseudo-PEA is a global hypotensive ischemic state with retained coordinated myocardial contractile activity and an organized ECG.IntroductionSimilar to ventricular fibrillation, pseudo-PEA causes a profound global ischemia and is often associated with post-resuscitation hypotension [7].", [["myocardial", "ANATOMY", 90, 100], ["ventricular", "ANATOMY", 166, 177], ["PEA", "CHEMICAL", 21, 24], ["hypotensive", "DISEASE", 37, 48], ["ventricular fibrillation", "DISEASE", 166, 190], ["PEA", "CHEMICAL", 199, 202], ["ischemia", "DISEASE", 228, 236], ["hypotension", "DISEASE", 285, 296], ["pseudo-PEA", "CHEMICAL", 14, 24], ["pseudo-PEA", "CHEMICAL", 192, 202], ["myocardial", "MULTI-TISSUE_STRUCTURE", 90, 100], ["ventricular", "MULTI-TISSUE_STRUCTURE", 166, 177], ["pseudo-PEA", "PROBLEM", 14, 24], ["a global hypotensive ischemic state", "PROBLEM", 28, 63], ["retained coordinated myocardial contractile activity", "PROBLEM", 69, 121], ["an organized ECG", "TEST", 126, 142], ["ventricular fibrillation", "PROBLEM", 166, 190], ["pseudo", "PROBLEM", 192, 198], ["PEA", "PROBLEM", 199, 202], ["a profound global ischemia", "PROBLEM", 210, 236], ["post-resuscitation hypotension", "PROBLEM", 266, 296], ["PEA", "OBSERVATION_MODIFIER", 21, 24], ["global", "OBSERVATION_MODIFIER", 30, 36], ["hypotensive ischemic state", "OBSERVATION", 37, 63], ["coordinated myocardial contractile activity", "OBSERVATION", 78, 121], ["ventricular", "ANATOMY", 166, 177], ["fibrillation", "OBSERVATION", 178, 190], ["profound", "OBSERVATION_MODIFIER", 212, 220], ["global", "OBSERVATION_MODIFIER", 221, 227], ["ischemia", "OBSERVATION", 228, 236]]], ["Extending Nieman\u2019s report of IV calcium responsive hypotension after resuscitation from fibrillation cardiac arrest, we now provide a preliminary report of a calcium pressor response in hypotension after resuscitation from pseudo-PEA.Surgical prep ::: MethodsThree cohorts (N = 38) of domestic farm raised Yorkshire swine weighing approximately 30 kg were fasted overnight with free access to water and then sedated with an intramuscular injection of ketamine (30 mg/kg).", [["cardiac", "ANATOMY", 101, 108], ["intramuscular", "ANATOMY", 424, 437], ["calcium", "CHEMICAL", 32, 39], ["hypotension", "DISEASE", 51, 62], ["fibrillation cardiac arrest", "DISEASE", 88, 115], ["calcium", "CHEMICAL", 158, 165], ["hypotension", "DISEASE", 186, 197], ["PEA", "CHEMICAL", 230, 233], ["ketamine", "CHEMICAL", 451, 459], ["calcium", "CHEMICAL", 32, 39], ["calcium", "CHEMICAL", 158, 165], ["pseudo-PEA", "CHEMICAL", 223, 233], ["ketamine", "CHEMICAL", 451, 459], ["calcium", "SIMPLE_CHEMICAL", 32, 39], ["calcium", "SIMPLE_CHEMICAL", 158, 165], ["pseudo-PEA", "SIMPLE_CHEMICAL", 223, 233], ["swine", "ORGANISM", 316, 321], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 424, 437], ["ketamine", "SIMPLE_CHEMICAL", 451, 459], ["swine", "SPECIES", 316, 321], ["IV calcium responsive hypotension", "PROBLEM", 29, 62], ["resuscitation", "TREATMENT", 69, 82], ["fibrillation cardiac arrest", "PROBLEM", 88, 115], ["a calcium pressor response", "TREATMENT", 156, 182], ["hypotension", "PROBLEM", 186, 197], ["resuscitation", "TREATMENT", 204, 217], ["pseudo", "PROBLEM", 223, 229], ["PEA", "PROBLEM", 230, 233], ["Methods", "TREATMENT", 252, 259], ["sedated", "TREATMENT", 408, 415], ["an intramuscular injection of ketamine", "TREATMENT", 421, 459], ["hypotension", "OBSERVATION", 51, 62], ["arrest", "OBSERVATION", 109, 115], ["hypotension", "OBSERVATION", 186, 197]]], ["After endotracheal intubation, anesthesia was initiated and maintained with isoflurane (0.5-4%) and oxygen (1-3 L/min).", [["endotracheal", "ANATOMY", 6, 18], ["isoflurane", "CHEMICAL", 76, 86], ["oxygen", "CHEMICAL", 100, 106], ["isoflurane", "CHEMICAL", 76, 86], ["oxygen", "CHEMICAL", 100, 106], ["isoflurane", "SIMPLE_CHEMICAL", 76, 86], ["oxygen", "SIMPLE_CHEMICAL", 100, 106], ["endotracheal intubation", "TREATMENT", 6, 29], ["anesthesia", "TREATMENT", 31, 41], ["isoflurane", "TREATMENT", 76, 86], ["oxygen", "TREATMENT", 100, 106], ["endotracheal intubation", "OBSERVATION", 6, 29]]], ["During preparation, ventilation was provided by a volume-controlled ventilator (GE Datex-Ohmeda Modulus SE, Madison, WI) with 100% O2 (tidal volume of 15-20 cc/kg and ventilation rate of 8-15 breaths per minute) during initiation, reducing to 30% shortly thereafter.", [["SE", "DISEASE", 104, 106], ["O2", "CHEMICAL", 131, 133], ["O2", "CHEMICAL", 131, 133], ["O2", "SIMPLE_CHEMICAL", 131, 133], ["ventilation", "TREATMENT", 20, 31], ["a volume-controlled ventilator", "TREATMENT", 48, 78], ["GE Datex", "TREATMENT", 80, 88], ["100% O2", "TREATMENT", 126, 133], ["tidal volume", "TEST", 135, 147], ["ventilation rate", "TEST", 167, 183]]], ["Ventilation rate and tidal volume were initially adjusted to maintain normocapnia (the end-expiratory partial pressure of CO2 between 35-45 mmHg) as measured continuously by a capnometer (CO2SMO, Novametrix, Wallingford, CT) placed in the airway.", [["airway", "ANATOMY", 239, 245], ["CO2", "CHEMICAL", 122, 125], ["airway", "MULTI-TISSUE_STRUCTURE", 239, 245], ["Ventilation rate", "TEST", 0, 16], ["tidal volume", "TREATMENT", 21, 33], ["normocapnia", "TEST", 70, 81], ["CO2", "TEST", 122, 125], ["Novametrix", "TREATMENT", 196, 206], ["CT", "TEST", 221, 223], ["airway", "ANATOMY", 239, 245]]], ["Arterial blood gases (I-Stat, Abbott Point of Care, Princeton, NJ) were analyzed to confirm adequate baseline ventilation.", [["Arterial blood", "ANATOMY", 0, 14], ["Arterial", "MULTI-TISSUE_STRUCTURE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["Arterial blood gases", "TEST", 0, 20]]], ["Throughout the experiment, the animals were monitored using ECG, end-tidal CO2, and arterial blood pressure.", [["arterial blood", "ANATOMY", 84, 98], ["CO2", "CHEMICAL", 75, 78], ["animals", "ORGANISM", 31, 38], ["arterial", "MULTI-TISSUE_STRUCTURE", 84, 92], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["ECG", "TEST", 60, 63], ["tidal CO2", "TEST", 69, 78], ["arterial blood pressure", "TEST", 84, 107], ["arterial", "ANATOMY", 84, 92]]], ["In addition, depth of anesthesia was continuously assessed.Surgical prep ::: MethodsThe animals were secured in a supine position and were given normal saline at a rate of 10 ml/kg per hour through a vein to maintain a central venous pressure of ~ 5 mmHg.", [["vein", "ANATOMY", 200, 204], ["venous", "ANATOMY", 227, 233], ["animals", "ORGANISM", 88, 95], ["saline", "SIMPLE_CHEMICAL", 152, 158], ["vein", "MULTI-TISSUE_STRUCTURE", 200, 204], ["venous", "MULTI-TISSUE_STRUCTURE", 227, 233], ["anesthesia", "TREATMENT", 22, 32], ["Methods", "TREATMENT", 77, 84], ["normal saline", "TREATMENT", 145, 158], ["a central venous pressure", "TEST", 217, 242], ["vein", "ANATOMY", 200, 204], ["central venous", "ANATOMY", 219, 233], ["pressure", "OBSERVATION_MODIFIER", 234, 242]]], ["Through either ultrasound-guided percutaneous cannulations or surgical cut-down, micromanometer catheters with a lumen were placed into (1) the right atrium via the femoral vein, and (2) the descending aorta through the femoral artery for pressure measurements.", [["percutaneous", "ANATOMY", 33, 45], ["lumen", "ANATOMY", 113, 118], ["right atrium", "ANATOMY", 144, 156], ["femoral vein", "ANATOMY", 165, 177], ["descending aorta", "ANATOMY", 191, 207], ["femoral artery", "ANATOMY", 220, 234], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 118], ["right atrium", "MULTI-TISSUE_STRUCTURE", 144, 156], ["femoral vein", "MULTI-TISSUE_STRUCTURE", 165, 177], ["aorta", "MULTI-TISSUE_STRUCTURE", 202, 207], ["femoral artery", "MULTI-TISSUE_STRUCTURE", 220, 234], ["either ultrasound", "TEST", 8, 25], ["guided percutaneous cannulations", "TREATMENT", 26, 58], ["surgical cut-down, micromanometer catheters", "TREATMENT", 62, 105], ["a lumen", "TREATMENT", 111, 118], ["pressure measurements", "TEST", 239, 260], ["right atrium", "ANATOMY", 144, 156], ["femoral vein", "ANATOMY", 165, 177], ["descending aorta", "ANATOMY", 191, 207], ["femoral artery", "ANATOMY", 220, 234], ["pressure", "OBSERVATION", 239, 247]]], ["Cohort 1 utilized Tru-Wave Pressure Transducers (Edwards Lifesciences, Irvine, CA), and cohorts 2 and 3 utilized SPR-350 (Millar Instruments, Houston, TX).", [["Tru-Wave Pressure Transducers", "TREATMENT", 18, 47]]], ["All catheters were positioned under fluoroscopic guidance, and unfractionated heparin (100 units/kg) was given to prevent catheter clotting.", [["catheter", "ANATOMY", 122, 130], ["heparin", "CHEMICAL", 78, 85], ["heparin", "SIMPLE_CHEMICAL", 78, 85], ["All catheters", "TREATMENT", 0, 13], ["unfractionated heparin", "TREATMENT", 63, 85], ["catheter clotting", "PROBLEM", 122, 139], ["catheters", "OBSERVATION", 4, 13], ["catheter clotting", "OBSERVATION", 122, 139]]], ["Flow probes were placed around the carotid artery (3 PS probe, Transonic, Ithaca, NY) and jugular vein (2.5 PS probe, Transonic, Ithaca, NY) via a cut-down procedure.Surgical prep ::: MethodsAfter instrumentation, baseline measurements were obtained for all variables including blood gas analyses.", [["carotid artery", "ANATOMY", 35, 49], ["jugular vein", "ANATOMY", 90, 102], ["blood", "ANATOMY", 278, 283], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 35, 49], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 90, 102], ["blood", "ORGANISM_SUBSTANCE", 278, 283], ["Flow probes", "TREATMENT", 0, 11], ["3 PS probe", "TREATMENT", 51, 61], ["2.5 PS probe", "TREATMENT", 104, 116], ["a cut-down procedure", "TREATMENT", 145, 165], ["MethodsAfter instrumentation", "TREATMENT", 184, 212], ["baseline measurements", "TEST", 214, 235], ["blood gas analyses", "TEST", 278, 296], ["carotid artery", "ANATOMY", 35, 49], ["jugular vein", "ANATOMY", 90, 102]]], ["Analog outputs of the physiological parameters were digitized and stored in data files on a personal computer for further analysis using a 16-channel computerized data-acquisition system at a sampling rate of 1000 Hz (Powerlab 16SP, ADInstruments, Castle Hill, Australia).", [["Analog outputs", "TEST", 0, 14], ["further analysis", "TEST", 114, 130], ["a sampling rate", "TEST", 190, 205]]], ["Raw data channels included ECG, aortic pressure, right atrial pressure, intra-cranial pressure, capnography, carotid blood flow, and jugular blood flow.Pseudo-PEA induction and chest compression ::: MethodsAnimals were converted to continuous intravenous anesthesia using ketamine (50 mcg/kg/min) and fentanyl (0.45 mcg/kg/min), isoflurane was gradually discontinued.", [["aortic", "ANATOMY", 32, 38], ["right atrial", "ANATOMY", 49, 61], ["intra-cranial", "ANATOMY", 72, 85], ["carotid", "ANATOMY", 109, 116], ["blood", "ANATOMY", 117, 122], ["jugular blood", "ANATOMY", 133, 146], ["chest", "ANATOMY", 177, 182], ["intravenous", "ANATOMY", 243, 254], ["Pseudo-PEA", "CHEMICAL", 152, 162], ["chest compression", "DISEASE", 177, 194], ["ketamine", "CHEMICAL", 272, 280], ["fentanyl", "CHEMICAL", 301, 309], ["isoflurane", "CHEMICAL", 329, 339], ["Pseudo-PEA", "CHEMICAL", 152, 162], ["ketamine", "CHEMICAL", 272, 280], ["fentanyl", "CHEMICAL", 301, 309], ["isoflurane", "CHEMICAL", 329, 339], ["aortic", "MULTI-TISSUE_STRUCTURE", 32, 38], ["atrial", "MULTI-TISSUE_STRUCTURE", 55, 61], ["carotid blood", "MULTI-TISSUE_STRUCTURE", 109, 122], ["jugular", "MULTI-TISSUE_STRUCTURE", 133, 140], ["blood", "ORGANISM_SUBSTANCE", 141, 146], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 243, 254], ["ketamine", "SIMPLE_CHEMICAL", 272, 280], ["fentanyl", "SIMPLE_CHEMICAL", 301, 309], ["isoflurane", "SIMPLE_CHEMICAL", 329, 339], ["ECG", "TEST", 27, 30], ["aortic pressure", "TEST", 32, 47], ["right atrial pressure", "TEST", 49, 70], ["intra-cranial pressure", "TEST", 72, 94], ["capnography", "TEST", 96, 107], ["carotid blood flow", "TEST", 109, 127], ["jugular blood flow", "TEST", 133, 151], ["Pseudo", "PROBLEM", 152, 158], ["PEA induction", "TREATMENT", 159, 172], ["continuous intravenous anesthesia", "TREATMENT", 232, 265], ["ketamine", "TREATMENT", 272, 280], ["fentanyl", "TREATMENT", 301, 309], ["isoflurane", "TREATMENT", 329, 339], ["aortic", "ANATOMY", 32, 38], ["pressure", "OBSERVATION_MODIFIER", 39, 47], ["right atrial", "ANATOMY", 49, 61], ["pressure", "OBSERVATION_MODIFIER", 62, 70], ["intra-cranial pressure", "OBSERVATION", 72, 94], ["carotid", "ANATOMY", 109, 116], ["jugular blood", "ANATOMY", 133, 146], ["PEA induction", "OBSERVATION", 159, 172], ["chest", "ANATOMY", 177, 182], ["compression", "OBSERVATION", 183, 194]]], ["Depth of anesthesia was ensured via monitoring blood pressure, heart rate, and jaw tone.", [["blood", "ANATOMY", 47, 52], ["heart", "ANATOMY", 63, 68], ["jaw", "ANATOMY", 79, 82], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["heart", "ORGAN", 63, 68], ["jaw", "ORGANISM_SUBDIVISION", 79, 82], ["anesthesia", "TREATMENT", 9, 19], ["monitoring blood pressure", "TEST", 36, 61], ["heart rate", "TEST", 63, 73], ["anesthesia", "OBSERVATION", 9, 19], ["heart", "ANATOMY", 63, 68], ["jaw", "ANATOMY", 79, 82]]], ["The IV anesthesia protocol was maintained 15 min to allow isoflurane washout and to establish a stable level of continuous IV anesthesia prior to initiation of the hypoxia protocol.Pseudo-PEA induction and chest compression ::: MethodsArterial blood gases were measured at baseline and after each episode of pseudo-PEA (i-STAT, Abbott Point of Care, Abbott Park, IL).", [["chest", "ANATOMY", 206, 211], ["blood", "ANATOMY", 244, 249], ["isoflurane", "CHEMICAL", 58, 68], ["hypoxia", "DISEASE", 164, 171], ["Pseudo-PEA", "CHEMICAL", 181, 191], ["chest compression", "DISEASE", 206, 223], ["PEA", "CHEMICAL", 315, 318], ["isoflurane", "CHEMICAL", 58, 68], ["Pseudo-PEA", "CHEMICAL", 181, 191], ["pseudo-PEA", "CHEMICAL", 308, 318], ["isoflurane", "SIMPLE_CHEMICAL", 58, 68], ["blood", "ORGANISM_SUBSTANCE", 244, 249], ["The IV anesthesia protocol", "TREATMENT", 0, 26], ["isoflurane washout", "TREATMENT", 58, 76], ["continuous IV anesthesia", "TREATMENT", 112, 136], ["the hypoxia protocol", "TREATMENT", 160, 180], ["Pseudo", "PROBLEM", 181, 187], ["PEA induction", "TREATMENT", 188, 201], ["MethodsArterial blood gases", "TEST", 228, 255], ["pseudo", "PROBLEM", 308, 314], ["PEA", "PROBLEM", 315, 318], ["hypoxia", "OBSERVATION", 164, 171], ["PEA induction", "OBSERVATION", 188, 201], ["chest", "ANATOMY", 206, 211], ["compression", "OBSERVATION", 212, 223]]], ["Measurements included: pH, pCO2, pO2, base excess, HCO3, TCO2, O2 percent saturation, Na (mmol/L), K (mmol/L), ionized calcium (iCa), glucose, hematocrit, and hemoglobin.Pseudo-PEA induction and chest compression ::: MethodsOnce adequate anesthesia has been confirmed, the animals were paralyzed using vecuronium (1.0 mg/kg) to minimize gasping [11].", [["chest", "ANATOMY", 195, 200], ["HCO3", "CHEMICAL", 51, 55], ["TCO2", "CHEMICAL", 57, 61], ["O2", "CHEMICAL", 63, 65], ["Na", "CHEMICAL", 86, 88], ["calcium", "CHEMICAL", 119, 126], ["iCa", "CHEMICAL", 128, 131], ["glucose", "CHEMICAL", 134, 141], ["Pseudo-PEA", "CHEMICAL", 170, 180], ["chest compression", "DISEASE", 195, 212], ["vecuronium", "CHEMICAL", 302, 312], ["HCO3", "CHEMICAL", 51, 55], ["TCO2", "CHEMICAL", 57, 61], ["O2", "CHEMICAL", 63, 65], ["Na", "CHEMICAL", 86, 88], ["calcium", "CHEMICAL", 119, 126], ["iCa", "CHEMICAL", 128, 131], ["glucose", "CHEMICAL", 134, 141], ["Pseudo-PEA", "CHEMICAL", 170, 180], ["vecuronium", "CHEMICAL", 302, 312], ["HCO3", "SIMPLE_CHEMICAL", 51, 55], ["TCO2", "SIMPLE_CHEMICAL", 57, 61], ["O2", "SIMPLE_CHEMICAL", 63, 65], ["Na", "SIMPLE_CHEMICAL", 86, 88], ["ionized", "SIMPLE_CHEMICAL", 111, 118], ["calcium", "SIMPLE_CHEMICAL", 119, 126], ["iCa", "SIMPLE_CHEMICAL", 128, 131], ["glucose", "SIMPLE_CHEMICAL", 134, 141], ["hematocrit", "SIMPLE_CHEMICAL", 143, 153], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 159, 169], ["animals", "ORGANISM", 273, 280], ["vecuronium", "SIMPLE_CHEMICAL", 302, 312], ["hemoglobin", "PROTEIN", 159, 169], ["pH", "TEST", 23, 25], ["pCO2", "TEST", 27, 31], ["pO2", "TEST", 33, 36], ["base excess", "TEST", 38, 49], ["HCO3", "TEST", 51, 55], ["TCO2", "TEST", 57, 61], ["O2 percent saturation", "TEST", 63, 84], ["Na", "TEST", 86, 88], ["K", "TEST", 99, 100], ["ionized calcium", "TEST", 111, 126], ["iCa", "TEST", 128, 131], ["glucose", "TEST", 134, 141], ["hematocrit", "TEST", 143, 153], ["hemoglobin", "TEST", 159, 169], ["Pseudo", "PROBLEM", 170, 176], ["PEA induction", "TREATMENT", 177, 190], ["MethodsOnce adequate anesthesia", "TREATMENT", 217, 248], ["vecuronium", "TREATMENT", 302, 312], ["gasping", "PROBLEM", 337, 344], ["PEA induction", "OBSERVATION", 177, 190], ["chest", "ANATOMY", 195, 200], ["compression", "OBSERVATION", 201, 212]]], ["Baseline data were measured before any injury occurred.", [["Baseline data", "TEST", 0, 13], ["any injury", "PROBLEM", 35, 45], ["injury", "OBSERVATION", 39, 45]]], ["Round 1 data were measured after resuscitation from the first pseudo-PEA injury.", [["PEA", "CHEMICAL", 69, 72], ["pseudo-PEA", "CHEMICAL", 62, 72], ["resuscitation", "TREATMENT", 33, 46], ["the first pseudo-PEA injury", "PROBLEM", 52, 79], ["PEA injury", "OBSERVATION", 69, 79]]], ["Data were also measured after resuscitation from subsequent pseudo-PEA injuries.", [["PEA", "CHEMICAL", 67, 70], ["pseudo-PEA", "CHEMICAL", 60, 70], ["resuscitation", "TREATMENT", 30, 43], ["subsequent pseudo-PEA injuries", "PROBLEM", 49, 79], ["PEA injuries", "OBSERVATION", 67, 79]]], ["The number of injuries per animal is variable, but the maximum number of hypoxic episodes is 5.", [["injuries", "DISEASE", 14, 22], ["injuries", "PROBLEM", 14, 22], ["hypoxic episodes", "PROBLEM", 73, 89], ["number", "OBSERVATION_MODIFIER", 4, 10], ["injuries", "OBSERVATION", 14, 22], ["variable", "OBSERVATION_MODIFIER", 37, 45], ["maximum", "OBSERVATION_MODIFIER", 55, 62], ["number", "OBSERVATION_MODIFIER", 63, 69], ["hypoxic episodes", "OBSERVATION", 73, 89]]], ["Animals were ventilated with a progressively hypoxic gas mixture of O2/N2.", [["O2/N2", "CHEMICAL", 68, 73], ["O2", "CHEMICAL", 68, 70], ["N2", "CHEMICAL", 71, 73], ["Animals", "ORGANISM", 0, 7], ["O2", "SIMPLE_CHEMICAL", 68, 70], ["a progressively hypoxic gas mixture", "PROBLEM", 29, 64], ["ventilated", "OBSERVATION", 13, 23]]], ["Gas concentrations were measured using an oxygen concentration analyzer (Oxygen Analyzer S-3A/II, Applied Electrochemistry, VMETEK) and the concentration of O2 was decreased until pseudo-PEA was achieved.", [["oxygen", "CHEMICAL", 42, 48], ["S-3A/II", "CHEMICAL", 89, 96], ["O2", "CHEMICAL", 157, 159], ["PEA", "CHEMICAL", 187, 190], ["oxygen", "CHEMICAL", 42, 48], ["Oxygen", "CHEMICAL", 73, 79], ["O2", "CHEMICAL", 157, 159], ["pseudo-PEA", "CHEMICAL", 180, 190], ["Gas", "SIMPLE_CHEMICAL", 0, 3], ["oxygen", "SIMPLE_CHEMICAL", 42, 48], ["Oxygen", "SIMPLE_CHEMICAL", 73, 79], ["O2", "SIMPLE_CHEMICAL", 157, 159], ["pseudo-PEA", "SIMPLE_CHEMICAL", 180, 190], ["Gas concentrations", "TEST", 0, 18], ["an oxygen concentration analyzer", "TREATMENT", 39, 71], ["Oxygen Analyzer", "TEST", 73, 88], ["the concentration of O2", "TREATMENT", 136, 159], ["pseudo", "PROBLEM", 180, 186], ["PEA", "PROBLEM", 187, 190], ["concentrations", "OBSERVATION_MODIFIER", 4, 18]]], ["Onset of pseudo-PEA was defined as sustained aortic systolic pressure \u2264 50 mmHg recorded by the aortic catheter in the presence of an organized cardiac rhythm.Pseudo-PEA induction and chest compression ::: MethodsAnimals were treated with mechanical chest compressions delivered at a depth of 5 cm and at a variable rate.", [["aortic", "ANATOMY", 45, 51], ["aortic", "ANATOMY", 96, 102], ["cardiac", "ANATOMY", 144, 151], ["chest", "ANATOMY", 184, 189], ["chest", "ANATOMY", 250, 255], ["Pseudo-PEA", "CHEMICAL", 159, 169], ["chest compression", "DISEASE", 184, 201], ["pseudo-PEA", "CHEMICAL", 9, 19], ["Pseudo-PEA", "CHEMICAL", 159, 169], ["pseudo-PEA", "SIMPLE_CHEMICAL", 9, 19], ["aortic", "MULTI-TISSUE_STRUCTURE", 45, 51], ["aortic", "MULTI-TISSUE_STRUCTURE", 96, 102], ["cardiac", "ORGAN", 144, 151], ["chest", "ORGANISM_SUBDIVISION", 250, 255], ["pseudo-PEA", "PROBLEM", 9, 19], ["sustained aortic systolic pressure", "TEST", 35, 69], ["the aortic catheter", "TREATMENT", 92, 111], ["Pseudo", "PROBLEM", 159, 165], ["PEA induction", "TREATMENT", 166, 179], ["MethodsAnimals", "TREATMENT", 206, 220], ["mechanical chest compressions", "TREATMENT", 239, 268], ["pseudo", "OBSERVATION", 9, 15], ["PEA", "ANATOMY_MODIFIER", 16, 19], ["aortic systolic", "ANATOMY", 45, 60], ["pressure", "OBSERVATION_MODIFIER", 61, 69], ["aortic", "ANATOMY", 96, 102], ["catheter", "OBSERVATION", 103, 111], ["cardiac", "ANATOMY", 144, 151], ["rhythm", "OBSERVATION", 152, 158], ["PEA induction", "OBSERVATION", 166, 179], ["chest", "ANATOMY", 184, 189], ["compression", "OBSERVATION", 190, 201], ["chest", "ANATOMY", 250, 255]]], ["Compressions were delivered for a total of 6 min.", [["Compressions", "TREATMENT", 0, 12]]], ["After 6 min of chest compressions, the FiO2 was set to 100%, and chest compressions were continued until ROSC was achieved.", [["chest", "ANATOMY", 15, 20], ["chest", "ANATOMY", 65, 70], ["chest", "ORGANISM_SUBDIVISION", 15, 20], ["chest", "ORGANISM_SUBDIVISION", 65, 70], ["chest compressions", "TREATMENT", 15, 33], ["the FiO2", "TREATMENT", 35, 43], ["chest compressions", "TREATMENT", 65, 83], ["ROSC", "TEST", 105, 109], ["chest", "ANATOMY", 15, 20], ["chest", "ANATOMY", 65, 70]]], ["ROSC was defined as a systolic pressure > 60 mmHg without chest compressions.", [["chest", "ANATOMY", 58, 63], ["chest", "ORGANISM_SUBDIVISION", 58, 63], ["ROSC", "TEST", 0, 4], ["a systolic pressure", "TEST", 20, 39], ["chest compressions", "TEST", 58, 76], ["chest", "ANATOMY", 58, 63]]], ["If ROSC was detected at any point during the chest compressions with ongoing hypoxia, compressions were terminated and FiO2 was set to 100%.Post resuscitation treatment ::: MethodsArterial blood gases were measured 10 min after ROSC in all animals and for all episodes of pseudo-PEA.", [["chest", "ANATOMY", 45, 50], ["blood", "ANATOMY", 189, 194], ["hypoxia", "DISEASE", 77, 84], ["PEA", "CHEMICAL", 279, 282], ["FiO2", "CHEMICAL", 119, 123], ["pseudo-PEA", "CHEMICAL", 272, 282], ["chest", "ORGANISM_SUBDIVISION", 45, 50], ["blood", "ORGANISM_SUBSTANCE", 189, 194], ["pseudo-PEA", "SIMPLE_CHEMICAL", 272, 282], ["ROSC", "PROBLEM", 3, 7], ["the chest compressions", "TEST", 41, 63], ["ongoing hypoxia", "PROBLEM", 69, 84], ["compressions", "TREATMENT", 86, 98], ["FiO2", "TREATMENT", 119, 123], ["resuscitation treatment", "TREATMENT", 145, 168], ["MethodsArterial blood gases", "TEST", 173, 200], ["ROSC", "TEST", 228, 232], ["pseudo-PEA", "PROBLEM", 272, 282], ["chest", "ANATOMY", 45, 50], ["hypoxia", "OBSERVATION", 77, 84]]], ["Three related experiments that utilized the same method of hypoxic injury and resuscitation were performed on three separate cohorts of swine (Tables 1 and 2).", [["hypoxic injury", "DISEASE", 59, 73], ["swine", "SPECIES", 136, 141], ["swine", "SPECIES", 136, 141], ["hypoxic injury", "PROBLEM", 59, 73], ["resuscitation", "TREATMENT", 78, 91], ["hypoxic", "OBSERVATION_MODIFIER", 59, 66], ["injury", "OBSERVATION", 67, 73]]], ["Animals in cohorts 1 and 2 did not receive ionized calcium.", [["calcium", "CHEMICAL", 51, 58], ["calcium", "CHEMICAL", 51, 58], ["calcium", "SIMPLE_CHEMICAL", 51, 58], ["ionized calcium", "TEST", 43, 58]]], ["The observation that ionic calcium concentration decreases following pseudo-PEA led to the addition of Ca gluconate to the treatment regimen post-resuscitation for the 14 animals in cohort 3.", [["calcium", "CHEMICAL", 27, 34], ["PEA", "CHEMICAL", 76, 79], ["Ca gluconate", "CHEMICAL", 103, 115], ["calcium", "CHEMICAL", 27, 34], ["pseudo-PEA", "CHEMICAL", 69, 79], ["Ca gluconate", "CHEMICAL", 103, 115], ["calcium", "SIMPLE_CHEMICAL", 27, 34], ["pseudo-PEA", "SIMPLE_CHEMICAL", 69, 79], ["Ca gluconate", "SIMPLE_CHEMICAL", 103, 115], ["ionic calcium concentration", "TREATMENT", 21, 48], ["pseudo-PEA", "PROBLEM", 69, 79], ["Ca gluconate", "TREATMENT", 103, 115], ["the treatment regimen post-resuscitation", "TREATMENT", 119, 159]]], ["Animals in cohort 3 were administered ionized calcium in an ad hoc fashion during the recovery phase when MAP was not sufficient or stable.", [["calcium", "CHEMICAL", 46, 53], ["calcium", "CHEMICAL", 46, 53], ["Animals", "ORGANISM", 0, 7], ["calcium", "SIMPLE_CHEMICAL", 46, 53], ["ionized calcium", "TEST", 38, 53], ["MAP", "TEST", 106, 109], ["stable", "OBSERVATION_MODIFIER", 132, 138]]], ["A bolus of Ca gluconate would be delivered intravenously if the aortic blood pressure was decreasing after resuscitation.", [["intravenously", "ANATOMY", 43, 56], ["aortic", "ANATOMY", 64, 70], ["blood", "ANATOMY", 71, 76], ["Ca gluconate", "CHEMICAL", 11, 23], ["Ca gluconate", "CHEMICAL", 11, 23], ["Ca gluconate", "SIMPLE_CHEMICAL", 11, 23], ["aortic blood", "MULTI-TISSUE_STRUCTURE", 64, 76], ["A bolus of Ca gluconate", "TREATMENT", 0, 23], ["the aortic blood pressure", "TEST", 60, 85], ["resuscitation", "TREATMENT", 107, 120], ["aortic", "ANATOMY", 64, 70]]], ["This meant that calcium might be given to treat blood pressures before the blood chemistries were drawn, resulting in some missing data.", [["blood", "ANATOMY", 48, 53], ["blood", "ANATOMY", 75, 80], ["calcium", "CHEMICAL", 16, 23], ["calcium", "CHEMICAL", 16, 23], ["calcium", "SIMPLE_CHEMICAL", 16, 23], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["calcium", "TREATMENT", 16, 23], ["blood pressures", "TEST", 48, 63], ["the blood chemistries", "TEST", 71, 92]]]], "PMC3903469": [["IntroductionOver nearly the last three decades, a new demographic phenomenon in China has attracted increasing attention [1].", [["a new demographic phenomenon", "PROBLEM", 48, 76], ["new", "OBSERVATION_MODIFIER", 50, 53]]], ["The \u2018floating population\u2019 (or liudong renkou in Chinese) refers to the large and increasing number of migrants without local household registration status (namely hukou).", [["floating", "OBSERVATION_MODIFIER", 5, 13], ["population", "OBSERVATION", 14, 24], ["large", "OBSERVATION_MODIFIER", 71, 76]]], ["According to the report of China National Bureau of Statistics, China had 230 million people in its floating population in 2011, representing 19% of the total population [2].", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92]]], ["This rural-urban migration poses significant challenges, especially for China's welfare system concerning both local and migrant residents.", [["China's welfare system", "TREATMENT", 72, 94]]], ["Without local household registration, the floating migrants are not entitled to some of the benefits that local people enjoy.", [["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118], ["local", "OBSERVATION_MODIFIER", 8, 13], ["household registration", "OBSERVATION", 14, 36]]], ["They face daunting problems, particularly with access to healthcare, adequate housing, employment opportunities, pension plans and school enrollment for their children.", [["children", "ORGANISM", 159, 167], ["children", "SPECIES", 159, 167]]], ["Recently, the National People's Congress of China has highlighted the plight of the \u2018floating population\u2019 and outlined policies for education and basic health services.IntroductionSome epidemiological investigation has been done on the health problems of floating population in China, such as some infected diseases [4], [5], unintentional injuries under six years old children [6] and so on.", [["infected diseases", "DISEASE", 298, 315], ["unintentional injuries", "DISEASE", 326, 348], ["children", "ORGANISM", 369, 377], ["People", "SPECIES", 23, 29], ["children", "SPECIES", 369, 377], ["some infected diseases", "PROBLEM", 293, 315], ["infected", "OBSERVATION", 298, 306]]], ["However, the characteristics of road traffic injuries (RTIs) among floating population have never been reported.", [["traffic injuries", "DISEASE", 37, 53], ["RTIs", "DISEASE", 55, 59], ["road traffic", "MULTI-TISSUE_STRUCTURE", 32, 44], ["road traffic injuries (RTIs) among floating population", "PROBLEM", 32, 86], ["road", "OBSERVATION_MODIFIER", 32, 36], ["traffic injuries", "OBSERVATION", 37, 53]]], ["There may be two reasons.", [["may be", "UNCERTAINTY", 6, 12]]], ["First, such a massive migration of people from undeveloped regions to developed regions was scarcely seen in the other countries of the world except China.", [["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41], ["a massive migration of people", "TREATMENT", 12, 41], ["massive", "OBSERVATION_MODIFIER", 14, 21], ["migration", "OBSERVATION_MODIFIER", 22, 31]]], ["Second, most studies about the floating population health were focused on the infected diseases, because the migration of people is closely related to the spread of infected diseases, and the impact of infected diseases is obviously seen.", [["infected diseases", "DISEASE", 78, 95], ["infected diseases", "DISEASE", 165, 182], ["infected diseases", "DISEASE", 202, 219], ["people", "ORGANISM", 122, 128], ["people", "SPECIES", 122, 128], ["the infected diseases", "PROBLEM", 74, 95], ["infected diseases", "PROBLEM", 165, 182], ["infected diseases", "PROBLEM", 202, 219], ["infected", "OBSERVATION_MODIFIER", 78, 86], ["diseases", "OBSERVATION", 87, 95], ["migration", "OBSERVATION_MODIFIER", 109, 118], ["infected", "OBSERVATION_MODIFIER", 165, 173], ["diseases", "OBSERVATION", 174, 182], ["infected", "OBSERVATION_MODIFIER", 202, 210], ["diseases", "OBSERVATION", 211, 219]]], ["An example is the SARS in 2003 of China [7], [8].", [["SARS", "DISEASE", 18, 22]]], ["However RTIs could happen on any people independent of the household registration, so research regarding the differences in RTIs, between local resident patients and floating migrant patients, has been scarce.", [["RTIs", "DISEASE", 8, 12], ["RTIs", "DISEASE", 124, 128], ["people", "ORGANISM", 33, 39], ["patients", "ORGANISM", 153, 161], ["patients", "ORGANISM", 183, 191], ["people", "SPECIES", 33, 39], ["patients", "SPECIES", 153, 161], ["patients", "SPECIES", 183, 191], ["RTIs", "PROBLEM", 8, 12]]], ["But the floating population of China had a fast increase from 7 million in 1982 to 22 million in 1990 to 79 million in 2000 and 230 million in 2011 [1].", [["a fast increase", "PROBLEM", 41, 56], ["floating", "OBSERVATION_MODIFIER", 8, 16], ["population", "OBSERVATION_MODIFIER", 17, 27], ["increase", "OBSERVATION_MODIFIER", 48, 56]]], ["Due to the high mobility characteristics of these people, the fast expansion of floating population could be a factor contributing to the high frequency of road traffic accidents.", [["traffic accidents", "DISEASE", 161, 178], ["people", "ORGANISM", 50, 56], ["people", "SPECIES", 50, 56], ["the fast expansion of floating population", "PROBLEM", 58, 99], ["high mobility", "OBSERVATION_MODIFIER", 11, 24], ["floating population", "OBSERVATION", 80, 99]]], ["In China, there were 3.9 million traffic accidents reported in 2010, in which 65 thousand people died and 2.5 million peoples were injured with a direct property loss of around 143 million dollars [9].", [["accidents", "DISEASE", 41, 50], ["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96]]], ["A sampling survey of injury deaths in Chinese people also found that, from 1991 to 2005, the proportion of all injury deaths due to traffic accident increased from 15.00% to 33.79% clearly showing a rising trend [10].", [["injury deaths", "DISEASE", 21, 34], ["deaths", "DISEASE", 118, 124], ["traffic accident", "DISEASE", 132, 148], ["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52], ["injury", "PROBLEM", 21, 27], ["all injury deaths", "PROBLEM", 107, 124], ["a rising trend", "PROBLEM", 197, 211]]], ["So it will make sense to have an investigation on the RTIs characteristics of the floating population that was unclear before.IntroductionIn this study, we collected the hospital records of RTI patients from the emergency department of the Fifth Center Hospital of Tianjin, and analyzed the RTIs characteristics of floating population in comparison with those of local residents.", [["RTI", "DISEASE", 190, 193], ["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 194, 202], ["an investigation", "TEST", 30, 46], ["the floating population", "PROBLEM", 78, 101], ["this study", "TEST", 141, 151], ["floating population", "PROBLEM", 315, 334], ["floating", "OBSERVATION_MODIFIER", 82, 90], ["population", "OBSERVATION", 91, 101], ["floating", "OBSERVATION_MODIFIER", 315, 323], ["population", "OBSERVATION", 324, 334]]], ["It is largest tertiary hospital in this district.", [["largest", "OBSERVATION_MODIFIER", 6, 13], ["tertiary", "OBSERVATION_MODIFIER", 14, 22]]], ["More than one-third of the RTI patients in this district were treated in this hospital.", [["RTI", "DISEASE", 27, 30], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["Other RTI patients were scattered among the hospitals near the accident spots.", [["RTI", "DISEASE", 6, 9], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["scattered", "OBSERVATION_MODIFIER", 24, 33]]], ["As an important harbor in north China, masses of freight were transported from neighboring regions to this district, which lead RTIs here having particular characteristics.", [["RTIs", "DISEASE", 128, 132], ["masses of freight", "PROBLEM", 39, 56], ["masses", "OBSERVATION", 39, 45]]], ["This area provides a good sample for research comparing RTIs between local residents and floating population in this district.Ethics statement ::: Materials and MethodsThe study was approved by the Research Ethics Committee at PKUPH and met international biomedical ethics guidelines.", [["RTIs", "DISEASE", 56, 60], ["Methods", "TREATMENT", 161, 168], ["The study", "TEST", 168, 177]]], ["The written consent was given by the patients and the next of kin for their information to be stored in the hospital database and used for research.Data source ::: Materials and MethodsThis descriptive study was performed based on the hospital records of RTI patients who suffered from motor vehicle accidents between the beginning of 2007 and the end of 2010.", [["RTI", "DISEASE", 255, 258], ["motor vehicle accidents", "DISEASE", 286, 309], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 259, 267], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 259, 267], ["Methods", "TREATMENT", 178, 185], ["This descriptive study", "TEST", 185, 207]]], ["The RTI patients were transferred to the Fifth Center Hospital of Tianjin, by ambulance or by themselves.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16]]], ["When patients arrived at the hospital, their personal information and general condition of the road traffic accidents was recorded on an emergency card by the patients themselves or by the accident witnesses.", [["accidents", "DISEASE", 108, 117], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 159, 167]]], ["After the initial treatment in the emergency ward, patients were transferred to other departments of this hospital for follow-up treatment.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["follow-up treatment", "TREATMENT", 119, 138]]], ["All the emergency patients were treated at best regardless of their household registration.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["There were no differences for dealing with local resident patients or floating migrant patients.", [["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 87, 95], ["no differences for", "UNCERTAINTY", 11, 29]]], ["Patient condition was classified as one of the following severity levels according to the examination results: mild, moderate, severe and dead.", [["Patient", "SPECIES", 0, 7], ["severity levels", "TEST", 57, 72], ["the examination", "TEST", 86, 101], ["mild, moderate, severe and dead", "PROBLEM", 111, 142], ["mild", "OBSERVATION_MODIFIER", 111, 115], ["moderate", "OBSERVATION_MODIFIER", 117, 125], ["severe", "OBSERVATION_MODIFIER", 127, 133]]], ["Traffic accidents sufferers who died before arriving at the hospital were not included, because the persons dead at the scene were not transferred to hospital.Data source ::: Materials and MethodsThe RTI patients' data were extracted from the medical records database of this hospital.", [["Traffic accidents", "DISEASE", 0, 17], ["persons", "ORGANISM", 100, 107], ["patients", "ORGANISM", 204, 212], ["persons", "SPECIES", 100, 107], ["patients", "SPECIES", 204, 212]]], ["Medical records of all RTI patients were reviewed and diagnosis codes were assigned by trained coders using the International Classification of Diseases 10th Revision (ICD-10).", [["RTI", "DISEASE", 23, 26], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["Revision (ICD", "TREATMENT", 158, 171]]], ["The following database information was provided to the research team: medical record number, date of birth, gender, date of admission, household status, severity of injury, injured parts of the body, admission diagnosis, inpatient diagnoses, ICD-10 diagnoses codes, inpatient duration, hospitalization cost and outcomes at discharge.Statistical methods ::: Materials and MethodsWe used the Excel software to collect the hospital records data and perform the basic statistical analysis.", [["body", "ANATOMY", 194, 198], ["body", "ORGANISM_SUBDIVISION", 194, 198], ["injury", "PROBLEM", 165, 171], ["ICD", "TREATMENT", 242, 245], ["the basic statistical analysis", "TEST", 454, 484], ["injury", "OBSERVATION", 165, 171], ["injured", "OBSERVATION", 173, 180], ["body", "ANATOMY", 194, 198]]], ["The parameters observed were age, gender, household status, severity of injury, injured parts of the body, diagnosis, inpatient duration, and hospitalization cost.Demographics and general characteristics ::: ResultsBetween 2007 and 2010, there were a total of 2,224 RTI patients transferred to the emergency department of this hospital.", [["body", "ANATOMY", 101, 105], ["RTI", "DISEASE", 266, 269], ["body", "ORGANISM_SUBDIVISION", 101, 105], ["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 270, 278], ["injury", "PROBLEM", 72, 78], ["injury", "OBSERVATION", 72, 78], ["injured", "OBSERVATION", 80, 87], ["body", "ANATOMY", 101, 105]]], ["The maximum and the minimum number of patients per year were 598 and 507 in 2007 and 2010, respectively.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["minimum", "OBSERVATION_MODIFIER", 20, 27], ["number", "OBSERVATION_MODIFIER", 28, 34]]], ["No increasing or decreasing trend in the number of patients per year was found.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["decreasing", "OBSERVATION_MODIFIER", 17, 27], ["trend", "OBSERVATION_MODIFIER", 28, 33]]], ["Patients examined over the four years, included 1,550 male and 674 female patients.", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 74, 82], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 74, 82]]], ["The number of male and female patients over the four years is shown in Figure 1.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["The proportion of female patients of local residents ranged yearly between 30.6% and 37.7%, while that of female patients of floating migrants ranged yearly between 17.4% and 28.6%.", [["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 113, 121]]], ["There were 1,295 local resident patients and 929 floating migrant patients seen over the four years.", [["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 66, 74]]], ["The proportion of floating migrant patients was 42.8%, 42.1%, 44.1% and 37.5% for each year of the study.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["the study", "TEST", 95, 104], ["floating", "OBSERVATION_MODIFIER", 18, 26], ["migrant", "OBSERVATION_MODIFIER", 27, 34]]], ["According to the Tianjin Statistical Yearbooks[11]\u2013[14], there were 507 thousand, 517 thousand, 529 thousand and 494 thousand people with local household registration in each year from 2007 to 2010.", [["people", "ORGANISM", 126, 132], ["people", "SPECIES", 126, 132]]], ["In contrast, the amounts of floating migrants in these four years were 107 thousand, 245 thousand, 272 thousand and 300 thousand people respectively.", [["people", "ORGANISM", 129, 135], ["people", "SPECIES", 129, 135], ["amounts", "OBSERVATION_MODIFIER", 17, 24], ["floating", "OBSERVATION_MODIFIER", 28, 36], ["migrants", "OBSERVATION_MODIFIER", 37, 45]]], ["So the average risks of RTI over the four years for local residents and floating migrants were 0.632 and 1.005 per thousand people.Age distribution of RTIs patients ::: ResultsThe age distribution of local and floating migrant RTI patients over the four years was calculated and is shown in Figure 2.", [["RTI", "DISEASE", 24, 27], ["RTIs", "DISEASE", 151, 155], ["RTI", "DISEASE", 227, 230], ["people", "ORGANISM", 124, 130], ["patients", "ORGANISM", 156, 164], ["patients", "ORGANISM", 231, 239], ["people", "SPECIES", 124, 130], ["patients", "SPECIES", 156, 164], ["patients", "SPECIES", 231, 239], ["RTI", "PROBLEM", 24, 27], ["local and floating migrant RTI", "PROBLEM", 200, 230], ["RTIs", "OBSERVATION", 151, 155], ["distribution", "OBSERVATION_MODIFIER", 184, 196], ["local", "OBSERVATION_MODIFIER", 200, 205], ["floating", "OBSERVATION_MODIFIER", 210, 218], ["migrant", "OBSERVATION_MODIFIER", 219, 226]]], ["The age range of RTI patients was between 0 and 84 years.", [["RTI", "DISEASE", 17, 20], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["Patients under the age of 16 were divided into two groups according to age: preschool age, which was defined as 0 to 6 years old and school age, which was defined as 7 to 15 years old.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["This is because most children in China go to school at the age of 7 and receive nine years of compulsory education.", [["children", "ORGANISM", 21, 29], ["children", "SPECIES", 21, 29], ["compulsory education", "TREATMENT", 94, 114]]], ["From 16 to the eldest age, patients were divided into seven groups with each group comprising approximately 10 years.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35]]], ["The results showed that, before the age of 16, the preschool age population had a higher distribution of RTIs compared to the school age population.", [["RTIs", "DISEASE", 105, 109], ["RTIs", "PROBLEM", 105, 109], ["higher distribution", "OBSERVATION_MODIFIER", 82, 101], ["RTIs", "OBSERVATION", 105, 109]]], ["The age distributions of local resident patients and floating migrant patients were also calculated.", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 70, 78]]], ["These distributions were compared and patients were divided into three groups according to age: younger than age 16, age 16 to 45, and age 46 to 84.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46]]], ["There were a greater number of local resident patients in the first and the last age groups than floating migrant patients.", [["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 114, 122], ["greater", "OBSERVATION_MODIFIER", 13, 20]]], ["The number of floating migrant patients was no fewer than that of local resident patients in the 16 to 45 age groups.", [["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 81, 89], ["number", "OBSERVATION_MODIFIER", 4, 10], ["floating", "OBSERVATION_MODIFIER", 14, 22], ["migrant", "OBSERVATION_MODIFIER", 23, 30]]], ["The peak number of local patients emerged between the ages of 46 and 55, while that of floating migrant patients occurred between the ages of 16 and 45.Monthly distribution of RTIs patients ::: ResultsOver the 4 years, the number of patients each month was counted and the sum over 12 months was calculated.", [["RTIs", "DISEASE", 176, 180], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 181, 189], ["patients", "ORGANISM", 233, 241], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 181, 189], ["patients", "SPECIES", 233, 241], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["local", "OBSERVATION_MODIFIER", 19, 24], ["RTIs", "OBSERVATION", 176, 180]]], ["The 3 months that had the most patients were October (218), March (217) and June (216).", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["In contrast, the 2 months that had the least patients were February (107) and January (146).", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["The proportion of floating migrant patients was also calculated for each month during the 4 years.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["floating", "OBSERVATION_MODIFIER", 18, 26], ["migrant", "OBSERVATION", 27, 34]]], ["In January and February, the proportions of floating migrant patients were just 27.4% and 33.6%, which were less than those of other months.Distribution of injured regions of the body in traffic accidents ::: ResultsInformation regarding injured regions of the body was registered for all of the patients who were in traffic accidents.", [["body", "ANATOMY", 179, 183], ["body", "ANATOMY", 261, 265], ["traffic accidents", "DISEASE", 187, 204], ["patients", "ORGANISM", 61, 69], ["body", "ORGANISM_SUBDIVISION", 179, 183], ["body", "ORGANISM_SUBDIVISION", 261, 265], ["patients", "ORGANISM", 296, 304], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 296, 304], ["floating", "OBSERVATION_MODIFIER", 44, 52], ["injured", "OBSERVATION", 156, 163], ["body", "ANATOMY", 179, 183], ["body", "ANATOMY", 261, 265]]], ["Patients were divided into 11 groups according to the injured regions: head, neck, thorax, abdomen, lower back, lumbar spine and pelvis, shoulder and upper arm, elbow and forearm, wrist and hand, hip and thigh, knee and lower leg, ankle and foot, and multiple regions of the body.", [["head", "ANATOMY", 71, 75], ["neck", "ANATOMY", 77, 81], ["thorax", "ANATOMY", 83, 89], ["abdomen", "ANATOMY", 91, 98], ["lower back", "ANATOMY", 100, 110], ["lumbar spine", "ANATOMY", 112, 124], ["pelvis", "ANATOMY", 129, 135], ["shoulder", "ANATOMY", 137, 145], ["upper arm", "ANATOMY", 150, 159], ["elbow", "ANATOMY", 161, 166], ["forearm", "ANATOMY", 171, 178], ["wrist", "ANATOMY", 180, 185], ["hand", "ANATOMY", 190, 194], ["hip", "ANATOMY", 196, 199], ["thigh", "ANATOMY", 204, 209], ["knee", "ANATOMY", 211, 215], ["lower leg", "ANATOMY", 220, 229], ["ankle", "ANATOMY", 231, 236], ["foot", "ANATOMY", 241, 245], ["body", "ANATOMY", 275, 279], ["Patients", "ORGANISM", 0, 8], ["head", "ORGANISM_SUBDIVISION", 71, 75], ["neck", "ORGANISM_SUBDIVISION", 77, 81], ["thorax", "ORGAN", 83, 89], ["abdomen", "ORGAN", 91, 98], ["lower back", "ORGANISM_SUBDIVISION", 100, 110], ["lumbar spine", "MULTI-TISSUE_STRUCTURE", 112, 124], ["pelvis", "ORGAN", 129, 135], ["shoulder", "ORGANISM_SUBDIVISION", 137, 145], ["upper arm", "ORGANISM_SUBDIVISION", 150, 159], ["elbow", "ORGANISM_SUBDIVISION", 161, 166], ["forearm", "ORGANISM_SUBDIVISION", 171, 178], ["wrist", "ORGANISM_SUBDIVISION", 180, 185], ["hand", "ORGANISM_SUBDIVISION", 190, 194], ["hip", "ORGANISM_SUBDIVISION", 196, 199], ["thigh", "ORGANISM_SUBDIVISION", 204, 209], ["knee", "ORGANISM_SUBDIVISION", 211, 215], ["lower", "ORGANISM_SUBDIVISION", 220, 225], ["leg", "ORGANISM_SUBDIVISION", 226, 229], ["ankle", "ORGANISM_SUBDIVISION", 231, 236], ["foot", "ORGANISM_SUBDIVISION", 241, 245], ["body", "ORGANISM_SUBDIVISION", 275, 279], ["Patients", "SPECIES", 0, 8], ["head, neck, thorax, abdomen, lower back, lumbar spine and pelvis, shoulder and upper arm, elbow and forearm, wrist and hand, hip and thigh, knee and lower leg, ankle and foot", "PROBLEM", 71, 245], ["head", "ANATOMY", 71, 75], ["neck", "ANATOMY", 77, 81], ["thorax", "ANATOMY", 83, 89], ["abdomen", "ANATOMY", 91, 98], ["lower", "ANATOMY_MODIFIER", 100, 105], ["back", "ANATOMY", 106, 110], ["lumbar spine", "ANATOMY", 112, 124], ["pelvis", "ANATOMY", 129, 135], ["shoulder", "ANATOMY", 137, 145], ["upper", "ANATOMY_MODIFIER", 150, 155], ["arm", "ANATOMY", 156, 159], ["elbow", "ANATOMY", 161, 166], ["forearm", "ANATOMY", 171, 178], ["wrist", "ANATOMY", 180, 185], ["hand", "ANATOMY", 190, 194], ["hip", "ANATOMY", 196, 199], ["thigh", "ANATOMY", 204, 209], ["knee", "ANATOMY", 211, 215], ["lower", "ANATOMY_MODIFIER", 220, 225], ["leg", "ANATOMY", 226, 229], ["ankle", "ANATOMY", 231, 236], ["foot", "ANATOMY", 241, 245], ["multiple", "ANATOMY_MODIFIER", 251, 259], ["regions", "ANATOMY_MODIFIER", 260, 267], ["body", "ANATOMY", 275, 279]]], ["The proportion of injured regions in RTIs is shown in Figure 4.", [["RTIs", "DISEASE", 37, 41], ["injured regions in RTIs", "PROBLEM", 18, 41], ["injured", "OBSERVATION", 18, 25], ["RTIs", "OBSERVATION", 37, 41]]], ["Most RTI patients had injuries to the head or had injuries to multiple regions of the body.", [["head", "ANATOMY", 38, 42], ["body", "ANATOMY", 86, 90], ["RTI", "DISEASE", 5, 8], ["injuries to the head", "DISEASE", 22, 42], ["injuries", "DISEASE", 50, 58], ["patients", "ORGANISM", 9, 17], ["head", "ORGANISM_SUBDIVISION", 38, 42], ["body", "ORGANISM_SUBDIVISION", 86, 90], ["patients", "SPECIES", 9, 17], ["injuries to the head", "PROBLEM", 22, 42], ["injuries", "PROBLEM", 50, 58], ["injuries", "OBSERVATION", 22, 30], ["head", "ANATOMY", 38, 42], ["injuries", "OBSERVATION", 50, 58], ["body", "ANATOMY", 86, 90]]], ["These two groups of patients accounted for 37% and 34.6% of all the patients, respectively.", [["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 68, 76]]], ["The injury severity and residence of these two groups of patients were analyzed and are shown in Table 1.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["The injury severity", "PROBLEM", 0, 19], ["injury", "OBSERVATION", 4, 10]]], ["Except for one patient that died as a result of traumatic rupture of the liver and another patient that died from a sudden cardiac event, patient deaths were caused by head injuries or multiple body region injuries.", [["liver", "ANATOMY", 73, 78], ["cardiac", "ANATOMY", 123, 130], ["head", "ANATOMY", 168, 172], ["body", "ANATOMY", 194, 198], ["rupture of the liver", "DISEASE", 58, 78], ["sudden cardiac event", "DISEASE", 116, 136], ["deaths", "DISEASE", 146, 152], ["head injuries", "DISEASE", 168, 181], ["patient", "ORGANISM", 15, 22], ["liver", "ORGAN", 73, 78], ["patient", "ORGANISM", 91, 98], ["cardiac", "ORGAN", 123, 130], ["patient", "ORGANISM", 138, 145], ["head", "ORGANISM_SUBDIVISION", 168, 172], ["body", "ORGANISM_SUBDIVISION", 194, 198], ["patient", "SPECIES", 15, 22], ["patient", "SPECIES", 91, 98], ["patient", "SPECIES", 138, 145], ["traumatic rupture of the liver", "PROBLEM", 48, 78], ["a sudden cardiac event", "PROBLEM", 114, 136], ["head injuries", "PROBLEM", 168, 181], ["multiple body region injuries", "PROBLEM", 185, 214], ["traumatic", "OBSERVATION_MODIFIER", 48, 57], ["rupture", "OBSERVATION", 58, 65], ["liver", "ANATOMY", 73, 78], ["cardiac", "ANATOMY", 123, 130], ["head", "ANATOMY", 168, 172], ["injuries", "OBSERVATION", 173, 181], ["multiple", "OBSERVATION_MODIFIER", 185, 193], ["body", "ANATOMY", 194, 198], ["region", "ANATOMY_MODIFIER", 199, 205], ["injuries", "OBSERVATION", 206, 214]]], ["In the head injury group, the proportions of floating migrant patients classified as mild, moderate and severe were 40.1%, 48.4% and 50% respectively.", [["head", "ANATOMY", 7, 11], ["head injury", "DISEASE", 7, 18], ["head", "ORGAN", 7, 11], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["mild, moderate and severe", "PROBLEM", 85, 110], ["head", "ANATOMY", 7, 11], ["injury", "OBSERVATION", 12, 18], ["mild", "OBSERVATION_MODIFIER", 85, 89], ["moderate", "OBSERVATION_MODIFIER", 91, 99], ["severe", "OBSERVATION_MODIFIER", 104, 110]]], ["In the multiple body regions injury group, these proportions were 39.3%, 42.1% and 46.3%, respectively.Injury characteristics among RTI patients ::: ResultsThe hospital diagnoses of all RTI patients were analyzed.", [["body", "ANATOMY", 16, 20], ["Injury", "DISEASE", 103, 109], ["RTI", "DISEASE", 132, 135], ["RTI", "DISEASE", 186, 189], ["body", "ORGANISM_SUBDIVISION", 16, 20], ["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 190, 198], ["these proportions", "TEST", 43, 60], ["multiple", "OBSERVATION_MODIFIER", 7, 15], ["body", "ANATOMY_MODIFIER", 16, 20], ["regions", "ANATOMY_MODIFIER", 21, 28], ["injury", "OBSERVATION", 29, 35]]], ["In total, 561 types of injuries were diagnosed.", [["injuries", "DISEASE", 23, 31], ["injuries", "PROBLEM", 23, 31]]], ["Frequently diagnosed injuries were classified as those that occurred no less than 20 times.", [["injuries", "DISEASE", 21, 29], ["Frequently diagnosed injuries", "PROBLEM", 0, 29], ["injuries", "OBSERVATION", 21, 29]]], ["There were 100 types of injuries that met this criteria.", [["injuries", "DISEASE", 24, 32], ["injuries", "PROBLEM", 24, 32], ["100 types", "OBSERVATION_MODIFIER", 11, 20], ["injuries", "OBSERVATION", 24, 32]]], ["A total of 10 diagnosed injuries involved the head or thorax (e.g. scalp hematoma and rib fracture).", [["head", "ANATOMY", 46, 50], ["thorax", "ANATOMY", 54, 60], ["scalp", "ANATOMY", 67, 72], ["rib", "ANATOMY", 86, 89], ["injuries", "DISEASE", 24, 32], ["hematoma", "DISEASE", 73, 81], ["rib fracture", "DISEASE", 86, 98], ["head", "ORGANISM_SUBDIVISION", 46, 50], ["thorax", "ORGAN", 54, 60], ["scalp", "ORGANISM_SUBDIVISION", 67, 72], ["rib", "ORGAN", 86, 89], ["10 diagnosed injuries involved the head or thorax (e.g. scalp hematoma", "PROBLEM", 11, 81], ["rib fracture", "PROBLEM", 86, 98], ["injuries", "OBSERVATION", 24, 32], ["head", "ANATOMY", 46, 50], ["thorax", "ANATOMY", 54, 60], ["scalp", "ANATOMY", 67, 72], ["hematoma", "OBSERVATION", 73, 81], ["rib", "ANATOMY", 86, 89], ["fracture", "OBSERVATION", 90, 98]]], ["These injuries are listed in Table S1 and ranked according to the proportion of floating migrant patients with each injury.", [["injuries", "DISEASE", 6, 14], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["These injuries", "PROBLEM", 0, 14], ["each injury", "PROBLEM", 111, 122], ["injuries", "OBSERVATION", 6, 14], ["injury", "OBSERVATION", 116, 122]]], ["The average, median, 25% percentile, 75% percentile and standard deviation of the age of the patients, that had each injury, were also calculated.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["each injury", "PROBLEM", 112, 123], ["average", "OBSERVATION_MODIFIER", 4, 11], ["injury", "OBSERVATION", 117, 123]]], ["For some injuries, there were apparent age differences between local and floating migrant patients.", [["injuries", "DISEASE", 9, 17], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["some injuries", "PROBLEM", 4, 17], ["injuries", "OBSERVATION", 9, 17]]], ["For example, the average age of local patients suffered from fracture of pelvis was 47.2\u00b118.1 years old, while that of floating migrant patients was just 33.9\u00b17.6 years old.Injury characteristics among RTI patients ::: ResultsOpen injuries need more care in the emergency ward because an open wound provides easy access for bacterial infections.", [["pelvis", "ANATOMY", 73, 79], ["wound", "ANATOMY", 293, 298], ["fracture", "DISEASE", 61, 69], ["Injury", "DISEASE", 173, 179], ["RTI", "DISEASE", 202, 205], ["ResultsOpen injuries", "DISEASE", 219, 239], ["bacterial infections", "DISEASE", 324, 344], ["patients", "ORGANISM", 38, 46], ["pelvis", "ORGAN", 73, 79], ["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 206, 214], ["wound", "PATHOLOGICAL_FORMATION", 293, 298], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 206, 214], ["fracture of pelvis", "PROBLEM", 61, 79], ["ResultsOpen injuries", "PROBLEM", 219, 239], ["an open wound", "PROBLEM", 285, 298], ["bacterial infections", "PROBLEM", 324, 344], ["fracture", "OBSERVATION", 61, 69], ["pelvis", "ANATOMY", 73, 79], ["wound", "OBSERVATION", 293, 298], ["infections", "OBSERVATION", 334, 344]]], ["The total number of open injuries, among all injuries, was calculated.", [["injuries", "DISEASE", 25, 33], ["injuries", "DISEASE", 45, 53], ["open injuries", "PROBLEM", 20, 33], ["all injuries", "PROBLEM", 41, 53], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["open", "OBSERVATION_MODIFIER", 20, 24], ["injuries", "OBSERVATION", 25, 33], ["injuries", "OBSERVATION", 45, 53]]], ["The result showed that there were 326 local resident patients and 406 floating migrant patients that had open injuries.", [["injuries", "DISEASE", 110, 118], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 87, 95], ["open injuries", "PROBLEM", 105, 118], ["injuries", "OBSERVATION", 110, 118]]], ["Table 2 lists the open injuries that occurred in at least 10 cases.", [["injuries", "DISEASE", 23, 31], ["the open injuries", "PROBLEM", 14, 31], ["injuries", "OBSERVATION", 23, 31]]], ["The amounts of floating migrant patients were more than those of local resident patients in each of the open injuries except open wound of thigh and elbow, indicating that floating migrant patients were more vulnerable to open injuries.Injury characteristics among RTI patients ::: ResultsFractures that appeared in at least 20 cases were sifted out.", [["wound", "ANATOMY", 130, 135], ["thigh", "ANATOMY", 139, 144], ["injuries", "DISEASE", 109, 117], ["injuries", "DISEASE", 227, 235], ["Injury", "DISEASE", 236, 242], ["RTI", "DISEASE", 265, 268], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 80, 88], ["wound", "PATHOLOGICAL_FORMATION", 130, 135], ["thigh", "ORGANISM_SUBDIVISION", 139, 144], ["elbow", "ORGANISM_SUBDIVISION", 149, 154], ["patients", "ORGANISM", 189, 197], ["patients", "ORGANISM", 269, 277], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 189, 197], ["patients", "SPECIES", 269, 277], ["the open injuries", "PROBLEM", 100, 117], ["open wound of thigh and elbow", "PROBLEM", 125, 154], ["open injuries", "PROBLEM", 222, 235], ["amounts", "OBSERVATION_MODIFIER", 4, 11], ["floating", "OBSERVATION_MODIFIER", 15, 23], ["migrant", "OBSERVATION_MODIFIER", 24, 31], ["injuries", "OBSERVATION", 109, 117], ["open", "OBSERVATION_MODIFIER", 125, 129], ["wound", "OBSERVATION", 130, 135], ["thigh", "ANATOMY", 139, 144], ["elbow", "ANATOMY", 149, 154], ["injuries", "OBSERVATION", 227, 235]]], ["These fractures are listed in Table S1 (Lines with yellow background).", [["fractures", "DISEASE", 6, 15], ["These fractures", "PROBLEM", 0, 15], ["fractures", "OBSERVATION", 6, 15]]], ["There were 30 kinds of fractures left after the selection.", [["fractures", "DISEASE", 23, 32], ["fractures", "PROBLEM", 23, 32], ["the selection", "TREATMENT", 44, 57], ["30 kinds", "OBSERVATION_MODIFIER", 11, 19], ["fractures", "OBSERVATION", 23, 32], ["left", "ANATOMY_MODIFIER", 33, 37]]], ["The ribs and clavicle are the most vulnerable parts of body to fracture and accounted for 11.4% and 5.1% of all traffic injuries, respectively.Inpatient duration and hospitalization cost distribution of traffic injury patients ::: ResultsInpatient duration and hospitalization cost were analyzed for all RTI patients.", [["ribs", "ANATOMY", 4, 8], ["clavicle", "ANATOMY", 13, 21], ["body", "ANATOMY", 55, 59], ["fracture", "DISEASE", 63, 71], ["traffic injuries", "DISEASE", 112, 128], ["traffic injury", "DISEASE", 203, 217], ["RTI", "DISEASE", 304, 307], ["ribs", "ORGAN", 4, 8], ["clavicle", "ORGAN", 13, 21], ["body", "ORGANISM_SUBDIVISION", 55, 59], ["patients", "ORGANISM", 218, 226], ["patients", "ORGANISM", 308, 316], ["patients", "SPECIES", 218, 226], ["patients", "SPECIES", 308, 316], ["fracture", "PROBLEM", 63, 71], ["all traffic injuries", "PROBLEM", 108, 128], ["ribs", "ANATOMY", 4, 8], ["clavicle", "ANATOMY", 13, 21], ["most vulnerable", "OBSERVATION_MODIFIER", 30, 45], ["body", "ANATOMY_MODIFIER", 55, 59], ["fracture", "OBSERVATION", 63, 71], ["traffic injuries", "OBSERVATION", 112, 128], ["traffic injury", "OBSERVATION", 203, 217]]], ["These patients were grouped according to the severity of injuries and their household status.", [["injuries", "DISEASE", 57, 65], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["injuries", "PROBLEM", 57, 65]]], ["The average, median, 25% percentile, 75% percentile and standard deviation of inpatient duration and total cost distribution of mild, moderate, severe and deceased groups were calculated and are listed in Table S2.", [["standard deviation of inpatient duration", "PROBLEM", 56, 96], ["total cost distribution of mild, moderate, severe and deceased groups", "PROBLEM", 101, 170], ["average", "OBSERVATION_MODIFIER", 4, 11], ["total", "OBSERVATION_MODIFIER", 101, 106], ["mild", "OBSERVATION_MODIFIER", 128, 132], ["moderate", "OBSERVATION_MODIFIER", 134, 142], ["severe", "OBSERVATION_MODIFIER", 144, 150]]], ["From the mild to severe group, the average, median, 25% percentile, 75% percentile and standard deviation of inpatient duration and total cost increased with the enhancement of severity.", [["standard deviation of inpatient duration", "PROBLEM", 87, 127], ["the enhancement of severity", "PROBLEM", 158, 185], ["mild", "OBSERVATION_MODIFIER", 9, 13], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["standard deviation", "OBSERVATION", 87, 105], ["total", "OBSERVATION_MODIFIER", 132, 137], ["cost", "OBSERVATION_MODIFIER", 138, 142], ["increased", "OBSERVATION_MODIFIER", 143, 152], ["enhancement", "OBSERVATION_MODIFIER", 162, 173], ["severity", "OBSERVATION_MODIFIER", 177, 185]]], ["In these three groups, the difference in these parameters, between local and floating migrant patients, was more apparent.DiscussionMotor vehicle accident is a common cause of road traffic injuries and deaths throughout the world.", [["Motor vehicle accident", "DISEASE", 132, 154], ["traffic injuries", "DISEASE", 181, 197], ["deaths", "DISEASE", 202, 208], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["these parameters", "TEST", 41, 57]]], ["According to a WHO report, traffic accidents cause 1.27 million deaths and 20 to 50 million injuries around the world annually [15].", [["traffic accidents", "DISEASE", 27, 44], ["deaths", "DISEASE", 64, 70], ["injuries", "DISEASE", 92, 100]]], ["In China, with the recent economic boom, vehicle volume and the number of traffic accident fatalities have become the highest in the world.", [["accident", "DISEASE", 82, 90], ["vehicle volume", "OBSERVATION", 41, 55]]], ["Wang el al. [16]estimated that deaths from vehicle collisions increased 97-fold from 1951 to 1999 in China; and RTIs had become a leading cause of death, accounting for 3.25 percent of all deaths and one third of all injury-related deaths between 2002 and 2006.", [["deaths", "DISEASE", 31, 37], ["RTIs", "DISEASE", 112, 116], ["death", "DISEASE", 147, 152], ["deaths", "DISEASE", 189, 195], ["injury", "DISEASE", 217, 223], ["deaths", "DISEASE", 232, 238], ["vehicle collisions", "TEST", 43, 61], ["RTIs", "PROBLEM", 112, 116], ["death", "PROBLEM", 147, 152], ["all injury", "PROBLEM", 213, 223], ["injury", "OBSERVATION", 217, 223]]], ["With such a severe situation in China's road traffic safety, there is an urgent need to study the RTIs characteristics and risk factors that determine traffic violations and traffic accident severity.DiscussionA lot of factors contribute to the fast increase of road traffic accidents and injuries in recent China.", [["accident", "DISEASE", 182, 190], ["accidents", "DISEASE", 275, 284], ["injuries", "DISEASE", 289, 297], ["road traffic", "MULTI-TISSUE_STRUCTURE", 40, 52], ["a severe situation", "PROBLEM", 10, 28], ["risk factors", "PROBLEM", 123, 135], ["injuries", "PROBLEM", 289, 297], ["severe", "OBSERVATION_MODIFIER", 12, 18]]], ["With the development of the social economy and increased living standard, the ownership of motor vehicles has quickly risen among the middle class population, which has resulted in more road traffic congestion and accidents [17], [18].", [["congestion", "DISEASE", 199, 209], ["accidents", "DISEASE", 214, 223], ["middle class", "OBSERVATION_MODIFIER", 134, 146], ["congestion", "OBSERVATION", 199, 209]]], ["Besides, increases in travel between the city and outside is one factor contributing to the high frequency of accidents [19].", [["accidents", "DISEASE", 110, 119], ["increases", "OBSERVATION_MODIFIER", 9, 18]]], ["Due to the high mobility characteristics of these people, the fast expansion of floating population could be a factor contributing to the high frequency of road traffic accidents.", [["traffic accidents", "DISEASE", 161, 178], ["people", "ORGANISM", 50, 56], ["people", "SPECIES", 50, 56], ["the fast expansion of floating population", "PROBLEM", 58, 99], ["high mobility", "OBSERVATION_MODIFIER", 11, 24], ["floating population", "OBSERVATION", 80, 99]]], ["On the other hand, most of the floating migrants were from rural area.", [["floating migrants", "OBSERVATION", 31, 48]]], ["A study about the risk factors of traffic accident severity in China showed that driver's gender, education level, household status and occupation were associated with traffic violations and injury severity [20].", [["traffic accident", "DISEASE", 34, 50], ["injury", "DISEASE", 191, 197], ["A study", "TEST", 0, 7], ["injury severity", "PROBLEM", 191, 206]]], ["So migrant workers exhibited a high risk for severe accidents.DiscussionIn our study, the RTIs characteristics of floating migrant population were analyzed through comparison with those of local residents.", [["accidents", "DISEASE", 52, 61], ["severe accidents", "PROBLEM", 45, 61], ["our study", "TEST", 75, 84], ["floating migrant population", "PROBLEM", 114, 141], ["floating", "OBSERVATION_MODIFIER", 114, 122]]], ["From 2007 to 2010, there were between 500 and 600 RTI patients seen by this hospital annually.", [["RTI", "DISEASE", 50, 53], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62]]], ["Floating migrant patients accounted for 41.6% of RTIs during the four years.", [["RTIs", "DISEASE", 49, 53], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["RTIs", "PROBLEM", 49, 53], ["migrant", "OBSERVATION_MODIFIER", 9, 16]]], ["This proportion reflected that a great deal of exchange was occurring between this harbor city and outside.", [["great", "OBSERVATION_MODIFIER", 33, 38]]], ["The average risks of RTIs over the four years for local residents and floating migrants were different (0.632 versus 1.005 per thousand people).", [["RTIs", "DISEASE", 21, 25], ["people", "SPECIES", 136, 142], ["RTIs", "PROBLEM", 21, 25], ["average", "OBSERVATION_MODIFIER", 4, 11]]], ["This result indicated that floating population exhibited a higher risk of RTIs compared to local residents.", [["RTIs", "DISEASE", 74, 78], ["floating population", "PROBLEM", 27, 46], ["RTIs", "PROBLEM", 74, 78], ["floating", "OBSERVATION_MODIFIER", 27, 35], ["RTIs", "OBSERVATION", 74, 78]]], ["In view of the gender distribution of RTIs patients, the proportion of male patients in these four years ranged between 2/3 and 3/4.", [["RTIs", "DISEASE", 38, 42], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 76, 84]]], ["Male patients made up the majority of traffic accident sufferers, likely because men are generally the main laborers in society.", [["traffic accident", "DISEASE", 38, 54], ["patients", "ORGANISM", 5, 13], ["men", "ORGANISM", 81, 84], ["patients", "SPECIES", 5, 13], ["men", "SPECIES", 81, 84]]], ["This phenomenon was more obvious in the floating migrant patients, because female RTIs patients with local household were less than those of floating migrants in each of the four years.DiscussionPatients between 16 and 55 years of age constituted the majority of RTI patients likely because people in this age range are the main labor force in society.", [["RTIs", "DISEASE", 82, 86], ["RTI", "DISEASE", 263, 266], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 87, 95], ["patients", "ORGANISM", 267, 275], ["people", "ORGANISM", 291, 297], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 267, 275], ["people", "SPECIES", 291, 297], ["This phenomenon", "PROBLEM", 0, 15], ["more obvious", "OBSERVATION_MODIFIER", 20, 32]]], ["This was also demonstrated in a recent study examining RTIs in Shanghai [21].", [["RTIs", "DISEASE", 55, 59], ["a recent study", "TEST", 30, 44]]], ["Pre-school children had a higher accident incidence compared to school-children under the age of 16.", [["accident", "DISEASE", 33, 41], ["children", "ORGANISM", 11, 19], ["children", "ORGANISM", 71, 79], ["children", "SPECIES", 11, 19], ["children", "SPECIES", 71, 79]]], ["The probable reason is that compulsory education in China starts in primary school.", [["probable reason is", "UNCERTAINTY", 4, 22]]], ["Before that age, pre-school children are not all taken to the nursery and some children stay at home with parents or grandparents.", [["children", "ORGANISM", 28, 36], ["children", "ORGANISM", 79, 87], ["children", "SPECIES", 28, 36], ["children", "SPECIES", 79, 87]]], ["The age distribution of local and floating migrant patients was also different.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["distribution", "OBSERVATION_MODIFIER", 8, 20], ["local", "OBSERVATION_MODIFIER", 24, 29], ["floating", "OBSERVATION_MODIFIER", 34, 42], ["migrant", "OBSERVATION_MODIFIER", 43, 50], ["different", "OBSERVATION_MODIFIER", 69, 78]]], ["Floating migrant patients had a higher accident incidence between ages 16 and 45, while local resident patients had a higher accident incidence between ages 46 and 55.", [["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 103, 111]]], ["The reason for this difference is likely that the majority of floating migrants in this city are mostly young people who came to the city for business.", [["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116]]], ["The detailed age distributions of locals and floating migrant population in this district were not available in any public dataset or yearbook.", [["locals", "PROBLEM", 34, 40], ["floating migrant population", "PROBLEM", 45, 72], ["floating", "OBSERVATION_MODIFIER", 45, 53], ["migrant", "OBSERVATION_MODIFIER", 54, 61]]], ["So we believed that the difference spread by age was partly due to different population demographics between local and floating migrant patients.", [["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144]]], ["For the local residents, increased age was related to the likelihood of injury from a traffic accident [22].DiscussionMarch, June and October were found to be the months with the most RTI patients with 217, 216 and 218 patients for each month, respectively.", [["injury", "DISEASE", 72, 78], ["traffic accident", "DISEASE", 86, 102], ["patients", "ORGANISM", 188, 196], ["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 188, 196], ["patients", "SPECIES", 219, 227], ["injury", "PROBLEM", 72, 78], ["injury", "OBSERVATION", 72, 78]]], ["February and January were the months that had fewer RTI patients with 107 and 146 patients, respectively.", [["RTI", "DISEASE", 52, 55], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 82, 90]]], ["The proportions of floating migrant patients were just 27.4% and 33.6% in these two months, which were less than those of other months too.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["proportions", "OBSERVATION_MODIFIER", 4, 15], ["floating", "OBSERVATION_MODIFIER", 19, 27], ["migrant", "OBSERVATION_MODIFIER", 28, 35]]], ["Most floating migrants go back home, thus there are fewer RTIs during these two months.", [["RTIs", "DISEASE", 58, 62], ["fewer", "OBSERVATION_MODIFIER", 52, 57], ["RTIs", "OBSERVATION", 58, 62]]], ["This monthly distribution result is also in accordance with that found in Beijing from 2004 to 2008 [23], which is near Tianjin.DiscussionIn a traffic accident, any part of body may be injured.", [["body", "ANATOMY", 173, 177], ["traffic accident", "DISEASE", 143, 159], ["body", "ORGANISM_SUBDIVISION", 173, 177], ["injured", "OBSERVATION", 185, 192]]], ["The data in this paper showed that most patients had head or multiple body region injuries.", [["head", "ANATOMY", 53, 57], ["body region", "ANATOMY", 70, 81], ["injuries", "DISEASE", 82, 90], ["patients", "ORGANISM", 40, 48], ["head", "ORGANISM_SUBDIVISION", 53, 57], ["body", "ORGANISM_SUBDIVISION", 70, 74], ["patients", "SPECIES", 40, 48], ["The data", "TEST", 0, 8], ["head or multiple body region injuries", "PROBLEM", 53, 90], ["head", "ANATOMY", 53, 57], ["multiple", "OBSERVATION_MODIFIER", 61, 69], ["body", "ANATOMY", 70, 74], ["region", "ANATOMY_MODIFIER", 75, 81], ["injuries", "OBSERVATION", 82, 90]]], ["These two groups accounted for 34.6% and 37% of all patients.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60]]], ["The numbers of local resident patients and floating migrant patients in these two groups were counted and classified according to the severity of injuries: mild, moderate, severe and deceased.", [["injuries", "DISEASE", 146, 154], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 60, 68], ["mild, moderate, severe and deceased", "PROBLEM", 156, 191], ["numbers", "OBSERVATION_MODIFIER", 4, 11], ["mild", "OBSERVATION_MODIFIER", 156, 160], ["moderate", "OBSERVATION_MODIFIER", 162, 170], ["severe", "OBSERVATION_MODIFIER", 172, 178]]], ["The proportion of floating migrant patients increased as the severity of injury increased from mild to severe.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["injury", "PROBLEM", 73, 79], ["mild to severe", "PROBLEM", 95, 109], ["proportion", "OBSERVATION_MODIFIER", 4, 14], ["floating", "OBSERVATION_MODIFIER", 18, 26], ["migrant", "OBSERVATION_MODIFIER", 27, 34], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["injury", "OBSERVATION", 73, 79], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["mild", "OBSERVATION_MODIFIER", 95, 99], ["to severe", "OBSERVATION_MODIFIER", 100, 109]]], ["We supposed that this was due to the fact that floating migrant patients likely traverse, not only the city district, but also between the city and outside.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72]]], ["On the highways, the speed limit is over that of city roads and there is no traffic regulation.", [["no", "UNCERTAINTY", 73, 75], ["traffic regulation", "OBSERVATION", 76, 94]]], ["Accidents that happen on the highway usually cause severe injuries or death [24].", [["Accidents", "DISEASE", 0, 9], ["injuries", "DISEASE", 58, 66], ["death", "DISEASE", 70, 75], ["severe injuries", "PROBLEM", 51, 66], ["death", "PROBLEM", 70, 75], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["injuries", "OBSERVATION", 58, 66]]], ["Meanwhile, many floating migrants have lower level of education.", [["floating", "OBSERVATION_MODIFIER", 16, 24]]], ["This is also a risk factor for traffic violation and accident severity.", [["accident", "DISEASE", 53, 61]]], ["Therefore, floating migrants are more vulnerable to severe RTIs compared with local residents.DiscussionStatistical analysis of RTIs means a lot to emergency clinics.", [["RTIs", "DISEASE", 59, 63], ["RTIs", "DISEASE", 128, 132], ["severe RTIs", "PROBLEM", 52, 63], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["RTIs", "OBSERVATION", 59, 63]]], ["Injuries that had occurred at least 20 times were reviewed.", [["Injuries", "DISEASE", 0, 8], ["Injuries", "PROBLEM", 0, 8]]], ["For each of these injuries, we calculated the floating migrant patient proportion with each injury, and the mean, median, 25% percentile and 75% percentile ages in both the local resident patient and floating migrant patient groups.", [["patient", "ORGANISM", 63, 70], ["patient", "ORGANISM", 188, 195], ["patient", "ORGANISM", 217, 224], ["patient", "SPECIES", 63, 70], ["patient", "SPECIES", 188, 195], ["patient", "SPECIES", 217, 224], ["these injuries", "PROBLEM", 12, 26], ["each injury", "PROBLEM", 87, 98], ["injuries", "OBSERVATION", 18, 26], ["injury", "OBSERVATION", 92, 98]]], ["The results showed that the top injuries with higher proportion of floating migrant patients were mostly associated with high energy accidents, for example traumatic spleen rupture, fracture of acetabulum, contusion of kidney or fracture of the shaft of the femur.", [["spleen", "ANATOMY", 166, 172], ["acetabulum", "ANATOMY", 194, 204], ["kidney", "ANATOMY", 219, 225], ["shaft", "ANATOMY", 245, 250], ["femur", "ANATOMY", 258, 263], ["injuries", "DISEASE", 32, 40], ["accidents", "DISEASE", 133, 142], ["spleen rupture", "DISEASE", 166, 180], ["fracture", "DISEASE", 182, 190], ["contusion", "DISEASE", 206, 215], ["fracture", "DISEASE", 229, 237], ["patients", "ORGANISM", 84, 92], ["spleen", "ORGAN", 166, 172], ["acetabulum", "ORGAN", 194, 204], ["kidney", "ORGAN", 219, 225], ["femur", "ORGAN", 258, 263], ["patients", "SPECIES", 84, 92], ["the top injuries", "PROBLEM", 24, 40], ["example traumatic spleen rupture", "PROBLEM", 148, 180], ["fracture of acetabulum", "PROBLEM", 182, 204], ["contusion of kidney", "PROBLEM", 206, 225], ["fracture of the shaft of the femur", "PROBLEM", 229, 263], ["top", "OBSERVATION_MODIFIER", 28, 31], ["injuries", "OBSERVATION", 32, 40], ["higher", "OBSERVATION_MODIFIER", 46, 52], ["traumatic", "OBSERVATION_MODIFIER", 156, 165], ["spleen", "ANATOMY", 166, 172], ["rupture", "OBSERVATION", 173, 180], ["fracture", "OBSERVATION", 182, 190], ["acetabulum", "ANATOMY", 194, 204], ["contusion", "OBSERVATION", 206, 215], ["kidney", "ANATOMY", 219, 225], ["fracture", "OBSERVATION", 229, 237], ["shaft", "ANATOMY_MODIFIER", 245, 250], ["femur", "ANATOMY", 258, 263]]], ["In contrast, the injuries with smaller proportions were generally upper extremity or neck injuries, or injuries or diseases associated with aging, for example fracture of humerus, superficial injury of neck, hypertension and type 2 diabetes.", [["extremity", "ANATOMY", 72, 81], ["neck", "ANATOMY", 85, 89], ["humerus", "ANATOMY", 171, 178], ["neck", "ANATOMY", 202, 206], ["injuries", "DISEASE", 17, 25], ["injuries", "DISEASE", 90, 98], ["injuries", "DISEASE", 103, 111], ["fracture", "DISEASE", 159, 167], ["hypertension", "DISEASE", 208, 220], ["type 2 diabetes", "DISEASE", 225, 240], ["upper extremity", "ORGANISM_SUBDIVISION", 66, 81], ["neck", "ORGANISM_SUBDIVISION", 85, 89], ["humerus", "ORGAN", 171, 178], ["neck", "ORGANISM_SUBDIVISION", 202, 206], ["the injuries", "PROBLEM", 13, 25], ["generally upper extremity or neck injuries", "PROBLEM", 56, 98], ["injuries", "PROBLEM", 103, 111], ["diseases", "PROBLEM", 115, 123], ["example fracture of humerus", "PROBLEM", 151, 178], ["superficial injury of neck", "PROBLEM", 180, 206], ["hypertension", "PROBLEM", 208, 220], ["type 2 diabetes", "PROBLEM", 225, 240], ["injuries", "OBSERVATION", 17, 25], ["smaller", "OBSERVATION_MODIFIER", 31, 38], ["upper", "ANATOMY_MODIFIER", 66, 71], ["extremity", "ANATOMY", 72, 81], ["neck", "ANATOMY", 85, 89], ["injuries", "OBSERVATION", 90, 98], ["fracture", "OBSERVATION", 159, 167], ["humerus", "ANATOMY", 171, 178], ["superficial", "ANATOMY_MODIFIER", 180, 191], ["injury", "OBSERVATION", 192, 198], ["neck", "ANATOMY", 202, 206], ["hypertension", "OBSERVATION", 208, 220], ["diabetes", "OBSERVATION", 232, 240]]], ["Among these injuries, the open injuries, except open wound of thigh and open wound of elbow, had the proportions more than 0.5, which indicated that floating migrant patients were more vulnerable to open injuries.", [["wound", "ANATOMY", 53, 58], ["thigh", "ANATOMY", 62, 67], ["wound", "ANATOMY", 77, 82], ["elbow", "ANATOMY", 86, 91], ["injuries", "DISEASE", 12, 20], ["injuries", "DISEASE", 31, 39], ["injuries", "DISEASE", 204, 212], ["wound", "PATHOLOGICAL_FORMATION", 53, 58], ["thigh", "ORGANISM_SUBDIVISION", 62, 67], ["wound", "PATHOLOGICAL_FORMATION", 77, 82], ["elbow", "ORGANISM_SUBDIVISION", 86, 91], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["these injuries", "PROBLEM", 6, 20], ["the open injuries", "PROBLEM", 22, 39], ["open wound of thigh", "PROBLEM", 48, 67], ["open wound of elbow", "TREATMENT", 72, 91], ["open injuries", "PROBLEM", 199, 212], ["injuries", "OBSERVATION", 12, 20], ["injuries", "OBSERVATION", 31, 39], ["open", "OBSERVATION_MODIFIER", 48, 52], ["wound", "OBSERVATION", 53, 58], ["thigh", "ANATOMY", 62, 67], ["open", "OBSERVATION_MODIFIER", 72, 76], ["wound", "OBSERVATION", 77, 82], ["elbow", "ANATOMY", 86, 91], ["injuries", "OBSERVATION", 204, 212]]], ["For fractures, those with larger proportions were usually associated with high-energy crashes.", [["fractures", "DISEASE", 4, 13], ["high-energy crashes", "DISEASE", 74, 93], ["fractures", "PROBLEM", 4, 13], ["high-energy crashes", "PROBLEM", 74, 93], ["fractures", "OBSERVATION", 4, 13]]], ["However, fractures with smaller proportions were usually associated with low-energy crashes or with aging, such as fracture of lumbar vertebra and intertrochanteric fracture of the femur.", [["lumbar vertebra", "ANATOMY", 127, 142], ["femur", "ANATOMY", 181, 186], ["fractures", "DISEASE", 9, 18], ["low-energy crashes", "DISEASE", 73, 91], ["fracture", "DISEASE", 115, 123], ["fracture", "DISEASE", 165, 173], ["lumbar vertebra", "MULTI-TISSUE_STRUCTURE", 127, 142], ["femur", "ORGAN", 181, 186], ["fractures", "PROBLEM", 9, 18], ["smaller proportions", "PROBLEM", 24, 43], ["low-energy crashes", "PROBLEM", 73, 91], ["fracture of lumbar vertebra", "PROBLEM", 115, 142], ["intertrochanteric fracture of the femur", "PROBLEM", 147, 186], ["fractures", "OBSERVATION", 9, 18], ["smaller", "OBSERVATION_MODIFIER", 24, 31], ["energy crashes", "OBSERVATION", 77, 91], ["fracture", "OBSERVATION", 115, 123], ["lumbar vertebra", "ANATOMY", 127, 142], ["intertrochanteric", "ANATOMY", 147, 164], ["fracture", "OBSERVATION", 165, 173], ["femur", "ANATOMY", 181, 186]]], ["To sum up, statistical analysis results of RTIs supports that local resident patients are usually associated with low-energy accidents while floating migrant patients are usually associated with high-energy accidents, and that ages have an impact on the RTI distribution among local resident patients.DiscussionDue to the reasons mentioned above, inpatient duration and hospitalization costs were different for local versus floating migrant patients.", [["RTIs", "DISEASE", 43, 47], ["low-energy accidents", "DISEASE", 114, 134], ["accidents", "DISEASE", 207, 216], ["RTI", "DISEASE", 254, 257], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 158, 166], ["patients", "ORGANISM", 292, 300], ["patients", "ORGANISM", 441, 449], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 158, 166], ["patients", "SPECIES", 292, 300], ["patients", "SPECIES", 441, 449], ["statistical analysis", "TEST", 11, 31], ["hospitalization costs", "TREATMENT", 370, 391]]], ["Hospitalization costs for floating migrant patients increased with the severity of injury (mild to severe) from below to a great deal above that of local residents.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["injury", "PROBLEM", 83, 89], ["mild to severe)", "PROBLEM", 91, 106], ["injury", "OBSERVATION", 83, 89], ["mild", "OBSERVATION_MODIFIER", 91, 95], ["severe", "OBSERVATION_MODIFIER", 99, 105]]], ["For the inpatient duration, there was an increase in both the local residents and floating migrants with injury, but that it increased more slowly among floating migrants.ConclusionIn the current paper the hospital records of RTI patients seen in a tertiary hospital in a harbor city of China between the year of 2007 and 2010, were analyzed.", [["RTI", "DISEASE", 226, 229], ["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 230, 238], ["injury", "PROBLEM", 105, 111], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["increased", "OBSERVATION_MODIFIER", 125, 134], ["more", "OBSERVATION_MODIFIER", 135, 139], ["slowly", "OBSERVATION_MODIFIER", 140, 146]]], ["The results showed that floating migrant patients had different characteristics than local resident patients in terms of age, the type and severity of injuries, inpatient duration, hospitalization cost.", [["injuries", "DISEASE", 151, 159], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 100, 108], ["injuries", "PROBLEM", 151, 159], ["floating", "OBSERVATION_MODIFIER", 24, 32], ["injuries", "OBSERVATION", 151, 159]]], ["In contrast, the population of local residents consists of different ages and elder people who are more vulnerable to injuries resulting from traffic accidents compared to younger people.", [["injuries", "DISEASE", 118, 126], ["traffic accidents", "DISEASE", 142, 159], ["people", "ORGANISM", 84, 90], ["people", "ORGANISM", 180, 186], ["people", "SPECIES", 84, 90], ["people", "SPECIES", 180, 186]]], ["In light of this study, further research should be done and more consideration given to the health of floating migrants.", [["this study", "TEST", 12, 22], ["further research", "TEST", 24, 40]]]], "8af9581d2e1b89c8f052a49980259917fd694094": [["issues in AL research and the need for methodological reform in the field.", [["methodological reform", "TREATMENT", 39, 60]]], ["They then provide a taxonomy of various approaches to research in AL and put forward a research cycle model that informs the organization of the handbook.", [["a research cycle model", "TREATMENT", 85, 107]]], ["This cycle consists of the five stages of thinking, designing, collecting, analyzing and disseminating.", [["five stages", "OBSERVATION_MODIFIER", 27, 38]]]]}